<SEC-DOCUMENT>0001213900-26-036502.txt : 20260330
<SEC-HEADER>0001213900-26-036502.hdr.sgml : 20260330
<ACCEPTANCE-DATETIME>20260330173912
ACCESSION NUMBER:		0001213900-26-036502
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260330
DATE AS OF CHANGE:		20260330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyrophyte Acquisition Corp. II
		CENTRAL INDEX KEY:			0002069238
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		ORGANIZATION NAME:           	05 Real Estate & Construction
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42752
		FILM NUMBER:		26813833

	BUSINESS ADDRESS:	
		STREET 1:		3262 WESTHEIMER ROAD, SUITE 706
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77098
		BUSINESS PHONE:		281-701-4234

	MAIL ADDRESS:	
		STREET 1:		3262 WESTHEIMER ROAD, SUITE 706
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77098
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0282458-10k_pyrophyte2.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:paii="http://pyrophyteacquisitioncorp2.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>paii-20251231</title>
    <meta http-equiv="Content-Type" content="text/html"/>
  </head>
  <body>
    <div style="display:none">
      <ix:header>
        <ix:hidden>
          <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="cref_1692716169" id="fc_174561091" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1330416410" id="fc_912153279" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockOtherValueOutstanding" contextRef="cref_333300986" id="fc_1028152249" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_575041159" id="fc_575041159" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:WorkingCapitalLoanOutstanding" contextRef="cref_333300986" id="fc_936727067" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="cref_1879775354" id="fc_162488177" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="cref_333300986" id="fc_216117793" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="cref_333300986" id="fc_1602604156" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1124168248" id="fc_1124168248" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_794524015" id="fc_794524015" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_50662810" id="fc_50662810" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_337383641" id="fc_337383641" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_575041159" id="fc_930201705" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1124168248" id="fc_441132902" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_794524015" id="fc_2113113059" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="cref_1270821457" id="fc_1534900816" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="cref_226959058" id="fc_226959058" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="cref_55172024" id="fc_2071760065" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_1270821457" id="fc_495288907" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_226959058" id="fc_592782723" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1343794665" id="fc_1343794665" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_326000575" id="fc_326000575" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1343794665" id="fc_1488256648" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="cref_1270821457" id="fc_346808071" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="cref_226959058" id="fc_1769645716" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_1270821457" id="fc_661146650" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_226959058" id="fc_1020165411" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_55172024" id="fc_371079441" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_1330416410" id="fc_901471383" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_226959058" id="fc_264447317" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_1257381007" id="fc_128932335" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_532706043" id="fc_2077135401" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_55172024" id="fc_1617784863" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_1330416410" id="fc_2114542320" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_226959058" id="fc_1999784281" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_1257381007" id="fc_1161507624" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_532706043" id="fc_1015604165" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_55172024" id="fc_1858594186" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_1330416410" id="fc_172479364" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" contextRef="cref_226959058" id="fc_1742904851" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" contextRef="cref_1257381007" id="fc_585283673" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_226959058" id="fc_1630524161" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_1257381007" id="fc_145799748" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_532706043" id="fc_1687994771" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_55172024" id="fc_2115620742" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_1330416410" id="fc_1261419997" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="cref_333300986" id="fc_1169747210" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="cref_333300986" id="fc_601645145" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_1879775354" id="fc_1175639479" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_1879775354" id="fc_1867186661" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_52832062" id="fc_52832062" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_52832062" id="fc_996209133" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonNumeric name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="cref_1330416410" id="fc_832639951">http://fasb.org/srt/2025#ChiefFinancialOfficerMember</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="cref_619992257" id="fc_560829149">00-0000000</ix:nonNumeric>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_226959058" id="fc_1934720917" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_1257381007" id="fc_2001304571" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_55172024" id="fc_1526338219" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_226959058" id="fc_1584484121" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_1257381007" id="fc_1701195832" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_55172024" id="fc_821862778" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_1270821457" id="fc_1645021734" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_226959058" id="fc_1210222640" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_1257381007" id="fc_1836776887" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_55172024" id="fc_244269380" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="cref_1257381007" id="fc_915645759" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1270821457" id="fc_1539544538" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_226959058" id="fc_1861594894" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1257381007" id="fc_822270604" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_532706043" id="fc_1247507169" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="dei:EntityPublicFloat" contextRef="cref_1844658907" id="fc_227438756" unitRef="uref_200602150" scale="0" decimals="0">0</ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1577949154" id="fc_1577949154" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="cref_1356153804" id="fc_131930771" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_1356153804" id="fc_1789097633" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_1356153804" id="fc_444998111" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_1356153804" id="fc_1757372007" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_1356153804" id="fc_1046165585" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_1356153804" id="fc_878587040" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_1356153804" id="fc_1702605431" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_1356153804" id="fc_521991325" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="cref_1356153804" id="fc_346553776" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1356153804" id="fc_1924657242" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable" contextRef="cref_1270821457" id="fc_35026678" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable" contextRef="cref_226959058" id="fc_605456837" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable" contextRef="cref_1257381007" id="fc_1906154546" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="cref_333300986" id="fc_1532244282" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="cref_333300986" id="fc_1353994326" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="cref_1886441502" id="fc_1886441502" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="cref_2088902046" id="fc_2088902046" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="cref_1692716169" id="fc_899188066" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_1879775354" id="fc_492491914" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_1879775354" id="fc_459141205" unitRef="uref_779585586" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="cref_333300986" id="fc_1781603387" unitRef="uref_200602150" xsi:nil="true"></ix:nonFraction>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="cref_619992257" id="ixv-6739">0002069238</ix:nonNumeric>
          <ix:nonNumeric name="dei:AmendmentFlag" contextRef="cref_619992257" id="ixv-6740">false</ix:nonNumeric>
          <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="cref_619992257" id="ixv-6741">FY</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="paii-20251231.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="cref_619992257">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_193655120">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">paii:ProbabilityOfMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1954112812">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1680536946">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1779705651">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1075758566">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1064750139">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_246701486">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_200602150">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1093905091">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1330416410">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_333300986">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_779585586">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1486745643">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1062301092">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_73988315">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1879775354">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1292095244">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_157283163">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1284032524">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1618928315">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_668677484">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_87236569">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_22280331">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1901841206">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2120962183">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:SponsorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_874887864">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-06-01</xbrli:startDate>
              <xbrli:endDate>2025-06-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1104949232">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-05</xbrli:startDate>
              <xbrli:endDate>2025-05-05</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1318038427">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-05-05</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_770479516">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-05</xbrli:startDate>
              <xbrli:endDate>2025-05-05</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1692716169">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1491172312">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-18</xbrli:startDate>
              <xbrli:endDate>2025-07-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2109124231">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1950299307">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1549419295">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1113090420">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-19</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_525945823">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1626106670">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1462063775">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-18</xbrli:startDate>
              <xbrli:endDate>2025-07-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1093598802">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1940925763">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_61013207">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1272538016">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">paii:InitialBusinessCombinationMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_329624284">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">paii:InitialBusinessCombinationMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1595368894">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-06-01</xbrli:startDate>
              <xbrli:endDate>2025-06-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1844658907">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-06-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_606805414">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-06-01</xbrli:startDate>
              <xbrli:endDate>2025-06-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1830146596">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-06-01</xbrli:startDate>
              <xbrli:endDate>2025-06-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_820702892">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-24</xbrli:startDate>
              <xbrli:endDate>2025-07-24</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1609389963">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-05</xbrli:startDate>
              <xbrli:endDate>2025-05-05</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2136458884">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-05-05</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_259502220">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_745494576">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1273128513">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_474135015">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-24</xbrli:startDate>
              <xbrli:endDate>2025-07-24</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1057160995">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-24</xbrli:startDate>
              <xbrli:endDate>2025-07-24</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_726704442">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-24</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1673988012">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-18</xbrli:startDate>
              <xbrli:endDate>2025-07-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_116935946">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:ClassBNonredeemableOrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1891084432">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:RedeemableClassAOrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_638126375">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_467896768">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_891586060">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_454030801">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-24</xbrli:startDate>
              <xbrli:endDate>2025-07-24</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1352642449">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-18</xbrli:startDate>
              <xbrli:endDate>2025-07-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_700951886">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_967608479">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-18</xbrli:startDate>
              <xbrli:endDate>2025-07-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_947942404">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-18</xbrli:startDate>
              <xbrli:endDate>2025-07-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1953308297">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-31</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_923664865">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-24</xbrli:startDate>
              <xbrli:endDate>2025-07-24</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_477826121">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-31</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2146548669">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1079647625">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1759141991">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_13105706">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_55172024">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_532706043">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1270821457">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1356153804">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1257381007">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_500152996">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_92406311">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1220869833">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-24</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_403242642">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1607445284">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1134978814">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_443960089">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1069151183">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:ClassAOrdinarySharesParValue00001PerShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_536182311">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_575041159">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1124168248">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_794524015">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_50662810">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_337383641">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_226959058">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-05-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1343794665">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_326000575">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_52832062">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1577949154">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1886441502">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2088902046">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0002069238</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="uref_193655120">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_246701486">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:USD</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="uref_200602150">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_599377219">
            <xbrli:measure>paii:segment</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_779585586">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_1001053603" fromRefs="fc_1534900816 fc_1986056237 fc_2071760065 fc_495288907 fc_2072477435 fc_193369983 fc_592782723 fc_1945644932 fc_1801047499 fc_452725222 fc_544349580 fc_226959058 fc_205363762 fc_158012640"/>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_1453435609" fromRefs="fc_1256945023 fc_888586232"/>
        </ix:resources>
      </ix:header>
    </div> <p style="text-indent: 0.25in; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> FORM <ix:nonNumeric name="dei:DocumentType" contextRef="cref_619992257" id="ixv-7547">10-K</ix:nonNumeric> </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="cref_619992257" format="ixt:fixed-true" id="ixv-7548">&#9746;</ix:nonNumeric></span> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="cref_619992257" format="ixt:date-monthname-day-year-en" id="ixv-7549"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="cref_619992257" format="ixt:date-monthname-day-en" id="ixv-7550">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="cref_619992257" format="ixt:num-dot-decimal" id="ixv-7551">2025</ix:nonNumeric></ix:nonNumeric> </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7552">&#9744;</ix:nonNumeric></span> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: normal">&#160;</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: normal">Commission File Number:</span> <ix:nonNumeric name="dei:EntityFileNumber" contextRef="cref_619992257" id="ixv-7553">001-42752</ix:nonNumeric> </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="cref_619992257" id="ixv-7554">PYROPHYTE ACQUISITION CORP. II</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: normal">(Exact name of registrant as specified in its charter)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="text-align: center; border-bottom: black 1.5pt solid; width: 49%"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="cref_619992257" format="ixt-sec:edgarprovcountryen" id="ixv-7555">Cayman Islands</ix:nonNumeric></span></td><td style="text-align: center; width: 2%">&#160;</td><td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 49%"><span style="font-weight: bold;"><span style="-sec-ix-hidden:fc_560829149">N/A</span></span></td> </tr> <tr style="vertical-align: top"> <td style="text-align: center">(State or other jurisdiction of<br/> incorporation or organization)</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">(I.R.S. Employer<br/> Identification Number)</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="cref_619992257" id="ixv-7556">3262 Westheimer Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="cref_619992257" id="ixv-7557">Suite 706</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="cref_619992257" id="ixv-7558">Houston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="cref_619992257" id="ixv-7559">TX</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="cref_619992257" id="ixv-7560">77098</ix:nonNumeric></span></p></td> </tr> <tr style="vertical-align: top"> <td style="font-size: 10pt; text-align: center">(Address of principal executive offices)</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center"> Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;"><ix:nonNumeric name="dei:CityAreaCode" contextRef="cref_619992257" id="ixv-7561">(281)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="cref_619992257" id="ixv-7562">701-4243</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-weight: bold;">Title of Each Class:</span></td> <td style="width: 2%"><span style="font-weight: bold;">&#160;</span></td> <td style="text-align: center; border-bottom: black 1.5pt solid; font-size: 10pt; width: 32%"><span style="font-weight: bold;">Trading Symbols</span></td> <td style="width: 2%"><span style="font-weight: bold;">&#160;</span></td> <td style="text-align: center; border-bottom: black 1.5pt solid; font-size: 10pt; width: 32%"><span style="font-weight: bold;">Name of Each Exchange on Which Registered:</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="cref_536182311" id="ixv-7563">Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-half of one redeemable warrant</ix:nonNumeric></td><td style="vertical-align: top">&#160;</td><td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="cref_536182311" id="ixv-7564">PAII.U</ix:nonNumeric></span></td><td style="vertical-align: top">&#160;</td><td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="cref_536182311" format="ixt-sec:exchnameen" id="ixv-7565">New York Stock Exchange</ix:nonNumeric></span></td> </tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="cref_1069151183" id="ixv-7566">Class A Ordinary Shares, par value $0.0001 per share</ix:nonNumeric></td><td style="vertical-align: top">&#160;</td><td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="cref_1069151183" id="ixv-7567">PAII</ix:nonNumeric></span></td><td style="vertical-align: top">&#160;</td><td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="cref_1069151183" format="ixt-sec:exchnameen" id="ixv-7568">New York Stock Exchange</ix:nonNumeric></span></td> </tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="font-size: 10pt; text-align: center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="cref_443960089" id="ixv-7569">Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share</ix:nonNumeric></td><td>&#160;</td><td style="font-size: 10pt; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="cref_443960089" id="ixv-7570">PAII WS</ix:nonNumeric></span></td><td>&#160;</td><td style="font-size: 10pt; text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="cref_443960089" format="ixt-sec:exchnameen" id="ixv-7571">New York Stock Exchange</ix:nonNumeric></span></td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="cref_619992257" id="ixv-7572">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="cref_619992257" id="ixv-7573">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="cref_619992257" id="ixv-7574">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="cref_619992257" id="ixv-7575">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 25%">Large accelerated filer</td> <td style="font-size: 10pt; width: 25%">&#9744;</td> <td style="font-size: 10pt; width: 25%">Accelerated filer</td> <td style="font-size: 10pt; width: 25%">&#9744;</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="cref_619992257" format="ixt-sec:entityfilercategoryen" id="ixv-7576">Non-accelerated filer</ix:nonNumeric></td><td style="font-size: 10pt">&#9746;</td><td style="font-size: 10pt">Smaller reporting company</td><td style="font-size: 10pt"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="cref_619992257" format="ixt:fixed-true" id="ixv-7577">&#9746;</ix:nonNumeric></td> </tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">Emerging growth company</td><td style="font-size: 10pt"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="cref_619992257" format="ixt:fixed-true" id="ixv-7578">&#9746;</ix:nonNumeric></td><td>&#160;</td><td>&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7579">&#9744;</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7580">&#9744;</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7581">&#9744;</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="cref_619992257" format="ixt:fixed-true" id="ixv-157">&#9746;<span style="font-family: Times New Roman, Times, Serif"></span></ix:nonNumeric> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The registrant was <span style="-sec-ix-hidden:fc_227438756">not</span> a public company as of June 30, 2025, and therefore it cannot calculate the aggregate market value of its voting and non-voting common equity held by non-affiliates as of such date. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> As of March 30, 2026, there were an aggregate of 27,266,871 ordinary shares of the registrant issued and outstanding, consisting of <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="cref_1134978814" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7582">20,041,150</ix:nonFraction> Class A Ordinary Shares, par value $0.0001 per share, and <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="cref_1607445284" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7583">7,225,721</ix:nonFraction> Class B ordinary shares, par value $0.0001 per share. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Documents Incorporated by Reference: <ix:nonNumeric name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="cref_619992257" escape="true" id="ixv-7584">None</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%">
<tbody><tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in">&#160;</td>
<td>&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0in; padding-bottom: 0in"><span style="font-weight: bold;">PAGE</span></td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
<td style="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_001">Part I</a></td>
<td style="width: 1%">&#160;</td>
<td style="width: 9%; text-align: center; padding-top: 0in; padding-bottom: 0in">1</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_002">Item 1. Business</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">1</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_003">Item 1A. Risk Factors</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">15</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_004">Item 1B. Unresolved Staff Comments</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_005">Item 1C. Cybersecurity</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_006">Item 2. Properties</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_007">Item 3. Legal Proceedings</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_008">Item 4. Mine Safety Disclosures</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_009">Part II</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_010">Item 5. Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_011">Item 6. [Reserved]</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_012">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_013">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_014">Item 8. Financial Statements and Supplementary Data</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_015">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_016">Item 9A. Controls and Procedures.</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_017">Item 9B. Other Information</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.625in"><a href="#a_018">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_019">Part III</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_020">Item 10. Directors, Executive Officers and Corporate Governance Officers and Directors</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_021">Item 11. Executive Compensation.</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_022">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters.</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_030">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">75</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_023">Item 14. Principal Accounting Fees and Services.</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">77</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_024">Part IV</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">78</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_025">Item 15. Exhibits, Financial Statement Schedules.</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">78</td></tr>
<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.25in"><a href="#a_026">Item 16. Form 10-K Summary</a></td>
<td>&#160;</td>
<td style="text-align: center; padding-top: 0in; padding-bottom: 0in">79</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS AND RISK FACTOR SUMMARY</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain statements in this
Annual Report on Form 10-K (this &#8220;Form 10-K&#8221;) may constitute &#8220;forward-looking statements&#8221; for purposes of the
federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s
expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The
words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Form 10-K may include,
for example, statements about:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to select an appropriate target business or businesses;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to complete our initial Business Combination (as defined below);</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our expectations around the performance of the prospective target business or businesses;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our success in retaining or recruiting, or changes required in, our officers, key employees or directors
following our initial Business Combination;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our officers and directors allocating their time to other businesses and potentially having conflicts
of interest with our business or in approving our initial Business Combination;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our potential ability to obtain additional financing to complete our initial Business Combination;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our pool of prospective target businesses;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the adverse impacts that events outside of our control, such as increased geopolitical unrest and increased
volatility in the debt and equity markets, may have on our ability to consummate an initial Business Combination;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our public securities&#8217; potential liquidity and trading;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the lack of a market for our securities;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the use of proceeds not held in the Trust Account (as defined below) or available to us from interest
income on the Trust Account balance;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the Trust Account not being subject to claims of third parties; or</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our financial performance.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
contained in this Form 10-K are based on our current expectations and beliefs concerning future developments and their potential effects
on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or
performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties
include, but are not limited to, those factors described under the section of this Form 10-K entitled &#8220;Risk Factors.&#8221; Should
one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in
material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities
laws.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 3; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summary of Risk Factors</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. The occurrence of one or more of the events or circumstances described in the section titled &#8220;<i>Risk
Factors</i>,&#8221; alone or in combination with other events or circumstances, may materially adversely affect our business, financial
condition and operating results. In that event, the trading price of our securities could decline, and you could lose all or part of your
investment. Such risks include, but are not limited to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our Public Shareholders (as defined below) may not be afforded an opportunity to vote on our proposed
initial Business Combination, and even if we hold a vote, holders of our Founder Shares (as defined below) will participate in such vote,
which means we may complete our initial Business Combination even though a majority of our Public Shareholders do not support such a combination.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we seek shareholder approval of our initial Business Combination, our initial shareholders and management
team have agreed to vote in favor of such initial Business Combination, regardless of how our Public Shareholders vote, and we may not
need any Public Shares (as defined below) in addition to our Founder Shares to be voted in favor of an initial Business Combination in
order to approve an initial Business Combination.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Your only opportunity to effect your investment decision regarding a potential Business Combination may
be limited to the exercise of your right to redeem your shares from us for cash.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The ability of our Public Shareholders to redeem their shares for cash may make our financial condition
unattractive to potential Business Combination targets, which may make it difficult for us to enter into a Business Combination with a
target.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The ability of our Public Shareholders to exercise redemption rights with respect to a large number of
our shares and the amount of deferred underwriting compensation may not allow us to complete the most desirable Business Combination or
optimize our capital structure, and may substantially dilute your investment in us.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If a shareholder fails to receive notice of our offer to redeem our Public Shares in connection with our
initial Business Combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">You will not be entitled to protections normally afforded to investors of many other blank check companies.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If the net proceeds of our Initial Public Offering (as defined below) and the sale of the Private Placement
Warrants (as defined below) not being held in the Trust Account are insufficient to allow us to operate for at least the duration of the
Completion Window (as defined below), it could limit the amount available to fund our search for a target business or businesses and complete
our initial Business Combination, and we will depend on loans from our sponsor, its affiliates or our management team to fund our search
and to complete our initial Business Combination.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect
our business, including our ability to negotiate and complete our initial Business Combination, and results of operations.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we are deemed to be an investment company under the Investment Company Act (as defined below), we may
be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to
complete our initial Business Combination.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our search for a Business Combination, and any target business with which we ultimately consummate a Business
Combination, may be materially adversely affected by the status of debt and equity markets.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 4; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Unlike some other similarly structured special purpose acquisition companies, our initial shareholders
will receive additional Class A Ordinary Shares (as defined below) if we issue certain shares to consummate an initial Business Combination
in order to provide anti-dilution protection to our initial shareholders.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our Sponsor (as defined below) will control the appointment of our board of directors until consummation
of our initial Business Combination and will hold a substantial interest in us. As a result, it will appoint all of our directors prior
to the consummation of our initial Business Combination and may exert a substantial influence on actions requiring a shareholder vote,
potentially in a manner that you do not support.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Transactions in connection with or in anticipation of our initial Business Combination and our structure
thereafter may not be tax-efficient to our shareholders and warrant holders. As a result of our business combination, our tax obligations
may be more complex, burdensome and/or uncertain.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may reincorporate in or transfer by way of continuation to another jurisdiction which may result in
taxes imposed on shareholders or warrant holders.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest
in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability
to complete our initial Business Combination.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">You will not have any rights or interests in funds from the Trust Account, except under certain limited
circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The</span> NYSE may delist our securities from
trading on its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional
trading restrictions.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The nominal purchase price paid by our Sponsor for the Founder Shares may result in significant dilution
to the implied value of your Public Shares upon the consummation of our initial Business Combination, and our sponsor is likely to make
a substantial profit on its investment in us in the event we consummate an initial Business Combination, even if the Business Combination
causes the trading price of our ordinary shares to materially decline.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">An investment in our securities may result in uncertain or adverse U.S. federal income tax consequences.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We are a blank check company with no operating history and no revenues, and you have no basis on which
to evaluate our ability to achieve our business objective.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Past performance by our management team, our directors, our advisors and their respective affiliates,
including investments and transactions in which they have participated and businesses with which they have been associated, may not be
indicative of future performance of an investment in the company.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may be a passive foreign investment company, or &#8220;PFIC,&#8221; which could result in adverse United
States federal income tax consequences to U.S. investors.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Excise Tax could be imposed
on redemptions of our ordinary shares if we were to become a &#8220;covered corporation&#8221; in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other risks
and uncertainties discussed in &#8220;<i>Risk Factors</i>&#8221; and elsewhere in this Annual Report on Form 10-K.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><!-- Field: Page; Sequence: 5; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><span id="a_001" style="display: inline-block;"></span>Part
I</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_002" style="display: inline-block;"></span>Item 1. Business</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>References in this Form
10-K to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; refer to Pyrophyte Acquisition Corp. II. References
to our &#8220;management&#8221; or our &#8220;management team&#8221; refer to our officers and directors.</i></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Introduction</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a blank check company
incorporated on May 1, 2025 as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange,
asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business Combination&#8221;).
We have 24 months from the closing of our initial public offering (&#8220;IPO&#8221; or &#8220;Initial Public Offering&#8221;), or until
such earlier liquidation date as our board of directors may approve (the &#8220;Completion Window&#8221;) to complete our initial Business
Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reviewed, and continue
to review, a number of opportunities to enter into a Business Combination, but we are not able to determine at this time whether we will
complete a Business Combination with any of the target businesses that we have reviewed or with any other target business. We may pursue
an acquisition opportunity in any industry, sector or geographic location. We also have neither engaged in any operations nor generated
any revenue to date. Based on our business activities, the Company is a &#8220;shell company&#8221; as defined under the Exchange Act
of 1934 (the &#8220;Exchange Act&#8221;) because we have no operations and nominal assets consisting almost entirely of cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration statement
for our IPO was declared effective on July 16, 2025. On July 18, 2025, we consummated the IPO of 17,500,000 units (the &#8220;Units&#8221;
and, with respect to the Class A Ordinary Shares included in the Units being offered, the &#8220;Public Shares&#8221; or &#8220;Class
A Ordinary Shares&#8221;). The Company granted the underwriters in the IPO (the &#8220;Underwriters&#8221;) a 45-day option to purchase
up to 2,625,000 additional Units to cover over-allotments, if any (the &#8220;Over-Allotment Option&#8221;). On July 24, 2025, the Company
closed the issuance and sale of an additional 2,541,150 Units in connection with the Underwriters&#8217; partial exercise of their Over-Allotment
Option. The Units were sold at a price of $10.00 per Unit, generating gross proceeds of $200,411,500. The balance of the Over-Allotment
Option was forfeited at that time. Each Unit consists of one Class A Ordinary Share and one-half of one redeemable warrant of the Company
(the &#8220;Public Warrants&#8221;), with each whole warrant entitling the holder thereof to purchase one Class A Ordinary Share at $11.50
per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 18, 2025, simultaneously
with the closing of our IPO, we consummated the sale of 5,050,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of
$1.00 per Private Placement Warrant, in a private placement to the Company&#8217;s Sponsor, Pyrophyte Acquisition II LLC, a Delaware limited
liability company (the &#8220;Sponsor&#8221;), generating gross proceeds of $5,050,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the IPO, on May 5, 2025, our Sponsor made a capital contribution of $25,000, or approximately $0.003 per share, to cover certain expenses
on our behalf in exchange for issuance of 7,255,952 Class B ordinary shares (the &#8220;Founder Shares&#8221;). In June 2025, our Sponsor
transferred 30,000 Founder Shares to each of our independent directors (for an aggregate of 90,000 Founder Shares) at the same per-share
price at which our Sponsor purchased such shares, or approximately $0.003 per share. The number of Founder Shares issued was determined
based on the expectation that such Founder Shares would represent 26.5% of the outstanding shares after the IPO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
IPO and the Over-Allotment Option, on July 24, 2025, an amount of $200,411,500 ($10.00 per Unit) from the net proceeds of the sale of
the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in the Trust Account (the &#8220;Trust
Account&#8221;) and will be held as cash or invested in U.S. government treasury obligations with a maturity of 185 days or less or in
money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government
treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company
to pay its taxes, if any, the proceeds from the Initial Public Offering and the sale of the Private Placement Warrants will not be released
from the Trust Account until the earliest of (i) the completion of the Company&#8217;s initial Business Combination or an earlier redemption
in connection with the commencement of the procedures to consummate the initial Business Combination if the Company determines it is desirable
to facilitate the completion of the initial Business Combination, (ii) the redemption of the Company&#8217;s Public Shares if the Company
is unable to complete the initial Business Combination the Completion Window, subject to applicable law, or (iii) the redemption of the
Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to amend the Company&#8217;s amended and restated
memorandum and articles of association to (A) modify the substance or timing of the Company&#8217;s obligation to allow redemption in
connection with the initial Business Combination or to redeem 100% of the Company&#8217;s Public Shares if the Company has not consummated
an initial Business Combination within the Completion Window or (B) with respect to any other material provisions relating to shareholders&#8217;
rights or pre-initial Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of
the Company&#8217;s creditors, if any, which could have priority over the claims of the Company&#8217;s Public Shareholders. To mitigate
the risk that might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer
that the Company holds investments in the Trust Account, the Company may, at any time in its own discretion, instruct the trustee to liquidate
the investments held in the Trust Account and instead to hold the funds in the Trust Account in an interest bearing bank demand deposit
account.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effecting Our Initial Business Combination</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not presently engaged
in, and we will not engage in, any operations for an indefinite period of time. We intend to effectuate our initial Business Combination
using cash from the proceeds of the Initial Public Offering and the private placement of the Private Placement Warrants, the proceeds
of the sale of our shares in connection with our initial Business Combination (including pursuant to forward purchase agreements or backstop
agreements we may enter into following the consummation of the Initial Public Offering or otherwise), shares issued to the owners of the
target, debt issued to bank or other lenders or the owners of the target, other securities issuances, or a combination of the foregoing.
We may seek to complete our initial Business Combination with a company or business that may be financially unstable or in its early stages
of development or growth, which would subject us to the numerous risks inherent in such companies and businesses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our initial Business Combination
is paid for using equity or debt securities, or not all of the funds released from the Trust Account are used for payment of the consideration
in connection with our initial Business Combination or used for redemptions of our Class A Ordinary Shares, we may use the balance of
the cash released to us from the Trust Account following the closing for general corporate purposes, including for maintenance or expansion
of operations of the post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial
Business Combination, to fund the purchase of other companies, or for working capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not selected any Business
Combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with
any Business Combination target. We may pursue an initial Business Combination in any business or industry and in any geographic region
but expect to focus on targets in the energy sector. Accordingly, there is no current basis for investors to evaluate the possible merits
or risks of the target business with which we may ultimately complete our initial Business Combination. Although our management will assess
the risks inherent in a particular target business with which we may combine, we cannot assure you that this assessment will result in
our identifying all risks that a target business may encounter. Furthermore, some of those risks may be outside of our control, meaning
that we can do nothing to control or reduce the chances that those risks will adversely affect a target business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek to raise additional
funds through a private offering of debt or equity securities in connection with the completion of our initial Business Combination and
we may effectuate our initial Business Combination using the proceeds of such offering rather than using the amounts held in the Trust
Account. In addition, we intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds
of the Initial Public Offering and the sale of the Private Placement Warrants, and, as a result, if the cash portion of the purchase price
exceeds the amount available from the Trust Account, net of amounts needed to satisfy any redemptions by holders of Public Units (&#8220;Public
Shareholders&#8221;), we may be required to seek additional financing to complete such proposed initial Business Combination. Subject
to compliance with applicable securities laws, we would expect to complete such financing only simultaneously with the completion of our
initial Business Combination. In the case of an initial Business Combination funded with assets other than the Trust Account assets, our
proxy materials or tender offer documents disclosing the initial Business Combination would disclose the terms of the financing and, only
if required by law, we would seek shareholder approval of such financing. There is no limitation on our ability to raise funds through
the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial Business
Combination, including pursuant to forward purchase agreements or backstop agreements we may enter into. At this time, we are not a party
to any arrangement or understanding with any third party with respect to raising any additional funds through the sale of securities or
otherwise. None of our Sponsor, officers, directors or shareholders is required to provide any financing to us in connection with or after
our initial Business Combination. For more information also see &#8220;<i>Item 1A. Risk Factors&#8212;Risks Relating to our Search for,
and Consummation of, or Inability to Consummate, a Business Combination&#8212;We may issue additional Class A Ordinary Shares or preference
shares to complete our initial Business Combination or under an employee incentive plan after completion of our initial Business Combination.
We may also issue Class A Ordinary Shares upon the conversion of the Class B ordinary shares at a ratio greater than one-to-one at the
time of our initial Business Combination as a result of the anti-dilution provisions contained therein. Any such issuances would dilute
the interest of our shareholders and likely present other risks</i>,&#8221; &#8220;<i>Risk Factors&#8212;Risks Relating to our Search
for, and Consummation of, or Inability to Consummate, a Business Combination&#8212;We may issue shares to investors in connection with
our initial Business Combination at a price which is less than $10.00 or the prevailing market price of our shares at that time, which
could dilute the interests of our existing shareholders and add costs</i>&#8221; or &#8220;<i>Risk Factors&#8212;Risks Relating to our
Search for, and Consummation of, or Inability to Consummate, a Business Combination&#8212;We may issue notes or other debt, or otherwise
incur substantial debt, to complete a Business Combination, which may adversely affect our leverage and financial condition and thus negatively
impact the value of our shareholders&#8217; investment in us</i>.&#8221;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 7; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sources of Target Business</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">We
anticipate that target business candidates will be brought to our attention from various unaffiliated sources, including investment bankers,
personal relationships, operating executives and private investment funds. Target businesses may be brought to our attention by such unaffiliated
sources as a result of being solicited by us through calls or mailings. These sources may also introduce us to target businesses in which
they think we may be interested on an unsolicited basis, since many of these sources will have read our registration statement and know
what types of businesses we are targeting. Our officers and directors, as well as their affiliates, may also bring to our attention target
business candidates that they become aware of through their business contacts as a result of formal or informal inquiries or discussions
they may have, as well as attending trade shows or conventions. In addition, we expect to receive a number of proprietary deal flow opportunities
that would not otherwise necessarily be available to us as a result of the track record and business relationships of our officers and
directors. While we do not presently anticipate engaging the services of professional firms or other individuals that specialize in business
acquisitions on any formal basis, we may engage these firms or other individuals in the future, in which event we may pay a finder&#8217;s
fee, consulting fee or other compensation to be determined in an arm&#8217;s length negotiation based on the terms of the transaction.</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">Prior
to or in connection with the completion of our initial Business Combination, there may be payment by the company to our officers, independent
directors, advisors, or their respective affiliates, of a finder&#8217;s fee, advisory fee, consulting fee or success fee for any services
they render in order to effectuate the completion of our initial Business Combination, which, if made prior to the completion of our initial
Business Combination, will be paid from funds held outside the Trust Account.</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-style: normal; font-weight: normal">&#160;</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">We
will engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not
otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management determines
is in our best interest to pursue. Payment of a finder&#8217;s fee is customarily tied to completion of a transaction, in which case any
such fee will be paid out of the funds held in the Trust Account.</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">We
are not prohibited from pursuing an initial Business Combination with a company that is affiliated with our Sponsor, officers, directors
or advisors (or their respective affiliates or related entities). In the event that we seek to complete our initial Business Combination
with a company that is affiliated (as defined in our amended and restated memorandum and articles of association) with our Sponsor, officers,
directors or advisors (or their respective affiliates or related entities), we, or a committee of independent directors, will obtain an
opinion from an independent investment banking firm which is a member of FINRA or an independent firm that commonly renders valuation
opinions for the type of company we are seeking to acquire or from an independent accounting firm that our initial Business Combination
is fair to our Company from a financial point of view. We are not required to obtain such an opinion in any other context.</span></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 8; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evaluation of a Target Business and
Structuring of Our Initial Business Combination</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In evaluating a prospective
target business, we expect to conduct a due diligence review which may encompass, among other things, meetings with incumbent management
and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as applicable, as well as a review of
financial, operational, legal and other information which will be made available to us. If we determine to move forward with a particular
target, we will proceed to structure and negotiate the terms of the Business Combination transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to select
and evaluate a target business and to structure and complete our initial Business Combination, and the costs associated with this process,
are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of,
and negotiation with, a prospective target business with which our initial Business Combination is not ultimately completed will result
in our incurring losses and will reduce the funds we can use to complete another Business Combination.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lack of Business Diversification</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For an indefinite period of
time after the completion of our initial Business Combination, the prospects for our success may depend entirely on the future performance
of a single business. Unlike other entities that have the resources to complete Business Combinations with multiple entities in one or
several industries, it is probable that we will not have the resources to diversify our operations and mitigate the risks of being in
a single line of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">By completing our initial
Business Combination with only a single entity, our lack of diversification may:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">subject us to negative economic, competitive and regulatory developments, any or all of which may have
a substantial adverse impact on the particular industry in which we operate after our initial Business Combination, and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">cause us to depend on the marketing and sale of a single product or limited number of products or services.</td></tr></tbody></table><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limited Ability to Evaluate the Target&#8217;s
Management Team</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we intend to closely
scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial Business Combination
with that business, our assessment of the target business&#8217;s management may not prove to be correct. In addition, the future management
may not have the necessary skills, qualifications or abilities to manage a public company. Furthermore, the future role of members of
our management team, if any, in the target business cannot presently be stated with any certainty. The determination as to whether any
of the members of our management team will remain with the combined company will be made at the time of our initial Business Combination.
While it is possible that one or more of our directors will remain associated in some capacity with us following our initial Business
Combination, it is unlikely that any of them will devote their full efforts to our affairs subsequent to our initial Business Combination.
Moreover, we cannot assure you that members of our management team will have significant experience or knowledge relating to the operations
of the particular target business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
any of our key personnel will remain in senior management or advisory positions with the combined company. The determination as to whether
any of our key personnel will remain with the combined company will be made at the time of our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following a Business Combination,
we may seek to recruit additional managers to supplement the incumbent management of the target business. We cannot assure you that we
will have the ability to recruit additional managers, or that additional managers will have the requisite skills, knowledge or experience
necessary to enhance the incumbent management.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 9; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders May Not Have the Ability
to Approve our Initial Business Combination</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may conduct redemptions
without a shareholder vote pursuant to the tender offer rules of the SEC subject to the provisions of our amended and restated memorandum
and articles of association. However, we will seek shareholder approval if it is required by applicable law or stock exchange listing
requirement, or we may decide to seek shareholder approval for business or other reasons.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the New York Stock
Exchange&#8217;s (&#8220;NYSE&#8221;) listing rules, shareholder approval would be required for our initial Business Combination if, for
example:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We issue ordinary shares that will be equal to or in excess of 20% of the number of our ordinary shares
then outstanding (other than in a public offering);</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Any of our directors, officers or substantial shareholders (as defined by NYSE rules) has a 5% or greater
interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be
acquired or otherwise and the present or potential issuance of ordinary shares could result in an increase in outstanding ordinary shares
or voting power of 5% or more; or</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The issuance or potential issuance of ordinary shares will result in our undergoing a change of control.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decision as to whether
we will seek shareholder approval of a proposed Business Combination in those instances in which shareholder approval is not required
by applicable law or stock exchange listing requirements will be made by us, solely in our discretion, and will be based on business and
legal reasons, which include a variety of factors, including, but not limited to: (i)&#160;the timing of the transaction, including in
the event we determine shareholder approval would require additional time and there is either not enough time to seek shareholder approval
or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the company; (ii)&#160;the
expected cost of holding a shareholder vote; (iii)&#160;the risk that the shareholders would fail to approve the proposed Business Combination;
(iv)&#160;other time and budget constraints of the company; and (v)&#160;additional legal complexities of a proposed Business Combination
that would be time-consuming&#160;and burdensome to present to shareholders.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Permitted Purchases of Our Securities</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we seek shareholder approval
of our initial Business Combination and we do not conduct redemptions in connection with our initial Business Combination pursuant to
the tender offer rules, our Sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase Public Shares
or warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial Business
Combination, although they are under no obligation or duty to do so. Such a purchase may include a contractual acknowledgment that such
shareholder, although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise
its redemption rights. In the event that our Sponsor, initial shareholders, directors, officers, advisors and their affiliates purchase
shares in privately negotiated transactions from Public Shareholders who have already elected to exercise their redemption rights, such
selling shareholders would be required to revoke their prior elections to redeem their shares. It is intended that, if Rule&#160;10b-18&#160;would
apply to purchases by our Sponsor, initial shareholders, directors, officers, advisors and their affiliates, then such purchases will
comply with Rule&#160;10b-18&#160;under the Exchange&#160;Act, to the extent it applies, which provides a safe harbor for purchases made
under certain conditions, including with respect to timing, pricing and volume of purchases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, at any time
at or prior to our initial Business Combination, subject to applicable securities laws (including with respect to material nonpublic information),
our Sponsor, initial shareholders, directors, officers, advisors and their affiliates may enter into transactions with investors and others
to provide them with incentives to acquire Public Shares, vote their Public Shares in favor of our initial Business Combination or not
redeem their Public Shares. However, they have no current commitments, plans or intentions to engage in such transactions and have not
formulated any terms or conditions for any such transactions. None of the funds in the Trust Account will be used to purchase Public Shares
or warrants in such transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of any such transactions
could be to (1)&#160;increase the likelihood of obtaining shareholder approval of the Business Combination, (2)&#160;reduce the number
of Public Warrants outstanding and/or increase the likelihood of approval on any matters submitted to the Public Warrant holders for approval
in connection with our initial Business Combination or (3)&#160;satisfy a closing condition in an agreement with a target that requires
us to have a minimum net worth or a certain amount of cash at the closing of our initial Business Combination, where it appears that such
requirement would otherwise not be met. Any such purchases of our securities may result in the completion of our initial Business Combination
that may not otherwise have been possible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 10; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if such purchases
are made, the public &#8220;float&#8221; of our securities may be reduced and the number of beneficial holders of our securities may be
reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities
exchange.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor, initial shareholders,
directors, officers, advisors and their affiliates anticipate that they may identify the shareholders with whom our Sponsor, initial shareholders,
directors, officers, advisors and their affiliates may pursue privately negotiated transactions by either the shareholders contacting
us directly or by our receipt of redemption requests submitted by shareholders (in the case of Class A Ordinary Shares) following our
mailing of proxy materials in connection with our initial Business Combination. To the extent that our Sponsor, initial shareholders,
directors, officers, advisors and their affiliates enter into a private transaction, they would identify and contact only potential selling
or redeeming shareholders who have expressed their election to redeem their shares for a pro rata share of the Trust Account or vote against
our initial Business Combination, whether or not such shareholder has already submitted a proxy with respect to our initial Business Combination
but only if such shares have not already been voted at the general meeting related to our initial Business Combination. Our Sponsor, initial
shareholders, directors, officers, advisors and their affiliates will select which shareholders to purchase shares from based on the negotiated
price and number of shares and any other factors that they may deem relevant, and will be restricted from purchasing shares if such purchases
do not comply with Regulation&#160;M under the Exchange&#160;Act and the other federal securities laws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor, initial shareholders,
directors, officers, advisors and their affiliates will be restricted from making purchases of shares if the purchases would violate Section&#160;9(a)(2)&#160;or
Rule&#160;10b-5&#160;of the Exchange&#160;Act. Any such purchases will be reported pursuant to Section&#160;13 and Section&#160;16 of
the Exchange&#160;Act to the extent such purchasers are subject to such reporting requirements. Additionally, in the event our Sponsor,
initial shareholders, directors, officers, advisors and their affiliates were to purchase Public Shares or warrants from Public Shareholders
after the announcement of our initial Business Combination, such purchases would be structured in compliance with the requirements of
Rule&#160;14e-5&#160;under the Exchange&#160;Act including, in pertinent part, through adherence to the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our registration statement/proxy statement filed for our Business Combination transaction would disclose
the possibility that our Sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase Public Shares
or warrants from Public Shareholders outside the redemption process, along with the purpose of such purchases;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">if our Sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase
Public Shares or warrants from Public Shareholders, they would do so at a price no higher than the price offered through our redemption
process;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our registration statement/proxy statement filed for our Business Combination transaction would include
a representation that any of our securities purchased by our Sponsor, initial shareholders, directors, officers, advisors and their affiliates
would not be voted in favor of approving the Business Combination transaction;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our Sponsor, initial shareholders, directors, officers, advisors and their affiliates would not possess
any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive such rights;
and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">we would disclose in a Current Report on Form&#160;8-K, before our security holder meeting to approve
the Business Combination transaction, the following material items:</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the amount of our securities purchased outside of the redemption
offer by our Sponsor, initial shareholders, directors, officers, advisors and their affiliates, along with the purchase price;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the purpose of the purchases by our Sponsor, initial shareholders,
directors, officers, advisors and their affiliates;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the impact, if any, of the purchases by our Sponsor, initial
shareholders, directors, officers, advisors and their affiliates on the likelihood that the Business Combination transaction will be
approved;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the identities of our security holders who sold to our Sponsor,
initial shareholders, directors, officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security
holders (e.g., 5% security holders) who sold to our Sponsor, initial shareholders, directors, officers, advisors and their affiliates;
and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the number of our securities for which we have received redemption
requests pursuant to our redemption offer.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt"></p><!-- Field: Page; Sequence: 11; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -26pt">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see &#8220;<i>Risk Factors&#8212;If
we seek shareholder approval of our initial Business Combination, our Sponsor, initial shareholders, directors, officers, advisors and
their affiliates may elect to purchase shares or Public Warrants from Public Shareholders, which may influence a vote on a proposed Business
Combination and reduce the public &#8220;float&#8221; of our Class A Ordinary Shares or Public Warrants</i>.&#8221;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Redemption Rights for Public Shareholders
Upon Completion of Our Initial Business Combination</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide our Public Shareholders with the opportunity to redeem,
regardless of whether they abstain, vote for, or vote against our initial Business Combination, all or a portion of their Public Shares
in connection with the completion of our initial Business Combination at a per-share&#160;price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account calculated as of two&#160;business days prior to the consummation of the initial Business
Combination, including interest earned on the funds held in the Trust Account (net of taxes paid or payable), divided by the number of
then issued and outstanding Public Shares, subject to the limitations and on the conditions described herein. The amount in the Trust
Account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem
their shares will not be reduced by the deferred underwriting commissions we will pay to the Underwriters. Our Sponsor, officers and directors
have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their
Founder Shares and any Public Shares they may hold in connection with the completion of our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proposed initial Business
Combination may impose a minimum cash requirement for (i)&#160;cash consideration to be paid to the target or its owners, (ii)&#160;cash
for working capital or other general corporate purposes or (iii)&#160;the retention of cash to satisfy other conditions. In the event
the aggregate cash consideration we would be required to pay for all Public Shares that are validly submitted for redemption plus any
amount required to satisfy cash conditions pursuant to the terms of the proposed initial Business Combination exceed the aggregate amount
of cash available to us, we will not complete the initial Business Combination or redeem any shares, and all Public Shares submitted for
redemption will be returned to the holders thereof. We may, however, raise funds through the issuance of equity-linked&#160;securities
or through loans, advances or other indebtedness in connection with our initial Business Combination, including pursuant to forward purchase
agreements or backstop arrangements we may enter into following consummation of the Initial Public Offering, in order to, among other
reasons, satisfy such net tangible assets or minimum cash requirements.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manner of Conducting Redemptions</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide our Public
Shareholders with the opportunity to redeem, regardless of whether they abstain, vote for, or vote against our initial Business Combination,
all or a portion of their Public Shares in connection with the completion of our initial Business Combination either (i)&#160;in connection
with a general meeting called to approve the Business Combination or (ii)&#160;without a shareholder vote by means of a tender offer.
The decision as to whether we will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made
by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms
of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirement or whether
we were deemed to be a foreign private issuer (which would require a tender offer rather than seeking shareholder approval under SEC rules),
as described above under the heading &#8220;<i>Shareholders May Not Have the Ability to Approve Our Initial Business Combination</i>.&#8221;
Asset acquisitions and share purchases would not typically require shareholder approval while direct mergers with our Company (other than
with a 90% subsidiary of ours) and any transactions where we issue more than 20% of our issued and outstanding ordinary shares or seek
to amend our amended and restated memorandum and articles of association would require shareholder approval. So long as we obtain and
maintain a listing for our securities on the NYSE, we will be required to comply with the NYSE&#8217;s shareholder approval rules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 12; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirement that we provide
our Public Shareholders with the opportunity to redeem their Public Shares by one of the two methods listed above are contained in provisions
of our amended and restated memorandum and articles of association and will apply whether or not we maintain our registration under the
Exchange&#160;Act or our listing on the NYSE.&#160;Such provisions may be amended if approved by a special resolution, which requires
the affirmative vote of at least two-thirds&#160;of the votes cast by such shareholders as, being entitled to do so, vote in person or,
where proxies are allowed, by proxy at the applicable general meeting of the Company, so long as we offer redemption in connection with
such amendment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we provide our Public
Shareholders with the opportunity to redeem their Public Shares in connection with a general meeting, we will, pursuant to our amended
and restated memorandum and articles of association:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation&#160;14A of the
Exchange&#160;Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">file proxy materials with the SEC.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that we seek
shareholder approval of our initial Business Combination, we will distribute proxy materials and, in connection therewith, provide our
Public Shareholders with the redemption rights described above upon completion of the initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we seek shareholder approval,
we will complete our initial Business Combination only if we obtain the approval of an ordinary resolution under Cayman Islands law and
our amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes
cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general
meeting of the company. A quorum for such meeting will be present if the holders of at least one third of issued and outstanding shares
entitled to vote at the meeting are represented in person or by proxy. Our Sponsor, officers and directors will count toward this quorum
and, pursuant to the letter agreement, our Sponsor, officers and directors have agreed to vote their Founder Shares and any Public Shares
purchased during or after the Initial Public Offering (including in open market and privately-negotiated&#160;transactions) in favor of
our initial Business Combination (including any proposals recommended by the Company&#8217;s board of directors in connection with such
Business Combination) (except with respect to any Public Shares which may not be voted in favor of approving the Business Combination
transaction in accordance with the requirements of Rule&#160;14e-5&#160;under the Exchange&#160;Act and any SEC interpretations or guidance
relating thereto). For purposes of seeking approval of an ordinary resolution, non-votes&#160;will have no effect on the approval of our
initial Business Combination once a quorum is obtained. As a result, in addition to our initial shareholders&#8217; Founder Shares, we
would need 6,407,716, or approximately 32.0%, of the 20,041,150 Public Shares sold in the Initial Public Offering to be voted in favor
of an initial Business Combination in order to have our initial Business Combination approved, assuming all outstanding shares are voted and the parties to the letter agreement do not acquire any Class A Ordinary Shares. Assuming
that only the holders of one-third&#160;of our issued and outstanding ordinary shares, representing a quorum under our amended and restated
memorandum and articles of association, vote their ordinary shares at a general meeting of the company, we will not need any Public Shares
in addition to our Founder Shares to be voted in favor of an initial Business Combination in order to approve an initial Business Combination.
However, if our initial Business Combination is structured as a statutory merger or consolidation with another company under Cayman Islands
law, the approval of our initial Business Combination will require the approval of a special resolution, which requires the affirmative
vote of at least two-thirds&#160;of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies
are allowed, by proxy at the applicable general meeting of the company. Assuming all outstanding shares are voted at an extraordinary
general meeting of the company and the parties to the letter agreement do not acquire
any Class A Ordinary Shares, we will need 10,952,194, or approximately 54.7%, Public Shares in addition to our Founder Shares to be voted
in favor of an initial Business Combination in order to approve an initial Business Combination. Assuming that only the holders of one-third&#160;of
our issued and outstanding ordinary shares, representing a quorum under our amended and restated memorandum and articles of association,
vote their ordinary shares at an extraordinary general meeting of the Company, we will not need any Public Shares in addition to our Founder
Shares to be voted in favor of an initial Business Combination in order to approve an initial Business Combination. In addition, prior
to the closing of our initial Business Combination, only holders of our Class&#160;B ordinary shares (i)&#160;will have the right to appoint
and remove directors prior to or in connection with the completion of our initial Business Combination and (ii)&#160;will be entitled
to vote on continuing our Company in a jurisdiction outside the Cayman Islands (including any special resolution required to amend our
constitutional documents or to adopt new constitutional documents, in each case, as a result of our approving a transfer by way of continuation
in a jurisdiction outside the Cayman Islands). These quorum and voting thresholds, and the voting agreement of our Sponsor, officers and
directors, may make it more likely that we will consummate our initial Business Combination. Each Public Shareholder may elect to redeem
their Public Shares irrespective of whether they vote for or against the proposed transaction, or whether they do not vote or abstain
from voting on the proposed transaction, or whether they were a Public Shareholder on the record date for the general meeting held to
approve the proposed transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 13; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a shareholder vote is not
required and we do not decide to hold a shareholder vote for business or other legal reasons, we will:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">conduct the redemptions pursuant to Rule&#160;13e-4&#160;and Regulation&#160;14E of the Exchange&#160;Act,
which regulate issuer tender offers, and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">file tender offer documents with the SEC prior to completing our initial Business Combination which contain
substantially the same financial and other information about the initial Business Combination and the redemption rights as is required
under Regulation&#160;14A of the Exchange&#160;Act, which regulates the solicitation of proxies</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event we conduct redemptions
pursuant to the tender offer rules, our offer to redeem will remain open for at least 20&#160;business days, in accordance with Rule&#160;14e-1(a)&#160;under
the Exchange&#160;Act, and we will not be permitted to complete our initial Business Combination until the expiration of the tender offer
period. In addition, the tender offer will be conditioned on Public Shareholders not tendering more than the number of Public Shares we
are permitted to redeem. If Public Shareholders tender more shares than we have offered to purchase, we will withdraw the tender offer
and not complete the initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the public announcement
of our initial Business Combination, if we elect to conduct redemption pursuant to the tender offer rules, we or our Sponsor will terminate
any plan established in accordance with Rule&#160;10b5-1&#160;to purchase our Class A Ordinary Shares in the open market, in order to
comply with Rule&#160;14e-5&#160;under the Exchange&#160;Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to require our Public
Shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in &#8220;street name,&#8221;
to, at the holder&#8217;s option, either deliver their share certificates to our transfer agent or deliver their shares to our transfer
agent electronically using the Depository Trust Company&#8217;s DWAC (Deposit/Withdrawal At Custodian) system, prior to the date set forth
in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two&#160;business
days prior to the scheduled vote on the proposal to approve the initial Business Combination. In addition, if we conduct redemptions in
connection with a shareholder vote, we intend to require a Public Shareholder seeking redemption of its Public Shares to also submit a
written request for redemption to our transfer agent two&#160;business days prior to the scheduled vote in which the name of the beneficial
owner of such shares is included. The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our
Public Shares in connection with our initial Business Combination will indicate whether we are requiring Public Shareholders to satisfy
such delivery requirements. We believe that this will allow our transfer agent to efficiently process any redemptions without the need
for further communication or action from the redeeming Public Shareholders, which could delay redemptions and result in additional administrative
cost. If the proposed initial Business Combination is not approved and we continue to search for a target company, we will promptly return
any certificates or shares delivered by Public Shareholders who elected to redeem their shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proposed initial Business
Combination may impose a minimum cash requirement for (i)&#160;cash consideration to be paid to the target or its owners, (ii)&#160;cash
for working capital or other general corporate purposes or (iii)&#160;the retention of cash to satisfy other conditions. In the event
the aggregate cash consideration we would be required to pay for all Public Shares that are validly submitted for redemption plus any
amount required to satisfy cash conditions pursuant to the terms of the proposed initial Business Combination exceed the aggregate amount
of cash available to us, we will not complete the initial Business Combination or redeem any shares, and all Public Shares submitted for
redemption will be returned to the holders thereof. We may, however, raise funds through the issuance of equity or equity-linked&#160;securities
or through loans, advances or other indebtedness in connection with our initial Business Combination, including pursuant to forward purchase
agreements or backstop arrangements we may enter into following consummation of the Initial Public Offering, in order to, among other
reasons, satisfy such net tangible assets or minimum cash requirements.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 14; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limitation on Redemption upon Completion
of Our Initial Business Combination if We Seek Shareholder Approval</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we seek shareholder approval
of our initial Business Combination and we do not conduct redemptions in connection with our initial Business Combination pursuant to
the tender offer rules, our amended and restated memorandum and articles of association provide that a Public Shareholder, together with
any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as
defined under Section&#160;13 of the Exchange&#160;Act), will be restricted from seeking redemption rights with respect to more than an
aggregate of 15% of the Public Shares without our prior consent, which we refer to as the &#8220;Excess Shares.&#8221; We believe this
restriction will discourage shareholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their
ability to exercise their redemption rights against a proposed Business Combination as a means to force us undesirable terms. Absent this
provision, a Public Shareholder holding more than an aggregate of 15% of the shares sold in the Initial Public Offering could threaten
to exercise its redemption rights if such holder&#8217;s shares are not purchased by us, our Sponsor or our management at a premium to
the then-current&#160;market price or on other undesirable terms. By limiting our shareholders&#8217; ability to redeem no more than 15%
of the shares sold in the Initial Public Offering without our prior consent, we believe we will limit the ability of a small group of
shareholders to unreasonably attempt to block our ability to complete our initial Business Combination, particularly in connection with
a Business Combination with a target that requires as a closing condition that we have a minimum net worth or a certain amount of cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, we would not be restricting
our shareholders&#8217; ability to vote all of their shares (including Excess Shares) for or against our initial Business Combination.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivering Share Certificates in Connection
with the Exercise of Redemption Rights</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described above, we intend
to require our Public Shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in
&#8220;street name,&#8221; to, at the holder&#8217;s option, either deliver their share certificates to our transfer agent or deliver
their shares to our transfer agent electronically using the Depository Trust Company&#8217;s DWAC (Deposit/Withdrawal At Custodian) system,
prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date
may be up to two&#160;business days prior to the scheduled vote on the proposal to approve the initial Business Combination. In addition,
if we conduct redemptions in connection with a shareholder vote, we intend to require a Public Shareholder seeking redemption of its Public
Shares to also submit a written request for redemption to our transfer agent two&#160;business days prior to the scheduled vote in which
the name of the beneficial owner of such shares is included. The proxy materials or tender offer documents, as applicable, that we will
furnish to holders of our Public Shares in connection with our initial Business Combination will indicate whether we are requiring Public
Shareholders to satisfy such delivery requirements. Accordingly, a Public Shareholder would have up to two&#160;business days prior to
the scheduled vote on the initial Business Combination if we distribute proxy materials, or from the time we send out our tender offer
materials until the close of the tender offer period, as applicable, to submit or tender its shares if it wishes to seek to exercise its
redemption rights. In the event that a shareholder fails to comply with these or any other procedures disclosed in the proxy or tender
offer materials, as applicable, its shares may not be redeemed. Given the relatively short exercise period, it is advisable for shareholders
to use electronic delivery of their Public Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a nominal cost associated
with the above-referenced&#160;process and the act of certificating the shares or delivering them through the DWAC system. The transfer
agent will typically charge the broker submitting or tendering shares a fee of approximately $100 and it would be up to the broker whether
or not to pass this cost on to the redeeming holder. However, this fee would be incurred regardless of whether or not we require holders
seeking to exercise redemption rights to submit or tender their shares. The need to deliver shares is a requirement of exercising redemption
rights regardless of the timing of when such delivery must be effectuated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any request to redeem such
shares, once made, may be withdrawn at any time up to the date set forth in the proxy materials or tender offer documents, as applicable.
Furthermore, if a holder of a public share delivered its certificate in connection with an election of redemption rights and subsequently
decides prior to the applicable date not to elect to exercise such rights, such holder may simply request that the transfer agent return
the certificate (physically or electronically). It is anticipated that the funds to be distributed to holders of our Public Shares electing
to redeem their shares will be distributed promptly after the completion of our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 15; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our initial Business Combination
is not approved or completed for any reason, then our Public Shareholders who elected to exercise their redemption rights would not be
entitled to redeem their shares for the applicable pro rata share of the Trust Account. In such case, we will promptly return any certificates
delivered by public holders who elected to redeem their shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our initial proposed Business
Combination is not completed, we may continue to try to complete a Business Combination with a different target until the end of the Completion
Window.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Redemption of Public Shares and Liquidation
if No Business Combination</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated memorandum
and articles of association provide that we will have only the duration of the Completion Window to complete our initial Business Combination.
If we have not completed our initial Business Combination within such time period, we will as promptly as reasonably possible but not
more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share&#160;price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the
Trust Account (which interest shall be net of amounts not previously released to us for permitted withdrawals and up to $100,000 of interest
to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish
Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), subject
to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will
be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless if we fail to complete
our initial Business Combination within the Completion Window.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor, officers and
directors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from
the Trust Account with respect to any Founder Shares held by them if we fail to complete our initial Business Combination within the Completion
Window, although they will entitled to liquidating distributions from assets outside the Trust Account. However, if our Sponsor or management
team acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust
Account with respect to such Public Shares if we fail to complete our initial Business Combination within the allotted Completion Window.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor, officers, directors
and director nominees have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our amended and
restated memorandum and articles of association (A)&#160;to modify the substance or timing of our obligation to allow redemption in connection
with our initial Business Combination or to redeem 100% of our Public Shares if we do not complete our initial Business Combination within
the Completion Window or (B)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial&#160;Business
Combination activity, in each case unless we provide our Public Shareholders with the opportunity to redeem their Public Shares upon approval
of any such amendment at a per-share&#160;price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account,
including interest earned on the funds held in the Trust Account (net of taxes paid or payable), divided by the number of then issued
and outstanding Public Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that all costs and
expenses associated with implementing our plan of dissolution, as well as payments to any creditors, will be funded from amounts remaining
out of the approximately $1,500,000 of proceeds held outside the Trust Account, although we cannot assure you that there will be sufficient
funds for such purpose. However, if those funds are not sufficient to cover the costs and expenses associated with implementing our plan
of dissolution, to the extent that there is any interest accrued in the Trust Account not required to pay taxes, we may request the trustee
to release to us an additional amount of up to $100,000 of such accrued interest to pay those costs and expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to expend all of
the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, other than the proceeds deposited in the
Trust Account, and without taking into account interest, if any, earned on the Trust Account less taxes paid or payable, the per-share&#160;redemption
amount received by shareholders upon our dissolution would be approximately $10.00. The proceeds deposited in the Trust Account could,
however, become subject to the claims of our creditors which would have higher priority than the claims of our Public Shareholders. We
cannot assure you that the actual per-share&#160;redemption amount received by shareholders will not be substantially less than $10.00.
While we intend to pay such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors&#8217;
claims.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 16; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we will seek to have
all vendors, service providers, prospective target businesses and other entities with which we do business execute agreements with us
waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit of our Public Shareholders,
there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from
bringing claims against the Trust Account including but not limited to fraudulent inducement, breach of fiduciary responsibility or other
similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect
to a claim against our assets, including the funds held in the Trust Account. If any third party refuses to execute an agreement waiving
such claims to the monies held in the Trust Account, our management will consider whether competitive alternatives are reasonably available
to us and will only enter into an agreement with such third party if management believes that such third party&#8217;s engagement would
be in the best interests of the company under the circumstances. Examples of possible instances where we may engage a third party that
refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management
to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable
to find a service provider willing to execute a waiver. WithumSmith+Brown, PC, our independent registered public accounting firm, and
the Underwriters of the Initial Public Offering will not execute agreements with us waiving such claims to the monies held in the Trust
Account. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result
of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the Trust Account for any
reason. In order to protect the amounts held in the Trust Account, our Sponsor has agreed that it will be liable to us if and to the extent
any claims by a third party for services rendered or products sold to us (except for the Company&#8217;s independent registered public
accounting firm), or a prospective target business with which we have entered into a written letter of intent, confidentiality or other
similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i)&#160;$10.00
per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust
Account, if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes paid or payable and
up to $100,000 of interest to pay liquidation expenses, provided that such liability will not apply to any claims by a third party or
prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver
is enforceable) nor will it apply to any claims under our indemnity of the Underwriters of the Initial Public Offering against certain
liabilities, including liabilities under the Securities Act. However, we have not asked our Sponsor to reserve for such indemnification
obligations, nor have we independently verified whether our Sponsor has sufficient funds to satisfy its indemnity obligations and we believe
that our Sponsor&#8217;s only assets are securities of our company. Therefore, we cannot assure you that our Sponsor would be able to
satisfy those obligations. As a result, if any such claims were successfully made against the Trust Account, the funds available for our
initial Business Combination and redemptions could be reduced to less than $10.00 per Public Share. In such event, we may not be able
to complete our initial Business Combination, and you would receive such lesser amount per share in connection with any redemption of
your Public Shares. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims
by vendors and prospective target businesses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the proceeds
in the Trust Account are reduced below the lesser of (i)&#160;$10.00 per Public Share and (ii)&#160;the actual amount per Public Share
held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in the
value of the trust assets, in each case less taxes paid or payable and up to $100,000 of interest to pay liquidation expenses, and our
Sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to
a particular claim, our independent directors would determine whether to take legal action against our Sponsor to enforce its indemnification
obligations. While we currently expect that our independent directors would take legal action on our behalf against our Sponsor to enforce
its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment may choose
not to do so in any particular instance if, for example, the cost of such legal action is deemed by the independent directors to be too
high relative to the amount recoverable or if the independent directors determine that a favorable outcome is not likely. Accordingly,
we cannot assure you that due to claims of creditors the actual value of the per-share&#160;redemption price will not be less than $10.00
per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 17; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will seek to reduce the
possibility that our Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service
providers, prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title,
interest or claim of any kind in or to monies held in the Trust Account. Our Sponsor will also not be liable as to any claims under our
indemnity of the Underwriters against certain liabilities, including liabilities under the Securities Act. We will have access to up to
approximately $1,500,000 from the proceeds of the Initial Public Offering with which to pay any such potential claims (including costs
and expenses incurred in connection with our liquidation, currently estimated to be no more than approximately $100,000). In the event
that we liquidate and it is subsequently determined that the reserve for claims and liabilities is insufficient, shareholders who received
funds from our Trust Account could be liable for claims made by creditors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we file a bankruptcy or
winding-up&#160;petition or an involuntary bankruptcy or winding-up&#160;petition is filed against us that is not dismissed, the proceeds
held in the Trust Account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy or insolvency
estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy or insolvency
claims deplete the Trust Account, we cannot assure you we will be able to return $10.00 per share to our Public Shareholders. Additionally,
if we file a bankruptcy or winding-up&#160;petition or an involuntary bankruptcy or winding-up&#160;petition is filed against us that
is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy/insolvency
laws as either a &#8220;preferential transfer&#8221; or a &#8220;fraudulent conveyance, preference or disposition.&#8221; As a result,
a liquidator or bankruptcy, insolvency or other court could seek to recover some or all amounts received by our shareholders. Furthermore,
our board of directors may be viewed as having breached its fiduciary duty to us or our creditors and/or may have acted in bad faith,
and thereby exposing itself and our Company to claims of punitive damages, by paying Public Shareholders from the Trust Account prior
to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Public Shareholders will
be entitled to receive funds from the Trust Account only (i)&#160;in the event of the redemption of our Public Shares if we do not complete
our initial Business Combination within the Completion Window, (ii)&#160;in connection with a shareholder vote to amend our amended and
restated memorandum and articles of association (A)&#160;to modify the substance or timing of our obligation to allow redemption in connection
with our initial Business Combination or to redeem 100% of our Public Shares if we do not complete our initial Business Combination within
the Completion Window or (B)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial&#160;Business
Combination activity or (iii)&#160;if they redeem their respective shares for cash in connection with the completion of our initial Business
Combination. In no other circumstances will a shareholder have any right or interest of any kind to or in the Trust Account. In the event
that we seek shareholder approval in connection with our initial Business Combination, a shareholder&#8217;s voting in connection with
the Business Combination alone will not result in a shareholder&#8217;s redeeming its shares to us for an applicable pro rata share of
the Trust Account. Such shareholder must have also exercised its redemption rights described above. These provisions of our amended and
restated memorandum and articles of association, like all provisions of our amended and restated memorandum and articles of association,
may be amended with a shareholder vote.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In identifying, evaluating
and selecting a target business for our initial Business Combination, we may encounter competition from other entities having a business
objective similar to ours, including other special purpose acquisition companies, private equity groups and leveraged buyout funds, public
companies and operating businesses seeking strategic acquisitions. Many of these entities are well established and have extensive experience
identifying and effecting Business Combinations directly or through affiliates. Moreover, many of these competitors possess similar or
greater financial, technical, human and other resources than us. Our ability to acquire larger target businesses will be limited by our
available financial resources. This inherent limitation gives others an advantage in pursuing the acquisition of a target business. Furthermore,
our obligation to pay cash in connection with our Public Shareholders who exercise their redemption rights may reduce the resources available
to us for our initial Business Combination and our issued and outstanding warrants, and the future dilution they potentially represent,
may not be viewed favorably by certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully
negotiating an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 18; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;">Employees</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have two officers:
Bernard Duroc-Danner and Sten Gustafson. These individuals are not obligated to devote any specific number of hours to our matters but
they intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial Business Combination.
The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial
Business Combination and the stage of the Business Combination process we are in. We do not intend to have any full-time employees prior
to the completion of our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;">Available Information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to file Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q with the SEC on a regular basis, and are required to disclose certain material
events (e.g., changes in corporate control, acquisitions or dispositions of a significant amount of assets other than in the ordinary
course of business and bankruptcy) in a Current Report on Form 8-K. The SEC maintains an Internet website that contains reports, proxy
and information statements and other information regarding issuers that file electronically with the SEC. The SEC&#8217;s Internet website
is located at <i>http://www.sec.gov</i>. In addition, we will provide copies of these documents without charge upon request from us in
writing at 3262 Westheimer Road, Suite 706, Houston, Texas 77098 or by telephone at (281) 701-4243.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging Growth Company and Smaller Reporting
Company</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As such, we are eligible to take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging
growth companies&#8221; including, but not limited to, not being required to comply with the auditor attestation requirements of Section
404 of the Sarbanes- Oxley Act reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any
golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less
active trading market for our securities and the prices of our securities may be more volatile.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Section 107 of
the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided
in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging
growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We intend to take advantage of the benefits of this extended transition period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO,
(b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer,
which means the market value of our Class A Ordinary Shares that are held by non-affiliates exceeds $700 million as of the prior June
30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we are a &#8220;smaller
reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced
disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (1) the market value of our ordinary shares held by non-affiliates is
equal to or exceeds $250 million as of the prior June 30th, or (2) our annual revenues equaled to or exceeded $100 million during such
completed fiscal year and the market value of our ordinary shares held by non-affiliates is equal to or exceeds $700 million as of the
prior June 30th.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 19; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_003" style="display: inline-block;"></span>Item 1A. Risk Factors</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our
securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the other information
contained in this Form 10-K. If any of the following events occur, our business, financial condition and operating results may be materially
adversely affected. In that event, the trading price of our securities could decline, and you could lose all or part of your investment.</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks Relating to our Search for, and Consummation
of or Inability to Consummate, a Business Combination</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: bold;"><i>Our Public Shareholders may not be afforded
an opportunity to vote on our proposed initial Business Combination, and even if we hold a vote, holders of our Founder Shares will participate
in such vote, which means we may complete our initial Business Combination even though a majority of our Public Shareholders do not support
such a combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may choose not to hold a
shareholder vote to approve our initial Business Combination unless the Business Combination would require shareholder approval under
applicable law or stock exchange listing requirements. In such case, the decision as to whether we will seek shareholder approval of a
proposed Business Combination or will allow shareholders to sell their shares to us in a tender offer will be made by us, solely in our
discretion, and will be based on a variety of factors, such as the timing of the transaction and whether the terms of the transaction
would otherwise require us to seek shareholder approval. Even if we seek shareholder approval, the holders of our Founder Shares will
participate in the vote on such approval. Accordingly, we may complete our initial Business Combination even if holders of a majority
of our ordinary shares do not approve of the Business Combination we complete. Please see the section entitled &#8220;<i>Item 1. Business&#160;&#8212;&#160;Effecting
Our Initial Business Combination&#160;&#8212;&#160;Shareholders May Not Have the Ability to Approve Our Initial Business Combination</i>&#8221;
for additional information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If we seek shareholder approval of our initial
Business Combination, our initial shareholders and management team have agreed to vote in favor of such initial Business Combination,
regardless of how our Public Shareholders vote, and we may not need any Public Shares in addition to our Founder Shares to be voted in
favor of an initial Business Combination in order to approve an initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our initial shareholders own
26.5% of our issued and outstanding ordinary shares. Our initial shareholders and management team also may from time to time purchase Class&#160;A
ordinary shares prior to our initial Business Combination. Our amended and restated memorandum and articles of association provides that,
if we seek shareholder approval of an initial Business Combination, such initial Business Combination will be approved if we obtain the
approval of an ordinary resolution under Cayman Islands law and our amended and restated memorandum and articles of association, which
requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person
or, where proxies are allowed, by proxy at the applicable general meeting of the company. As a result, in addition to our initial shareholders&#8217;
Founder Shares, we would need 6,407,716, or 32%, of the 20,041,150 Public Shares sold in the Initial Public Offering to be voted in
favor of an initial Business Combination in order to have our initial Business Combination approved, assuming all outstanding shares are
voted and the parties to the letter agreement do not acquire any Class&#160;A ordinary shares. Assuming that only the holders of one-third&#160;of
our issued and outstanding ordinary shares, representing a quorum under our amended and restated memorandum and articles of association,
vote their ordinary shares at a general meeting of the company, we will not need any Public Shares in addition to our Founder Shares to
be voted in favor of an initial Business Combination in order to approve an initial Business Combination. However, if our initial Business
Combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial
Business Combination will require the approval of a special resolution, which requires the affirmative vote of at least two-thirds&#160;of
the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable
general meeting of the company. Assuming all outstanding shares are voted at a special meeting of the Company and the parties to the letter
agreement do not acquire any Class&#160;A ordinary shares, we will need 10,952,194, or 54.7%, Public Shares in addition to our Founder
Shares to be voted in favor of an initial Business Combination in order to approve an initial Business Combination. Assuming that only
the holders of one-third&#160;of our issued and outstanding ordinary shares, representing a quorum under our amended and restated memorandum
and articles of association, vote their ordinary shares at a special meeting of the Company, we will not need any Public Shares in addition
to our Founder Shares to be voted in favor of an initial Business Combination in order to approve an initial Business Combination. Accordingly,
if we seek shareholder approval of our initial Business Combination, the agreement by our initial shareholders and management team to
vote in favor of our initial Business Combination will increase the likelihood that an ordinary resolution will be passed, being the requisite
shareholder approval for such initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 20; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Your only opportunity to effect your investment
decision regarding a potential Business Combination may be limited to the exercise of your right to redeem your shares from us for cash.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the time of your investment
in us, you will not be provided with an opportunity to evaluate the specific merits or risks of our initial Business Combination. Since
our board of directors may complete a Business Combination without seeking shareholder approval, Public Shareholders may not have the
right or opportunity to vote on the Business Combination, unless we seek such shareholder vote. Accordingly, your only opportunity to
effect your investment decision regarding our initial Business Combination may be limited to exercising your redemption rights within
the period of time (which will be at least 20&#160;business days) set forth in our tender offer documents mailed to our Public Shareholders
in which we describe our initial Business Combination. The per share amount we will distribute to shareholders who properly exercise their
redemption rights will not be reduced by the deferred underwriting commission and after such redemptions, the per-share&#160;value of
shares held by non-redeeming&#160;shareholders will reflect our obligation to pay the deferred underwriting commissions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The ability of our Public Shareholders to
redeem their shares for cash may make our financial condition unattractive to potential Business Combination targets, which may make it
difficult for us to enter into a Business Combination with a target.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek to enter into a
Business Combination transaction agreement with a minimum cash requirement for (i)&#160;cash consideration to be paid to the target or
its owners, (ii)&#160;cash for working capital or other general corporate purposes or (iii)&#160;the retention of cash to satisfy other
conditions. If too many Public Shareholders exercise their redemption rights, we would not be able to meet such closing condition and,
as a result, would not be able to proceed with the Business Combination. Consequently, if accepting all properly submitted redemption
requests would not allow us to satisfy a closing condition as described above, we would not proceed with such redemption and the related
Business Combination and may instead search for an alternate Business Combination. Prospective targets will be aware of these risks and,
thus, may be reluctant to enter into a Business Combination transaction with us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The ability of our Public Shareholders to
exercise redemption rights with respect to a large number of our shares and the amount of deferred underwriting compensation may not allow
us to complete the most desirable Business Combination or optimize our capital structure, and may substantially dilute your investment
in us.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the time we enter into an
agreement for our initial Business Combination, we will not know how many shareholders may exercise their redemption rights, and therefore
will need to structure the transaction based on our expectations as to the number of shares that will be submitted for redemption. If
our initial Business Combination agreement requires us to use a portion of the cash in the Trust Account to pay the purchase price, or
requires us to have a minimum amount of cash at closing, we will need to reserve a portion of the cash in the Trust Account to meet such
requirements, or arrange for third party financing. In addition, if a larger number of shares are submitted for redemption than we initially
expected, we may need to restructure the transaction to reserve a greater portion of the cash in the Trust Account or arrange for third
party financing. Raising additional third party financing may involve dilutive equity issuances or the incurrence of indebtedness at higher
than desirable levels. Furthermore, this dilution would increase to the extent that the anti-dilution&#160;provision of the Class&#160;B
ordinary shares results in the issuance of Class A Ordinary Shares on a greater than one-to-one&#160;basis upon conversion of the Class&#160;B
ordinary shares immediately prior to, concurrently with or immediately following the consummation of our initial Business Combination.
The above considerations may limit our ability to complete the most desirable Business Combination available to us or optimize our capital
structure. As a result, our obligations to redeem Public Shares for which redemption is requested and to pay the deferred underwriting
commissions may not allow us to complete the most desirable Business Combination or optimize our capital structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, raising additional
third-party&#160;financing may involve dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. Furthermore,
this dilution would increase to the extent that the anti-dilution&#160;provisions of the Class&#160;B ordinary shares result in the issuance
of Class A Ordinary Shares on a greater than one-to-one&#160;basis upon conversion of the Class&#160;B ordinary shares at the time of
our Business Combination. The above considerations may limit our ability to complete the most desirable Business Combination available
to us or optimize our capital structure and may result in substantial dilution from your purchase of our Class A Ordinary Shares. The
effect of this dilution will be greater for shareholders who do not redeem. We may not be able to generate sufficient value from the completion
of our initial Business Combination in order to overcome the dilutive impact of these and other factors, and, accordingly, you may incur
a net loss on your investment. Please see &#8220;&#8212;&#160;<i>Risks Relating to Our Securities&#160;&#8212;&#160;The nominal purchase
price paid by our Sponsor for the Founder Shares may result in significant dilution to the implied value of your Public Shares upon the
consummation</i>&#160;<i>of our initial Business Combination, and our Sponsor is likely to make a substantial profit on its investment
in us in the event we consummate an initial Business Combination, even if the Business Combination causes the trading price of our ordinary
shares to materially decline</i>.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 21; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The ability of our Public Shareholders to
exercise redemption rights with respect to a large number of our shares could increase the probability that our initial Business Combination
would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our initial Business Combination
agreement requires us to use a portion of the cash in the Trust Account to pay the purchase price, or requires us to have a minimum amount
of cash at closing, the probability that our initial Business Combination would be unsuccessful is increased. If our initial Business
Combination is unsuccessful, you would not receive your pro rata portion of the funds in the Trust Account until we liquidate the Trust
Account. If you are in need of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our
shares may trade at a discount to the pro rata amount per share in the Trust Account. In either situation, you may suffer a material loss
on your investment or lose the benefit of funds expected in connection with your exercise of redemption rights until we liquidate or you
are able to sell your shares in the open market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The requirement that we complete our initial
Business Combination within the Completion Window may give potential target businesses leverage over us in negotiating a Business Combination
and may limit the time we have in which to conduct due diligence on potential Business Combination targets, in particular as we approach
our liquidation deadline, which could undermine our ability to complete our initial Business Combination on terms that would produce value
for our shareholders.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any potential target business
with which we enter into negotiations concerning a Business Combination will be aware that we must complete our initial Business Combination
within the Completion Window. Consequently, such target business may obtain leverage over us in negotiating a Business Combination, knowing
that if we do not complete our initial Business Combination with that particular target business, we may be unable to complete our initial
Business Combination with any target business. This risk will increase as we get closer to the timeframe described above. In addition,
we may have limited time to conduct due diligence and may enter into our initial Business Combination on terms that we would have rejected
upon a more comprehensive investigation. The length of time it may take us to complete our diligence and negotiate a Business Combination
may reduce the amount of time available for us to ultimately complete an initial Business Combination should such diligence or negotiations
not lead to a consummated initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may engage one or more of our Underwriters
or one of their respective affiliates to provide additional services to us after our Initial Public Offering, which may include acting
as M&amp;A advisor in connection with an initial Business Combination or as placement agent in connection with a related financing transaction.
Our Underwriters are entitled to receive deferred underwriting commissions that will be released from the Trust Account only upon a completion
of an initial Business Combination. These financial incentives may cause them to have potential conflicts of interest in rendering any
such additional services to us after our Initial Public Offering, including, for example, in connection with the sourcing and consummation
of an initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may engage one or more of
our Underwriters or one of their respective affiliates to provide additional services to us after our Initial Public Offering, including,
for example, identifying potential targets, providing M&amp;A advisory services, acting as a placement agent in a private offering or
arranging debt financing transactions. We may pay such underwriter or its affiliate fair and reasonable fees or other compensation that
would be determined at that time in an arm&#8217;s length negotiation; provided that no agreement will be entered into with any of the
Underwriters or their respective affiliates and no fees or other compensation for such services will be paid to any of the Underwriters
or their respective affiliates prior to the date that is 60&#160;days from the date of our Initial Public Offering, unless such payment
would not be deemed Underwriters&#8217; compensation in connection with the Initial Public Offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Underwriters are also entitled
to receive deferred underwriting commissions that are conditioned on the completion of an initial Business Combination. The Underwriters&#8217;
or their respective affiliates&#8217; financial interests tied to the consummation of a Business Combination transaction may give rise
to potential conflicts of interest in providing any such additional services to us, including potential conflicts of interest in connection
with the sourcing and consummation of an initial Business Combination. The Underwriters are under no obligation to provide any further
services to us in order to receive all or any part of the deferred underwriting commissions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 22; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may not be able to complete our initial
Business Combination within the Completion Window, in which case we would redeem our Public Shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to find
a suitable target business and complete our initial Business Combination within the Completion Window. In recent&#160;years, a number
of SPACs have liquidated due to an inability to complete an initial Business Combination within their allotted time periods. Furthermore,
our ability to complete our initial Business Combination may be negatively impacted by general market conditions, volatility in the capital
and debt markets and the other risks described herein, including the impact of events such as the conflict between Russia and Ukraine
and the war between Israel and Hamas. If we have not completed our initial Business Combination within such time period, we will as promptly
as reasonably possible but not more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem
the Public Shares, at a per-share&#160;price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including
interest earned on the funds held in the Trust Account (which interest shall be net of amounts not previously released to us for permitted
withdrawals and up to $100,000 of interest to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares,
which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive further
liquidating distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. In such case, our Public Shareholders may only receive $10.00 per share, or possibly less, and our warrants will
expire without value to the holder. In certain circumstances, our Public Shareholders may receive less than $10.00 per share on the redemption
of their shares. See &#8220;&#8212;&#160;<i>If third parties bring claims against us, the proceeds held in the Trust Account could be
reduced and the&#160;per-share&#160;redemption amount received by shareholders may be less than $10.00 per share</i>&#8221; and other
risk factors described in this &#8220;<i>Risk Factors</i>&#8221; section.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may decide not to extend the term we
have to consummate our initial Business Combination, in which case we would redeem our Public Shares, and the warrants may be worthless.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have until the date that
is 24&#160;months from the closing of our Initial Public Offering or until such earlier liquidation date as our board of directors may
approve, to consummate our initial Business Combination. If we anticipate that we may be unable to consummate our initial Business Combination
within such period, we may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend
the date by which we must consummate our initial Business Combination. However, we may decide not to seek to extend the date by which
we must consummate our initial Business Combination. If we do not seek to extend the date by which we must consummate our initial Business
Combination, and we are unable to consummate our initial Business Combination within the applicable time period, we will as promptly as
reasonably possible but not more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem the
Public Shares, at a per-share&#160;price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including
interest earned on the funds held in the Trust Account (which interest shall be net of amounts not previously released to us for permitted
withdrawals and up to $100,000 for liquidation expenses), divided by the number of then issued and outstanding Public Shares, which redemption
will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions,
if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable
law. In such event, the warrants may be worthless.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If we seek shareholder approval of our initial
Business Combination, our Sponsor, initial shareholders, directors, officers, advisors and their affiliates may elect to purchase shares
or Public Warrants from Public Shareholders, which may influence a vote on a proposed Business Combination and reduce the public &#8220;float&#8221;
of our Class A Ordinary Shares or Public Warrants.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we seek shareholder approval
of our initial Business Combination and we do not conduct redemptions in connection with our initial Business Combination pursuant to
the tender offer rules, our Sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase Public Shares
or warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial Business
Combination, although they are under no obligation or duty to do so. Such a purchase may include a contractual acknowledgment that such
shareholder, although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise
its redemption rights. In the event that our Sponsor, initial shareholders, directors, officers, advisors and their affiliates purchase
shares in privately negotiated transactions from Public Shareholders who have already elected to exercise their redemption rights, such
selling shareholders would be required to revoke their prior elections to redeem their shares. It is intended that, if Rule&#160;10b-18&#160;would
apply to purchases by our Sponsor, initial shareholders, directors, officers, advisors and their affiliates, then such purchases will
comply with Rule&#160;10b-18&#160;under the Exchange&#160;Act, to the extent it applies, which provides a safe harbor for purchases made
under certain conditions, including with respect to timing, pricing and volume of purchases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 23; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, at any time at
or prior to our initial Business Combination, subject to applicable securities laws (including with respect to material nonpublic information),
our Sponsor, initial shareholders, directors, officers, advisors and their affiliates may enter into transactions with investors and others
to provide them with incentives to acquire Public Shares, vote their Public Shares in favor of our initial Business Combination or not
redeem their Public Shares. However, they have no current commitments, plans or intentions to engage in such transactions and have not
formulated any terms or conditions for any such transactions. None of the funds in the Trust Account will be used to purchase Public Shares
or warrants in such transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of any such transactions
could be to (1)&#160;increase the likelihood of obtaining shareholder approval of the Business Combination, (2)&#160;reduce the number
of Public Warrants outstanding and/or increase the likelihood of approval on any matters submitted to the Public Warrant holders for approval
in connection with our initial Business Combination or (3)&#160;satisfy a closing condition in an agreement with a target that requires
us to have a minimum net worth or a certain amount of cash at the closing of our initial Business Combination, where it appears that such
requirement would otherwise not be met. Any such purchases of our securities may result in the completion of our initial Business Combination
that may not otherwise have been possible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if such purchases
are made, the public &#8220;float&#8221; of our securities may be reduced and the number of beneficial holders of our securities may be
reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities
exchange. Any such purchases will be reported pursuant to Section&#160;13 and Section&#160;16 of the Exchange&#160;Act to the extent such
purchasers are subject to such reporting requirements. Additionally, in the event our Sponsor, initial shareholders, directors, officers,
advisors and their affiliates were to purchase Public Shares or warrants from Public Shareholders after the announcement of our initial
Business Combination, such purchases would be structured in compliance with the requirements of Rule&#160;14e-5&#160;under the Exchange&#160;Act
including, in pertinent part, through adherence to the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our registration statement/proxy statement filed for our Business
Combination transaction would disclose the possibility that our Sponsor, initial shareholders, directors, officers, advisors and their
affiliates may purchase Public Shares or warrants from Public Shareholders outside the redemption process, along with the purpose of
such purchases;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if our Sponsor, initial shareholders, directors, officers, advisors
and their affiliates were to purchase Public Shares or warrants from Public Shareholders, they would do so at a price no higher than
the price offered through our redemption process;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our registration statement/proxy statement filed for our Business
Combination transaction would include a representation that any of our securities purchased by our Sponsor, initial shareholders, directors,
officers, advisors and their affiliates would not be voted in favor of approving the Business Combination transaction;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our Sponsor, initial shareholders, directors, officers, advisors
and their affiliates would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption
rights, they would waive such rights; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we would disclose in a Form&#160;8-K, before our security holder
meeting to approve the Business Combination transaction, the following material items:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the amount of our securities purchased outside of the redemption
offer by our Sponsor, initial shareholders, directors, officers, advisors and their affiliates, along with the purchase price;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the purpose of the purchases by our Sponsor, initial shareholders,
directors, officers, advisors and their affiliates;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the impact, if any, of the purchases by our Sponsor, initial
shareholders, directors, officers, advisors and their affiliates on the likelihood that the Business Combination transaction will be
approved;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 24; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the identities of our security holders who sold to our Sponsor,
initial shareholders, directors, officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security
holders (e.g., 5% security holders) who sold to our Sponsor, initial shareholders, directors, officers, advisors and their affiliates;
and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the number of our securities for which we have received redemption
requests pursuant to our redemption offer.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see &#8220;<i>Item 1.
Business&#160;&#8212;&#160;Effecting Our Initial Business Combination&#160;&#8212;&#160;Permitted Purchases of Our Securities</i>&#8221;
for a description of how such persons will determine from which shareholders to seek to acquire securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If a shareholder fails to receive notice
of our offer to redeem our Public Shares in connection with our initial Business Combination, or fails to comply with the procedures for
submitting or tendering its shares, such shares may not be redeemed.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will comply with the proxy
rules or tender offer rules, as applicable, when conducting redemptions in connection with our initial Business Combination. Despite our
compliance with these rules, if a shareholder fails to receive our proxy materials or tender offer documents, as applicable, such shareholder
may not become aware of the opportunity to redeem its shares. In addition, proxy materials or tender offer documents, as applicable, that
we will furnish to holders of our Public Shares in connection with our initial Business Combination will describe the various procedures
that must be complied with in order to validly tender or submit Public Shares for redemption. For example, we intend to require our Public
Shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in &#8220;street name,&#8221;
to, at the holder&#8217;s option, either deliver their share certificates to our transfer agent, or to deliver their shares to our transfer
agent electronically prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy
materials, this date may be up to two&#160;business days prior to the scheduled vote on the proposal to approve the initial Business Combination.
In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a Public Shareholder seeking redemption
of its Public Shares to also submit a written request for redemption to our transfer agent two&#160;business days prior to the scheduled
vote in which the name of the beneficial owner of such shares is included. In the event that a shareholder fails to comply with these
or any other procedures disclosed in the proxy or tender offer materials, as applicable, its shares may not be redeemed. See the section
of this Annual Report on Form 10-K entitled &#8220;<i>Item 1. Business&#160;&#8212;&#160;Delivering Share Certificates in Connection with
the Exercise of Redemption Rights.</i>&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>You will not be entitled to protections
normally afforded to investors of other blank check companies subject to Rule&#160;419 of the Securities Act.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the net proceeds of the
IPO and the sale of the Private Placement Warrants are intended to be used to complete one or more initial Business Combinations with
a target business or businesses that has not been selected, we may be deemed to be a &#8220;blank check&#8221; company under the United
States securities laws. However, because we will be listed on a national securities exchange meeting certain quantitative requirements
set out in Rule 3a51-1(a)(2) of the Exchange Act, we are exempt from rules promulgated by the SEC to protect investors in blank check
companies, such as Rule 419. Accordingly, investors will not be afforded the benefits or protections of those rules. Among other things,
this means our Units will be immediately tradable and we will have a longer period of time to complete our respective initial Business
Combinations than do companies subject to Rule 419.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, if our IPO were subject
to Rule 419, that rule would prohibit the release of any interest earned on funds held in the Trust Account to us unless and until the
funds in the Trust Account were released to us in connection with our completion of an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, if we are not able
to list our ordinary shares on the NYSE or any other national stock exchange, and if we fail to have net tangible assets in excess of
$5,000,000, we may be required to comply with the &#8220;penny stock rules&#8221; and this could negatively affect the market for our
securities and our ability to complete an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 25; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If we seek shareholder approval of our initial
Business Combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a &#8220;group&#8221; of shareholders
are deemed to hold in excess of 15% of our Class A Ordinary Shares, you may lose the ability to redeem all such shares in excess of 15%
of our Class A Ordinary Shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we seek shareholder approval
of our initial Business Combination and we do not conduct redemptions in connection with our initial Business Combination pursuant to
the tender offer rules, our amended and restated memorandum and articles of association provides that a Public Shareholder, together with
any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as
defined under Section&#160;13 of the Exchange&#160;Act), will be restricted from redeeming its shares with respect to more than an aggregate
of 15% of the then outstanding Public Shares, which we refer to as the &#8220;Excess Shares,&#8221; without our prior consent. However,
we would not be restricting our shareholders&#8217; ability to vote all of their shares (including Excess Shares) for or against our initial
Business Combination. Your inability to redeem the Excess Shares will reduce your influence over our ability to complete our initial Business
Combination and you could suffer a material loss on your investment in us if you sell Excess Shares in open market transactions. Additionally,
you will not receive redemption distributions with respect to the Excess Shares if we complete our initial Business Combination. And as
a result, you will continue to hold that number of shares exceeding 15% and, in order to dispose of such shares, would be required to
sell your shares in open market transactions, potentially at a loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Because of our limited resources and the
significant competition for Business Combination opportunities, it may be more difficult for us to complete our initial Business Combination.
If we are unable to complete our initial Business Combination, our Public Shareholders may receive only their pro rata portion of the
funds in the Trust Account that are available for distribution to Public Shareholders, and our warrants will expire worthless.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to encounter competition
from other entities having a business objective similar to ours, including private investors (which may be individuals or investment partnerships),
other blank check companies and other entities, domestic and international, competing for the types of businesses we intend to acquire.
Many of these individuals and entities are well-established&#160;and have extensive experience in identifying and effecting, directly
or indirectly, acquisitions of companies operating in or providing services to various industries. Many of these competitors possess similar
or greater technical, human and other resources to ours or more local industry knowledge than we do and our financial resources will be
relatively limited when contrasted with those of many of these competitors. While we believe there are numerous target businesses we could
potentially acquire with the net proceeds of our Initial Public Offering and the sale of the Private Placement Warrants, our ability to
compete with respect to the acquisition of certain target businesses that are sizable will be limited by our available financial resources.
This inherent competitive limitation gives others an advantage in pursuing the acquisition of certain target businesses. Furthermore,
we are obligated to offer holders of our Public Shares the right to redeem their shares for cash at the time of our initial Business Combination
in conjunction with a shareholder vote or via a tender offer. Target companies will be aware that this may reduce the resources available
to us for our initial Business Combination. Any of these obligations may place us at a competitive disadvantage in successfully negotiating
a Business Combination. If we are unable to complete our initial Business Combination, our Public Shareholders may receive only their
pro rata portion of the funds in the Trust Account that are available for distribution to Public Shareholders, and our warrants will expire
worthless.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If the net proceeds of our Initial Public
Offering and the sale of the Private Placement Warrants not being held in the Trust Account are insufficient to allow us to operate for
at least the duration of the Completion Window, it could limit the amount available to fund our search for a target business or businesses
and complete our initial Business Combination, and we will depend on loans from our Sponsor or management team to fund our search and
to complete our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, $442,500
was available to us outside the Trust Account to fund our working capital requirements. We believe that the funds available to us outside
of the Trust Account will be sufficient to allow us to operate for at least the duration of the Completion Window; however, we cannot
assure you that our estimate is accurate. Of the funds available to us, we could use a portion of the funds available to us to pay fees
to consultants to assist us with our search for a target business. We could also use a portion of the funds as a down payment or to fund
a &#8220;no-shop&#8221; provision (a provision in letters of intent or merger agreements designed to keep target businesses from &#8220;shopping&#8221;
around for transactions with other companies or investors on terms more favorable to such target businesses) with respect to a particular
proposed Business Combination, although we do not have any current intention to do so. If we entered into a letter of intent or merger
agreement where we paid for the right to receive exclusivity from a target business and were subsequently required to forfeit such funds
(whether as a result of our breach or otherwise), we might not have sufficient funds to continue searching for, or conduct due diligence
with respect to, a target business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 26; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither our Sponsor, members
of our management team nor any of their affiliates is under any obligation to advance funds to us in such circumstances. Any such advances
would be repaid only from funds held outside the Trust Account or from funds released to us upon completion of our initial Business Combination.
Up to $1,500,000 of such loans may be convertible into Private Placement Warrants of the post-Business Combination entity at a price of
$1.00 per warrant at the option of the lender. Such warrants would be identical to the Private Placement Warrants. Prior to the completion
of our initial Business Combination, we do not expect to seek loans from parties other than our Sponsor or an affiliate of our Sponsor
as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to
funds in our Trust Account. If we are unable to complete our initial Business Combination because we do not have sufficient funds available
to us, we will be forced to liquidate the Trust Account. Consequently, our Public Shareholders may only receive an estimated $10.00 per
share, or possibly less, on our redemption of our Public Shares, and our warrants will expire worthless.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If third parties bring claims against us,
the proceeds held in the Trust Account could be reduced and the&#160;per-share&#160;redemption amount received by shareholders may be
less than $10.00 per share.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our placing of funds in the
Trust Account may not protect those funds from third party claims against us. Although we will seek to have all vendors, service providers
(except for our independent registered public accounting firm), prospective target businesses and other entities with which we do business
execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the
benefit of our Public Shareholders, such parties may not execute such agreements, or even if they execute such agreements they may not
be prevented from bringing claims against the Trust Account, including, but not limited to, fraudulent inducement, breach of fiduciary
responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain
advantage with respect to a claim against our assets, including the funds held in the Trust Account. If any third party refuses to execute
an agreement waiving such claims to the monies held in the Trust Account, our management will consider whether competitive alternatives
are reasonably available to us and will only enter into an agreement with such third party if management believes that such third party&#8217;s
engagement would be in the best interests of the company under the circumstances. WithumSmith+Brown, PC, our independent registered public
accounting firm, and the Underwriters of our Initial Public Offering will not execute agreements with us waiving such claims to the monies
held in the Trust Account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Examples of possible instances
where we may engage a third party that refuses to execute a waiver include the engagement of a third-party&#160;consultant whose particular
expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute
a waiver or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee
that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts
or agreements with us and will not seek recourse against the Trust Account for any reason. Upon redemption of our Public Shares, if we
are unable to complete our initial Business Combination within the prescribed timeframe, or upon the exercise of a redemption right in
connection with our initial Business Combination, we will be required to provide for payment of claims of creditors that were not waived
that may be brought against us within the 10&#160;years following redemption. Accordingly, the per-share&#160;redemption amount received
by Public Shareholders could be less than the $10.00 per Public Share initially held in the Trust Account, due to claims of such creditors.
Pursuant to the letter agreement, our Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party
for services rendered or products sold to us (except for the Company&#8217;s independent registered public accounting firm), or a prospective
target business with which we have entered into a written letter of intent, confidentiality or other similar agreement or Business Combination
agreement, reduce the amount of funds in the Trust Account to below the lesser of (i)&#160;$10.00 per Public Share and (ii)&#160;the actual
amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public
Share due to reductions in the value of the trust assets, in each case less taxes paid or payable and up to $100,000 of interest to pay
liquidation expenses, provided that such liability will not apply to any claims by a third party or prospective target business who executed
a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to
any claims under our indemnity of the Underwriters against certain liabilities, including liabilities under the Securities Act. However,
we have not asked our Sponsor to reserve for such indemnification obligations, nor have we independently verified whether our Sponsor
has sufficient funds to satisfy its indemnity obligations and we believe that our Sponsor&#8217;s only assets are securities of our Company.
Therefore, we cannot assure you that our Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully
made against the Trust Account, the funds available for our initial Business Combination and redemptions could be reduced to less than
$10.00 per Public Share. In such event, we may not be able to complete our initial Business Combination, and you would receive such lesser
amount per share in connection with any redemption of your Public Shares. None of our officers or directors will indemnify us for claims
by third parties including, without limitation, claims by vendors and prospective target businesses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 27; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our directors may decide not to enforce
the indemnification obligations of our Sponsor, resulting in a reduction in the amount of funds in the Trust Account available for distribution
to our Public Shareholders.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the proceeds
in the Trust Account are reduced below the lesser of (i)&#160;$10.00 per Public Share and (ii)&#160;the actual amount per Public Share
held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions
in the value of the trust assets, in each case less taxes paid or payable and up to $100,000 of interest to pay liquidation expenses,
and our Sponsor asserts that it is unable to satisfy his, her or its obligations or that he has no indemnification obligations related
to a particular claim, our independent directors would determine whether to take legal action against our Sponsor to enforce its indemnification
obligations. While we currently expect that our independent directors would take legal action on our behalf against our Sponsor to enforce
its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment and subject
to their fiduciary duties may choose not to do so in any particular instance if, for example, the cost of such legal action is deemed
by the independent directors to be too high relative to the amount recoverable or if the independent directors determine that a favorable
outcome is not likely. If our independent directors choose not to enforce these indemnification obligations, the amount of funds in the
Trust Account available for distribution to our Public Shareholders may be reduced below $10.00 per Public Share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may not have sufficient funds to satisfy
indemnification claims of our directors and officers.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify
our officers and directors to the fullest extent permitted by law, including for any liability incurred in their capacities as such, except
through their own actual fraud, willful default or willful neglect. However, our officers and directors have agreed to waive any right,
title, interest or claim of any kind in or to any monies in the Trust Account and to not seek recourse against the Trust Account for any
reason whatsoever (except to the extent they are entitled to funds from the Trust Account due to their ownership of Public Shares). Accordingly,
any indemnification provided will be able to be satisfied by us only if (i)&#160;we have sufficient funds outside of the Trust Account
or (ii)&#160;we consummate an initial Business Combination. Our obligation to indemnify our officers and directors may discourage shareholders
from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect
of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected to the extent we pay
the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If, after we distribute the proceeds in
the Trust Account to our Public Shareholders, we file a bankruptcy or&#160;winding-up&#160;petition or an involuntary bankruptcy or&#160;winding-up&#160;petition
is filed against us that is not dismissed, a liquidator or a bankruptcy, insolvency or other court may seek to recover such proceeds,
and the members of our board of directors may be viewed as having breached their fiduciary duties to us or our creditors, thereby exposing
the members of our board of directors and us to claims of punitive damages.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, after we distribute the
proceeds in the Trust Account to our Public Shareholders, we file a bankruptcy or winding-up&#160;petition or an involuntary bankruptcy
or winding-up&#160;petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under
applicable debtor/creditor and/or bankruptcy/insolvency laws as either a &#8220;preferential transfer&#8221; or a &#8220;fraudulent conveyance,
preference or disposition.&#8221; As a result, a liquidator or a bankruptcy, insolvency or other court could seek to recover some or all
amounts received by our shareholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to us or
our creditors and/or having acted in bad faith, thereby exposing itself and us to claims of punitive damages, by paying Public Shareholders
from the Trust Account prior to addressing the claims of creditors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 28; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If, before distributing the proceeds in
the Trust Account to our Public Shareholders, we file a bankruptcy or&#160;winding-up&#160;petition or an involuntary bankruptcy or&#160;winding-up&#160;petition
is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders
and the&#160;per-share&#160;amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, before distributing the
proceeds in the Trust Account to our Public Shareholders, we file a bankruptcy or winding-up&#160;petition or an involuntary bankruptcy
or winding-up&#160;petition is filed against us that is not dismissed, the proceeds held in the Trust Account could be subject to applicable
bankruptcy or insolvency law, and may be included in our bankruptcy or insolvency estate and subject to the claims of third parties with
priority over the claims of our shareholders. To the extent any bankruptcy or insolvency claims deplete the Trust Account, the per-share&#160;amount
that would otherwise be received by our shareholders in connection with our liquidation may be reduced.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Changes in laws or regulations, or a failure
to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial
Business Combination, and results of operations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to laws and
regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other
legal requirements and numerous complex tax laws. Compliance with, and monitoring of, applicable laws and regulations may be difficult,
time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those
changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply
with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability
to negotiate and complete our initial Business Combination, and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&#160;24, 2024, the
SEC adopted a series of new rules relating to SPACs (the &#8220;SPAC Rules&#8221;) requiring, among other items, (i)&#160;additional disclosures
relating to SPAC Business Combination transactions; (ii)&#160;additional disclosures relating to dilution and to conflicts of interest
involving Sponsors and their affiliates in both SPAC initial public offerings and de-SPAC&#160;transactions; (iii)&#160;the use of projections
by SPACs in SEC filings in connection with proposed Business Combination transactions; and (iv)&#160;both the SPAC and the target company&#8217;s
status as co-registrants&#160;on de-SPAC&#160;registration statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the SEC&#8217;s
adopting release provided guidance describing circumstances in which a SPAC could become subject to regulation under the Investment Company
Act, including its duration, asset composition, business purpose, and the activities of the SPAC and its management team in furtherance
of such goals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compliance with the SPAC Rules
and related guidance may increase the costs of and the time needed to negotiate and complete an initial Business Combination and may constrain
the circumstances under which we could complete an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If we are deemed to be an investment company
under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted,
which may make it difficult for us to complete our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described in the risk factor
above entitled &#8220;<i>Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our
business, including our ability to negotiate and complete our initial Business Combination, and results of operations</i>,&#8221; the
SEC&#8217;s adopting release with respect to the SPAC Rules provided guidance describing the extent to which SPACs could become subject
to regulation under the Investment Company Act and the regulations thereunder. Whether a SPAC is an investment company will be a question
of facts and circumstances. If our facts and circumstances change over time, we will update our disclosure to reflect how those changes
impact the risk that we may be considered to be operating as an unregistered investment company. We can give no assurance that a claim
will not be made that we have been operating as an unregistered investment company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are deemed to be an investment
company under the Investment Company Act, we may have to change our operations, wind down our operations, or register as an investment
company under the Investment Company Act. Our activities may be restricted, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">restrictions on the nature of our investments; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">restrictions on the issuance of securities, each of which may
make it difficult for us to complete our initial Business Combination.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In addition, we may have imposed upon us burdensome requirements,
including:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">registration as an investment company;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 29; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">adoption of a specific form of corporate structure; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reporting, record keeping, voting, proxy and disclosure requirements
and other rules and regulations.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order not to be regulated
as an investment company under the Investment Company Act, unless we can qualify for an exclusion, we must ensure that we are engaged
primarily in a business other than investing, reinvesting or trading in securities and that our activities do not include investing, reinvesting,
owning, holding or trading &#8220;investment securities&#8221; constituting more than 40% of our total assets (exclusive of U.S.&#160;government
securities and cash items) on an unconsolidated basis. Our business will be to identify and complete a Business Combination and thereafter
to operate the post-transaction&#160;business or assets for the long term. We do not intend to spend a considerable amount of time actively
managing the assets in the Trust Account for the primary purpose of achieving investment returns. We do not plan to buy businesses or
assets with a view to resale or profit from their resale. We do not plan to buy unrelated businesses or assets or to be a passive investor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that our
anticipated principal activities will subject us to the Investment Company Act. To this end, the proceeds held in the Trust Account may
only be held as cash, including in demand deposit accounts at a bank, or invested in U.S.&#160;&#8220;government securities&#8221; within
the meaning of Section&#160;2(a)(16)&#160;of the Investment Company Act having a maturity of 185&#160;days or less or in money market
funds meeting certain conditions under Rule&#160;2a-7&#160;promulgated under the Investment Company Act which invest only in direct U.S.&#160;government
treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the
intended Business Combination and may at any time be held as cash or cash items, including in demand deposit accounts at a bank. Pursuant
to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds
to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying
and selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an &#8220;investment
company&#8221; within the meaning of the Investment Company Act. The Trust Account is intended as a holding place for funds pending the
earliest to occur of: (i)&#160;the completion of our initial Business Combination; (ii)&#160;the redemption of any Public Shares properly
submitted in connection with an amendment of our amended and restated memorandum and articles of association (A)&#160;to modify the substance
or timing of our obligation to provide for the redemption of our Public Shares in connection with an initial Business Combination or to
redeem 100% of our Public Shares if we have not consummated our initial Business Combination within the Completion Window or (B)&#160;with
respect to any other material provisions relating to shareholders&#8217; rights or pre-initial&#160;Business Combination activity; or
(iii)&#160;absent an initial Business Combination within the Completion Window, our return of the funds held in the Trust Account to our
Public Shareholders as part of our redemption of the Public Shares. If we do not invest the proceeds as discussed above, we may be deemed
to be subject to the Investment Company Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, under the subjective
test of a &#8220;investment company&#8221; pursuant to Section&#160;3(a)(1)(A)&#160;of the Investment Company Act, even if the funds deposited
in the Trust Account were invested in the assets discussed above (U.S.&#160;government securities or money market funds registered under
the Investment Company Act), such assets, other than cash, are &#8220;securities&#8221; for purposes of the Investment Company Act and,
therefore, nevertheless, there is a risk that we could be deemed an unregistered investment company and subject to the Investment Company
Act at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the adopting release for
the SPAC Rules, the SEC provided guidance that a SPAC&#8217;s potential status as an &#8220;investment company&#8221; depends on a variety
of factors, such as a SPAC&#8217;s duration, asset composition, business purpose and activities and &#8220;is a question of facts and
circumstances&#8221; requiring individualized analysis. If we were deemed to be an unregistered investment company and subject to compliance
with and regulation under the Investment Company Act, we would be subject to additional regulatory burdens and expenses for which we have
not allotted funds. Unless we are able to modify our activities so that we would not be deemed an investment company, we would either
register as an investment company or wind-down&#160;and abandon our efforts to complete a Business Combination and instead liquidate the
Trust Account. As a result, our Public Shareholders may only receive their pro rata portion of the funds in the Trust Account that are
available for distribution to Public Shareholders and would be unable to realize the potential benefits of an initial Business Combination,
including the possible appreciation of the combined company&#8217;s securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 30; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>To mitigate the risk that we might be deemed
to be an investment company for purposes of the Investment Company Act, we may, at any time, instruct the trustee to liquidate the securities
held in the Trust Account and instead to hold the funds in the Trust Account in cash until the earlier of the consummation of our initial
Business Combination or our liquidation. As a result, following the liquidation of securities in the Trust Account, the interest earned,
on the funds held in the Trust Account may be materially reduced, which would reduce the dollar amount our Public Shareholders would receive
upon any redemption or liquidation of the Company.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to initially hold
the funds in the Trust Account as cash, including in demand deposit accounts at a bank, or in U.S.&#160;government treasury obligations
with a maturity of 185&#160;days or less or in money market funds investing solely in U.S.&#160;government treasury obligations and meeting
certain conditions under Rule&#160;2a-7&#160;under the Investment Company Act. U.S.&#160;government treasury obligations are considered
&#8220;securities&#8221; for purposes of the Investment Company Act, while cash is not. As noted above, one of the factors the SEC identified
as relevant to the determination of whether a SPAC which holds securities could potentially be deemed an &#8220;investment company&#8221;
under the Investment Company Act is the SPAC&#8217;s duration. To mitigate the risk of us being deemed to be an unregistered investment
company (including under the subjective test of Section&#160;3(a)(1)(A)&#160;of the Investment Company Act) and thus subject to regulation
under the Investment Company Act, we may, at any time, instruct Continental Stock Transfer &amp; Trust Company, the trustee with respect
to the Trust Account, to liquidate the U.S.&#160;government treasury obligations or money market funds held in the Trust Account and thereafter
to hold all funds in the Trust Account in cash until the earlier of consummation of our initial Business Combination or liquidation of
the company. Following such liquidation, the rate of interest we receive on the funds held in the Trust Account may be materially decreased.
However, interest previously earned on the funds held in the Trust Account still may be released to us for permitted withdrawals and certain
other expenses as permitted. As a result, any decision to liquidate the securities held in the Trust Account and thereafter to hold all
funds in the Trust Account in cash would reduce the dollar amount our Public Shareholders would receive upon any redemption or liquidation
of the company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our search for a Business Combination, and
any target business with which we ultimately consummate a Business Combination, may be materially adversely affected by the status of
debt and equity markets.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to consummate a
transaction may be dependent on the ability to raise equity and debt financing which may be impacted by certain events, including as a
result of increased market volatility, decreased market liquidity and third-party&#160;financing being unavailable on terms acceptable
to us or at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our search for an initial Business Combination,
and any target business with which we may ultimately consummate an initial Business Combination, may be materially adversely affected
by current global geopolitical conditions resulting from the ongoing&#160;Russia-Ukraine&#160;conflict and the recent escalation of conflict
in the Middle East and Southwest Asia.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">United&#160;States and global
markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine&#160;conflict
and the recent escalation of conflict in the Middle East and Southwest Asia. In response to the ongoing Russia-Ukraine&#160;conflict,
the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United&#160;States,
the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus
and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank
Financial Telecommunication (SWIFT) payment system. Certain countries, including the United&#160;States, have also provided and may continue
to provide military aid or other assistance to Ukraine and to Israel, or have undertaken or will undertake military strikes in Southwest
Asia, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of conflict in
the Middle East and Southwest Asia and the resulting measures that have been taken, and could be taken in the future, by NATO, the United&#160;States,
the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that
could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable,
they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply
chain interruptions and increased cyber-attacks&#160;against U.S.&#160;companies. Additionally, any resulting sanctions could adversely
affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the above mentioned
factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian
invasion of Ukraine, the escalation of conflict in the Middle East and Southwest Asia and subsequent sanctions or related actions, may
lead to increased volume and price volatility for publicly traded securities or could adversely affect our search for an initial Business
Combination by adversely affecting the operations or financial condition of potential target companies, any of which could make it more
difficult for us to identify a Business Combination target and consummate an initial Business Combination on acceptable commercial terms,
or at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 31; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent and duration of
the ongoing conflicts, resulting sanctions and any related market disruptions are impossible to predict, but could be substantial, particularly
if current or new sanctions continue for an extended period of time or if geopolitical tensions result in expanded military operations
on a global scale. Any such disruptions may also have the effect of heightening many of the other risks described in this section. If
these disruptions or other matters of global concern continue for an extensive period of time, our ability to consummate an initial Business
Combination may be materially adversely affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If we are unable to consummate our initial
Business Combination within the Completion Window, our Public Shareholders may be forced to wait beyond such period before redemption
from our Trust Account.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to consummate
our initial Business Combination within the Completion Window, the proceeds then on deposit in the Trust Account, including interest earned
on the funds held in the Trust Account (which interest shall be net of amounts not previously released to us for permitted withdrawals
and up to $100,000 of interest to pay liquidation expenses), will be used to fund the redemption of our Public Shares. Any redemption
of Public Shareholders from the Trust Account will be effected automatically by function of our amended and restated memorandum and articles
of association prior to any voluntary winding up. If we are required to wind-up, liquidate the Trust Account and distribute such amount
therein, pro rata, to our Public Shareholders, as part of any liquidation process, such winding up, liquidation and distribution must
comply with the applicable provisions of the Companies Act. In that case, investors may be forced to wait beyond the end of the Completion
Window before the redemption proceeds of our Trust Account become available to them, and they receive the return of their pro rata portion
of the proceeds from our Trust Account. We have no obligation to return funds to investors prior to the date of our redemption or liquidation
unless we consummate our initial Business Combination prior thereto and only then in cases where investors have sought to redeem their
Public Shares. Only upon our redemption or any liquidation will Public Shareholders be entitled to distributions if we are unable to complete
our initial Business Combination. Our amended and restated memorandum and articles of association provides that, if we wind up for any
other reason prior to the consummation of our initial Business Combination, we will follow the foregoing procedures with respect to the
liquidation of the Trust Account as promptly as reasonably possible but not more than ten&#160;business days thereafter, subject to applicable
Cayman Islands law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our shareholders may be held liable for
claims by third parties against us to the extent of distributions received by them upon redemption of their shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are forced to enter into
an insolvent liquidation, any distributions received by shareholders could be viewed as an unlawful payment if it was proved that immediately
following the date on which the distribution was made, we were unable to pay our debts as they fall due in the ordinary course of business.
As a result, a liquidator could seek to recover some or all amounts received by our shareholders. Furthermore, our directors may be viewed
as having breached their fiduciary duties to us or our creditors and/or may have acted in bad faith, thereby exposing themselves and our
company to claims, by paying Public Shareholders from the Trust Account prior to addressing the claims of creditors. We cannot assure
you that claims will not be brought against us for these reasons. We and our directors and officers who knowingly and willfully authorized
or permitted any distribution to be paid out of our share premium account while we were unable to pay our debts as they fall due in the
ordinary course of business would be guilty of an offence and may be liable to a fine of approximately $18,293 and to imprisonment for
five&#160;years in the Cayman Islands.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may not hold an annual general meeting
until after the consummation of our initial Business Combination, which could delay the opportunity for our Public Shareholders to discuss
company affairs with management, and the holders of our Class A Ordinary Shares will not have the right to vote on the appointment or
removal of directors or continuing the company in a jurisdiction outside the Cayman Islands until after the consummation of our initial
Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the NYSE
corporate governance requirements, we are not required to hold an annual general meeting until no later than one year after our first
fiscal year end following our listing on the NYSE. There is no requirement under the Companies Act for us to hold annual or extraordinary
general meetings to appoint directors. Until we hold an annual general meeting, Public Shareholders may not be afforded the opportunity
to discuss company affairs with management. In addition, as holders of our Class A Ordinary Shares, our Public Shareholders will not have
the right to vote on the appointment or removal of directors or continuing the company in a jurisdiction outside the Cayman Islands until
after the consummation of our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><!-- Field: Page; Sequence: 32; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The warrants may become exercisable and
redeemable for a security other than the Class A Ordinary Shares, and you will not have any information regarding such other security
at this time.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain situations, including
if we are not the surviving entity in our initial Business Combination, the warrants may become exercisable for a security other than
the Class A Ordinary Shares. As a result, if the surviving company redeems your warrants for securities pursuant to the warrant agreement,
you may receive a security in a company of which you do not have information at this time. Pursuant to the warrant agreement, the surviving
company will be required to use commercially reasonable efforts to register the issuance of the security underlying the warrants within
20&#160;business days of the closing of an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Because we are neither limited to evaluating
a target business in a particular industry sector nor have we selected any target businesses with which to pursue our initial Business
Combination, you will be unable to ascertain the merits or risks of any particular target business&#8217;s operations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our efforts to identify a prospective
initial Business Combination target will not be limited to a particular industry, sector or geographic region. While we may pursue an
initial Business Combination opportunity in any industry or sector, we intend to capitalize on the ability of our management team to identify
and acquire a business or businesses that can benefit from our management team&#8217;s established global relationships and operating
experience. Our management team has extensive experience in identifying and executing strategic investments globally and has done so successfully
in a number of sectors. Our amended and restated memorandum and articles of association prohibits us from effectuating a Business Combination
solely with another blank check company or similar company with nominal operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have not yet selected
any specific target business with respect to a Business Combination, there is no basis to evaluate the possible merits or risks of any
particular target business&#8217;s operations, results of operations, cash flows, liquidity, financial condition or prospects. To the
extent we complete our initial Business Combination, we may be affected by numerous risks inherent in the business operations with which
we combine. For example, if we combine with a financially unstable business or an entity lacking an established record of sales or earnings,
we may be affected by the risks inherent in the business and operations of a financially unstable or a development stage entity. In recent&#160;years,
a number of target businesses have underperformed financially post-Business Combination. There are no assurances that the target business
with which we consummate our initial Business Combination will perform as anticipated. Although our officers and directors will endeavor
to evaluate the risks inherent in a particular target business, we cannot assure you that we will properly ascertain or assess all of
the significant risk factors or that we will have adequate time to complete due diligence. Furthermore, some of these risks may be outside
of our control and leave us with no ability to control or reduce the chances that those risks will adversely impact a target business.
We also cannot assure you that an investment in our Units will ultimately prove to be more favorable to investors than a direct investment,
if such opportunity were available, in a Business Combination target. Accordingly, any shareholders who choose to remain shareholders
following the Business Combination could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a
remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers
or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities
laws that the proxy solicitation or tender offer materials, as applicable, relating to the Business Combination contained an actionable
material misstatement or material omission.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may seek Business Combination opportunities
in industries or sectors that may be outside of our management&#8217;s areas of expertise.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will consider a Business
Combination outside of our management&#8217;s areas of expertise if a Business Combination candidate is presented to us and we determine
that such candidate offers an attractive Business Combination opportunity for our company. Although our management will endeavor to evaluate
the risks inherent in any particular Business Combination candidate, we cannot assure you that we will adequately ascertain or assess
all of the significant risk factors. We also cannot assure you that an investment in our Units will not ultimately prove to be less favorable
to investors than a direct investment, if an opportunity were available, in a Business Combination candidate. In the event we elect to
pursue a Business Combination outside of the areas of our management&#8217;s expertise, our management&#8217;s expertise may not be directly
applicable to its evaluation or operation, and the information contained regarding the areas of our management&#8217;s expertise would
not be relevant to an understanding of the business that we elect to acquire. As a result, our management may not be able to ascertain
or assess adequately all of the relevant risk factors. Accordingly, any shareholders who choose to remain shareholders following our initial
Business Combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy for such reduction
in value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 33; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Although we have identified general criteria
and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial Business Combination
with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial
Business Combination may not have attributes entirely consistent with our general criteria and guidelines.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have identified
general criteria and guidelines for evaluating prospective target businesses, it is possible that a target business with which we enter
into our initial Business Combination will not have all of these positive attributes. If we complete our initial Business Combination
with a target that does not meet some or all of these guidelines, such combination may not be as successful as a combination with a business
that does meet all of our general criteria and guidelines. In addition, if we announce a prospective Business Combination with a target
that does not meet our general criteria and guidelines, a greater number of shareholders may exercise their redemption rights, which may
make it difficult for us to meet any closing condition with a target business that requires us to have a minimum net worth or a certain
amount of cash. In addition, if shareholder approval of the transaction is required by applicable law or stock exchange listing requirements,
or we decide to obtain shareholder approval for business or other reasons, it may be more difficult for us to attain shareholder approval
of our initial Business Combination if the target business does not meet our general criteria and guidelines. If we have not completed
our initial Business Combination within the Completion Window, our Public Shareholders may only receive their pro rata portion of the
funds in the Trust Account that are available for distribution to Public Shareholders, and our warrants will expire worthless.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We are not required to obtain an opinion
from an independent accounting or investment banking firm or from an independent entity that commonly renders valuation opinions, and
consequently, you may have no assurance from an independent source that the price we are paying for the business is fair to our shareholders
from a financial point of view.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we complete our initial
Business Combination with a company that is affiliated with our Sponsor, officers or directors (or their respective affiliates or related
entities), we are not required to obtain an opinion from an independent investment banking firm which is a member of FINRA or an independent
firm that commonly renders valuation opinions for the type of company we are seeking to acquire or from an independent accounting firm
that our initial Business Combination is fair to our Company from a financial point of view. If no opinion is obtained, our shareholders
will be relying on the judgment of our board of directors, who will determine fair market value based on standards generally accepted
by the financial community. Such standards used will be disclosed in our proxy materials or tender offer documents, as applicable, related
to our initial Business Combination; provided that such conversion of Founder Shares will never occur on a less than one-for-one&#160;basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may issue additional Class A Ordinary
Shares or preference shares to complete our initial Business Combination or under an employee incentive plan after completion of our initial
Business Combination. We may also issue Class A Ordinary Shares upon the conversion of the Founder Shares at a ratio greater than&#160;one-to-one
at the time of our initial Business Combination as a result of the&#160;anti-dilution&#160;provisions contained therein. Any such issuances
would dilute the interest of our shareholders and likely present other risks.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
memorandum and articles of association authorizes the issuance of up to 200,000,000 Class A Ordinary Shares, par value $0.0001 per
share, 20,000,000 Class&#160;B ordinary shares, par value $0.0001 per share, and 1,000,000 preference shares, par value $0.0001 per
share. As of the date of this Form 10-K, there are 179,958,850 and 12,774,279 authorized but unissued Class A Ordinary Shares and
Class&#160;B ordinary shares, respectively, available for issuance which amount does not take into account shares reserved for
issuance upon exercise of outstanding warrants or shares issuable upon conversion of the Class&#160;B ordinary shares. The
Class&#160;B ordinary shares are automatically convertible into Class A Ordinary Shares (which such Class A Ordinary Shares issued
upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if we fail to
consummate an initial Business Combination) immediately prior to, concurrently with or immediately following the consummation of our
initial Business Combination or at any time prior thereto at the option of the holder, initially at a one-for-one&#160;ratio but
subject to adjustment as set forth herein and in our amended and restated memorandum and articles of association, including in
certain circumstances in which we issue Class A Ordinary Shares or equity-linked&#160;securities related to our initial Business
Combination. There are no preference shares issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 34; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue a substantial
number of additional Class A Ordinary Shares or preference shares to complete our initial Business Combination or under an employee incentive
plan after completion of our initial Business Combination. We may also issue Class A Ordinary Shares upon conversion of the Class&#160;B
ordinary shares at a ratio greater than one-to-one&#160;at the time of our initial Business Combination as a result of the anti-dilution&#160;provisions
as set forth therein. Such issuance of additional ordinary or preference shares could involve costs to us and our shareholders that would
not otherwise be incurred in a traditional initial public offering, including but not limited to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">significant dilution of the equity interest of investors,
which dilution would increase if the anti-dilution&#160;provisions in the Class&#160;B ordinary shares resulted in the issuance of Class
A Ordinary Shares on a greater than one-to-one&#160;basis upon conversion of the Class&#160;B ordinary shares;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">subordination of the rights of holders of Class A Ordinary
Shares if preference shares are issued with rights senior to those afforded our Class A Ordinary Shares;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">additional costs involved in registering the resale of the
securities being sold in any PIPE transactions and potential additional downward pressure on our share price due to the ability of investors
in such PIPE transactions being able to sell their securities after registration;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">potential change in control if a substantial number of Class
A Ordinary Shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any,
and could result in the resignation or removal of our present officers and directors;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">potential delaying or preventing of a change of control of
us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">adverse impact on prevailing market prices for our Units,
Class A Ordinary Shares and/or warrants.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, issuances of additional
ordinary or preference shares may not result in adjustment to the exercise price of our warrants. Such issuances may be structured in
a way intended to provide a return on investment to the investors in return for funds facilitating the completion of the Business Combination
or providing additional liquidity to the post-Business Combination company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Unlike some other similarly structured special
purpose acquisition companies, our initial shareholders will receive additional Class A Ordinary Shares if we issue certain shares to
consummate an initial Business Combination in order to provide&#160;anti-dilution&#160;protection to our initial shareholders.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Founder Shares will automatically
convert into Class A Ordinary Shares (which such Class A Ordinary Shares issued upon conversion will not have any redemption rights or
be entitled to liquidating distributions from the Trust Account if we fail to consummate an initial Business Combination) immediately
prior to, concurrently with or immediately following the consummation of our initial Business Combination or at any time prior thereto
at the option of the holder on a one-for-one&#160;basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations,
recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares,
or any other equity-linked&#160;securities, are issued or deemed issued in excess of the amounts sold in our Initial Public Offering and
related to or in connection with the closing of the initial Business Combination, the ratio at which Class&#160;B ordinary shares convert
into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class&#160;B ordinary shares agree
to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issuable
upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 26.5% of the sum of (i)&#160;the total number of all ordinary
shares outstanding (excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor), plus (ii)&#160;all
Class A Ordinary Shares and equity-linked&#160;securities issued or deemed issued in connection with our initial Business Combination
(excluding any shares or equity-linked&#160;securities issued, or to be issued, to any seller in the initial Business Combination and
any private placement-equivalent&#160;warrants issued to our Sponsor or any of its affiliates or to our officers and directors upon conversion
of working capital loans) minus (iii)&#160;any redemptions of Class A Ordinary Shares by Public Shareholders prior to or in connection
with an initial Business Combination. The purpose of such adjustment to provide anti-dilution&#160;protection to our initial shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 35; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may issue our shares to investors in
connection with our initial Business Combination at a price which is less than the prevailing market price of our shares at that time.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with our initial
Business Combination, we may issue shares to investors in private placement transactions (so-called&#160;PIPE transactions) at a price
of $10.00 per share or lower, at a price that approximates the per-share&#160;amounts in our Trust Account at such time. The purpose of
such issuances will be to enable us to provide sufficient liquidity and capital to the post-Business Combination entity. The price of
the shares we issue may therefore be less, and potentially significantly less, than the market price for our shares at such time. Any
such issuances of equity securities could dilute the interests of our existing shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Since only holders of our Class&#160;B ordinary
shares will have the right to vote on the appointment of directors, the NYSE may consider us to be a &#8220;controlled company&#8221;
within the meaning of the NYSE rules and, as a result, we may qualify for exemptions from certain corporate governance requirements.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation of
a Business Combination, only holders of our Class&#160;B ordinary shares will have the right to vote on the appointment of directors.
As a result, the NYSE will consider us to be a &#8220;controlled company&#8221; within the meaning of the NYSE corporate governance standards.
Under the NYSE corporate governance standards, a company of which more than 50% of the voting power for the appointment of directors is
held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate
governance requirements, including the requirements that:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we have a board that includes a majority of &#8220;independent
directors,&#8221; as defined under the rules of the NYSE; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">we have a compensation committee of our board that is comprised
entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not intend
to rely on the &#8220;controlled company&#8221; exemption, but may do so in the future. Accordingly, if we choose to do so, you will not
have the same protections afforded to shareholders of companies that are subject to all of the NYSE corporate governance requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Resources could be wasted in researching
potential Business Combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire
or merge with another business. If we are unable to complete our initial Business Combination, our Public Shareholders may only receive
their pro rata portion of the funds in the Trust Account that are available for distribution to Public Shareholders, and our warrants
will expire worthless.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the investigation
of each specific target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments
will require substantial management time and attention and substantial costs for accountants, attorneys, consultants and others. If we
decide not to complete a specific initial Business Combination, the costs incurred up to that point for the proposed transaction likely
would not be recoverable. Furthermore, if we reach an agreement relating to a specific target business, we may fail to complete our initial
Business Combination for any number of reasons including those beyond our control. Any such event will result in a loss to us of the related
costs incurred which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we
are unable to complete our initial Business Combination within the Completion Window, our Public Shareholders may only receive their pro
rata portion of the funds in the Trust Account that are available for distribution to Public Shareholders, and our warrants will expire
worthless.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 36; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may engage in a Business Combination
with one or more target businesses that have relationships with entities that may be affiliated with our Sponsor, officers, directors
or existing holders which may raise potential conflicts of interest.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the involvement
of our Sponsor, its managing member, and our officers and directors with other entities, we may decide to acquire one or more businesses
affiliated with or competitive with our Sponsor, officers, directors and their respective affiliates or existing holders. Our directors
also serve as officers and/or board members for other entities. Our Sponsor, officers and directors may sponsor, form or participate in
other blank check companies similar to ours during the period in which we are seeking an initial Business Combination. Such entities may
compete with us for Business Combination opportunities. Our Sponsor, officers and directors are not currently aware of any specific opportunities
for us to complete our initial Business Combination with any entities with which they are affiliated, and there have been no substantive
discussions concerning a Business Combination with any such entity or entities. Although we will not be specifically focusing on, or targeting,
any transaction with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met our
criteria for a Business Combination as set forth in &#8220;<i>Item 1. Business&#160;&#8212;&#160;Effecting our Initial Business Combination&#160;&#8212;&#160;Evaluation
of a Target Business and Structuring of our Initial Business Combination</i>&#8221; and such transaction was approved by a majority of
our independent and disinterested directors. Despite our obligation to obtain an opinion from an independent investment banking firm or
an independent entity that commonly renders valuation opinions for the type of company we are seeking to acquire or from an independent
accounting firm regarding the fairness to our company from a financial point of view of a Business Combination with one or more domestic
or international businesses affiliated with our Sponsor, officers or directors (or their respective affiliates or related entities), potential
conflicts of interest still may exist and, as a result, the terms of the Business Combination may not be as advantageous to our Public
Shareholders as they would be absent any conflicts of interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Since our Sponsor, officers and directors,
any other holder of our Founder Shares, and the Underwriters may lose their entire investment in us if our initial Business Combination
is not completed (other than with respect to Public Shares), a conflict of interest may arise in determining whether a particular Business
Combination target is appropriate for our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On May 5, 2025, our
Sponsor paid $25,000, or approximately $0.003 per share, to cover certain of our offering costs in exchange for 7,255,952 Founder Shares. In June 2025, our Sponsor transferred 30,000 Founder Shares to each of our independent directors (for an aggregate of 90,000
Founder Shares) at the same per-share price at which our Sponsor purchased such shares, or approximately $0.003 per share. On July
24, 2025, the Underwriters partially exercised their Over-Allotment Option and forfeited their right to purchase the remaining
83,850 Units under the Over-Allotment Option. As a result, the Sponsor forfeited 30,231 Founder Shares, resulting in our Sponsor
holding 7,135,721 Founder Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the initial investment
in the company of $25,000 by the Sponsor, the Company had no assets, tangible or intangible. The purchase price of the Founder Shares
was determined by dividing the amount of cash contributed to the Company by the number of Founder Shares issued. The number of Founder
Shares outstanding was determined based on the expectation that the total size of the Initial Public Offering would be a maximum of 20,125,000&#160;Units,
and therefore that such Founder Shares would represent 26.5% of the outstanding shares after the Initial Public Offering. The Founder Shares
will be worthless if we do not complete an initial Business Combination, except to the extent they receive liquidating distributions from
assets outside of the Trust Account. In addition, our Sponsor purchased 5,050,000 Private Placement Warrants, each exercisable to purchase
one Class A Ordinary Share at $11.50 per share, at a price of $1.00 per warrant, or $5,050,000 in the aggregate, in a private placement
that closed simultaneously with the closing of the Initial Public Offering. If we do not complete an initial Business Combination within
the Completion Window, the Private Placement Warrants will be worthless. The personal and financial interests of our officers and directors
may influence their motivation in identifying and selecting a target Business Combination, completing an initial Business Combination
and influencing the operation of the business following the initial Business Combination. This risk may become more acute as the end of
the Completion Window nears, which is the deadline for our completion of an initial Business Combination, unless such Completion Window
is extended as described herein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 37; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may issue notes or other debt securities,
or otherwise incur substantial debt, to complete a Business Combination, which may adversely affect our leverage and financial condition
and thus negatively impact the value of our shareholders&#8217; investment in us.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have no commitments
as of the date of this Form 10-K to issue any notes or other debt securities, or to otherwise incur outstanding debt, we may choose to
incur substantial debt to complete our initial Business Combination. The incurrence of debt could have a variety of negative effects,
including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">default and foreclosure on our assets if our operating revenues
after an initial Business Combination are insufficient to repay our debt obligations;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">acceleration of our obligations to repay the indebtedness
even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial
ratios or reserves without a waiver or renegotiation of that covenant;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our immediate payment of all principal and accrued interest,
if any, if the debt security is payable on demand;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our inability to obtain necessary additional financing if
the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">using a substantial portion of our cash flow to pay principal
and interest on our debt, which will reduce the funds available for expenses, capital expenditures, acquisitions and other general corporate
purposes;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">limitations on our flexibility in planning for and reacting
to changes in our business and in the industry in which we operate;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">increased vulnerability to adverse changes in general economic,
industry and competitive conditions and adverse changes in government regulation; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">limitations on our ability to borrow additional amounts for
expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages
compared to our competitors who have less debt.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may only be able to complete one Business
Combination with the proceeds of our Initial Public Offering and the sale of the Private Placement Warrants, which will cause us to be
solely dependent on a single business which may have a limited number of products or services. This lack of diversification may negatively
impact our operations and profitability. </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may effectuate our initial
Business Combination with a single target business or multiple target businesses simultaneously or within a short period of time. However,
we may not be able to effectuate our initial Business Combination with more than one target business because of various factors, including
the existence of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the SEC that
present operating results and the financial condition of several target businesses as if they had been operated on a combined basis. By
completing our initial Business Combination with only a single entity, our lack of diversification may subject us to numerous economic,
competitive and regulatory developments. Further, we would not be able to diversify our operations or benefit from the possible spreading
of risks or offsetting of losses, unlike other entities which may have the resources to complete several Business Combinations in different
industries or different areas of a single industry. Accordingly, the prospects for our success may be:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">solely dependent upon the performance of a single business,
property or asset, or</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">dependent upon the development or market acceptance of a
single or limited number of products, processes or services.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This lack of diversification
may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon
the particular industry in which we may operate subsequent to our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 38; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may attempt to simultaneously complete
Business Combinations with multiple prospective targets, which may hinder our ability to complete our initial Business Combination and
give rise to increased costs and risks that could negatively impact our operations and profitability.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we determine to simultaneously
acquire several businesses that are owned by different sellers, we will need for each of such sellers to agree that our purchase of its
business is contingent on the simultaneous closings of the other Business Combinations, which may make it more difficult for us, and delay
our ability, to complete our initial Business Combination. With multiple Business Combinations, we could also face additional risks, including
additional burdens and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers)
and the additional risks associated with the subsequent assimilation of the operations and services or products of the acquired companies
in a single operating business. If we are unable to adequately address these risks, it could negatively impact our profitability and results
of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may attempt to complete our initial Business
Combination with a private company about which little information is available, which may result in a Business Combination with a company
that is not as profitable as we suspected, if at all.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pursuing our Business Combination
strategy, we may seek to effectuate our initial Business Combination with a privately held company. Very little public information generally
exists about private companies, and we could be required to make our decision on whether to pursue a potential initial Business Combination
on the basis of limited information, which may result in a Business Combination with a company that is not as profitable as we suspected,
if at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We do not have a specified maximum redemption
threshold. The absence of such a redemption threshold may make it possible for us to complete our initial Business Combination with which
a substantial majority of our shareholders do not agree.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated memorandum
and articles of association do not provide a specified maximum redemption threshold. Our proposed initial Business Combination may impose
a minimum cash requirement for (i)&#160;cash consideration to be paid to the target or its owners, (ii)&#160;cash for working capital
or other general corporate purposes or (iii)&#160;the retention of cash to satisfy other conditions. As a result, we may be able to complete
our initial Business Combination even though a substantial majority of our Public Shareholders do not agree with the transaction and have
redeemed their shares. In the event the aggregate cash consideration we would be required to pay for all Public Shares that are validly
submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed Business Combination
exceed the aggregate amount of cash available to us, we will not complete the Business Combination or redeem any shares, all Public Shares
submitted for redemption will be returned to the holders thereof, and we instead may search for an alternate Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>In order to effectuate an initial Business
Combination, special purpose acquisition companies have, in the recent past, amended various provisions of their charters and other governing
instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our amended and restated memorandum
and articles of association or governing instruments in a manner that will make it easier for us to complete our initial Business Combination
that our shareholders or warrant holders, as applicable, may not support.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to effectuate a Business
Combination, special purpose acquisition companies have, in the recent past, amended various provisions of their charters and governing
instruments, including their warrant agreements. For example, special purpose acquisition companies have extended the time to consummate
an initial Business Combination and, with respect to their warrants, amended their warrant agreements to require the warrants to be exchanged
for cash and/or other securities. Amending our amended and restated memorandum and articles of association requires the approval of a
special resolution under Cayman Islands law, which requires the affirmative vote of at least two-thirds&#160;(or, with respect to the
appointment or removal of directors or continuing the company outside of the Cayman Islands, 90%) of the votes cast by such shareholders
as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company,
and amending our warrant agreement requires a vote of holders of at least 50% of the Public Warrants and, solely with respect to any amendment
to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants
(including, for the avoidance of doubt, the forfeiture or cancellation of any Private Placement Warrants or working capital warrants),
50% of the then outstanding Private Placement Warrants. In addition, our amended and restated memorandum and articles of association requires
us to provide our Public Shareholders with the opportunity to redeem their Public Shares, regardless of whether they abstain, vote for,
or against, our initial Business Combination, for cash if we propose an amendment to our amended and restated memorandum and articles
of association (A)&#160;to modify the substance or timing of our obligation to allow redemption in connection with our initial Business
Combination or to redeem 100% of our Public Shares if we do not complete an initial Business Combination within the Completion Window
or (B)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial&#160;Business Combination
activity. Many SPACs have faced delisting of their securities following redemptions of shares by Public Shareholders in connection with
proposed amendments to their corporate charters since, after redeeming a large number of publicly held shares, they no longer meet the
continued listing requirements of the stock exchange. To the extent any of such amendments would be deemed to fundamentally change the
nature of the securities offered through this registration statement, we would register, or seek an exemption from registration for, the
affected securities. We cannot assure you that we will not seek to amend our charter or governing instruments or extend the time to consummate
an initial Business Combination in order to effectuate our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 39; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The provisions of our amended and restated
memorandum and articles of association that relate to our&#160;pre-Business Combination activity (and corresponding provisions of the
agreement governing the release of funds from our Trust Account) may be amended with the approval of holders of not less than&#160;two-thirds&#160;of
our ordinary shares which are represented in person or by proxy and are voted at a general meeting of the company, which is a lower amendment
threshold than that of some other special purpose acquisition companies. It may be easier for us, therefore, to amend our amended and
restated memorandum and articles of association to facilitate the completion of an initial Business Combination that some of our shareholders
may not support.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated memorandum
and articles of association provide that any of its provisions related to pre-Business Combination activity (including the requirement
to deposit proceeds of the Initial Public Offering and the private placement of warrants into the Trust Account and not release such amounts
except in specified circumstances, and to provide redemption rights to Public Shareholders as described herein, and other than amendments
relating to the provisions regulating the appointment and removal of directors and continuing the company in a jurisdiction outside the
Cayman Islands, which require the approval of a special resolution passed by the affirmative vote of at least 90% (or, where such amendment
is proposed in respect of the consummation of our initial Business Combination, two-thirds) of the votes cast by such shareholders as,
being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company) may
be amended if approved by special resolution under Cayman Islands law. Except as specified above with respect to matters requiring a 90%
majority, a special resolution requires the affirmative vote of at least two-thirds&#160;of the votes cast by such shareholders as, being
entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company. Corresponding
provisions of the trust agreement governing the release of funds from our Trust Account may be amended if approved by the affirmative
vote of at least two-thirds&#160;of our ordinary shares which are represented in person or by proxy and are voted at a general meeting
of the Company. Our initial shareholders who beneficially own 26.5% of our ordinary shares, will participate in any vote to amend our amended and restated
memorandum and articles of association and/or trust agreement and will have the discretion to vote in any manner they choose. As a result,
we may be able to amend the provisions of our amended and restated memorandum and articles of association which govern our pre-Business
Combination behavior more easily than some other special purpose acquisition companies, and this may increase our ability to complete
a Business Combination with which you do not agree.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor, officers, directors
and director nominees have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our amended and
restated memorandum and articles of association (A)&#160;to modify the substance or timing of our obligation to allow redemption in connection
with our initial Business Combination or to redeem 100% of our Public Shares if we do not complete our initial Business Combination within
the Completion Window or (B)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial&#160;Business
Combination activity, in each case unless we provide our Public Shareholders with the opportunity to redeem their Public Shares upon approval
of any such amendment at a per-share&#160;price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account,
including interest earned on the funds held in the Trust Account (net of taxes paid or payable) and not previously released to us for
permitted withdrawals, divided by the number of then issued and outstanding Public Shares. Our shareholders are not parties to, or third-party&#160;beneficiaries
of, these agreements and, as a result, will not have the ability to pursue remedies against our Sponsor, officers, directors or director
nominees for any breach of these agreements. As a result, in the event of a breach, our shareholders would need to pursue a shareholder
derivative action, subject to applicable law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 40; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may be unable to obtain additional financing
to complete our initial Business Combination or to fund the operations and growth of a target business, which could compel us to restructure
or abandon a particular Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not selected any specific
Business Combination target but intend to target businesses with enterprise values that are greater than we could acquire with the net
proceeds of our Initial Public Offering and the sale of the Private Placement Warrants. As a result, if the cash portion of the purchase
price exceeds the amount available from the Trust Account, net of amounts needed to satisfy any redemption by Public Shareholders, we
may be required to seek additional financing to complete such proposed initial Business Combination. We cannot assure you that such financing
will be available on acceptable terms, if at all. To the extent that additional financing proves to be unavailable when needed to complete
our initial Business Combination, we would be compelled to either restructure the transaction or abandon that particular Business Combination
and seek an alternative target business candidate. Further, we may be required to obtain additional financing in connection with the closing
of our initial Business Combination for general corporate purposes, including for maintenance or expansion of operations of the post-transaction&#160;businesses,
the payment of principal or interest due on indebtedness incurred in completing our initial Business Combination, or to fund the purchase
of other companies. If we are unable to complete our initial Business Combination, our Public Shareholders may only receive their pro
rata portion of the funds in the Trust Account that are available for distribution to Public Shareholders, and our warrants will expire
worthless. In addition, even if we do not need additional financing to complete our initial Business Combination, we may require such
financing to fund the operations or growth of the target business. The failure to secure additional financing could have a material adverse
effect on the continued development or growth of the target business. None of our officers, directors or shareholders is required to provide
any financing to us in connection with or after our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our initial shareholders control the appointment
of our board of directors until consummation of our initial Business Combination and hold a substantial interest in us. As a result, they
will appoint all of our directors prior to the consummation of our initial Business Combination and may exert a substantial influence
on actions requiring a shareholder vote, potentially in a manner that you do not support.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor and members of
our management team own 26.5% of our issued and outstanding ordinary shares. Accordingly, they may exert a substantial influence on actions
requiring a shareholder vote, potentially in a manner that you do not support, including amendments to our amended and restated memorandum
and articles of association. This potential concentration of influence could be disadvantageous to other shareholders with interests different
from those of our initial shareholders. In addition, the Founder Shares, all of which are held by our initial shareholders, will entitle
the holders to appoint all of our directors prior to the consummation of our initial Business Combination. Holders of our Public Shares
will have no right to vote on the appointment or removal of directors during such time. Further, prior to the closing of our initial Business
Combination, only holders of our Class&#160;B ordinary shares will be entitled to vote on continuing our company in a jurisdiction outside
the Cayman Islands (including any special resolution required to amend our constitutional documents or to adopt new constitutional documents,
in each case, as a result of our approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). In addition,
our board of directors is and will be divided into three classes, each of which will generally serve for a term for three&#160;years with
only one class of directors being appointed in each year. These provisions of our amended and restated memorandum and articles of association
may only be amended if approved by a special resolution passed by the affirmative vote of at least 90% (or, where such amendment is proposed
in respect of the consummation of our initial Business Combination, two-thirds) of the votes cast by such shareholders as, being entitled
to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. In addition, our board
of directors, whose members were or will be appointed by our Sponsor, is and will be divided into three classes, each of which will generally
serve for a term for three&#160;years with only one class of directors being appointed in each year. As a result, you will not have any
influence over the appointment or removal of directors prior to our initial Business Combination or any influence over our continuation
in a jurisdiction outside the Cayman Islands prior to our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our initial shareholders
purchase any additional Class A Ordinary Shares in the aftermarket or in privately negotiated transactions, this would increase their
control. Neither our Sponsor nor, to our knowledge, any of our officers or directors, have any current intention to purchase additional
securities. Factors that would be considered in making such additional purchases would include consideration of the current trading price
of our Class A Ordinary Shares. We may not hold an annual or extraordinary general meeting to appoint new directors prior to the completion
of our initial Business Combination, in which case all of the current directors will continue in office until at least the completion
of the Business Combination. In addition, since only holders of our Class&#160;B ordinary shares will have the right to vote on directors
prior to our initial Business Combination, our initial shareholders will continue to exert control at least until the completion of our
initial Business Combination. Accordingly, our Sponsor will continue to exert control at least until the completion of our initial Business
Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 41; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may not be able to complete an initial
Business Combination because such initial Business Combination may be subject to regulatory review and approval requirements, including
foreign investment regulations and review by government entities such as the Committee on Foreign Investment in the United&#160;States
(&#8220;CFIUS&#8221;), or may be ultimately prohibited.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our initial Business Combination
may be subject to regulatory review and approval requirements by governmental entities, or ultimately prohibited. For example, CFIUS has
authority to review direct or indirect foreign investments in U.S.&#160;companies. Among other things, CFIUS is empowered to require certain
foreign investors to make mandatory filings, to charge filing fees related to such filings, and to self-initiate&#160;national security
reviews of foreign direct and indirect investments in U.S.&#160;companies if the parties to that investment choose not to file voluntarily.
In the case that CFIUS determines an investment to be a threat to national security, CFIUS has the power to unwind or place restrictions
on the investment. Whether CFIUS has jurisdiction to review an acquisition or investment transaction depends on&#160;&#8212;&#160;among
other factors&#160;&#8212;&#160;the nature and structure of the transaction, including the level of beneficial ownership interest and
the nature of any information or governance rights involved. For example, investments that result in &#8220;control&#8221; of a U.S.&#160;business
by a foreign person always are subject to CFIUS jurisdiction. CFIUS&#8217;s expanded jurisdiction under the Foreign Investment Risk Review
Modernization Act&#160;of&#160;2018 and implementing regulations that became effective on February&#160;13, 2020 further includes investments
that do not result in control of a U.S.&#160;business by a foreign person but afford certain foreign investors certain information or
governance rights in a U.S.&#160;business that has a nexus to &#8220;critical technologies,&#8221; &#8220;critical infrastructure&#8221;
and/or &#8220;sensitive personal data.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a particular proposed initial
Business Combination with a U.S.&#160;business falls within CFIUS&#8217;s jurisdiction, we may determine that we are required to make
a mandatory filing or that we will submit to CFIUS review on a voluntary basis, or to proceed with the transaction without submitting
to CFIUS and risk CFIUS intervention, before or after closing the transaction. CFIUS may decide to block or delay our proposed initial
Business Combination, impose conditions with respect to such initial Business Combination or request the President of the United&#160;States
to order us to divest all or a portion of the U.S.&#160;target business of our initial Business Combination that we acquired without first
obtaining CFIUS approval, which may limit the attractiveness of, delay or prevent us from pursuing certain target companies that we believe
would otherwise be beneficial to us and our shareholders. As a result, the pool of potential targets with which we could complete an initial
Business Combination may be limited and we may be adversely affected in terms of competing with other special purpose acquisition companies
which do not have any foreign ownership issues. In addition, certain federally licensed businesses may be subject to rules or regulations
that limit foreign ownership.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of government review,
whether by CFIUS or otherwise, could be lengthy. Because we have only a limited time to complete our initial Business Combination, our
failure to obtain any required approvals within the requisite time period may require us to liquidate. If we are unable to consummate
our initial Business Combination within the applicable time period required under our amended and restated memorandum and articles of
association, including as a result of extended regulatory review of a potential initial Business Combination, we will as promptly as reasonably
possible but not more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem the Public Shares,
at a per-share&#160;price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned
on the funds held in the Trust Account (which interest shall be net of amounts not previously released to us for permitted withdrawals
and up to $100,000 of interest to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares, which
redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating
distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of
other applicable law. In such event, our shareholders will miss the opportunity to benefit from an investment in a target company and
the appreciation in value of such investment. Additionally, our warrants may be worthless.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Due to the number of special purpose acquisition
companies evaluating targets, attractive targets may become more scarce and there may be more competition for attractive targets or such
attractive targets may not be interested in consummating a Business Combination with a SPAC due to a negative public perception of mergers
involving SPACs. This could increase the cost of our initial Business Combination and could even result in our inability to find a target
or to consummate an initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2021 and 2022, the number
of special purpose acquisition companies that have been formed increased substantially. Many potential targets for special purpose acquisition
companies have already entered into an initial Business Combination, and there are still many special purpose acquisition companies preparing
for an initial public offering, as well as many such companies currently in registration. As a result, at times, fewer attractive targets
may be available to consummate an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 42; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, because there
are more special purpose acquisition companies seeking to enter into an initial Business Combination with available targets, the competition
for available targets with attractive fundamentals or business models may increase, which could cause target companies to demand improved
financial terms. Attractive deals could also become more scarce for other reasons, such as economic or industry sector downturns (including
a negative public perception of mergers involving SPACs), geopolitical tensions, or increases in the cost of additional capital needed
to close Business Combinations or operate targets post-Business Combination. This could increase the cost of, delay or otherwise complicate
or frustrate our ability to find and consummate an initial Business Combination and may result in our inability to consummate an initial
Business Combination on terms favorable to our investors altogether.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Adverse developments affecting the financial
services industry, including events or concerns involving liquidity, defaults or&#160;non-performance&#160;by financial institutions,
could adversely affect our business, financial condition or results of operations, or our prospects.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The funds in our operating
account and our Trust Account will initially be held in banks or other financial institutions and will be invested only in U.S.&#160;government
treasury obligations with a maturity of 185&#160;days or less or in money market funds meeting certain conditions under Rule&#160;2a-7&#160;under
the Investment Company Act which invest only in direct U.S.&#160;government treasury obligations; the holding of these assets in this
form is intended to be temporary and for the sole purpose of facilitating the intended Business Combination. To mitigate the risk that
we might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that we hold
investments in the Trust Account, we may, at any time (based on our management team&#8217;s ongoing assessment of all factors related
to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the Trust Account
and instead to hold the funds in the Trust Account in cash or in an interest-bearing&#160;demand deposit account at a bank. Our cash held
in these accounts may exceed any applicable Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. Should events,
including limited liquidity, defaults, non-performance&#160;or other adverse developments occur with respect to the banks or other financial
institutions that hold our funds, or that affect financial institutions or the financial services industry generally, or concerns or rumors
about any events of these kinds or other similar risks, the value of the assets in our Trust Account could be impaired, which could have
a material impact on our operating results, liquidity, financial condition and prospects. For example, on March&#160;10, 2023, the FDIC
announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. We cannot guarantee
that the banks or other financial institutions that will hold our funds will not experience similar issues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Because we must furnish our shareholders
with target business financial statements, we may lose the ability to complete an otherwise advantageous initial Business Combination
with some prospective target businesses.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal proxy rules require
that a proxy statement with respect to a vote on an initial Business Combination meeting certain financial significance tests include
historical and pro forma financial statement disclosure. We will include the same financial statement disclosure in connection with our
tender offer documents, whether or not they are required under the tender offer rules. These financial statements may be required to be
prepared in accordance with, or be reconciled to, accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;)
or international financial reporting standards as issued by the International Accounting Standards Board (&#8220;IFRS&#8221;) depending
on the circumstances and the historical financial statements may be required to be audited in accordance with the standards of the Public
Company Accounting Oversight Board (United&#160;States) (&#8220;PCAOB&#8221;). These financial statement requirements may limit the pool
of potential target businesses we may acquire because some targets may be unable to provide such financial statements in time for us to
disclose such financial statements in accordance with federal proxy rules and complete our initial Business Combination within the prescribed
time frame.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 43; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Compliance obligations under the&#160;Sarbanes-Oxley&#160;Act
may make it more difficult for us to effectuate our initial Business Combination, require substantial financial and management resources,
and increase the time and costs of completing an initial Business Combination</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;404 of the Sarbanes-Oxley&#160;Act
requires that we evaluate and report on our system of internal controls beginning with our Annual Report on Form&#160;10-K&#160;for the
year ending December&#160;31, 2026. Only in the event we are deemed to be a large accelerated filer or an accelerated filer, and no longer
qualify as an emerging growth company, will we be required to comply with the independent registered public accounting firm attestation
requirement on our internal control over financial reporting. Further, for as long as we remain an emerging growth company, we will not
be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial
reporting. The fact that we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley&#160;Act particularly
burdensome on us as compared to other public companies because a target business with which we seek to complete our initial Business Combination
may not be in compliance with the provisions of the Sarbanes-Oxley&#160;Act regarding adequacy of its internal controls. The development
of the internal control of any such entity to achieve compliance with the Sarbanes-Oxley&#160;Act may increase the time and costs necessary
to complete any such Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks Relating to the&#160;Post-Business Combination
Company</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Subsequent to our completion of our initial
Business Combination, we may be required to take&#160;write-downs&#160;or&#160;write-offs, restructuring and impairment or other charges
that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which
could cause you to lose some or all of your investment.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we conduct due diligence
on a target business with which we combine, we cannot assure you that this diligence will identify all material issues that may be present
within a particular target business, that it would be possible to uncover all material issues through a customary amount of due diligence,
or that factors outside of the target business and outside of our control will not later arise. As a result of these factors, we may be
forced to later write-down&#160;or write-off&#160;assets, restructure our operations, or incur impairment or other charges that could
result in our reporting losses. Even if our due diligence successfully identifies certain risks, unexpected risks may arise and previously
known risks may materialize in a manner not consistent with our preliminary risk analysis. Even though these charges may be non-cash&#160;items
and not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market
perceptions about us or our securities. In addition, charges of this nature may cause us to violate net worth or other covenants to which
we may be subject as a result of assuming pre-existing&#160;debt held by a target business or by virtue of our obtaining debt financing
to partially finance the initial Business Combination or thereafter. Accordingly, any shareholders who choose to remain shareholders following
the Business Combination could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a remedy for
such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors
of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws
that the proxy solicitation or tender offer materials, as applicable, relating to the Business Combination contained an actionable material
misstatement or material omission.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The officers and directors of an acquisition
candidate may resign upon completion of our initial Business Combination. The loss of a Business Combination target&#8217;s key personnel
could negatively impact the operations and profitability of our&#160;post-combination&#160;business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of an acquisition
candidate&#8217;s key personnel upon the completion of our initial Business Combination cannot be ascertained at this time. Although we
contemplate that certain members of an acquisition candidate&#8217;s management team will remain associated with the acquisition candidate
following our initial Business Combination, it is possible that members of the management of an acquisition candidate will not wish to
remain in place. The departure of an acquisition candidate&#8217;s key personnel could negatively impact the operations and profitability
of our post-combination&#160;business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our management may not be able to maintain
control of a target business after our initial Business Combination. We cannot provide assurance that, upon loss of control of a target
business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may structure our initial
Business Combination so that the post-transaction&#160;company in which our Public Shareholders own shares will own less than 100% of
the equity interests or assets of a target business, but we will only complete such Business Combination if the post-transaction&#160;company
owns or acquires 50% or more of the outstanding voting securities of the target or is otherwise not to be required to register as an investment
company under the Investment Company Act. We will not consider any transaction that does not meet such criteria. Even if the post-transaction&#160;company
owns 50% or more of the voting securities of the target, our shareholders prior to our initial Business Combination may collectively own
a minority interest in the post-Business Combination company, depending on valuations ascribed to the target and us in the Business Combination.
For example, we could pursue a transaction in which we issue a substantial number of new Class A Ordinary Shares in exchange for all of
the outstanding capital stock, shares or other equity interests of a target. In this case, we would acquire a 100% interest in the target.
However, as a result of the issuance of a substantial number of new Class A Ordinary Shares, our shareholders immediately prior to such
transaction could own less than a majority of our issued and outstanding Class A Ordinary Shares subsequent to such transaction. In addition,
other minority shareholders may subsequently combine their holdings resulting in a single person or group obtaining a larger share of
the company&#8217;s shares than we initially acquired. Accordingly, this may make it more likely that our management will not be able
to maintain control of the target business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 44; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may have a limited ability to assess
the management of a prospective target business and, as a result, may effect our initial Business Combination with a target business whose
management may not have the skills, qualifications or abilities to manage a public company.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When evaluating the desirability
of effecting our initial Business Combination with a prospective target business, our ability to assess the target business&#8217;s management
may be limited due to a lack of time, resources or information. Our assessment of the capabilities of the target business&#8217;s management,
therefore, may prove to be incorrect and such management may lack the skills, qualifications or abilities we suspected. Should the target
business&#8217;s management not possess the skills, qualifications or abilities necessary to manage a public company, the operations and
profitability of the post-combination&#160;business may be negatively impacted. Accordingly, any shareholders who choose to remain shareholders
following the Business Combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy
for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors
of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws
that the proxy solicitation or tender offer materials, as applicable, relating to the Business Combination contained an actionable material
misstatement or material omission.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may seek Business Combination opportunities
with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our
desired results.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek Business Combination
opportunities with large, highly complex companies that we believe would benefit from operational improvements. While we intend to implement
such improvements, to the extent that our efforts are delayed or we are unable to achieve the desired improvements, the Business Combination
may not be as successful as we anticipate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent we complete our
initial Business Combination with a large complex business or entity with a complex operating structure, we may also be affected by numerous
risks inherent in the operations of the business with which we combine, which could delay or prevent us from implementing our strategy.
Although our management team will endeavor to evaluate the risks inherent in a particular target business and its operations, we may not
be able to properly ascertain or assess all of the significant risk factors until we complete our Business Combination. If we are not
able to achieve our desired operational improvements, or the improvements take longer to implement than anticipated, we may not achieve
the gains that we anticipate. Furthermore, some of these risks and complexities may be outside of our control and leave us with no ability
to control or reduce the chances that those risks and complexities will adversely impact a target business. Such combination may not be
as successful as a combination with a smaller, less complex organization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Transactions in connection with or in anticipation
of our initial Business Combination and our structure thereafter may not be&#160;tax-efficient&#160;to our shareholders and warrant holders.
As a result of our Business Combination, our tax obligations may be more complex, burdensome and/or uncertain.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we will attempt to
structure the transactions in connection with our initial Business Combination in a tax-efficient&#160;manner, tax structuring considerations
are complex, the relevant facts and law are uncertain and may change, and we may prioritize commercial and other considerations over tax
considerations. For example, in anticipation of or in connection with our initial Business Combination and subject to any requisite shareholder
approval, we may: enter into one or more transactions that require or structure our Business Combination in a manner that requires shareholders
and/or warrant holders to recognize gain or income for tax purposes or otherwise increase their tax burden; effect a Business Combination
with a target company in another jurisdiction; or reincorporate in a different jurisdiction (including, but not limited to, the jurisdiction
in which the target company or business is located). We do not intend to make any cash distributions to shareholders or warrant holders
to pay taxes in connection with our Business Combination or thereafter. Accordingly, a shareholder or a warrant holder may need to satisfy
any liability resulting from our initial Business Combination with cash from its own funds or by selling all or a portion of the shares
or warrants received.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 45; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may effect
a Business Combination with a target company that has business operations outside of the United&#160;States, and possibly, business operations
in multiple jurisdictions. If we effect such a Business Combination, we could be subject to significant income, withholding and other
tax obligations in a number of jurisdictions with respect to income, operations and subsidiaries related to those jurisdictions. Due to
the complexity of tax obligations and filings in other jurisdictions, we may have a heightened risk related to audits or examinations
by U.S.&#160;federal, state, local and non-U.S.&#160;taxing authorities. This additional complexity and risk could have an adverse effect
on our after-tax&#160;profitability and financial condition. In addition, shareholders and warrant holders may be subject to additional
income, withholding or other taxes with respect to their ownership of us after any such transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks Relating to Acquiring and Operating a
Business in Foreign Countries</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If we effect our initial Business Combination
with a company located outside of the United&#160;States, we would be subject to a variety of additional risks that may adversely affect
us.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we pursue a target company
with operations or opportunities outside of the United&#160;States for our initial Business Combination, we may face additional burdens
in connection with investigating, agreeing to and completing such initial Business Combination, and if we effect such initial Business
Combination, we would be subject to a variety of additional risks that may negatively impact our operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we pursue a target company
with operations or opportunities outside of the United&#160;States for our initial Business Combination, we would be subject to risks
associated with cross-border&#160;Business Combinations, including in connection with investigating, agreeing to and completing our initial
Business Combination, conducting due diligence in a foreign jurisdiction, having such transaction approved by any local governments, regulators
or agencies and changes in the purchase price based on fluctuations in foreign exchange rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we effect our initial Business
Combination with such a company, we would be subject to any special considerations or risks associated with companies operating in an
international setting, including any of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">costs and difficulties inherent in executing cross-border&#160;transactions,
managing cross-border&#160;business operations and complying with different commercial and legal requirements of overseas market;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">rules and regulations regarding currency redemption;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">complex corporate withholding taxes on individuals;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">laws governing the manner in which future Business Combinations
may be effected;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">exchange listing and/or delisting requirements;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">tariffs and trade barriers;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">regulations related to customs and import/export matters;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">local or regional economic policies and market conditions;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">unexpected changes in regulatory requirements;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">challenges in managing and staffing international operations;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">longer payment cycles;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">tax issues, such as tax law changes and variations in tax
laws as compared to the United&#160;States;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 46; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">currency fluctuations and exchange controls;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">rates of inflation;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">challenges in collecting accounts receivable;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">cultural and language differences;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">employment regulations;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">underdeveloped or unpredictable legal or regulatory systems;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">corruption;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">protection of intellectual property;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">social unrest, crime, strikes, riots and civil disturbances;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">regime changes and political upheaval;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">terrorist attacks, natural disasters, widespread health emergencies
and wars; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">deterioration of political relations with the United&#160;States.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to adequately
address these additional risks. If we were unable to do so, we may be unable to complete such initial Business Combination, or, if we
complete such initial Business Combination, our operations might suffer, either of which may adversely impact our business, financial
condition and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may reincorporate in or transfer by way
of continuation to another jurisdiction in connection with our Business Combination, and such reincorporation may result in taxes imposed
on shareholders or warrant holders.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may, in connection with
our initial Business Combination or otherwise and, to the extent applicable, subject to requisite shareholder approval by special resolution
under the Companies Act (with respect to which only holders of Class&#160;B ordinary shares will be entitled to vote prior to our initial
Business Combination), reincorporate in or transfer by way of continuation to the jurisdiction in which the target company or business
is located or in another jurisdiction. The transaction may require a shareholder or warrant holder to recognize taxable income in the
jurisdiction in which the shareholder or warrant holder is a tax resident or in which its members are resident if it is a tax transparent
entity (or may otherwise result in adverse tax consequences). We do not intend to make any cash distributions to shareholders or warrant
holders to pay such taxes. Shareholders or warrant holders may be subject to withholding taxes or other taxes with respect to their ownership
of our Class A Ordinary Shares or warrants after the reincorporation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, although we
may attempt to structure any change in our jurisdiction of incorporation (if any) in a tax-efficient&#160;manner (including, if possible,
in a manner that is tax-deferred&#160;for U.S.&#160;federal income tax purposes), tax structuring considerations are complex, the relevant
facts and law may be uncertain and may change, we may prioritize commercial and other considerations over tax considerations, and we may
prioritize company-level&#160;tax considerations over the tax considerations of our shareholders and warrant holders. As a result, the
change in our jurisdiction of incorporation may have adverse tax consequences to us or to our shareholders and warrant holders, including
the recognition of substantial gain for U.S.&#160;federal income tax purposes, and because you may not have prior notice of our change
in jurisdiction, you may not be able to avoid such consequences. For example, under certain circumstances, including if we are treated
as a PFIC, a U.S.&#160;Holder may be subject to U.S.&#160;federal income tax on gain or a deemed dividend upon the exchange of our ordinary
shares or warrants for our successor&#8217;s shares or warrants, and such taxes may be substantial. For a more detailed discussion of
the PFIC rules and the related tax considerations for U.S.&#160;investors, see the section of IPO registration statement captioned &#8220;<i>Certain
Income Tax Considerations&#160;&#8212;&#160;Material United&#160;States Federal Income Tax Considerations&#160;&#8212;&#160;U.S.&#160;Holders&#160;&#8212;&#160;Passive
Foreign Investment Company Rules.</i>&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 47; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the immediate
consequences of a change in our jurisdiction of incorporation, holding our successor&#8217;s shares or warrants following a change in
our jurisdiction of incorporation could have different, potentially adverse, consequences as compared to those of holding our shares or
warrants prior to any such change. For example, if we were to change our jurisdiction of incorporation from the Cayman Islands to Delaware,
this could have a number of adverse consequences to non-U.S.&#160;Holders who own our successor&#8217;s shares or warrants by exposing
them to U.S.&#160;taxation and reporting obligations, such as the taxation of dividends from our successor or the taxation of dispositions
of our successor&#8217;s shares or warrants. Because such persons may not have prior notice of our change in jurisdiction, they may not
be able to change the manner in which they hold our shares or warrants or dispose of our shares or warrants prior to any such change in
our jurisdiction of incorporation, and therefore such persons may not be able to avoid any adverse consequences of holding our successor&#8217;s
shares or warrants after such change.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, it is possible that
we would change our jurisdiction of incorporation in anticipation of consummating a specific Business Combination but not complete that
Business Combination for any number of reasons. If we are unable to consummate a Business Combination with a specific Business Combination
target following such a change in our jurisdiction of incorporation, our new jurisdiction of incorporation could have disadvantages to
us or our shareholders and/or warrant holders, particularly if we subsequently pursue a Business Combination with a target that is incorporated
in a different jurisdiction. In such circumstances, we may not be as competitive with other special purpose acquisition companies incorporated
in the Cayman Islands when pursuing certain target companies, the consummation of our initial Business Combination could be more complex,
or it may be more difficult to structure such an initial Business Combination in a tax-efficient&#160;manner. For example, we may change
our jurisdiction of incorporation to the United&#160;States in anticipation of a Business Combination with a U.S.&#160;target company
but ultimately effect our initial Business Combination with a non-U.S.&#160;target company. In such a case, we may be unable to structure
our initial Business Combination in a tax-deferred&#160;manner, and our shareholders and/or warrant holders may be required to pay substantial
U.S.&#160;federal income or other taxes in connection with the consummation of the initial Business Combination. In addition, the initial
Business Combination may result in tax inefficiencies for the post-Business Combination company, including that, if the post-Business
Combination company is organized outside of the United&#160;States, it may nevertheless be treated as a U.S.&#160;corporation for U.S.&#160;federal
income tax purposes, which treatment may result in substantial tax inefficiencies for both the post-Business Combination company and for
our shareholders and/or warrant holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you when or
whether we will change our jurisdiction of incorporation or, if we do change our jurisdiction of incorporation, the jurisdiction in which
we will ultimately be incorporated. Accordingly, there is significant uncertainty as to the legal, tax and other considerations that may
be applicable to us or to our shareholders and warrant holders, and we cannot provide you with specific or comprehensive examples of such
potential consequences. The rules governing a change in our jurisdiction of incorporation and the transactions that may occur in connection
with our initial Business Combination are complex, and the consequences arising from such rules or transactions will depend on a holder&#8217;s
particular circumstances and on the circumstances surrounding our change in jurisdiction and initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may reincorporate in or transfer by way
of continuation to another jurisdiction in connection with our initial Business Combination, and the laws of such jurisdiction may govern
some or all of our future material agreements and we may not be able to enforce our legal rights.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with our initial
Business Combination, we may relocate the home jurisdiction of our business from the Cayman Islands to another jurisdiction. If we determine
to do this, the laws of such jurisdiction may govern some or all of our future material agreements. The system of laws and the enforcement
of existing laws in such jurisdiction may not be as certain in implementation and interpretation as in the United&#160;States. The inability
to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business, business opportunities
or capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We are subject to changing law and regulations
regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of&#160;non-compliance.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to rules and
regulations by various governing bodies, including, for example, the SEC, which are charged with the protection of investors and the oversight
of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable law. Our efforts to comply
with new and changing laws and regulations have resulted in, and are likely to continue to result in, increased general and administrative
expenses and a diversion of management time and attention from revenue-generating&#160;activities to compliance activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 48; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, because these laws,
regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes
available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing
revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes,
we may be subject to penalty and our business may be harmed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>If our management following our initial
Business Combination is unfamiliar with United&#160;States securities laws, they may have to expend time and resources becoming familiar
with such laws, which could lead to various regulatory issues.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following our initial Business
Combination, our management may resign from their positions as officers or directors of the company and the management of the target business
at the time of the Business Combination will remain in place. Management of the target business may not be familiar with United&#160;States
securities laws. If new management is unfamiliar with United&#160;States securities laws, they may have to expend time and resources becoming
familiar with such laws. This could be expensive and time-consuming&#160;and could lead to various regulatory issues which may adversely
affect our operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Exchange rate fluctuations and currency
policies may cause a target business&#8217; ability to succeed in the international markets to be diminished.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event we acquire a non-U.S.&#160;target,
all revenues and income would likely be received in a foreign currency, and the dollar equivalent of our net assets and distributions,
if any, could be adversely affected by reductions in the value of the local currency. The value of the currencies in our target regions
fluctuate and are affected by, among other things, changes in political and economic conditions. Any change in the relative value of such
currency against our reporting currency may affect the attractiveness of any target business or, following consummation of our initial
Business Combination, our financial condition and results of operations. Additionally, if a currency appreciates in value against the
dollar prior to the consummation of our initial Business Combination, the cost of a target business as measured in dollars will increase,
which may make it less likely that we are able to consummate such transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>After our initial Business Combination,
substantially all of our assets may be located in a foreign country and substantially all of our revenue will be derived from our operations
in such country. Accordingly, our results of operations and prospects will be subject, to a significant extent, to the economic, political
and legal policies, developments and conditions in the country in which we operate.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The economic, political and
social conditions, as well as government policies, of the country in which our operations are located could affect our business. Economic
growth could be uneven, both geographically and among various sectors of the economy and such growth may not be sustained in the future.
If in the future such country&#8217;s economy experiences a downturn or grows at a slower rate than expected, there may be less demand
for spending in certain industries. A decrease in demand for spending in certain industries could materially and adversely affect our
ability to find an attractive target business with which to consummate our initial Business Combination and if we effect our initial Business
Combination, the ability of that target business to become profitable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks Relating to our Sponsor and Management
Team</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>A change of ownership or control of our
Sponsor could adversely affect our ability to consummate our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no restrictions on
our Sponsor&#8217;s managing members&#8217; ability to transfer equity interests in our Sponsor held by the managing member or otherwise
consent to a transfer of such equity interests by another member of our Sponsor. Transfers of equity interests in the Sponsor or its direct
or indirect parent entities may result in a change of ownership or control of our Sponsor. Such change of ownership or control of our
Sponsor could adversely affect our ability to consummate our initial Business Combination, as there can be no assurances that a new Sponsor
will possess the requisite skills, investor relationships and expertise to select an appropriate target business, obtain the necessary
financing and consummate the initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 49; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We are dependent upon our officers and directors
and their loss, or a reduction in the amount of time they can dedicate to our initial Business Combination, could adversely affect our
ability to operate.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are dependent
upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success depends on the
continued service of our officers and directors, at least until we have completed our initial Business Combination. In addition, our officers
and directors are not required to commit any specified amount of time to our affairs and, accordingly, will have conflicts of interest
in allocating their time among various business activities, including identifying potential Business Combinations and monitoring the related
due diligence. We do not have an employment agreement with, or key-man&#160;insurance on the life of, any of our directors or officers.
The unexpected loss of the services of one or more of our directors or officers could have a detrimental effect on us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our ability to successfully effect our initial
Business Combination and to be successful thereafter will be dependent upon the efforts of our key personnel, some of whom may join us
following our initial Business Combination. The loss of key personnel could negatively impact the operations and profitability of our&#160;post-combination&#160;business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to successfully
effect our initial Business Combination is dependent upon the efforts of our key personnel. The role of our key personnel in the target
business, however, cannot presently be ascertained. Although some of our key personnel may remain with the target business in senior management
or advisory positions following our initial Business Combination, it is likely that some or all of the management of the target business
will remain in place. While we intend to closely scrutinize any individuals we engage after our initial Business Combination, we cannot
assure you that our assessment of these individuals will prove to be correct. These individuals may be unfamiliar with the requirements
of operating a company regulated by the SEC, which could cause us to have to expend time and resources helping them become familiar with
such requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our key personnel may negotiate employment
or consulting agreements with a target business in connection with a particular Business Combination, and a particular Business Combination
may be conditioned on the retention or resignation of such key personnel. These agreements may provide for them to receive compensation
following our initial Business Combination and as a result, may cause them to have conflicts of interest in determining whether a particular
Business Combination is the most advantageous.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our key personnel may be able
to remain with our company after the completion of our initial Business Combination only if they are able to negotiate employment or consulting
agreements in connection with the Business Combination. Such negotiations would take place simultaneously with the negotiation of the
Business Combination and could provide for such individuals to receive compensation in the form of cash payments and/or our securities
for services they would render to us after the completion of the Business Combination. Such negotiations also could make such key personnel&#8217;s
retention or resignation a condition to any such agreement. The personal and financial interests of such individuals may influence their
motivation in identifying and selecting a target business, subject to their fiduciary duties under Cayman Islands law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our officers and directors will allocate
their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs.
This conflict of interest could have a negative impact on our ability to complete our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our officers and directors
are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their
time between our operations and our search for a Business Combination and their other businesses. We do not intend to have any full-time
employees prior to the completion of our initial Business Combination. Each of our officers is engaged in other business endeavors for
which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per
week to our affairs. Our independent directors also serve as officers and board members for other entities. If our officers&#8217; and
directors&#8217; other business affairs require them to devote substantial amounts of time to such affairs in excess of their current
commitment levels, it could limit their ability to devote time to our affairs which may have a negative impact on our ability to complete
our initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing
an initial business combination target. In particular, Messrs. Duroc-Danner and Gustafson also serve as Chief Executive Officer and Chief
Financial Officer, respectively, of Pyrophyte Acquisition Corp. (&#8220;Pyrophyte I&#8221;), a special purpose acquisition company that
consummated its initial public offering in October 2021. Pyrophyte I is currently in the process of consummating its initial business
combination with Sio Silica Corporation. Like us, Pyrophyte I may pursue initial business combination targets in any businesses or industries.
Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination.
However, because Pyrophyte I is currently in the process of consummating its initial business combination with Sio Silica Corporation,
we do not believe that such duties or obligations will materially affect our ability to complete our initial business combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 50; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our officers and directors presently have,
and any of them in the future may have additional, fiduciary or contractual obligations to other entities, including other blank check
companies, and, accordingly, may have conflicts of interest in allocating their time and in determining to which entity a particular business
opportunity should be presented.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we consummate our initial
Business Combination, we intend to engage in the business of identifying and combining with one or more businesses. Our Sponsor, its managing
member, and our officers and directors are, or may in the future become, affiliated with entities (such as operating companies or investment
vehicles) that are engaged in a similar business. We do not have employment contracts with our officers and directors that will limit
their ability to work at other businesses. In addition, our Sponsor, officers and directors may participate in the formation of, or become
an officer or director of, any other blank check company prior to completion of our initial Business Combination. As a result, our Sponsor,
officers and directors could have conflicts of interest in determining whether to present Business Combination opportunities to us or
to any other blank check company with which they may become involved. Our Sponsor, officers and directors have complete discretion, subject
to applicable fiduciary duties, as to which blank check company they choose to pursue a Business Combination and the order in which they
pursue Business Combinations for any of their existing or future blank check companies. As a result, our Sponsor, officers and directors
may pursue Business Combinations for blank check companies that it has sponsored in any order, which could result in its more recent blank
check companies completing Business Combinations prior to its blank check companies that were launched earlier. Each of our officers and
directors presently has, and any of them in the future may have additional, fiduciary, contractual or other obligations or duties to one
or more other entities pursuant to which such officer or director is or will be required to present a Business Combination opportunity
to such entities. Accordingly, if any of our officers or directors becomes aware of a Business Combination opportunity which is suitable
for an entity to which he or she has then current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual
obligations to present such Business Combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands
law. Our amended and restated memorandum and articles of association provide that, to the fullest extent permitted by law: (i)&#160;no
individual serving as a director or an officer, among other persons, shall have any duty, except and to the extent expressly assumed by
contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us, and (ii)&#160;we
renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which
(a)&#160;may be a corporate opportunity for any director or officer, on the one hand, and us, on the other or (b)&#160;the presentation
of which would breach an existing legal obligation of a director or officer to any other entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our officers, directors, advisors, security
holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not adopted a policy
that expressly prohibits our directors, officers, advisors, security holders or affiliates from having a direct or indirect pecuniary
or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest.
In fact, we may enter into a Business Combination with a target business that is affiliated with our Sponsor, our directors or officers,
although we do not intend to do so. Nor do we have a policy that expressly prohibits any such persons from engaging for their own account
in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests
and ours. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial Business Combination
target. In particular, Messrs. Duroc-Danner and Gustafson also serve as Chief Executive Officer and Chief Financial Officer, respectively,
of Pyrophyte Acquisition Corp. (&#8220;Pyrophyte I&#8221;), a special purpose acquisition company that consummated its initial public
offering in October 2021. Pyrophyte I is currently in the process of consummating its initial business combination with Sio Silica Corporation.
Like us, Pyrophyte I may pursue initial business combination targets in any businesses or industries. Any such companies, businesses or
investments may present additional conflicts of interest in pursuing an initial business combination. However, because Pyrophyte I is
currently in the process of consummating its initial business combination with Sio Silica Corporation, we do not believe that such duties
or obligations will materially affect our ability to complete our initial business combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 51; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The personal and financial
interests of our directors and officers may influence their motivation in timely identifying and selecting a target business and completing
a Business Combination. Consequently, our directors&#8217; and officers&#8217; discretion in identifying and selecting a suitable target
business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular Business Combination
are appropriate and in our best interest. If this were the case, it may be a breach of their fiduciary duties to us as a matter of Cayman
Islands law and claims against such individuals may arise for a breach of such duties. However, we might not ultimately be successful
in any claim we may make against them for such reason.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Members of our management team and board
of directors and our advisors have significant experience as founders, board members, officers, executives or employees of other companies.
Certain of those persons have been, are currently, or may become, involved in litigation, investigations or other proceedings, including
related to those companies or otherwise. This may have an adverse effect on us, which may impede our ability to consummate an initial
Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of their
careers, members of our management team and board of directors and our advisors have had significant experience as founders, board members,
officers, executives or employees of other companies including SPACs. Certain of those persons have been, are currently and may in the
future become involved in litigation, investigations or other proceedings, including but not limited to issues relating to breach of fiduciary
duty and/or the business affairs of such companies, including SPACs; transactions entered into by such companies, including SPACs; or
otherwise. Any such litigation, investigations or other proceedings may divert the attention and resources of our management team and
board of directors away from identifying and selecting a target business or businesses for our initial Business Combination and may result
in findings, orders, or other determinations adverse to members of our management team and board of directors or otherwise negatively
affect our reputation, which may impede our ability to complete an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Members of our management team and affiliated
companies may have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of our management team
have been (and intend to be) involved in a wide variety of businesses. Such involvement has, and may lead to, media coverage and public
awareness. As a result, members of our management team and affiliated companies may have been, and may in the future be, involved in civil
disputes or governmental investigations unrelated to our business. Any such claims or investigations may be detrimental to our reputation
and could negatively affect our ability to identify and complete an initial Business Combination and may have an adverse effect on the
price of our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our letter agreement with our Sponsor, officers
and directors may be amended without shareholder approval.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our letter agreement with our Sponsor, officers and directors contain
provisions relating to transfer restrictions of our Founder Shares and Private Placement Warrants, indemnification of the Trust Account,
waiver of redemption rights and participation in liquidating distributions from the Trust Account. The letter agreement may be amended
without shareholder approval (although releasing the parties from the restriction not to transfer the Founder Shares for one year following
the date of our Initial Public Offering requires the prior written consent of the Underwriters). While we do not expect our board to approve
any amendment to the letter agreement prior to our initial Business Combination, it may be possible that our board, in exercising its
business judgment and subject to its fiduciary duties, chooses to approve one or more amendments to the letter agreement. Any such amendments
to the letter agreement would not require approval from our shareholders and may have an adverse effect on the value of an investment
in our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks Relating to our Securities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>You will not have any rights or interests
in funds from the Trust Account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced
to sell your Public Shares or warrants, potentially at a loss.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Public Shareholders will
be entitled to receive funds from the Trust Account only upon the earliest to occur of: (i)&#160;our completion of an initial Business
Combination, and then only in connection with those Class A Ordinary Shares that such shareholder properly elected to redeem, subject
to the limitations and on the conditions described herein, (ii)&#160;the redemption of any Public Shares properly submitted in connection
with a shareholder vote to amend our amended and restated memorandum and articles of association (A)&#160;to modify the substance or timing
of our obligation to allow redemption in connection with our initial Business Combination or to redeem 100% of our Public Shares if we
do not complete our initial Business Combination within the Completion Window or (B)&#160;with respect to any other material provisions
relating to shareholders&#8217; rights or pre-initial&#160;Business Combination activity, and (iii)&#160;the redemption of our Public
Shares if we are unable to complete an initial Business Combination within the Completion Window, subject to applicable law and as further
described herein. In no other circumstances will a Public Shareholder have any right or interest of any kind in the Trust Account. Holders
of warrants will not have any right to the proceeds held in the Trust Account with respect to the warrants. Accordingly, to liquidate
your investment, you may be forced to sell your Public Shares or warrants, potentially at a loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 52; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The NYSE may delist our securities from
trading on its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional
trading restrictions.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Units, Class A Ordinary
Shares and Public Warrants on listed on the NYSE. We cannot assure you that our securities will continue to be listed on the NYSE in the
future or prior to our initial Business Combination. In order to continue listing our securities on the NYSE prior to our initial Business
Combination, we must maintain certain financial, distribution and share price levels. Generally, we must maintain a minimum market value
of listed securities (generally $50,000,000) and a minimum number of holders of our securities (generally 400 public holders). Additionally,
in connection with our initial Business Combination, we will be required to demonstrate compliance with the NYSE&#8217;s initial listing
requirements, which are more rigorous than the NYSE&#8217;s continued listing requirements, in order to continue to maintain the listing
of our securities on the NYSE. For instance, unless we decide to list on a different the NYSE tier such as the NYSE Capital Market which
has different initial listing requirements, our share price would generally be required to be at least $4.00 per share and we would be
required to have a minimum of 400 round lot holders of our securities. We cannot assure you that we will be able to meet those initial
listing requirements at that time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the NYSE delists our securities
from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities
could be quoted on an over-the-counter&#160;market. If this were to occur, we could face significant material adverse consequences, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a limited availability of market quotations for our securities;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reduced liquidity for our securities;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a determination that our Class A Ordinary Shares are a &#8220;penny
stock&#8221; which will require brokers trading in our Class A Ordinary Shares to adhere to more stringent rules and possibly result
in a reduced level of trading activity in the secondary trading market for our securities;</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a limited amount of news and analyst coverage; and</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a decreased ability to issue additional securities or obtain
additional financing in the future.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Securities Markets
Improvement Act&#160;of&#160;1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities,
which are referred to as &#8220;covered securities.&#8221; Because we expect that our Units and eventually our Class A Ordinary Shares
and warrants will be listed on the NYSE, our Units, Class A Ordinary Shares and warrants will qualify as covered securities under the
statute. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate
companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the
sale of covered securities in a particular case. While we are not aware of a state having used these powers to prohibit or restrict the
sale of securities issued by blank check companies, other than the State of Idaho, certain state securities regulators view blank check
companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities of blank check companies
in their states. Further, if we were no longer listed on the NYSE, our securities would not qualify as covered securities under the statute
and we would be subject to regulation in each state in which we offer our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 53; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our initial shareholders paid an aggregate
of $25,000, or approximately $0.003 per Founder Share and, accordingly, you will experience immediate and substantial dilution from the
purchase of our Class A Ordinary Shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The difference between the
public offering price per share (allocating all of the Unit purchase price to the Class A Ordinary Shares and none to the warrant included
in the Unit) and the pro forma net tangible book value per share of our Class A Ordinary Shares after the Initial Public Offering constitutes
the dilution to you and the other investors. Our initial shareholders acquired the Founder Shares at a nominal price of $25,000, or approximately
$0.003 per share, significantly contributing to this dilution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, the dilution that
our Public Shareholders will experience increases the more Public Shares are redeemed. The issuance of additional ordinary or preference
shares may also significantly dilute the equity interest of investors, which dilution would even further increase if the anti-dilution&#160;provisions
in the Class&#160;B ordinary shares resulted in the issuance of Class A Ordinary Shares on a greater than one-to-one&#160;basis upon conversion
of the Class&#160;B ordinary shares. In addition, because of the anti-dilution&#160;protection in the Class&#160;B ordinary shares, any
equity or equity-linked&#160;securities issued in connection with our initial Business Combination would be disproportionately dilutive
to our Class A Ordinary Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Public Shareholders will
experience dilution even if no Public Shares are redeemed in connection with an initial Business Combination or another redemption event,
for instance in connection with an amendment to our amended and restated memorandum and articles of association (A)&#160;to modify the
substance or timing of our obligation to allow redemption in connection with our initial Business Combination or to redeem 100% of our
Public Shares if we have not consummated an initial Business Combination within the Completion Window or (B)&#160;with respect to any
other material provisions relating to shareholders&#8217; rights or pre-initial&#160;Business Combination activity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, while our Public Shareholders
will experience dilution even if none of our Public Shares are redeemed, the dilution they will experience will decrease the more of our
Public Shares remain issued and outstanding following a redemption event. For instance, if we seek shareholder approval of our initial
Business Combination and we do not conduct redemptions in connection with our initial Business Combination pursuant to the tender offer
rules, our Sponsor, directors, officers, advisors or their affiliates may purchase Units, Public Shares, rights or equity-linked&#160;securities
in privately negotiated transactions or in the open market either prior to or following the completion of our initial Business Combination,
although they are under no obligation to do so. In the event of any such purchases of our shares prior to the completion of our initial
Business Combination or if we enter into non-redemption&#160;agreements with certain of our shareholders, the number of Class A Ordinary
Shares subject to redemption will be reduced by the amount of any such purchases or shares subject to non-redemption&#160;agreements,
increasing the pro forma net tangible book value per share. See &#8220;<i>Item 1. Business&#160;&#8212;&#160;Effecting Our Initial Business
Combination&#160;&#8212;&#160;Permitted Purchases of Our Securities</i>.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The nominal purchase price paid by our Sponsor
for the Founder Shares may result in significant dilution to the implied value of your Public Shares upon the consummation of our initial
Business Combination, and our Sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial
Business Combination, even if the Business Combination causes the trading price of our ordinary shares to materially decline.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to our Initial Public
Offering, our Sponsor paid a nominal aggregate purchase price of $25,000 for the Founder Shares, or approximately $0.003 per share. As
a result, the value of your Public Shares may be significantly diluted upon the consummation of our initial Business Combination, when
the Founder Shares are converted into Public Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows the
Public Shareholders&#8217; and our Sponsor&#8217;s investment per share and how these compare to the implied value of one Class A Ordinary
Share upon the completion of our initial Business Combination. The following table assumes that (i)&#160;our valuation is $191,011,810
(which is the amount we would have in the Trust Account for our initial Business Combination following payment of the maximum deferred
underwriting commissions), (ii)&#160;no interest is earned on the funds held in the Trust Account, (iii)&#160;no Public Shares are redeemed
in connection with our initial Business Combination and (iv)&#160;all Founder Shares are held by our initial shareholders upon completion
of our initial Business Combination, and does not take into account other potential impacts on our valuation at the time of the initial
Business Combination, such as (i)&#160;the value of our public and Private Placement Warrants, (ii)&#160;the trading price of our Class
A Ordinary Shares, (iii)&#160;the initial Business Combination transaction costs (other than the payment of up to $9,399,690 of deferred
underwriting commissions), (iv)&#160;any equity issued or cash paid to the target&#8217;s sellers, (v)&#160;any equity issued to other
third party investors, or (vi)&#160;the target&#8217;s business itself.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 54; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-indent: -10pt; padding-left: 10pt">Public Shares:</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,041,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Founder Shares:</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,225,721</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 10pt">Total shares:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">27,266,871</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total funds in trust available for initial Business Combination:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">191,011,810</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Public Shareholders&#8217; investment per Class A Ordinary Share<span style="font-size: 10pt"><sup>(1)</sup></span>:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">10.00</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Sponsor&#8217;s investment per Class&#160;B ordinary share<span style="font-size: 10pt"><sup>(2)</sup></span>:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 10pt">Initial implied value per Public Share:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">10.00</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Implied value per share upon consummation of initial Business Combination<span style="font-size: 10pt"><sup>(3)</sup></span>:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">7.01</td><td style="text-align: left">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><!-- Field: Rule-Page --><div style="width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">While the Public Shareholders&#8217; investment is in both the
Public Shares and the Public Warrants, for purposes of this table the full investment amount is ascribed to the Public Shares only.</td>
</tr></tbody></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">The total investment in the equity of the company by the Sponsor
is $5,075,000, consisting of (i)&#160;$25,000 paid by the Sponsor for the Founder Shares and (ii)&#160;$5,050,000 paid by the Sponsor
for 5,050,000 Private Placement Warrants. For purposes of this table, the full investment amount is ascribed to the Founder Shares only.</td>
</tr></tbody></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">All Founder Shares would automatically convert into Class A
Ordinary Shares upon completion of our initial Business Combination, or at any time prior thereto at the option of the holders thereof,
on a one-for-one&#160;basis, subject to adjustment, as described therein.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on these assumptions,
each Class A Ordinary Share would have an implied value of $7.01 per share upon completion of our initial Business Combination, representing
an approximately 29.9% decrease from the initial implied value of $10.00 per Public Share. While the implied value of $7.01 per Class
A Ordinary Share upon completion of our initial Business Combination would represent a dilution to our Public Shareholders, this would
represent a significant increase in value for our Sponsor relative to the price it paid for each Founder Share. At $7.01 per Class A Ordinary
Share, the 7,135,721 Class A Ordinary Shares that the Sponsor would own upon completion of our initial Business Combination (after automatic
conversion of the 7,135,721 Founder Shares) would have an aggregate implied value of $50,021,404. As a result, even if the trading price
of our Class A Ordinary Shares significantly declines, the value of the Founder Shares held by our Sponsor will be significantly greater
than the amount our Sponsor paid to purchase such shares. In addition, our Sponsor could potentially recoup its entire investment in our
company even if the trading price of our Class A Ordinary Shares after the initial Business Combination is as low as $0.70 per share.
As a result, our Sponsor is likely to earn a substantial profit on its investment in us upon disposition of its Class A Ordinary Shares
even if the trading price of our Class A Ordinary Shares declines after we complete our initial Business Combination. Our Sponsor may
therefore be economically incentivized to complete an initial Business Combination with a riskier, weaker-performing&#160;or less-established&#160;target
business than would be the case if our Sponsor had paid the same per share price for the Founder Shares as our Public Shareholders paid
for their Public Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This dilution would increase
to the extent that the anti-dilution&#160;provisions of the Founder Shares result in the issuance of Class A Ordinary Shares on a greater
than one-to-one&#160;basis upon conversion of the Founder Shares at the time of our initial Business Combination and would become exacerbated
to the extent that Public Shareholders seek redemptions from the trust for their Public Shares. In addition, because of the anti-dilution&#160;protection
in the Founder Shares, any equity or equity-linked&#160;securities issued in connection with our initial Business Combination would be
disproportionately dilutive to our Class A Ordinary Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The value of the Founder Shares following
completion of our initial Business Combination is likely to be substantially higher than the nominal price paid for them, even if the
trading price of our ordinary shares at such time is substantially less than $10.00 per Public Share.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor has invested in
us an aggregate of $5,075,000, comprised of the $25,000 purchase price for the Founder Shares and the $5,050,000 purchase price for the
Private Placement Warrants. Assuming a trading price of $10.00 per Public Share upon consummation of our initial Business Combination,
the 7,135,721 Founder Shares would have an aggregate implied value of $7.35. Even if the trading price of our ordinary shares were as
low as $0.70 per share, and the Private Placement Warrants are worthless, the value of the Founder Shares would be equal to our Sponsor&#8217;s
aggregate initial investment in us. As a result, our Sponsor is likely to be able to make a substantial profit on its investment in us
at a time when our Public Shares have lost significant value. Accordingly, members of our management team, who own interests in our Sponsor,
may be more willing to pursue a Business Combination with a riskier or less-established&#160;target business than would be the case if
our Sponsor had paid the same per share price for the Founder Shares as our Public Shareholders paid for their Public Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 55; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Because we are incorporated under the laws
of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S.&#160;federal
courts may be limited.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an exempted company
incorporated under the laws of the Cayman Islands. As a result, it may be difficult for investors to effect service of process within
the United&#160;States upon our directors or officers, or enforce judgments obtained in the United&#160;States courts against our directors
or officers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate affairs are governed
by our amended and restated memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands and the common
law of the Cayman Islands. We will also be subject to the federal securities laws of the United&#160;States. The rights of shareholders
to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under
Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived
in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, the decisions of whose
courts are of persuasive authority, but are not binding on a court in the Cayman Islands.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights of our shareholders
and the fiduciary responsibilities of our directors under Cayman Islands law are different from what they would be under statutes or judicial
precedent in some jurisdictions in the United&#160;States. In particular, the Cayman Islands has a different body of securities laws as
compared to the United&#160;States, and certain states, such as Delaware, may have more fully developed and judicially interpreted bodies
of corporate law. In addition, Cayman Islands companies may not have standing to initiate a shareholders derivative action in a Federal
court of the United&#160;States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been advised by Maples
and Calder (Cayman) LLP, our Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i)&#160;to recognize or
enforce against us judgments of courts of the United&#160;States predicated upon the civil liability provisions of the federal securities
laws of the United&#160;States or any state; and (ii)&#160;in original actions brought in the Cayman Islands, to impose liabilities against
us predicated upon the civil liability provisions of the federal securities laws of the United&#160;States or any state, so far as the
liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the
Cayman Islands of judgments obtained in the United&#160;States, the courts of the Cayman Islands will recognize and enforce a foreign
money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a
competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain
conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a
liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the
same matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is, contrary to natural
justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy).
A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of all of the above,
Public Shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the
board of directors or controlling shareholders than they would as Public Shareholders of a United&#160;States company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 56; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>After our initial Business Combination,
it is possible that a majority of our directors and officers will live outside the United&#160;States and all of our assets will be located
outside the United&#160;States; therefore, investors may not be able to enforce federal securities laws or their other legal rights.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that after our
initial Business Combination, a majority of our directors and officers will reside outside of the United&#160;States and all of our assets
will be located outside of the United&#160;States. As a result, it may be difficult, or in some cases not possible, for investors in the
United&#160;States to enforce their legal rights, to effect service of process upon all of our directors or officers or to enforce judgments
of United&#160;States courts predicated upon civil liabilities and criminal penalties on our directors and officers under United&#160;States
laws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Provisions in our amended and restated memorandum
and articles of association may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future
for our Class A Ordinary Shares and could entrench management.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated memorandum
and articles of association contain provisions that may discourage unsolicited takeover proposals that shareholders may consider to be
in their best interests. These provisions include the ability of the board of directors to designate the terms of and issue new series
of preference shares, which may make the removal of management more difficult and may discourage transactions that otherwise could involve
payment of a premium over prevailing market prices for our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our amended and restated memorandum and
articles of association provide that the courts of the Cayman Islands will be the exclusive forums for certain disputes between us and
our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for complaints against us or
our directors, officers or employees.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated memorandum
and articles of association provide that unless we consent in writing to the selection of an alternative forum, the courts of the Cayman
Islands shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with our amended and restated memorandum
and articles of association or otherwise related in any way to each shareholder&#8217;s shareholding in us, including but not limited
to (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of any fiduciary
or other duty owed by any of our current or former directors, officers or other employees to us or our shareholders, (iii)&#160;any action
asserting a claim arising pursuant to any provision of the Companies Act or our amended and restated memorandum and articles of association,
or (iv)&#160;any action asserting a claim against us governed by the internal affairs doctrine (as such concept is recognized under the
laws of the United&#160;States of America) and that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of
the Cayman Islands over all such claims or disputes. The forum selection provision in our amended and restated memorandum and articles
of association will not apply to actions or suits brought to enforce any liability or duty created by the Securities Act, Exchange&#160;Act
or any claim for which the federal district courts of the United&#160;States of America are, as a matter of the laws of the United&#160;States
of America, the sole and exclusive forum for determination of such a claim.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated memorandum
and articles of association also provide that, without prejudice to any other rights or remedies that we may have, each of our shareholders
acknowledges that damages alone would not be an adequate remedy for any breach of the selection of the courts of the Cayman Islands as
exclusive forum and that accordingly we shall be entitled, without proof of special damages, to the remedies of injunction, specific performance
or other equitable relief for any threatened or actual breach of the selection of the courts of the Cayman Islands as exclusive forum.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This choice of forum provision
may increase a shareholder&#8217;s cost and limit the shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers
and other employees. Any person or entity purchasing or otherwise acquiring any of our shares or other securities, whether by transfer,
sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions.
There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions
in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find this type
of provisions to be inapplicable or unenforceable, and if a court were to find this provision in our amended and restated memorandum and
articles of association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the
dispute in other jurisdictions, which could have an adverse effect on our business and financial performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 57; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Economic substance legislation of the Cayman
Islands may adversely impact us or our operations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Cayman Islands, together
with several other non-European&#160;Union jurisdictions, have introduced legislation aimed at addressing concerns raised by the Organisation
for Economic Co-operation&#160;and Development&#8217;s (OECD) Base Erosion and Profit Shifting (BEPS) initiative as to offshore structures
engaged in certain activities which attract profits without real economic activity. The International Tax Co-operation&#160;(Economic
Substance) Act, (As Revised) (the &#8220;Economic Substance Act&#8221;) contains economic substance requirements for in-scope&#160;Cayman
Islands entities which are engaged in certain &#8220;relevant activities.&#8221; As we are a Cayman Islands company, our compliance obligations
will include filing an annual notification, which need to state whether we are carrying out any relevant activities and if so, whether
we have satisfied economic substance tests to the extent required under the Economic Substance Act. If the Cayman Islands Tax Information
Authority determines that the Company or any of its Cayman Islands subsidiaries has failed to meet the requirements imposed by the Economic
Substance Act the Company may face significant financial penalties, restriction on the regulation of its business activities and/or may
be struck off as a registered entity in the Cayman Islands.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As it is still a relatively
new regime, it is anticipated that the Economic Substance Act and associated guidance will evolve and may be subject to further clarification
and amendments. We may need to allocate additional resources to keep updated with these developments, and may have to make changes to
our operations in order to comply with all requirements under the Economic Substance Act. Failure to satisfy these requirements may subject
us to penalties under the Economic Substance Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in order to comply
with legislation, regulations and guidance aimed at the prevention of money laundering, terrorist financing and proliferation financing,
and sanctions legislation the Company may be required to adopt and maintain anti-money&#160;laundering procedures, and may require subscribers
and their beneficial owners, controllers or authorized persons (where applicable) (&#8220;Related Persons&#8221;) to provide evidence
to verify their identity. Where permitted, and subject to certain conditions, the Company may also rely on, or delegate to, a suitable
person the maintenance of our anti-money&#160;laundering procedures (including the acquisition of due diligence information).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company reserves the right
to request such information as is necessary to verify the identity of a subscriber or their Related Persons. In the event of delay or
failure on the part of the subscriber in producing any information required for verification purposes, we may refuse to accept the application,
in which case any funds received will be returned without interest to the account from which they were originally debited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also reserves the
right to refuse to make any redemption payment to a shareholder if directors or officers suspect or are advised that the payment of redemption
proceeds to such shareholder might result in a breach of applicable anti-money&#160;laundering, sanctions or other laws or regulations
by any person in any relevant jurisdiction, or if such refusal is considered necessary or appropriate to ensure compliance with any such
laws or regulations in any applicable jurisdiction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any person in the Cayman
Islands knows or suspects, or has reasonable grounds for knowing or suspecting that another person is engaged in criminal conduct or money
laundering, or is involved with terrorism or terrorist financing and property, and the information for that knowledge or suspicion came
to their attention in the course of business in the regulated sector, or other trade, profession, business or employment, the person will
be required to report such knowledge or suspicion to (i)&#160;the Financial Reporting Authority of the Cayman Islands (&#8220;FRA&#8221;),
pursuant to the Proceeds of Crime Act (As Revised) of the Cayman Islands, if the disclosure relates to criminal conduct or money laundering,
or (ii)&#160;a police officer of the rank of constable or higher, or the FRA, pursuant to the Terrorism Act (As Revised) of the Cayman
Islands, if the disclosure relates to involvement with terrorism or terrorist financing and property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 58; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>An investment in our securities, and certain
subsequent transactions with respect to our securities, may result in uncertain or adverse U.S.&#160;federal income tax consequences.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our securities,
and certain subsequent transactions with respect to our securities, may result in uncertain or adverse U.S.&#160;federal income tax consequences.
For instance, because there are no authorities that directly address the U.S.&#160;federal income tax implications of instruments similar
to the Units issued in the Initial Public Offering, the allocation an investor makes with respect to the purchase price of a Unit between
the Class A Ordinary Share and the one-half&#160;of a warrant to purchase one Class A Ordinary Share included in each Unit could be challenged
by the U.S.&#160;Internal Revenue Service (&#8220;IRS&#8221;) or courts. In addition, the U.S.&#160;federal income tax consequences of
a cashless exercise of warrants included in the Units we are issued in the Initial Public Offering is unclear under current law. Finally,
it is unclear whether the redemption rights with respect to our Class A Ordinary Shares suspend the running of a U.S.&#160;Holder&#8217;s
(as defined in section titled &#8220;<i>Certain Income Tax Considerations</i>&#160;&#8212;&#160;<i>Material</i>&#160;<i>United&#160;States
Federal Income Tax Considerations</i>&#160;&#8212;&#160;<i>U.S.&#160;Holders</i>&#8221; in the IPO registration statement) holding period
for purposes of determining whether any gain or loss realized by such holder on the sale or exchange of Class A Ordinary Shares is long-term&#160;capital
gain or loss and for determining whether any dividend we pay would be considered &#8220;qualified dividend income&#8221; for U.S.&#160;federal
income tax purposes. See the section titled &#8220;<i>Certain Income Tax Considerations</i>&#160;&#8212;&#160;<i>Material United&#160;States
Federal Income Tax Considerations</i>&#8221; in the IPO registration statement for a summary of certain material U.S.&#160;federal income
tax considerations of an investment in our securities. Prospective investors are urged to consult their tax advisors with respect to these
and other tax consequences when acquiring, owning or disposing of our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The U.S.&#160;federal income tax consequences
to a shareholder of a redemption of Class A Ordinary Shares will depend on such investor&#8217;s particular facts and circumstances.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S.&#160;federal income
tax treatment of a redemption of Class A Ordinary Shares to a shareholder will depend on whether the redemption qualifies as a sale of
such Class A Ordinary Shares under Section&#160;302(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;),
which will depend largely on the total number of our shares treated as held by the shareholder electing to redeem Class A Ordinary Shares
(including any shares constructively owned by the holder as a result of owning Private Placement Warrants or Public Warrants or otherwise)
relative to all of our shares outstanding both before and after the redemption. If such redemption is not treated as a sale of Class A
Ordinary Shares for U.S.&#160;federal income tax purposes, the redemption will instead be treated as a corporate distribution of cash
from us. For more information about the U.S.&#160;federal income tax treatment of the redemption of Class A Ordinary Shares, see the sections
entitled &#8220;<i>Certain Income Tax Considerations&#160;&#8212;&#160;Material United&#160;States Federal Income Tax Considerations&#160;&#8212;&#160;U.S.&#160;Holders&#160;&#8212;&#160;Redemption
of</i>&#160;<i>Class A ordinary shares</i>&#8221; or &#8220;<i>Certain Income Tax Considerations&#160;&#8212;&#160;Material United&#160;States
Federal Income Tax Considerations&#160;&#8212;&#160;Non-U.S.&#160;Holders</i>,&#8221; in the IPO registration statement, as applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may amend the terms of the warrants in
a manner that may be adverse to holders of Public Warrants with the approval by the holders of at least 50% of the then outstanding Public
Warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened, the number of Class
A Ordinary Shares purchasable upon exercise of a warrant could be decreased.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our warrants will be issued
in registered form under a warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and us. The warrant
agreement provides that the terms of the warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity
or to correct any defective provision or mistake, including to conform the provisions of the warrant agreement to the description of the
terms of the warrants and the warrant agreement set forth in the registration statement in connection with our Initial Public Offering,
(ii) adjusting the provisions relating to cash dividends on ordinary shares as contemplated by and in accordance with the warrant agreement
or (iii) adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to
the warrant agreement may deem necessary or desirable, provided that the approval by the holders of at least 50% of the then issued and
outstanding public warrants is required to make any such change. Accordingly, we may amend the terms of the Public Warrants in a manner
adverse to a holder of Public Warrants if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. Although
our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then outstanding Public Warrants is unlimited,
examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants
into cash or shares, shorten the exercise period, decrease the number of Class A Ordinary Shares purchasable upon exercise of a warrant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 59; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our warrant agreement designates the courts
of the State of New&#160;York or the United&#160;States District Court for the Southern District of New&#160;York as the sole and exclusive
forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of
warrant holders to obtain a favorable judicial forum for disputes with our company.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our warrant agreement provides
that, subject to applicable law, (i)&#160;any action, proceeding or claim against us arising out of or relating in any way to the warrant
agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New&#160;York or the United&#160;States
District Court for the Southern District of New&#160;York, and (ii)&#160;that we irrevocably submit to such jurisdiction, which jurisdiction
shall be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum. With respect to any complaint asserting a cause of action arising under the Securities
Act or the rules and regulations promulgated thereunder, we note, however, that there is uncertainty as to whether a court would enforce
this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22
of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
these provisions of the warrant agreement will not apply to suits brought to enforce any liability or duty created by the Exchange&#160;Act
or any other claim for which the federal district courts of the United&#160;States of America are the sole and exclusive forum. Any person
or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and to have consented
to the forum provisions in our warrant agreement. If any action, the subject matter of which is within the scope the forum provisions
of the warrant agreement, is filed in a court other than a court of the State of New&#160;York or the United&#160;States District Court
for the Southern District of New&#160;York (a &#8220;foreign action&#8221;) in the name of any holder of our warrants, such holder shall
be deemed to have consented to: (x)&#160;the personal jurisdiction of the state and federal courts located in the State of New&#160;York
in connection with any action brought in any such court to enforce the forum provisions (an &#8220;enforcement action&#8221;), and (y)&#160;having
service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#8217;s counsel in
the foreign action as agent for such warrant holder. This choice-of-forum&#160;provision may limit a warrant holder&#8217;s ability to
bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Alternatively,
if a court were to find this provision of our warrant agreement inapplicable or unenforceable with respect to one or more of the specified
types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could
materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and
resources of our management and board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>A provision of our warrant agreement may
make it more difficult for us to consummate an initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If (i)&#160;we issue additional
ordinary shares or equity-linked&#160;securities for capital raising purposes in connection with the closing of our initial Business Combination
at a Newly Issued Price of less than $9.20 per Class A Ordinary Share, (ii)&#160;the aggregate gross proceeds from such issuances represent
more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination, and (iii)&#160;the
Market Value of our Class A Ordinary Shares is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the
nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger
prices will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. This may
make it more difficult for us to consummate an initial Business Combination with a target business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may redeem your unexpired warrants prior
to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have the ability to redeem
outstanding warrants at any time prior to their expiration, at a price of $0.01 per warrant, provided that the closing price of our Class
A Ordinary Shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the
exercise price of a warrant) for any 20&#160;trading days within a 30 trading-day&#160;period commencing at least 30&#160;days after completion
of our initial Business Combination and ending on the third&#160;trading day prior to the date on which we give proper notice of such
redemption to the warrants holders and provided certain other conditions are met. We will not redeem the warrants as described above unless
a registration statement under the Securities Act covering the issuance of the Class A Ordinary Shares issuable upon exercise of the warrants
is then effective and a current prospectus relating to those Class A Ordinary Shares is available throughout the measurement period. If
and when the warrants become redeemable by us, we may not exercise our redemption right if the issuance of ordinary shares upon exercise
of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such
registration or qualification. We will use our best efforts to register or qualify such ordinary shares under the blue sky laws of the
state of residence in those states in which the warrants were offered by us in our Initial Public Offering. Redemption of the outstanding
warrants could force you to (i)&#160;exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous
for you to do so, (ii)&#160;sell your warrants at the then-current&#160;market price when you might otherwise wish to hold your warrants
or (iii)&#160;accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to
be substantially less than the market value of your warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 60; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Our warrants may have an adverse effect
on the market price of our Class A Ordinary Shares and make it more difficult to effectuate our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We issued warrants to purchase
8,750,000 of our Class A Ordinary Shares as part of the Units and, simultaneously with the closing of the Initial Public Offering, we
will issued in a private placement an aggregate of 5,050,000 Private Placement Warrants at $1.00 per warrant. In addition, if the Sponsor
makes any working capital loans, it may convert those loans into up to an additional 1,500,000 Private Placement Warrants, at the price
of $1.00 per warrant. To the extent we issue ordinary shares to effectuate a business transaction, the potential for the issuance of a
substantial number of additional Class A Ordinary Shares upon exercise of these warrants could make us a less attractive acquisition vehicle
to a target business. Such warrants, when exercised, will increase the number of issued and outstanding Class A Ordinary Shares and reduce
the value of the Class A Ordinary Shares issued to complete the business transaction. Therefore, our warrants may make it more difficult
to effectuate a business transaction or increase the cost of acquiring the target business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Holders of Class A Ordinary Shares will
not be entitled to vote on continuing the company in a jurisdiction outside of the Cayman Islands.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As holders of our Class A Ordinary
Shares, our Public Shareholders will not have the right to vote on the appointment of directors and continuing our company in a jurisdiction
outside the Cayman Islands (including any special resolution required to amend our constitutional documents or to adopt new constitutional
documents, in each case, as a result of our approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands).
In addition, prior to our initial Business Combination, holders of a majority of our Founder Shares may remove a member of the board of
directors for any reason. Accordingly, you will not have any say in the management of our company prior to the consummation of an initial
Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>You will not be permitted to exercise your
warrants unless we register and qualify the underlying Class A Ordinary Shares or certain exemptions are available.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the issuance of the Class
A Ordinary Shares upon exercise of the warrants is not registered, qualified or exempt from registration or qualification under the Securities
Act and applicable state securities laws, holders of warrants will not be entitled to exercise such warrants and such warrants may have
no value and expire worthless. In such event, holders who acquired their warrants as part of a purchase of Units will have paid the full
Unit purchase price solely for the Class A Ordinary Shares included in the Units.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We registered the Class A Ordinary
Shares issuable upon exercise of the warrants in the registration statement for our Initial Public Offering because the warrants will
become exercisable 30&#160;days after the completion of our initial Business Combination, which may be within one year of our Initial
Public Offering. However, because the warrants will be exercisable until their expiration date of up to five&#160;years after the completion
of our initial Business Combination, in order to comply with the requirements of Section&#160;10(a)(3)&#160;of the Securities Act following
the consummation of our initial Business Combination, under the terms of the warrant agreement, we have agreed that, as soon as practicable,
but in no event later than 20&#160;business days, after the closing of our initial Business Combination, we will use our commercially
reasonable efforts to file with the SEC a post-effective&#160;amendment to the registration statement or a new registration statement
covering the registration under the Securities Act&#160;of&#160;the Class A Ordinary Shares issuable upon exercise of the warrants and
thereafter will use our commercially reasonable efforts to cause the same to become effective within 60&#160;business days following our
initial Business Combination and to maintain a current prospectus relating to the Class A Ordinary Shares issuable upon exercise of the
warrants until the expiration of the warrants in accordance with the provisions of the warrant agreement. We cannot assure you that we
will be able to do so if, for example, any facts or events arise which represent a fundamental change in the information set forth in
the registration statement or prospectus, the financial statements contained or incorporated by reference therein are not current or correct
or the SEC issues a stop order.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 61; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Class A Ordinary Shares
issuable upon exercise of the warrants are not registered under the Securities Act, under the terms of the warrant agreement, holders
of warrants who seek to exercise their warrants will not be permitted to do so for cash and, instead, will be required to do so on a cashless
basis in accordance with Section&#160;3(a)(9)&#160;of the Securities Act or another exemption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In no event will warrants be
exercisable for cash or on a cashless basis, and we will not be obligated to issue any shares to holders seeking to exercise their warrants,
unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising
holder, or an exemption from registration or qualification is available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our Class A Ordinary Shares
are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of &#8220;covered
securities&#8221; under Section&#160;18(b)(1)&#160;of the Securities Act, we may, at our option, not permit holders of warrants who seek
to exercise their warrants to do so for cash and, instead, require them to do so on a cashless basis in accordance with Section&#160;3(a)(9)&#160;of
the Securities Act; in the event we so elect, we will not be required to file or maintain in effect a registration statement or register
or qualify the shares underlying the warrants under applicable state securities laws, and in the event we do not so elect, we will use
our commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not
available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In no event will we be required
to net cash settle any warrant, or issue securities (other than upon a cashless exercise as described above) or other compensation in
exchange for the warrants in the event that we are unable to register or qualify the shares underlying the warrants under the Securities
Act or applicable state securities laws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>You may only be able to exercise your Public
Warrants on a &#8220;cashless basis&#8221; under certain circumstances, and if you do so, you will receive fewer Class A Ordinary Shares
from such exercise than if you were to exercise such warrants for cash.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrant agreement provides
that in the following circumstances holders of warrants who seek to exercise their warrants will not be permitted to do for cash and will,
instead, be required to do so on a cashless basis in accordance with Section&#160;3(a)(9)&#160;of the Securities Act: (i)&#160;if the
Class A Ordinary Shares issuable upon exercise of the warrants are not registered under the Securities Act in accordance with the terms
of the warrant agreement; (ii)&#160;if we have so elected and the Class A Ordinary Shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that they satisfy the definition of &#8220;covered securities&#8221; under Section&#160;18(b)(1)&#160;of
the Securities Act; and (iii)&#160;if we have so elected and we call the Public Warrants for redemption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you exercise your Public
Warrants on a cashless basis, you would pay the warrant exercise price by surrendering the warrants for that number of Class A Ordinary
Shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Class A Ordinary Shares underlying the warrants,
multiplied by the excess of the &#8220;fair market value&#8221; of our Class A Ordinary Shares (as defined in the next sentence) over
the exercise price of the warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; is the average reported closing
price of the Class A Ordinary Shares for the 10&#160;trading days ending on the third&#160;trading day prior to the date on which the
notice of exercise is received by the warrant agent or on which the notice of redemption is sent to the holders of warrants, as applicable.
As a result, you would receive fewer Class A Ordinary Shares from such exercise than if you were to exercise such warrants for cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The grant of registration rights to our
Sponsor, the Underwriters and other holders of our Private Placement Warrants may make it more difficult to complete our initial Business
Combination, and the future exercise of such rights may adversely affect the market price of our Class A Ordinary Shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to an agreement entered
into concurrently with the issuance and sale of the securities in Initial Public Offering, our Sponsor, the Underwriters, and their permitted
transferees can demand that we register the Class A Ordinary Shares into which Founder Shares are convertible, holders of our Private
Placement Warrants and their permitted transferees can demand that we register the Private Placement Warrants and the Class A Ordinary
Shares issuable upon exercise of the Private Placement Warrants or holders of securities that may be issued upon conversion of working
capital loans and their permitted transferees may demand that we register such Units, shares, warrants or the Class A Ordinary Shares
issuable upon exercise of such warrants and any other securities of the Company acquired by them prior to the consummation of our initial
Business Combination. We will bear the cost of registering these securities. The registration and availability of such a significant number
of securities for trading in the public market may have an adverse effect on the market price of our Class A Ordinary Shares. In addition,
the existence of the registration rights may make our initial Business Combination more costly or difficult to conclude. This is because
the shareholders of the target business may increase the equity stake they seek in the combined entity or ask for more cash consideration
to offset the negative impact on the market price of our Class A Ordinary Shares that is expected when the ordinary shares owned by our
initial shareholders, holders of our Private Placement Warrants or holders of our working capital loans or their respective permitted
transferees are registered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 62; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">General Risk Factors</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We are a blank check company with no operating
history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a blank check company
incorporated under the laws of the Cayman Islands with no operating results. Because we lack an operating history, you have no basis upon
which to evaluate our ability to achieve our business objective of completing our initial Business Combination. We have no plans, arrangements
or understandings with any prospective target business concerning a Business Combination and may be unable to complete our initial Business
Combination. If we fail to complete our initial Business Combination, we will never generate any operating revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Past performance by our management team,
our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses with
which they have been associated, may not be indicative of future performance of an investment in the Company.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information regarding our management
team, our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses
with which they have been associated, is presented for informational purposes only. Any past experience and performance by our management
team, our advisors and their respective affiliates and the businesses with which they have been associated, is not a guarantee that we
will be able to successfully identify a suitable candidate for our initial Business Combination, that we will be able to provide positive
returns to our shareholders, or of any results with respect to any initial Business Combination we may consummate. You should not rely
on the historical experiences of our management team, our advisors and their respective affiliates, including investments and transactions
in which they have participated and businesses with which they have been associated, as indicative of the future performance of an investment
in us or as indicative of every prior investment by each of the members of our management team, our advisors or their respective affiliates.
The market price of our securities may be influenced by numerous factors, many of which are beyond our control, and our shareholders may
experience losses on their investment in our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Cyber incidents or attacks directed at us
could result in information theft, data corruption, operational disruption and/or financial loss.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on digital technologies,
including information systems, infrastructure and cloud applications and services, including those of third parties with which we may
deal. Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure
of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential
data. As an early stage company without significant investments in data security protection, we may not be sufficiently protected against
such occurrences. We may not have sufficient resources to adequately protect against, or to investigate and remediate any vulnerability
to, cyber incidents. It is possible that any of these occurrences, or a combination of them, could have adverse consequences on our business
and lead to financial loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 63; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We may be a passive foreign investment company,
or &#8220;PFIC,&#8221; which could result in adverse United&#160;States federal income tax consequences to U.S.&#160;investors.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC for any taxable
year (or portion thereof) that is included in the holding period of a U.S.&#160;Holder (as defined in the section of the IPO registration
statement captioned &#8220;<i>Certain Income</i>&#160;<i>Tax Considerations&#160;&#8212;&#160;Material United&#160;States Federal Income
Tax Considerations&#160;&#8212;&#160;U.S Holders</i>&#8221;) of our Class A Ordinary Shares or warrants, the U.S.&#160;Holder may be subject
to adverse U.S.&#160;federal income tax consequences and may be subject to additional reporting requirements. Our PFIC status for our
current and subsequent taxable&#160;years may depend on whether we qualify for the PFIC start-up&#160;exception (see the section of the
IPO registration statement captioned &#8220;<i>Certain Income</i>&#160;<i>Tax&#160;Considerations&#160;&#8212;&#160;Material United&#160;States
Federal Income Tax Considerations&#160;&#8212;&#160;U.S.&#160;Holders&#160;&#8212;&#160;Passive Foreign Investment Company Rules</i>&#8221;).
Depending on the particular circumstances the application of the start-up&#160;exception may be subject to uncertainty, and there cannot
be any assurance that we will qualify for the start-up&#160;exception. Our actual PFIC status for any taxable year, however, will not
be determinable until after the end of such taxable year (and, in the case of the start-up&#160;exception, potentially not until after
the two taxable&#160;years following our current taxable year). Accordingly, there can be no assurances with respect to our status as
a PFIC for our current taxable year or any subsequent taxable year. Moreover, if we determine that we are a PFIC for any taxable year,
upon written request, we will endeavor to provide to a U.S.&#160;Holder such information as the IRS may require, including a PFIC annual
information statement, in order to enable the U.S.&#160;Holder to make and maintain a &#8220;qualified electing fund&#8221; election,
but there can be no assurance that we will timely provide such required information, and under current law such election would be unavailable
with respect to our warrants. We urge U.S.&#160;investors to consult their own tax advisors regarding the possible application of the
PFIC rules in general, and in particular to our warrants. For a more detailed explanation of the tax consequences of PFIC classification
to U.S.&#160;Holders, see the section of the IPO registration statement captioned &#8220;<i>Certain Income</i>&#160;<i>Tax Considerations&#160;&#8212;&#160;Material
United&#160;States Federal Income Tax Considerations&#160;&#8212;&#160;U.S.&#160;Holders&#160;&#8212;&#160;Passive Foreign Investment
Company Rules</i>.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>The Excise Tax could be imposed on redemptions
of our ordinary shares if we were to become a &#8220;covered corporation&#8221; in the future.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Inflation Reduction Act&#160;of&#160;2022,
among other things, generally imposes the Excise Tax on certain repurchases of stock by &#8220;covered corporations&#8221; (which include
publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign (i.e., non-U.S.) corporations)
occurring on or after January&#160;1, 2023. The Excise Tax is imposed on the repurchasing corporation itself, not its stockholders from
which the stock is repurchased. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased at the
time of the repurchase. However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market
value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year (the &#8220;netting
rule&#8221;). In addition, certain exceptions apply to the Excise Tax. The U.S.&#160;Department of the Treasury (the &#8220;Treasury&#8221;)
has authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of, the Excise Tax. On April&#160;9,
2024, the Treasury issued proposed regulations on which taxpayers may rely until final Treasury regulations addressing the Excise Tax
are published, which generally adopt (but in some respects expand or modify) the rules and guidance set forth in IRS Notice 2023-2, published
on January&#160;17, 2023, providing initial guidance regarding the application of the Excise Tax. On&#160;June&#160;28, 2024, the Treasury
finalized certain of the proposed regulations (those relating to procedures for reporting and paying the&#160;Excise Tax). Although IRS
Notice 2023-2&#160;and proposed Treasury regulations clarify certain aspects of the Excise Tax, the interpretation and operation of certain
other aspects of the Excise Tax remain unclear. There can be no assurance that final Treasury regulations will not adversely affect the
accuracy of the below description of the Excise Tax considerations that may be applicable to us if we were to become a &#8220;covered
corporation&#8221; in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently not a &#8220;covered
corporation&#8221; for purposes of the Excise Tax. Accordingly, we generally would not be subject to the Excise Tax on a redemption of
our stock, whether in connection with the consummation of our initial Business Combination or otherwise. If we were to become a &#8220;covered
corporation&#8221; in the future, whether in connection with the consummation of our initial Business Combination with a U.S.&#160;company
(including if we were to redomicile as a U.S.&#160;corporation in connection therewith) or otherwise, whether and to what extent we would
be subject to the Excise Tax on a redemption of our stock would depend on a number of factors, including (i)&#160;whether the redemption
is treated as a repurchase of stock for purposes of the Excise Tax, (ii)&#160;the fair market value of the redemption treated as a repurchase
of stock, (iii)&#160;the structure of our initial Business Combination, (iv)&#160;the nature and amount of any &#8220;PIPE&#8221; or other
equity issuances (whether in connection with our initial Business Combination or otherwise) issued within the same taxable year of a redemption
treated as a repurchase of stock and (v)&#160;the content of forthcoming regulations and other guidance from the Treasury. As noted above,
the Excise Tax would be payable by the repurchasing corporation, and not by the redeeming holder. The imposition of the Excise Tax on
us as a result of redemptions by us could, however, reduce the amount of cash available to the target business in connection with our
initial Business Combination, which could cause investors in our securities who do not redeem or the other shareholders of the combined
company to economically bear the impact of such Excise Tax. However, we will not use the proceeds placed in the Trust Account, or the
interest earned on the proceeds placed in the Trust Account, to pay for possible Excise Tax or any other fees or taxes that may be levied
on us on any redemptions or stock buybacks by us pursuant to any current, pending or further rules or laws, including without limitation
any Excise Tax, prior to release of such funds from the Trust Account following our initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 64; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>We are an emerging growth company and a
smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements
available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and
may make it more difficult to compare our performance with other public companies.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging growth
company&#8221; within the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but
not limited to, not being required to comply with the auditor internal controls attestation requirements of Section&#160;404 of the Sarbanes-Oxley&#160;Act,
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments
not previously approved. As a result, our shareholders may not have access to certain information they may deem important. We could be
an emerging growth company for up to five&#160;years, although circumstances could cause us to lose that status earlier, including if
the market value of our Class A Ordinary Shares held by non-affiliates&#160;exceeds $700&#160;million as of the prior June&#160;30, in
which case we would no longer be an emerging growth company as of December&#160;31 in the same year. We cannot predict whether investors
will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive
as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there
may be a less active trading market for our securities and the trading prices of our securities may be more volatile.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)&#160;of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards. The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging&#160;growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging
growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences
in accounting standards used.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we are a &#8220;smaller
reporting company&#8221; as defined in Item&#160;10(f)(1)&#160;of Regulation&#160;S-K.&#160;Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two&#160;years of audited financial statements.
We will remain a smaller reporting company until the last&#160;day of the fiscal year in which (1)&#160;the market value of our ordinary
shares held by non-affiliates&#160;is equal to or exceeds $250&#160;million as of the prior June&#160;30, or (2)&#160;our annual revenues
equaled or exceeded $100&#160;million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates&#160;is
equal to or exceeds $700&#160;million as of the prior June&#160;30. To the extent we take advantage of such reduced disclosure obligations,
it may also make comparison of our financial statements with other public companies difficult or impossible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Changes in the market for directors and
officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market for directors and
officers liability insurance for special purpose acquisition companies has changed in ways adverse to us and our management team. Fewer
insurance companies are offering quotes for directors and officers liability coverage, the premiums charged for such policies have generally
increased and the terms of such policies have generally become less favorable. These trends may continue into the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increased cost and decreased
availability of directors and officers liability insurance could make it more difficult and more expensive for us to negotiate an initial
Business Combination. In order to obtain directors and officers liability insurance or modify its coverage as a result of becoming a public
company, the post-Business Combination entity might need to incur greater expense, accept less favorable terms or both. However, any failure
to obtain adequate directors and officers liability insurance could have an adverse impact on the post-Business Combination&#8217;s ability
to attract and retain qualified officers and directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 65; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even after we
were to complete an initial Business Combination, our directors and officers could still be subject to potential liability from claims
arising from conduct alleged to have occurred prior to the initial Business Combination. As a result, in order to protect our directors
and officers, the post-Business Combination entity may need to purchase additional insurance with respect to any such claims (&#8220;run-off&#160;insurance&#8221;).
The need for run-off&#160;insurance would be an added expense for the post-Business Combination entity, and could interfere with or frustrate
our ability to consummate an initial Business Combination on terms favorable to our investors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Recent increases in inflation in the United&#160;States
and elsewhere could make it more difficult for us to complete our initial Business Combination.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent increases in inflation
in the United&#160;States and elsewhere may lead to increased price volatility for publicly traded securities, including ours, or other
national, regional or international economic disruptions, any of which could make it more difficult for us to complete our initial Business
Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_004" style="display: inline-block;"></span>Item 1B. Unresolved Staff Comments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_005" style="display: inline-block;"></span>Item 1C. Cybersecurity</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" contextRef="cref_619992257" escape="true" id="ixv-2980">As a blank check company, <ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" contextRef="cref_619992257" escape="true" id="ixv-7585">we have no operations and therefore do <ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7586">not</ix:nonNumeric> have any operations of our own that face cybersecurity threats.</ix:nonNumeric> However, we do depend on the digital technologies of <ix:nonNumeric name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" contextRef="cref_619992257" format="ixt:fixed-true" id="ixv-7587">third parties</ix:nonNumeric>, and as noted in &#8220;<i>Item 1A. Risk Factors</i>&#8221; of this Form 10-K, any sophisticated and deliberate attacks on, or security breaches in, systems or infrastructure or the cloud that we utilize, including those of third parties, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. Because of our reliance on the technologies of third parties, we also depend upon the personnel and the processes of third parties to protect against cybersecurity threats, and we have no personnel or processes of our own for this purpose. Our board of directors oversees risk for our Company, and prior to filings with the SEC, <ix:nonNumeric name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" contextRef="cref_619992257" escape="true" id="ixv-2982">our <ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" contextRef="cref_619992257" escape="true" id="ixv-7588">board of directors</ix:nonNumeric> reviews our risk factors, including the descriptions of the risks we face from cybersecurity threats, as described in &#8220;<i>Item 1A. Risk Factors</i>&#8221; of this Form 10-K.</ix:nonNumeric></ix:nonNumeric> </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_006" style="display: inline-block;"></span>Item 2. Properties</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive offices are
located at 3262 Westheimer Road, Suite 706, Houston, Texas 77098. Our executive offices are provided to us by our Sponsor, and we have
agreed to pay our Sponsor $35,000 per month for office space, utilities and secretarial and administrative support. We consider our current
office space adequate for our current operations.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_007" style="display: inline-block;"></span>Item 3. Legal Proceedings</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no material litigation,
arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_008" style="display: inline-block;"></span>Item 4. Mine Safety Disclosures</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></p><!-- Field: Page; Sequence: 66; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><span id="a_009" style="display: inline-block;"></span>Part
II</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_010" style="display: inline-block;"></span>Item 5. Market for Registrant&#8217;s Common
Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market Information</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Units, Class A Ordinary
Shares, and Public Warrants are listed on the NYSE under the symbols &#8220;PAII.U,&#8221; &#8220;PAII&#8221; and &#8220;PAII WS&#8221;,
respectively.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, there
was one holder of record of our Units, one holder of record of our Class A Ordinary Shares, four holders of record of our Class B ordinary
shares, and two holders of record of our warrants.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any cash
dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of an initial Business Combination.
The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general
financial conditions subsequent to completion of an initial Business Combination. The payment of any cash dividends subsequent to an initial
Business Combination will be within the discretion of our board of directors at such time. Further, if we incur any indebtedness, our
ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities Authorized for Issuance under
Equity Compensation Plans</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent Sales of Unregistered Securities and
Use of Proceeds from Registered Offerings</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_011" style="display: inline-block;"></span>Item 6. [Reserved]</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_012" style="display: inline-block;"></span>Item 7. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of the Company&#8217;s financial condition and results of operations should be read in conjunction with our audited financial
statements and the notes related thereto which are included in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of this
Form 10-K. Certain information contained in the discussion and analysis set forth below includes forward-looking statements. Our actual
results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those
set forth under &#8220;Special Note Regarding Forward-Looking Statements,&#8221; &#8220;Item 1A. Risk Factors&#8221; and elsewhere in
this Form 10-K.</i></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a blank check company
incorporated on May 1, 2025 as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share
exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business
Combination&#8221;). We have not selected any Business Combination target and we have not, nor has anyone on our behalf, initiated any
substantive discussions, directly or indirectly, with any Business Combination target. We may pursue an initial Business Combination in
any business or industry and in any geographic region but expect to target companies that are in the energy sector that constitute critical
links in the supply chain for, and/or service, the growing segments from the full spectrum of the energy ecosystem. Specifically, we seek
to focus on differentiated targets that provide critical minerals and materials, equipment, and/or technologies that support the span
of energy solutions from traditional to renewable energy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 67; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to effectuate our
initial Business Combination using cash from the proceeds of the initial public offering (the &#8220;IPO&#8221; or &#8220;Initial Public
Offering&#8221;) and the private placement of the Private Placement Warrants (as defined below), the proceeds of the sale of our shares
in connection with our initial Business Combination (pursuant to forward purchase agreements or backstop agreements we may enter into),
shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, other securities issuances,
or a combination of the foregoing or other sources.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of additional
shares in connection with a Business Combination to the owners of the target or other investors:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">may significantly dilute the equity interest of investors, which dilution would increase if the anti-dilution
provisions in the Class B ordinary shares (&#8220;Founder Shares&#8221;) resulted in the issuance of Class A Ordinary Shares on a greater
than one-to-one basis upon conversion of the Class B ordinary shares;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">may subordinate the rights of holders of Class A Ordinary Shares if preference shares are issued with
rights senior to those afforded our Class A Ordinary Shares;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">could cause a change in control if a substantial number of our Class A Ordinary Shares are issued, which
may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation
or removal of our present officers and directors;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">may have the effect of delaying or preventing a change of control of us by diluting the share ownership
or voting rights of a person seeking to obtain control of us; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">may adversely affect prevailing market prices for our Class A Ordinary Shares and/or warrants.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, if we issue debt
securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">default and foreclosure on our assets if our operating revenues after an initial Business Combination
are insufficient to repay our debt obligations;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments
when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation
of that covenant;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our immediate payment of all principal and accrued interest, if any, if the debt security is payable on
demand;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our inability to obtain necessary additional financing if the debt security contains covenants restricting
our ability to obtain such financing while the debt security is outstanding;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce
the funds available for expenses, capital expenditures, acquisitions and other general corporate purposes;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">limitations on our flexibility in planning for and reacting to changes in our business and in the industry
in which we operate;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">increased vulnerability to adverse changes in general economic, industry and competitive conditions and
adverse changes in government regulation; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions,
debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less
debt.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 68; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration statement
for our Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, we consummated the public offering of 20,041,150
units (the &#8220;Units&#8221; and, with respect to the Class A Ordinary Shares, par value $0.0001 per share, included in the Units being
offered the &#8220;Public Shares&#8221; or the &#8220;Class A Ordinary Shares&#8221;), at $10.00 per Unit, generating gross proceeds of
$200,411,500, and incurring transaction costs of approximately $12.8 million, consisting of $2.6 million of upfront underwriting fees,
approximately $9.4 million of deferred underwriting fees and approximately $740,000 of other offering costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Simultaneously with the consummation
of the Initial Public Offering, we consummated the sale of 5,050,000 private placement warrants (the &#8220;Private Placement Warrants&#8221;)
at a price of $1.00 per Private Placement Warrant in a private placement to Pyrophyte Acquisition II LLC (the &#8220;Sponsor&#8221;),
generating gross proceeds of $5,050,000 (the &#8220;Private Placement&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 24, 2025, the underwriters
of the Initial Public Offering (the &#8220;Underwriters&#8221;) partially exercised their over-allotment option to purchase an additional
2,541,150 units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $25,411,500. The Underwriters forfeited
their option to purchase an additional 83,850 units.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approximately $200,411,500
($10.00 per Unit) of the net proceeds of the Initial Public Offering (including approximately $9.4 million of the Underwriters&#8217;
deferred discount) and certain of the proceeds of the Private Placement were placed in a trust account (the &#8220;Trust Account&#8221;)
located in the United States with the Continental Stock Transfer &amp; Trust Company, and invested only in U.S. &#8220;government securities,&#8221;
within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;),
with a maturity of one hundred eighty-five (185) days or less, or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2),
(d)(3) and (d)(4) of Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations, as
determined by the Company, until the earlier of: (i) the completion of our Initial Public Offering and (ii) the distribution of the Trust
Account as otherwise permitted under our amended and restated memorandum and articles of association.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Company&#8217;s
amended and restated memorandum and articles of association, if it has not completed its initial Business Combination within 24 months
from the closing of the Initial Public Offering, it will as promptly as reasonably possible but not more than ten business days thereafter
(and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be
net of amounts not previously released to the Company for permitted withdrawals and up to $100,000 of interest to pay liquidation expenses),
divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of holders
of Public Shares (&#8220;Public Shareholders&#8221;) as shareholders (including the right to receive further liquidating distributions,
if any), subject to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of
other applicable law. The Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they
have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company
fails to complete its initial Business Combination within 24 months from the closing of the Initial Public Offering. However, if the Sponsor
or management team acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from
the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the prescribed
time period.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results of Operations</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have neither engaged in
any operations nor generated any revenues to date. Our only activities from May 1, 2025 (inception) through December 31, 2025 were organizational
activities, those necessary to prepare for the Initial Public Offering, described below, and subsequent to the Initial Public Offering,
the Company&#8217;s search for a target business with which to complete an initial Business Combination. We do not expect to generate
any operating revenues until after the completion of our initial Business Combination, at the earliest. Following the Initial Public Offering,
we will generate non-operating income in the form of interest income on marketable securities. We are incurring expenses as a result of
being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in
connection with completing an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 69; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the period from May 1,
2025 (inception) through December 31, 2025, we reported net income of $2,973,863 which consisted of interest on cash held in Trust Account
of $3,601,747, interest income of $329, offset by general and administrative expenses of $628,213.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity and Capital Resources</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: normal">As
of December 31, 2025, the Company had a cash balance of $442,500. The consummation of the Initial Public Offering, the Company&#8217;s
liquidity needs are satisfied through using net proceeds from the Initial Public Offering and sale of Private Placement Warrants for existing
accounts payable, identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target
businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents
and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating
the initial business combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company&#8217;s estimates
of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial Business Combination are
less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an
initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination
or because it becomes obligated to redeem a significant number of its public shares upon completion of an initial Business Combination,
in which case the Company may issue additional securities or incur debt in connection with such initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Contractual Obligations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Registration Rights</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the (i) Founder
Shares, which were issued in the Private Placement prior to the closing of the Initial Public Offering, (ii) Private Placement Warrants
and the Class A Ordinary Shares underlying such Private Placement Warrants and (iii) Private Placement Warrants that may be issued upon
conversion of working capital loans will have registration rights to require the Company to register a sale of any of the Company&#8217;s
securities held by them and any other securities of the Company acquired by them prior to the consummation of the Company&#8217;s initial
Business Combination pursuant to a registration rights agreement signed on the effective date of the Initial Public Offering. The holders
of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities.
In addition, the holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent
to the Company&#8217;s completion of the Company&#8217;s initial Business Combination. The Company will bear the expenses incurred in
connection with the filing of any such registration statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Underwriting Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 18, 2025, the Underwriters
were entitled to, and the Company paid, an underwriting discount of $0.15 per Unit, or $2,625,000 in the aggregate, upon closing of the
Initial Public Offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, $0.45 per Unit,
or approximately $9,399,690 in the aggregate, will be payable to the Underwriters for deferred underwriting commissions. The deferred
fee will become payable to the Underwriters from the amounts held in the Trust Account solely in the event that we complete an initial
Business Combination, subject to the terms of the underwriting agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 70; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Administrative Services Agreement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing on the date that
our securities were first listed and continuing until the earlier of our consummation of an initial Business Combination or our liquidation,
we have agreed to pay an affiliate of our Sponsor a total of $35,000 per month for office space, utilities, secretarial support and administrative
support made available to the Company. Upon completion of an initial Business Combination or the Company&#8217;s liquidation, we will
cease paying these monthly fees. The Company paid $192,500 in administrative fees for the period from May 1, 2025 (inception) through
December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Critical Accounting Policies and Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant accounting policies in Note 2 - <i>Summary
of Significant Accounting Policies</i>, of the Notes to Financial Statements included in this Form 10-K. Our financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Certain
of our accounting policies require that the Company&#8217;s management apply significant judgments in defining the appropriate assumptions
integral to financial estimates including stock-based compensation and the classification and valuation of the Company&#8217;s Public
and Private Placement Warrants. On an ongoing basis, the Company&#8217;s management reviews the accounting policies, assumptions, estimates
and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. Judgments are based on historical
experience, terms of existing contracts, industry trends and information available from outside sources, as appropriate. However, by their
nature, judgments are subject to an inherent degree of uncertainty, and, therefore, actual results could differ from our estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Off-Balance Sheet Arrangements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Annual
Report on Form 10-K, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">JOBS Act</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2012, the Jumpstart
Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was signed into law. The JOBS Act contains provisions that, among other
things, relax certain reporting requirements for qualifying public companies. We qualify as an &#8220;emerging growth company&#8221; under
the JOBS Act and are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly
traded) companies. We elected to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new
or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.
As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as
of public company effective dates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an &#8220;emerging growth
company,&#8221; we are not required to, among other things, (i) provide an auditor&#8217;s attestation report on our system of internal
controls over financial reporting, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public
companies, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory
audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements
(auditor discussion and analysis), and (iv) disclose comparisons of the CEO&#8217;s compensation to median employee compensation. These
exemptions will apply for a period of five (5) years following the completion of our Initial Public Offering or until we otherwise no
longer qualify as an &#8220;emerging growth company.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_013" style="display: inline-block;"></span>Item 7A. Quantitative and Qualitative Disclosures
about Market Risk</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended. As a result, pursuant to Item 305(e) of Regulation
S-K, we are not required to provide the information required by this item.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_014" style="display: inline-block;"></span>Item 8. Financial Statements and Supplementary
Data</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This information appears following
Item 15 of this Report and is included herein by reference.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_015" style="display: inline-block;"></span>Item 9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><!-- Field: Page; Sequence: 71; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_016" style="display: inline-block;"></span>Item 9A. Controls and Procedures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Evaluation of Disclosure Controls and Procedures</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure controls and procedures
are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and
forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including
our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and
with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation
of the effectiveness of our disclosure controls and procedures as of the fiscal year ended December 31, 2025, as such term is defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial
officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were
effective during the period covered by this report.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Management&#8217;s Report on Internal Controls Over Financial Reporting</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation
report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public
companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Changes in Internal Control over Financial Reporting</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no change in our
internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred during
the fiscal quarter ended December 31, 2025 covered by this Annual Report that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_017" style="display: inline-block;"></span>Item 9B. Other Information</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7589"><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7590"><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7591"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" contextRef="cref_619992257" format="ixt:fixed-false" id="ixv-7592">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_018" style="display: inline-block;"></span>Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 72; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><span id="a_019" style="display: inline-block;"></span>Part
III</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_020" style="display: inline-block;"></span>Item 10. Directors, Executive Officers and Corporate
Governance Officers and Directors</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers and
directors are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-weight: bold;">NAME</span></td>
<td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%">&#160;</td>
<td style="text-align: center; border-bottom: black 1.5pt solid; width: 5%"><span style="font-weight: bold;">AGE</span></td>
<td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 51%"><span style="font-weight: bold;">POSITION</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Bernard J. Duroc-Danner</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; padding-right: 3.25pt">72</td>
<td style="white-space: nowrap">&#160;</td>
<td>Chief Executive Officer and Director</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Sten Gustafson</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; padding-right: 3.25pt">59</td>
<td style="white-space: nowrap">&#160;</td>
<td>Chief Financial Officer and Director</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Per Hornung Pedersen</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; padding-right: 3.25pt">71</td>
<td style="white-space: nowrap">&#160;</td>
<td>Director</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Jamie Saxton</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; padding-right: 3.25pt">65</td>
<td style="white-space: nowrap">&#160;</td>
<td>Director</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Matteo Pasquali</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; padding-right: 3.25pt">57</td>
<td style="white-space: nowrap">&#160;</td>
<td>Director</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Bernard J. Duroc-Danner</i></span>,
72, has been our Chief Executive Officer since May 2025. Mr. Duroc-Danner has also been the chief executive officer of Pyrophyte I (OTCMKTS:
PHYTF) since March 2023 and has served as the chairman of its board of directors since October 2021. Since 2018, Mr. Duroc-Danner has
co-founded, developed and helped fund a number of technology and operating companies in the energy industry worldwide. Mr. Duroc-Danner
started EVI, Inc. (NYSE: EVI), an oilfield services and equipment company, in May 1987, for which he served as Chairman, President and
CEO until he retired in 2016, and upon retirement was named Chairman Emeritus of Weatherford, EVI&#8217;s successor company. Mr. Duroc-Danner
also served as Chairman of Grant Prideco (NYSE: GRP) upon its spinoff from Weatherford in April 2000 until June 2003. Grant Prideco had
been a core part of EVI since the first year of its history. Grant Prideco was subsequently acquired in April 2008 by National Oilwell
(NYSE:NOV) for $7.5 billion in cash and stock. Mr. Duroc-Danner was named an Outstanding Texas Entrepreneur by the Texas House of Representatives
in September 2011 and the Ernst &amp; Young recipient of the Worldwide Entrepreneur of the Year award for the Energy and Chemical Industry
in June 2008. Over the years, Mr. Duroc-Danner has been a director of a number of public companies with global operations. Prior to the
startup of EVI, Mr. Duroc-Danner was a management consultant with Arthur D. Little in Boston, working in the metals, minerals and power
generating industries. Mr. Duroc-Danner received an MBA and a PhD degree from The Wharton School of the University of Pennsylvania. Mr.
Duroc-Danner is qualified to serve on our board of directors because of his extensive operational and transactional experience in building
companies around the globe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Sten Gustafson</i></span>,
59, has been our Chief Financial Officer since May 2025. In addition, Mr. Gustafson has served as Pyrophyte I&#8217;s (OTCMKTS: PHYTF)
Chief Financial Officer since March 2023 and has served on its board of directors since February 12, 2021. Previously, Mr. Gustafson was
Pyrophyte I&#8217;s Chief Executive Officer from February 2021 until March 2023. Mr. Gustafson is a highly experienced energy services
industry executive, investment banker and corporate securities attorney. From March 2020 to January 2022, Mr. Gustafson served as an independent
director for Western Rare Earths, the U.S. subsidiary of the publicly-listed Australian rare earth mining company American Rare Earths
(ASX: ARR), and since January 2022 has served as an independent director of American Rare Earths. From April 2012 to August 2014, Mr.
Gustafson was Chief Executive Officer and Director of Era Group Inc. (previously NYSE: ERA), where he led the successful spin out of Era
from Seacor Holdings in January 2013, generating record quarterly revenues every quarter during his tenure while meaningfully de-leveraging
the balance sheet. From September 2017 to August 2018, Mr. Gustafson served as a member of the Founding Steering Committee created by
the Public Investment Fund of Saudi Arabia to establish a private commercial helicopter operator (The Helicopter Company) in the Kingdom
of Saudi Arabia. From July 2017 to January 2019, Mr. Gustafson served as a director at CHC Helicopter. From January 2018 to November 2023,
Mr. Gustafson served as Chairman of the Board of Directors of the publicly traded Norwegian company Golden Energy Offshore (OSL: GEOS).
Mr. Gustafson earned a B.A. in English from Rice University and earned a Juris Doctor from the University of Houston Law Center. With
over 25 years of experience in the global energy sector, Mr. Gustafson is well qualified to serve on our board of directors, having advised
on over 100 corporate transactions around the world for over $100 billion of transaction value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 73; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Per Hornung Pedersen</i></span>,
71, has served on our board of directors since July 2025. Mr. Pedersen is a highly experienced veteran in the renewable energy industry,
working the last 25 years as a senior executive as well as an Independent Directors leading global companies in the renewable energy industry
across the value chain. Mr. Pedersen joined the Wind industry in March 2000 as CFO of the Danish Wind turbine manufacturer NEG Micon/Vestas.
In July 2004, he became CEO of Suzlon Energy, a Wind turbine manufacturer based in India, building a global presence from a startup. In
December 2007 Mr. Pedersen then became CEO of Senvion (f/k/a Repower AG) a German manufacturer of Wind turbines. Mr. Pedersen has extensive
M&amp;A experience and has been instrumental in a number of transactions in the renewable industry. Since April 2011, Mr. Pedersen has
worked as an Independent Director and Industry Advisor in the renewable industry. Since October 2021, Mr. Pedersen has served as an independent
director for Pyrophyte Acquisition Corp. (OTCMKTS:PHYTF). Mr. Pedersen has been the chairman of PNE AG Germany (ETR:PNE3), one of Europe&#8217;s
Largest project developers in onshore and Offshore Wind as well as solar since October 2015. Mr. Pedersen has also served as an independent
director of Suzlon Energy Ltd India (NSE: SUZLON) since September 2015, an independent director of Swire Renewables since August 2019
and an independent director of SeaTower AS, Norway since February 2012. Since July 2017, Mr. Pedersen has served as a senior advisor to
McKinsey and as an independent member of the Investment Committee of the Caribbean Clean Energy Fund. Mr. Pedersen has been the chairman
of Nordic Solar A/S, a leading Project Developer and IPP in solar and BESS, active in 10 countries, since April 2025. Mr. Pedersen has
also served as an independent director of Silbitz Group Germany since January 2023 as well as member of the advisory board of EQT Active
Core infrastructure investment in TION AG since August 2023. Mr. Pedersen received his MBA with honors from Copenhagen Business School
(University of Copenhagen) and holds a BSc in Finance and Accounting from Copenhagen Business School. We believe Mr. Pedersen is well-qualified
to serve on our board of directors because of his experience in the renewable energy industry.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Jamie Saxton</i></span>,
65, has served on our board of directors since July 2025. Mr. Saxton began his finance career at Lehman Brothers, where he spent 12 years
and rose to the position of managing director and head of the oilfield services practice. From 2008 to 2014, Mr. Saxton was a partner
at White Deer Energy, a private equity firm focused on energy investments, with $2.5 billion under management. In 2014, he became a partner
at PPHB, a boutique investment bank specializing in energy, where he handled oilfield services financings, mergers, divestitures and capital
structure advisory engagements. Between 2017 and 2024, Mr. Saxton served as the Director of U.S. Operations and was a shareholder at Interra
Energy Services. Currently, he is a partner and COO at Encore Global Management, a hedge fund located in Houston. Mr. Saxton holds an
MBA from the University of Chicago Booth School of Business and a BS in Petroleum Engineering from the University of Texas at Austin.
We believe Mr. Saxton is well-qualified to serve on our board of directors because of his financial experience in the energy industry.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Matteo Pasquali</i></span>,
57, has served on our board of directors since July 2025. Dr. Pasquali
joined Rice University in 2000 and has served as Co-Director of the Carbon Nanotechnology Laboratory from 2005 to 2008, Magister of Lovett
College from 2009 to 2014, Chair of the Chemistry Department from 2014 to 2018, and Chief Scientific Advisor for Nanotechnology at Shell
(sabbatical) from 2018 to 2019. Since 2014, Dr. Pasquali has served as the A. J. Hartsook Professor of Chemical &amp; Biomolecular Engineering,
Chemistry, and Materials Science &amp; NanoEngineering at Rice University. He has also served as a board member of the Rice Sustainability
Institute since 2023 and a director and scientific advisor for DexMat, Inc. since 2015. His laboratory studies the interplay of energy,
materials and carbon, and is pioneering system-level pathways to decarbonize the industrial sector by using carbon materials while co-producing
clean hydrogen. Dr. Pasquali leads an academic team that received the first Kavli Foundation Exploration Award in Nanoscience for Sustainability
in 2023. Dr. Pasquali is also the founding director of the Carbon Hub, a partnership formed in 2019 between academia, industry and federal
labs encompassing over 20 organizations across four continents. The Carbon Hub develops and deploys pathways for simultaneously harvesting
zero-emission hydrogen and carbon materials that can reduce emissions from industry and transportation. Dr. Pasquali is an elected Fellow
of the American Physical Society, the American Association for the Advancement of Science, the Society of Rheology and has won numerous
awards including the NSF CAREER in 2001, the Goradia Innovation Grand Prize in 2014, the Herschel Rich Invention Award in 2016, the Schlack
Prize for Man-Made Fibers in 2014, the Rice Presidential Mentoring Award in 2020, and the AIChE Braskem Award for Excellence in Materials
Science and Engineering in 2025. Since 2018, Dr. Pasquali has also served as president of Pasquali SWNT Consulting, LLC, for which he
provides strategic advice on carbon nanotechnology. We believe Mr. Pasquali is well-qualified to serve on our board of directors because
of his academic experience in the energy industry.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 74; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number and Terms of Office of Officers and
Directors</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors consists
of five members and is divided into three classes with only one class of directors being appointed in each year, and with each class (except
for those directors appointed prior to our first annual general meeting) serving a three-year term. In accordance with the NYSE corporate
governance requirements, we are not required to hold an annual general meeting until one year after our first fiscal year end following
our listing on the NYSE. The term of office of the first class of directors, consisting of Matteo Pasquali, will expire at our first annual
general meeting. The term of office of the second class of directors, consisting of Per Hornung Pedersen and Jamie Saxton, will expire
at the second annual general meeting. The term of office of the third class of directors, consisting of Bernard J. Duroc-Danner and Sten
Gustafson, will expire at the third annual general meeting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our officers are appointed
by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of
directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director Independence</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rules of the NYSE require
that a majority of our board of directors be independent within one year of our Initial Public Offering. An &#8220;independent director&#8221;
is defined generally as a person who, in the opinion of the company&#8217;s board of directors, has no material relationship with the
listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company).
Our board of directors has determined that each of Per Hornung Pedersen, Jamie Saxton and Matteo Pasqauli is an &#8220;independent director&#8221;
as defined in the NYSE listing standards and applicable SEC rules. In accordance with the NYSE&#8217;s phase-in rules, we intend to have
a majority of our board members be independent within one year of the closing of our Initial Public Offering. We expect such additional
director to enter into a letter agreement substantially similar to the letter agreement signed by our directors. Our independent directors
will have regularly scheduled meetings at which only independent directors are present.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Committees of the Board of Directors</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. Each of our
audit committee, our compensation committee and our and nominating and corporate governance committee are composed solely of independent
directors. Subject to phase-in rules, the rules of the NYSE and Rule 10A-3 of the Exchange Act require that the audit committee of a listed
company be comprised solely of independent directors, and the rules of the NYSE require that the compensation committee and the nominating
and corporate governance committee of a listed company be comprised solely of independent directors. Each committee operates under a charter
that was approved by our board and has the composition and responsibilities described below. The charter of each committee is available
on our website.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our audit committee
are Per Hornung Pedersen, Matteo Pasquali and Jamie Saxton. Under the NYSE listing standards and applicable SEC rules, we are required
to have at least three members of the audit committee, all of whom must be independent. Each of Per Hornung Pedersen, Matteo Pasquali
and Jamie Saxton meet the independent director standard under the NYSE listing standards and under Rule 10-A-3(b)(1) of the Exchange Act.
Mr. Pedersen serves as chair of the audit committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each member of the audit committee
is financially literate and our board of directors has determined that Mr. Saxton qualifies as an &#8220;audit committee financial expert&#8221;
as defined in applicable SEC rules and has accounting or related financial management expertise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 75; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted an audit committee
charter, which details the principal functions of the audit committee, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal
and regulatory requirements, (3) our independent auditor&#8217;s qualifications and independence, and (4) the performance of our internal
audit function and independent auditors; the appointment, compensation, retention, replacement, and oversight of the work of the independent
auditors and any other independent registered public accounting firm engaged by us;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">pre-approving all audit and non-audit services to be provided by the independent auditors or any other
registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; reviewing and discussing with
the independent auditors all relationships the auditors have with us in order to evaluate their continued independence;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">setting clear policies for audit partner rotation in compliance with applicable laws and regulations;
obtaining and reviewing a report, at least annually, from the independent auditors describing (1) the independent auditor&#8217;s internal
quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the
audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting
one or more independent audits carried out by the firm and any steps taken to deal with such issues;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">meeting to review and discuss our annual audited financial statements and quarterly financial statements
with management and the independent auditor, including reviewing our specific disclosures under &#8220;<i>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</i>&#8221;;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of
Regulation S-K promulgated by the SEC prior to us entering into such transaction reviewing and approving any related party transaction
required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal,
regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published
reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting
standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</td></tr></tbody></table><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Committee</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our compensation
committee are Jamie Saxton and Matteo Pasqauli. Under the NYSE listing standards and applicable SEC rules, we are required to have at
least two members of the compensation committee, all of whom must be independent. Each of Jamie Saxton and Matteo Pasqauli are independent.
Mr. Saxton chairs the compensation committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a compensation
committee charter, which details the principal functions of the compensation committee, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive
Officer&#8217;s compensation, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining
and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing and making recommendations to our board of directors with respect to the compensation, and any
incentive compensation and equity based plans that are subject to board approval of all of our other officers;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing our executive compensation policies and plans;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 76; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">implementing and administering our incentive compensation equity-based remuneration plans;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">assisting management in complying with our proxy statement and annual report disclosure requirements;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">approving all special perquisites, special cash payments and other special compensation and benefit arrangements
for our officers and employees;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">producing a report on executive compensation to be included in our annual proxy statement; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
other than the payment of $35,000 per month to our Sponsor for office space, utilities and secretarial and administrative support and
reimbursement of expenses, no compensation of any kind, including finders, consulting or other similar fees, will be paid to any of our
existing shareholders, officers, directors or any of their respective affiliates, prior to, or for any services they render in order to
effectuate the consummation of an initial Business Combination. Accordingly, it is likely that prior to the consummation of an initial
Business Combination, the compensation committee will only be responsible for the review and recommendation of any compensation arrangements
to be entered into in connection with such initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant,
independent legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of
any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser,
the compensation committee will consider the independence of each such adviser, including the factors required by the NYSE and the SEC.</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nominating and Corporate Governance
Committee</p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our nominating
and corporate governance are Jamie Saxton and Matteo Pasquali. Each of Jamie Saxton and Matteo Pasqauli are independent. Mr.&#160;Pasquali
chairs of the nominating and corporate governance committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a nominating
and corporate governance committee charter, which details the purpose and responsibilities of the nominating and corporate governance
committee, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria
approved by the board, and recommending to the board of directors candidates for nomination for appointment at the annual general meeting
of shareholders or to fill vacancies on the board of directors;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">developing and recommending to the board of directors and overseeing implementation of our corporate governance
guidelines;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">coordinating and overseeing the annual self-evaluation&#160;of the board of directors, its committees,
individual directors and management in the governance of the company; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reviewing on a regular basis our overall corporate governance and recommending improvements as and when
necessary.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The charter also provides
that the nominating and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any
search firm to be used to identify director candidates, and is directly responsible for approving the search firm&#8217;s fees and other
retention terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not formally established
any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying
and evaluating nominees for director, the board of directors considers educational background, diversity of professional experience, knowledge
of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders.
Prior to our initial Business Combination, holders of our Public Shares will not have the right to recommend director candidates for nomination
to our board of directors.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 77; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Committee Interlocks and Insider
Participation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our officers currently
serves, or in the past year has served, as a member of the compensation committee of any entity that has one or more officers serving
on our board of directors.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Code of Business Conduct and Ethics, Insider
Trading Policy and Committee Charters</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Ethics applicable to our directors, officers and employees. We have filed a copy of our Code of Ethics as an exhibit to this Form 10-K.
You are able to review this document by accessing our public filings at the SEC&#8217;s web site at <i>www.sec.gov</i>. In addition, a
copy of the Code of Ethics and the charters of the committees of our board of directors can be provided without charge upon request from
us. If we make any amendments to our Code of Ethics other than technical, administrative or other non-substantive amendments, or grant
any waiver, including any implicit waiver, from a provision of the Code of Ethics applicable to our principal executive officer, principal
financial officer principal accounting officer or controller or persons performing similar functions requiring disclosure under applicable
SEC or the NYSE rules, we will disclose the nature of such amendment or waiver on our website. The information included on our website
is not incorporated by reference into this Form 10-K or in any other report or document we file with the SEC, and any references to our
website are intended to be inactive textual references only.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have also <ix:nonNumeric name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="cref_619992257" format="ixt:fixed-true" id="ixv-7593">adopted</ix:nonNumeric> a policy regarding insider training and dissemination of inside information (the &#8220;Insider Trading Policy&#8221;) governing the purchase, sale, and other disposition of our securities by our directors, officers, and employees as well as by the Company that we believe is reasonably designed to promote compliance with insider trading laws, rules, and regulations and listing standards applicable to the Company. A copy of our Insider Trading Policy is filed as Exhibit 19 to this Form 10-K. </p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limitation on Liability and Indemnification
of Officers and Directors</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cayman Islands law does not
limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors,
except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against willful default, fraud or the consequences of committing a crime. Our amended and restated memorandum and articles of association
provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred
in their capacities as such, except through their own actual fraud, willful default or willful neglect. We have purchased a policy of
directors&#8217; and officers&#8217; liability insurance that insures our officers and directors against the cost of defense, settlement
or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our officers and directors
have agreed to waive any right, title, interest or claim of any kind in or to any monies in the Trust Account, and have agreed to waive
any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to
us and will not seek recourse against the Trust Account for any reason whatsoever. Accordingly, any indemnification provided will only
be able to be satisfied by us if (i) we have sufficient funds outside of the Trust Account or (ii) we consummate an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our indemnification obligations
may discourage shareholders from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action,
if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that these provisions,
the insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><!-- Field: Page; Sequence: 78; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_021" style="display: inline-block;"></span>Item 11. Executive Compensation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our executive officers
or directors has received any cash compensation for services rendered. We will pay our Sponsor $35,000 for office space, secretarial and
administrative services provided to members of our management team until the consummation of our initial Business Combination. No compensation
of any kind, including any finder&#8217;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid
by us to our Sponsor, officers and directors, or any affiliate of theirs, for services rendered prior to, or for any services rendered
in order to effectuate, the consummation of our initial Business Combination (regardless of the type of transaction that it is). However,
these individuals will be entitled to certain payments including, but not limited to, reimbursement for any out-of-pocket expenses incurred
in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable Business
Combinations. Our audit committee will review on a quarterly basis all payments that were made to our Sponsor, officers or directors,
or our or their affiliates. Any such payments prior to an initial Business Combination will be made using funds held outside the Trust
Account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing
our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with identifying
and consummating an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of our
initial Business Combination, directors or members of our management team who remain with us may be paid consulting or management fees
from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the tender offer materials
or proxy solicitation materials furnished to our shareholders in connection with a proposed initial Business Combination. We have not
established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It
is unlikely the amount of such compensation will be known at the time of the proposed initial Business Combination, because the directors
of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to
our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted
solely by independent directors or by a majority of the independent directors on our board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to take any
action to ensure that members of our management team maintain their positions with us after the consummation of our initial Business Combination,
although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with
us after our initial Business Combination. The existence or terms of any such employment or consulting arrangements to retain their positions
with us may influence our management&#8217;s motivation in identifying or selecting a target business but we do not believe that the ability
of our management to remain with us after the consummation of our initial Business Combination will be a determining factor in our decision
to proceed with any potential Business Combination. We are not party to any agreements with our officers and directors that provide for
benefits upon termination of employment.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_022" style="display: inline-block;"></span>Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Shareholder Matters.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of our ordinary shares as of March 30, 2026,
by:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each person known by us to be the beneficial owner of more than 5% of our outstanding ordinary shares;</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each of our officers and directors; and</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">all our officers and directors as a group.</td></tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
we believe that all persons named in the table below have sole voting and investment power with respect to all ordinary shares beneficially
owned by them. The following table does not reflect beneficial ownership of the Public Warrants or Private Placement Warrants as these
warrants are not exercisable within 60 days of the date of this Form 10-K.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 79; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have based our calculation
of the percentage of beneficial ownership on 20,041,150 Class A Ordinary Shares and 7,225,721 Class B ordinary shares issued and outstanding
as of March 30, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center">Class A</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center">Class B</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Approximate</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Percentage&#160;of</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Approximate</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Approximate</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Beneficially</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Percentage</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Beneficially</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Percentage</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Ordinary</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owner(1)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">of Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Owned(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">of Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic">Directors, Executive Officers and Founders</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left"><span style="font-size: 10pt">Bernard J. Duroc-Danner<sup>(3)</sup></span></td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,135,721</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">26.2</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Sten Gustafson<sup>(3)</sup></span></td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">7,135,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">98.8</td><td style="text-align: left">%</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">26.2</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in">Per Hornung Pedersen</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt"><span style="font-weight: bold;">*</span></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt"><span style="font-weight: bold;">*</span></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Jamie Saxton</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matteo Pasquali</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt"><span style="font-weight: bold;">*</span></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt"><span style="font-weight: bold;">*</span></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">All executive officers and directors
    as a group (5 individuals)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7,225,721</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">100.0</td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">26.5</td><td style="font-weight: bold; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Five Percent Holders</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Pyrophyte Acquisition II LLC<sup>(3)</sup></span></td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">7,135,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">98.8</td><td style="text-align: left">%</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">26.2</td><td style="text-align: left">%</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Less than 1%</td>
</tr></tbody></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Unless otherwise noted, the business address of each of the
following entities or individuals is c/o Pyrophyte Acquisition Corp. II, 3262 Westheimer Road, Suite 706, Houston, Texas 77098.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Interests shown consist solely of Founder Shares, classified
as Class B ordinary shares. Such shares will automatically convert into Class A Ordinary Shares concurrently with or immediately following
the consummation of our initial Business Combination, or earlier at the option of the holders thereof, on a one-for-one basis, subject
to adjustment.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Pyrophyte Acquisition II LLC, our sponsor, is the record holder
of the shares reported herein. Bernard J. Duroc-Danner and Sten Gustafson are the managing members of Pyrophyte Acquisition II LLC and
have voting and investment discretion over the securities held by Pyrophyte Acquisition II LLC.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_030" style="display: inline-block;"></span>Item 13. Certain Relationships and Related Transactions,
and Director Independence</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in">Founder Shares</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2025, our
Sponsor purchased an aggregate of 7,255,952 Founder Shares for an aggregate purchase price of $25,000, or approximately $0.003 per
share. In June 2025, our Sponsor transferred 30,000 Founder Shares to each of our independent directors (for an aggregate of 90,000
Founder Shares) at the same per-share price at which our Sponsor purchased such shares, or approximately $0.003 per share. The
number of Founder Shares issued was determined based on the expectation that such Founder Shares would represent 26.5% of the
outstanding shares after the IPO. On July 24, 2025, we closed the issuance and sale of an additional 2,541,150 Units to the Underwriters as part of their partial exercise
of their Over-Allotment Option. The Underwriters forfeited the balance of their Over-Allotment Option and, as a result, the Sponsor forfeited
30,231 Founder Shares, resulting in it holding an aggregate of 7,135,721 Founder Shares.</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in">Private Placement
Warrants</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Sponsor purchased an aggregate
of 5,050,000 Private Placement Warrants for an aggregate purchase price of $5,050,000, or $1.00 per warrant, in a private placement that
occurred simultaneously with the closing of the IPO. The Private Placement Warrants are identical to the warrants sold as part of the
Units in the IPO except that, so long as they are held by our Sponsor or its respective permitted transferees, (i) may not (including
the underlying securities), subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after
the completion of our initial Business Combination, (ii) and will be entitled to registration rights. A portion of the purchase price
of the Private Placement Warrants were added to the proceeds from the IPO to be held in the Trust Account such that $200,411,500 is held
in the Trust Account, (iii) may be exercised by the holders on a cashless basis and (iv) will be entitled to registration. If we do not
complete our initial Business Combination within the Completion Window, the Private Placement Warrants will expire worthless. The Private
Placement Warrants and Private Placement Warrants are subject to the transfer restrictions described above. Otherwise, the Private Placement
Warrants have terms and provisions that are identical to those of the Units being sold in the IPO.</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 80; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in">Administrative Services
Agreement</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into an Administrative
Services Agreement with our Sponsor in connection with the IPO. Pursuant to the terms of that agreement, we agreed to pay our Sponsor
$35,000 per month for office space, secretarial, administrative and support services provided to us and members of our management team.
Upon completion of our initial Business Combination or our liquidation, we will cease paying these monthly fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No compensation of any kind,
including finder&#8217;s and consulting fees, will be paid by the Company to our Sponsor, executive officers and directors, or any of
their respective affiliates, for services rendered prior to or in connection with the completion of an initial Business Combination without
shareholder approval. However, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities
on our behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. Our audit
committee will review on a quarterly basis all payments that were made to our Sponsor, officers, directors or our or their affiliates.</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in">Promissory Note</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2025, the Sponsor
agreed to loan the Company up to $300,000 pursuant to a promissory note (the &#8220;Note&#8221;). The Note is non-interest bearing, unsecured
and due on the earlier of December 31, 2025 or the closing of the Initial Public Offering. At December 31, 2025, there are no amounts
outstanding and no further borrowings are permitted under the Note.</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in">Working Capital Loans</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in order to finance
transaction costs in connection with an intended initial Business Combination, our Sponsor or an affiliate of our Sponsor or certain of
our officers and directors may, but are not obligated to, loan us funds as may be required on a non-interest basis. If we complete an
initial Business Combination, we would repay such loaned amounts. In the event that the initial Business Combination does not close, we
may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account
would be used for such repayment. Up to $1,500,000 of such loans may be convertible into Private Placement Warrants at a price of $1.00
per warrant, at the option of the lender. The warrants would be identical to the Private Placement Warrants, including as to exercisability
and exercise price. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist
with respect to such loans. Prior to the completion of our initial Business Combination, we do not expect to seek loans from parties other
than our Sponsor or an affiliate of our Sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver
against any and all rights to seek access to funds in our Trust Account. Except for the foregoing, the terms of such working capital loans,
if any, have not been determined and no written agreements exist with respect to such loans. As of December 31, 2025, the Company had
no borrowings under the working capital loans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the foregoing payments
to our Sponsor, repayments of loans from our Sponsor or repayments of working capital loans prior to our initial Business Combination
will be made using funds held outside the Trust Account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After our initial Business
Combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company
with any and all amounts being fully disclosed to our shareholders, to the extent then known, in the proxy solicitation or tender offer
materials, as applicable, furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution
of such tender offer materials or at the time of a shareholder meeting held to consider our initial Business Combination, as applicable,
as it will be up to the directors of the post- combination business to determine executive and director compensation.</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 81; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in">Registration Rights
Agreement</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Founder Shares,
Private Placement Warrants and warrants that may be issued upon conversion of working capital loans (and any ordinary shares issuable
upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the working capital loans), will be entitled
to registration rights pursuant to a registration rights agreement signed upon the consummation of the Initial Public Offering. These
holders will be entitled to certain demand and &#8220;piggyback&#8221; registration rights. We will bear the expenses incurred in connection
with the filing of any such registration statements.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_023" style="display: inline-block;"></span>Item 14. Principal Accounting Fees and Services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The firm of WithumSmith+Brown,
PC acts as our independent registered public accounting firm. The following is a summary of fees paid to WithumSmith+Brown, PC for services
rendered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Audit Fees</i>. During the period from May 1, 2025 (inception) through December 31,
2025, fees for our independent registered public accounting firm were approximately $135,660 for the services WithumSmith+Brown, PC performed
in connection with our Initial Public Offering and the audit of our December 31, 2025 financial statements included in this Form 10-K.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Audit-Related Fees.</i>
During the period from May 1, 2025 (inception) through December 31, 2025, our independent registered public accounting firm did not render
assurance and related services related to the performance of the audit or review of financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tax Fees</i>. During the
period from May 1, 2025 (inception) through December 31, 2025, our independent registered public accounting firm did not render services
to us for tax compliance, tax advice and tax planning.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>All Other Fees</i>. During
the period from May 1, 2025 (inception) through December 31, 2025, there were no fees billed for products and services provided by our
independent registered public accounting firm other than those set forth above.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-Approval Policy</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee was formed
upon the consummation of our Initial Public Offering. As a result, the audit committee did not pre-approve all of the foregoing services,
although any services rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation
of our audit committee, and on a going-forward basis, the audit committee has and will pre-approve all auditing services and permitted
non-audit services to be performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions
for non-audit services described in the Exchange Act which are approved by the audit committee prior to the completion of the audit).</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><!-- Field: Page; Sequence: 82; Options: NewSection; Value: 77 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><span id="a_024" style="display: inline-block;"></span>Part
IV</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_025" style="display: inline-block;"></span>Item 15. Exhibits, Financial Statement Schedules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">The following documents are filed as part of this Form 10-K:</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Financial Statements: See &#8220;Index to Financial Statements&#8221;
at &#8220;Item 8. Financial Statements and Supplementary Data&#8221; herein.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(b)</td><td style="text-align: justify">Financial Statement Schedules. All schedules are omitted for
the reason that the information is included in the financial statements or the notes thereto or that they are not required or are not
applicable.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(c)</td><td style="text-align: justify">Exhibits: The exhibits listed in the Exhibit Index below are
filed or incorporated by reference as part of this Form 10-K.</td>
</tr></tbody></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit Index</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: left"><span style="font-weight: bold;">Number</span></td>
<td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
<td style="text-align: justify; vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">Description</span></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">3.1</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex3-1_pyrophyte2.htm">Amended and Restated Memorandum and Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">4.1</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025062125/ea024343003ex4-1_pyrophyte2.htm">Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-288391), filed with the SEC on July 8, 2025).</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">4.2</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025062125/ea024343003ex4-2_pyrophyte2.htm">Specimen Ordinary Shares Certificate (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-279638), filed with the SEC on July 8, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">4.3</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025059054/ea024343002ex4-4_pyrophyte2.htm">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-279638), filed with the SEC on July 8, 2025).</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">4.4</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex4-1_pyrophyte2.htm">Warrant Agreement, dated July 16, 2025, by and between the Registrant and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">4.5*</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex4-5.htm">Description of Securities.</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">10.1</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex10-1_pyrophyte2.htm">Letter Agreement, dated July 16, 2025, by and among the Registrant, its&#160;&#160;executive officers, directors, its advisors and the Sponsor (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">10.2</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex10-2_pyrophyte2.htm">Investment Management Trust Agreement, dated July 16, 2025, by and between the Registrant and Continental Stock Transfer &amp; Trust Company, as trustee (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">10.3</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex10-3_pyrophyte2.htm">Registration Rights Agreement, dated July 16, 2025, by and among the Registrant, the Sponsor and the other holders party thereto (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">10.4</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex10-4_pyrophyte2.htm">Private Placement Warrants Purchase Agreement, dated July 16, 2025, by and between the Registrant and the Sponsor (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">10.6</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025062125/ea024343003ex10-5_pyrophyte2.htm">Form of Indemnity Agreement (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-288391), filed with the SEC on July 8, 2025).</a></td>
</tr>
</tbody></table><p style="margin: 0">&#160;</p><p style="margin: 0"></p><!-- Field: Page; Sequence: 83; Value: 77 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="background-color: White">
<td style="vertical-align: top; width: 9%">10.7</td>
<td style="vertical-align: top; width: 1%">&#160;</td>
<td style="text-align: justify; vertical-align: bottom; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025066199/ea024959201ex10-5_pyrophyte2.htm">Administrative Services Agreement, dated July 16, 2025, by and between the Company and Centurion Sponsor LP (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-42752), filed with the SEC on July 21, 2025).</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">10.8</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025059054/ea024343002ex10-6_pyrophyte2.htm">Promissory Note issued to Pyrophyte Acquisition II LLC (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-288391), filed with the SEC on June 27, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">10.9</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025059054/ea024343002ex10-7_pyrophyte2.htm">Securities Subscription Agreement between Pyrophyte Acquisition II LLC and the Registrant (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-288391), filed with the SEC on June 27, 2025).</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">14.1</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/2069238/000121390025062125/ea024343003ex14-1_pyrophyte2.htm">Business
    Conduct and Code of Ethics (incorporated by reference to Exhibit 14.1 to Amendment No. 1 to the Registrant&#8217;s Registration
    Statement on Form S-1 (File No. 333-288391), filed with the SEC on July 8, 2025).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">19.1*</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex19-1.htm">Insider Trading Policy.</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">24.1*</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="#poa_028">Power of Attorney (included on the signature pages herein).</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">31.1*</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex31-1.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">31.2*</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex31-2.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">32.1**</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">32.2**</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">97.1*</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom"><a href="ea028245801ex97-1.htm">Policy relating to the recovery of erroneously awarded compensation.</a></td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">101.INS</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Inline XBRL Instance Document</td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">101.SCH</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Inline XBRL Taxonomy Extension Schema Document</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">101.CAL</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: top">101.DEF</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: top">101.LAB</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Inline XBRL Taxonomy Extension Label Linkbase Document</td>
</tr>
<tr style="background-color: White">
<td style="vertical-align: bottom">101.PRE</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="vertical-align: bottom">104</td>
<td style="vertical-align: top">&#160;</td>
<td style="text-align: justify; vertical-align: bottom">Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)</td>
</tr>
</tbody></table><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="font-size: 10pt; width: 0.25in">*</td>
<td style="font-size: 10pt">Filed herewith.</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt">&#160;</td>
<td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt">**</td>
<td style="font-size: 10pt">Furnished herewith.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span id="a_026" style="display: inline-block;"></span>Item 16. Form 10-K Summary</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 84; Value: 77 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_027" style="display: inline-block;"></span>SIGNATURES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Form 10-K to be signed
on its behalf by the undersigned, thereunto duly authorized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="vertical-align: top; font-size: 10pt">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt"><span style="font-weight: bold;">PYROPHYTE ACQUISITION CORP. II</span></td></tr>
<tr>
<td style="vertical-align: top; width: 60%">&#160;</td>
<td style="vertical-align: bottom; width: 5%">&#160;</td>
<td style="vertical-align: bottom; width: 35%">&#160;</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt">By:</td>
<td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1pt; font-size: 10pt">/s/ Bernard J. Duroc-Danner</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt">Name:&#160; </td>
<td style="vertical-align: bottom; font-size: 10pt">Bernard J. Duroc-Danner</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top; font-size: 10pt">Title:</td>
<td style="vertical-align: bottom; font-size: 10pt">Chief Executive Officer and Director</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt">(Principal executive officer)</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt">Dated: March 30, 2026</td>
<td colspan="2">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="poa_028" style="display: inline-block;"></span>POWER OF ATTORNEY</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints Bernard J. Duroc-Danner and Sten Gustafson, and each
or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in
his name, place and stead, in any and all capacities, to sign any and all amendments to this Form 10-K, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his or her substitutes or substitute, may lawfully
do or cause to be done by virtue hereof.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this Form 10-K has been signed below by the following persons on behalf of the Registrant in
the capacities and on the dates indicated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; width: 25%"><span style="font-weight: bold;">Name</span></td>
<td style="white-space: nowrap; width: 2%">&#160;</td>
<td style="text-align: center; border-bottom: black 1.5pt solid; font-size: 10pt; width: 46%"><span style="font-weight: bold;">Title</span></td>
<td style="white-space: nowrap; width: 2%">&#160;</td>
<td style="text-align: center; border-bottom: black 1.5pt solid; font-size: 10pt; width: 25%"><span style="font-weight: bold;">Date</span></td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td>&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Bernard J. Duroc-Danner</td>
<td style="white-space: nowrap">&#160;</td>
<td style="font-size: 10pt">Chief Executive Officer and Director</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt">March 30, 2026</td></tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt"><span style="font-weight: bold;">Bernard J. Duroc-Danner</span></td>
<td style="white-space: nowrap">&#160;</td>
<td style="font-size: 10pt">(<i>Principal Executive Officer)</i></td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Sten Gustafson</td>
<td style="white-space: nowrap">&#160;</td>
<td style="font-size: 10pt">Chief Financial Officer and Director</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt">March 30, 2026</td></tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt"><span style="font-weight: bold;">Sten Gustafson</span></td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap; font-size: 10pt"><i>(Principal Financial and Accounting Officer)</i></td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Per Hornung Pedersen</td>
<td style="white-space: nowrap">&#160;</td>
<td style="font-size: 10pt">Director</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt">March 30, 2026</td></tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt"><span style="font-weight: bold;">Per Hornung Pedersen</span></td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Jamie Saxton</td>
<td style="white-space: nowrap">&#160;</td>
<td style="font-size: 10pt">Director</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt">March 30, 2026</td></tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt"><span style="font-weight: bold;">Jamie Saxton</span></td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
<tr>
<td style="border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Matteo Pasquali</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap; font-size: 10pt">Director</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap; font-size: 10pt">March 30, 2026</td></tr>
<tr>
<td style="font-size: 10pt"><span style="font-weight: bold;">Matteo Pasquali</span></td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="white-space: nowrap">&#160;</td>
<td style="text-align: center; white-space: nowrap">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 85; Value: 77 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PYROPHYTE ACQUISITION CORP. II<br/>
INDEX TO FINANCIAL STATEMENTS</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 1.05pt; width: 90%"><a href="#fin_001">Report of Independent Registered Public Accounting Firm</a></td>
<td style="width: 1%">&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt; width: 9%">F-2</td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 1.05pt; font-size: 10pt">Financial Statements:</td>
<td>&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.95pt; font-size: 10pt"><a href="#fin_002">Balance Sheet as of December 31, 2025</a></td>
<td>&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt">F-3</td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.95pt; font-size: 10pt"><a href="#fin_003">Statement of Operations for the Period from May 1, 2025 (Inception) Through December 31, 2025</a></td>
<td>&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt">F-4</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.95pt; font-size: 10pt"><a href="#fin_004">Statement of Changes in Shareholders&#8217; Deficit for the Period from May 1, 2025 (Inception) Through December 31, 2025</a></td>
<td>&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt">F-5</td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.95pt; font-size: 10pt"><a href="#fin_005">Statement of Cash Flows for the Period from May 1, 2025 (Inception) Through December 31, 2025</a></td>
<td>&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt">F-6</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.95pt; font-size: 10pt"><a href="#fin_006">Notes to Financial Statements</a></td>
<td>&#160;</td>
<td style="vertical-align: bottom; text-align: center; padding-right: 1.05pt; font-size: 10pt">F-7 to F-22</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 86; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_001" style="display: inline-block;"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Shareholders of</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pyrophyte Acquisition Corp. II:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <ix:nonNumeric name="dei:AuditorOpinionTextBlock" contextRef="cref_619992257" escape="true" id="ixv-4476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Opinion on the Financial Statements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance sheet of Pyrophyte Acquisition Corp. II (the &#8220;Company&#8221;) as of December 31, 2025 and the related statements of operations, changes in shareholder&#8217;s deficit and cash flows for the period from May 1, 2025 (Inception) through December 31, 2025, and the related notes to the financial statements (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of Pyrophyte Acquisition Corp. II as of December 31, 2025 and the results of its operations and its cash flows for the period from May 1, 2025 (Inception) through December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Going Concern</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements the Company&#8217;s current liquidity condition raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Basis for Opinion</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility of the entity&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to Pyrophyte Acquisition Corp. II in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Pyrophyte Acquisition Corp. II is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> /s/ <ix:nonNumeric name="dei:AuditorName" contextRef="cref_619992257" id="ixv-7594">WithumSmith+Brown, PC</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <ix:nonNumeric name="dei:AuditorLocation" contextRef="cref_619992257" id="ixv-7595">New York, New York</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2026</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> PCAOB ID Number <ix:nonNumeric name="dei:AuditorFirmId" contextRef="cref_619992257" id="ixv-7596">100</ix:nonNumeric>&#160; </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><!-- Field: Page; Sequence: 87; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="fin_002" style="display: inline-block;"></span>PYROPHYTE ACQUISITION CORP. II </span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BALANCE SHEET</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DECEMBER 31, 2025</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="font-weight: bold">ASSETS</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Current Asset</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-indent: -9pt; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7597">442,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7598">301,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Total current assets</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7599">744,430</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Marketable securities held in Trust Account</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7600">204,013,247</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid insurance - long term</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7601">45,228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7602">204,802,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current liabilities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7603">38,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7604">25,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total current liabilities</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7605">63,948</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Deferred underwriting fees payable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="paii:DeferredUnderwritingFeesPayableNoncurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7606">9,399,690</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7607">9,463,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and Contingencies (Note 5)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1781603387">&#160;</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Class A Ordinary Shares subject to possible redemption, $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="cref_1879775354" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7608">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="cref_1879775354" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7609">20,041,150</ix:nonFraction> ordinary shares at $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="cref_1879775354" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7610">10.08</ix:nonFraction> per share</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="cref_1879775354" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7611">204,013,247</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shareholders&#8217; deficit</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="cref_333300986" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7612">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="cref_333300986" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7613">1,000,000</ix:nonFraction> shares authorized; <span style="-sec-ix-hidden:fc_1169747210"><span style="-sec-ix-hidden:fc_601645145">none</span></span> issued or outstanding</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_216117793">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Class&#160;A Ordinary Shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_1879775354" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7614">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_1879775354" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7615">200,000,000</ix:nonFraction> shares authorized; <span style="-sec-ix-hidden:fc_1175639479"><span style="-sec-ix-hidden:fc_1867186661">none</span></span> issued or outstanding (excluding 20,041,500 ordinary&#160;shares subject to possible redemption)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_162488177">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Class B ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="fc_452725222" contextRef="cref_1901841206" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="fc_1945644932" contextRef="cref_1901841206" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="fc_193369983" contextRef="cref_1901841206" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="fc_1801047499" contextRef="cref_1901841206" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal">7,225,721</ix:nonFraction></ix:nonFraction> shares issued and outstanding<sup>(1)</sup></td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" id="fc_544349580" contextRef="cref_1901841206" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal">723</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1602604156">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Share subscription receivable</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:ShareSubscriptionReceivable" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7621">353,445</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7622">8,321,258</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total shareholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7623">8,673,980</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders&#8217; Deficit</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7624">204,802,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/><td style="width: 0.25in; text-align: left"><i>(1)</i></td><td style="text-align: justify"><i><ix:footnote id="fref_1001053603" xml:lang="en-US">This number includes an aggregate of up to <ix:nonFraction name="paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" contextRef="cref_403242642" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7626">946,428</ix:nonFraction> Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining <ix:nonFraction name="paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" contextRef="cref_1220869833" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7627">83,850</ix:nonFraction> units under the over-allotment option. As a result, the Sponsor forfeited <ix:nonFraction name="paii:StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" contextRef="cref_92406311" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7628">30,231</ix:nonFraction> Class B ordinary shares. All share and per share data have been retroactively applied.</ix:footnote></i></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center">The accompanying notes are an integral
part of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 88; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 0; text-align: center"><span style="font-weight: bold;"><span id="fin_003" style="display: inline-block;"></span>PYROPHYTE ACQUISITION CORP. II</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 0; text-align: center"><span style="font-weight: bold;">STATEMENT OF OPERATIONS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 0; text-align: center"><span style="font-weight: bold;">FOR THE PERIOD FROM MAY 1, 2025 (INCEPTION)
THROUGH DECEMBER 31, 2025</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7629">628,213</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7630">628,213</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Dividends and interest earned on marketable securities held in the Trust Account</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7631">3,601,747</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Interest income on cash account</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7632">329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7633">2,973,863</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average shares outstanding of Class A Ordinary Shares subject to possible redemption, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_500152996" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7634"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_500152996" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7635">13,598,470</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_500152996" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7636"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_500152996" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7637">0.14</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average shares outstanding of Class B non-redeemable ordinary shares, basic</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_116935946" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7638">6,911,596</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Basic net income per share, Class B non-redeemable ordinary shares<sup>(1)</sup></span></span></td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="fc_1256945023" contextRef="cref_116935946" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average shares outstanding of Class B non-redeemable ordinary shares, diluted</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_116935946" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7640">6,997,607</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Diluted net income per share, Class B non-redeemable ordinary shares<sup>(1)</sup></span></span></td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="fc_888586232" contextRef="cref_116935946" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/><td style="width: 0.25in; text-align: left"><i>(1)</i></td><td style="text-align: justify"><i><ix:footnote id="fref_1453435609" xml:lang="en-US">This number excludes                                             an aggregate of up to <ix:nonFraction name="paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" contextRef="cref_477826121" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7643">946,428</ix:nonFraction> Class B ordinary shares subject to forfeiture if the over-allotment                                             option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters                                             partially exercised their over-allotment option and forfeited their right to purchase the                                             remaining <ix:nonFraction name="paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" contextRef="cref_923664865" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7644">83,850</ix:nonFraction> units under the over-allotment option. As a result, the Sponsor forfeited                                             <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="cref_1953308297" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7645">30,231</ix:nonFraction> Class B ordinary shares. All share and per share data have been retroactively applied.</ix:footnote></i></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center">The accompanying notes are an integral
part of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 89; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_004" style="display: inline-block;"></span>PYROPHYTE ACQUISITION CORP. II<br/>
STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT<br/>
FOR THE PERIOD FROM MAY 1, 2025 (INCEPTION) THROUGH DECEMBER 31, 2025</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares Subject to Possible Redemption</td><td style="border-right: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Share</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A</td><td style="border-right: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class A</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Class B</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Paid-In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Subscription</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="border-right: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balance as of May 1, 2025 (inception)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_441132902">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_1124168248">-</span></td><td style="border-right: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_52832062">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_996209133">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_2113113059">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_794524015">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_50662810">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_1577949154">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_337383641">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_930201705">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="width: 25%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of Class B ordinary shares to Sponsor<sup>(1)</sup></td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden:fc_495288907">-</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden:fc_1534900816">-</span></td><td style="border-right: Black 1.5pt solid; width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden:fc_592782723">-</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden:fc_226959058">-</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="fc_2072477435" contextRef="cref_1257381007" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal">7,255,952</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="fc_1986056237" contextRef="cref_1257381007" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal">726</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="fc_205363762" contextRef="cref_532706043" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal">24,274</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden:fc_131930771">-</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden:fc_2071760065">-</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="fc_158012640" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Forfeiture of Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_346808071">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_661146650">-</span></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1769645716">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1020165411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="cref_1257381007" unitRef="uref_779585586" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7650">30,231</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_1257381007" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7651">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" contextRef="cref_532706043" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7652">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1789097633">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_371079441">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_901471383">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Proceeds from the sale of Units</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" contextRef="cref_1270821457" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7653">20,041,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" contextRef="cref_1270821457" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7654">200,411,500</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1742904851">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1630524161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_585283673">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_145799748">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1687994771">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_444998111">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2115620742">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1261419997">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Paid underwriters fees</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:StockIssuedDuringPeriodValuePaidUnderwritersFees" contextRef="cref_1270821457" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7655">2,625,000</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_264447317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_128932335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2077135401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1757372007">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1617784863">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2114542320">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Deferred underwriting fees payable</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" contextRef="cref_1270821457" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7656">9,399,690</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1999784281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1161507624">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1015604165">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1046165585">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1858594186">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_172479364">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Fair value of Public Warrants, at issuance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_1270821457" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7657">3,724,648</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1934720917">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2001304571">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_532706043" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7658">3,724,648</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_878587040">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1526338219">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7659">3,724,648</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Allocated value of transaction costs to Class A Ordinary Shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_1270821457" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7660">487,752</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1584484121">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1701195832">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_532706043" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7661">255,209</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1702605431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_821862778">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7662">255,209</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Proceeds from the sale of Private Placement Warrants</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1645021734">-</span></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1210222640">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1836776887">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_532706043" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7663">5,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_521991325">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_244269380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7664">5,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in">Share subscription receivable</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_35026678">-</span></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_605456837">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1906154546">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable" contextRef="cref_1356153804" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7665">353,445</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7666">353,445</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Remeasurement of Class A Ordinary Shares to redemption value</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="cref_1270821457" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7667">19,838,837</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_915645759">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="cref_532706043" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7668">8,543,716</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_346553776">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="cref_55172024" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7669">11,295,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7670">19,838,837</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1539544538">-</span></td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1861594894">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_822270604">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1247507169">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1924657242">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_55172024" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7671">2,973,863</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7672">2,973,863</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance as of December 31, 2025</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_13105706" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7673">20,041,150</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_13105706" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7674">204,013,247</ix:nonFraction></td><td style="border-right: Black 1.5pt solid; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_1488256648">-</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_1343794665">-</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="cref_1759141991" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7675">7,225,721</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1759141991" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7676">723</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden:fc_326000575">-</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1079647625" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7677">353,445</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_2146548669" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7678">8,321,258</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7679">8,673,980</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/><td style="width: 0.25in; text-align: left"><i>(1)</i></td><td style="text-align: justify"><i>This number includes an aggregate of up to <ix:nonFraction name="paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" contextRef="cref_477826121" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7680">946,428</ix:nonFraction> Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining <ix:nonFraction name="paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" contextRef="cref_923664865" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7681">83,850</ix:nonFraction> units under the over-allotment option. As a result, the Sponsor forfeited <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="cref_1953308297" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7682">30,231</ix:nonFraction> Class B ordinary shares. All share and per share data have been retroactively applied.</i></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center">The accompanying notes are an integral
part of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 90; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fin_005" style="display: inline-block;"></span>PYROPHYTE ACQUISITION CORP. II<br/>
STATEMENT OF CASH FLOWS<br/>
FOR THE PERIOD FROM MAY 1, 2025 (INCEPTION) THROUGH DECEMBER 31, 2025</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="font-weight: bold">Cash Flows from Operating Activities</td><td>&#160;</td>
<td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Net income</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7683">2,973,863</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Adjustments to reconcile net income&#160;to net cash used in operating activities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Dividends and interest earned on marketable securities held in the Trust Account</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7684">3,601,747</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Formation and operating expenses paid in exchange for Founder Shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="paii:FormationAndOperatingExpensesPaidInExchangeForFounderShares" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7685">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Prepaid expenses</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7686">347,158</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7687">38,948</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7688">25,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7689">906,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Investment of cash into Trust Account</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7690">200,411,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7691">200,411,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Proceeds from sale of Units</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7692">200,411,500</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Proceeds from sale of Private Placement Warrants</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7693">4,396,555</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Offering costs paid</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7694">3,047,961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7695">201,760,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net increase in cash</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7696">442,500</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Cash - beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_575041159">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Cash - end of period</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7697">442,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left">Supplemental disclosure of noncash investing and financing activities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Private Placement Warrants issued through forgiveness of promissory note - related party</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="paii:PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7698">300,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Offering costs paid through the issuance of Founder Shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="paii:OfferingCostsPaidThroughTheIssuanceOfFounderShares" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7699">20,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Offering costs paid through promissory note - related party</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="paii:PrepaidExpensePaidThroughPromissoryNoteRelatedParty" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7700">300,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Deferred underwriting fees payable</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="paii:DeferredUnderwritingFeesPayable" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7701">9,399,690</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0; text-align: center">The accompanying notes are an integral
part of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 91; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5738"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="fin_006" style="display: inline-block;"></span>NOTE 1&#8212; ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pyrophyte Acquisition Corp.&#160;II (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on May&#160;1, 2025. The Company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business Combination&#8221;). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any Business Combination target with respect to an initial Business Combination with the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, the Company had not yet commenced operations. All activity for the period from <ix:nonNumeric name="paii:YearOfInception" contextRef="cref_1330416410" id="ixv-7702">May&#160;1, 2025 (inception) through December 31, 2025</ix:nonNumeric> relates to the Company&#8217;s formation and initial public offering (the &#8220;Initial Public Offering&#8221;). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering and sale of Private Placement Warrants (defined below). The Company has selected December&#160;31 as its fiscal year end. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The registration statement for the Company&#8217;s Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, the Company consummated its Initial Public Offering of <ix:nonFraction name="paii:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="cref_1673988012" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7703">17,500,000</ix:nonFraction> units (the &#8220;Units&#8221;). The Units were sold at a price of $<ix:nonFraction name="paii:PriceIssuedPerShare" contextRef="cref_1673988012" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7704">10.00</ix:nonFraction> per Unit, generating gross proceeds to the Company of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="cref_1673988012" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7705">175,000,000</ix:nonFraction>, which is described in Note 3. Each Unit consists of <ix:nonFraction name="paii:NumberOfSharesInEachUnit" contextRef="cref_947942404" unitRef="uref_779585586" scale="0" decimals="0" format="ixt-sec:numwordsen" id="ixv-7706">one</ix:nonFraction> Class A ordinary share, par value $<ix:nonFraction name="paii:PriceIssuedPerShare" contextRef="cref_967608479" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7707">0.0001</ix:nonFraction> per share (the &#8220;Class A Ordinary Shares&#8221;) and one-half of one redeemable warrant (each whole warrant, a &#8220;Public Warrant&#8221;) of the Company. Each Public Warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_700951886" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7708">11.50</ix:nonFraction> per share, subject to adjustment. The Company granted UBS Securities LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the &#8220;Underwriters&#8221;) in the Initial Public Offering a 45-day option to purchase up to <ix:nonFraction name="paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues" contextRef="cref_1352642449" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7709">2,625,000</ix:nonFraction> additional Units to cover over-allotments, if any. On July 24, 2025, the Underwriters partially exercised their over-allotment option to purchase an additional <ix:nonFraction name="paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues" contextRef="cref_1057160995" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7710">2,541,150</ix:nonFraction> Units at a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_726704442" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7711">10.00</ix:nonFraction> per Unit, generating additional gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="cref_1057160995" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7712">25,411,500</ix:nonFraction>. The Underwriters forfeited their option to purchase the remaining <ix:nonFraction name="paii:SharesIssuedSharesShareBasedPaymentArrangementForfeited" contextRef="cref_454030801" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7713">83,850</ix:nonFraction> Units under their over-allotment option. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1273128513" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7714">5,050,000</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;) at a purchase price of $<ix:nonFraction name="paii:ClassOfWarrantsAndRightsIssuedPricePerWarrant" contextRef="cref_891586060" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7715">1.00</ix:nonFraction> per Private Placement Warrant (the &#8220;Private Placement&#8221;) to Pyrophyte Acquisition II LLC (the &#8220;Sponsor&#8221;) and the Company&#8217;s independent directors, generating gross proceeds to the Company of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_891586060" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7716">5,050,000</ix:nonFraction>. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Transaction costs amounted to $<ix:nonFraction name="paii:TransactionCosts" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7717">12,767,651</ix:nonFraction>, including $<ix:nonFraction name="paii:DeferredUnderwritingFeesPayableNoncurrent" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7718">9,399,690</ix:nonFraction> in deferred underwriting fees, $<ix:nonFraction name="paii:UpforntUnderwritingFees" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7719">2,625,000</ix:nonFraction> in upfront underwriting fees, and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="cref_467896768" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7720">742,961</ix:nonFraction> in other offering costs related to the Initial Public Offering. In addition, cash of $<ix:nonFraction name="us-gaap:Cash" contextRef="cref_467896768" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7721">1,500,000</ix:nonFraction> (including share subscription receivable of $<ix:nonFraction name="paii:ShareSubscriptionReceivable" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7722">353,445</ix:nonFraction>) was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As a result of the Initial Public Offering and subsequent partial exercise of the over-allotment option, a total of $<ix:nonFraction name="paii:NetProceedsAmount" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7723">200,411,500</ix:nonFraction> of the net proceeds from the Initial Public Offering and the sale of the over-allotment option units was deposited in a U.S.-based Trust Account maintained by Continental Stock Transfer &amp; Trust Company, acting as trustee (the &#8220;Trust Account&#8221;). Except with respect to interest earned on the funds in the Trust Account that may be released to the Company to pay its taxes, the proceeds from the Initial Public Offering held in the Trust Account will not be released until the earlier of (i) the consummation of the initial Business Combination and (ii) the distribution of the Trust Account proceeds as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses. <span style="font-size: 10pt">&#160;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 92; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The proceeds held in the Trust Account are invested only in U.S. government treasury bills with a maturity of one hundred eighty-five (<ix:nonNumeric name="paii:USTreasuryGovernmentBillsMaturityTerm" contextRef="cref_1330416410" format="ixt-sec:durday" id="ixv-7724">185</ix:nonNumeric>) days or less or in money market funds that meet certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;) and that invest only in direct U.S. government obligations or in an interest bearing demand deposit account. Funds will remain in the Trust Account until the earlier of (i) the consummation of the initial Business Combination or (ii) the distribution of the Trust Account proceeds as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete a Business Combination with one or more target businesses that together have a fair market value equal to at least <ix:nonFraction name="paii:MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7725">80</ix:nonFraction>% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held and taxes paid or payable on the income earned on the Trust Account) at the time of the signing of an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires <ix:nonFraction name="paii:MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7726">50</ix:nonFraction>% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Upon the closing of the Initial Public Offering, an aggregate of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="cref_467896768" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7727">10.00</ix:nonFraction> per Unit sold in the Initial Public Offering was held in a Trust Account as cash and will be invested only in U.S.&#160;government treasury obligations with a maturity of 185&#160;days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, which invest only in direct U.S.&#160;government treasury obligations, or held as cash; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the initial Business Combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that it holds investments in the Trust Account, the Company may, at any time (based on the management team&#8217;s ongoing assessment of all factors related to the potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in cash or in an interest or non-interest bearing demand deposit account at a U.S.&#160;chartered commercial bank with consolidated assets of $<ix:nonFraction name="us-gaap:OtherAssets" contextRef="cref_333300986" unitRef="uref_200602150" scale="9" decimals="-9" format="ixt:num-dot-decimal" id="ixv-7728">100</ix:nonFraction>&#160;billion or more selected by the trustee that is reasonably satisfactory to the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to pay the Company&#8217;s taxes, the proceeds from the Initial Public Offering and the sale of the Private Placement Warrants will not be released from the Trust Account until the earliest to occur of (i)&#160;the completion of the Company&#8217;s initial Business Combination (including the release of funds to pay any amounts due to any public shareholders who properly exercise their redemption rights in connection therewith), (ii)&#160;the redemption of any public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company&#8217;s amended and restated memorandum and articles of association (A)&#160;in a manner that would affect the substance or timing of the Company&#8217;s obligation to redeem <ix:nonFraction name="paii:SharesRedemptionObligationPercentage" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7729">100</ix:nonFraction>% of its public shares if it does not complete an initial Business Combination within 24&#160;months from the closing of the Initial Public Offering or (B)&#160;with respect to any other material provision relating to the rights of holders of Class A Ordinary Shares (the &#8220;Public Shareholders&#8221;) or pre-initial Business Combination activity or (iii)&#160;the redemption of the Company&#8217;s public shares if it is unable to complete a Business Combination within 24&#160;months from the closing of Initial Public Offering, subject to applicable law. If the Company does not complete an initial Business Combination within 24&#160;months from the closing of the Initial Public Offering, the Company and the Underwriters have agreed that (1)&#160;the Underwriters will forfeit any rights or claims to their deferred underwriting discounts and commissions, including any accrued interest thereon, then in the Trust Account; and (2)&#160;that the deferred Underwriters&#8217; discounts and commissions will be distributed on a pro rata basis, together with any accrued interest thereon (which interest shall be net of taxes paid or payable) to the Public Shareholders. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 93; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company will provide its Public Shareholders with the opportunity to redeem, regardless of whether they abstain, vote for, or vote against the Company&#8217;s initial Business Combination, all or a portion of their Public Shares in connection with the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two&#160;business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account (net of taxes paid or payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations and on the conditions described herein. The amount in the Trust Account is initially anticipated to be $<ix:nonFraction name="paii:NewlyAdjustedIssueSharePrice" contextRef="cref_1330416410" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7730">10.00</ix:nonFraction> per Public Share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the Underwriters. The Company&#8217;s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their redemption rights with respect to their Founder Shares (as defined in Note 4) and Public Shares in connection with the completion of the Company&#8217;s initial Business Combination. Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction with their initial Business Combinations and provide for related redemptions of Public Shares for cash upon completion of such initial Business Combinations even when a vote is not required by law, if a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, it will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;), and file tender offer documents with the SEC prior to completing its initial Business Combination. The Company&#8217;s amended and restated memorandum and articles of association require these tender offer documents to contain substantially the same financial and other information about the initial Business Combination and the redemption rights as is required under the SEC&#8217;s proxy rules. If, however, a shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, it will, like many special purpose acquisition companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval, it will complete its initial Business Combination only if it obtains the approval of an ordinary resolution under Cayman Islands law and its amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. However, if the Company&#8217;s initial Business Combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of its initial Business Combination will require the approval of a special resolution, which requires the affirmative vote of at least two-thirds of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. However, the participation of the Company&#8217;s Sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions, if any, could result in the approval of an initial Business Combination even if a majority of the Public Shareholders vote, or indicate their intention to vote, against such initial Business Combination. For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of the initial Business Combination once a quorum is obtained. The Company&#8217;s amended and restated memorandum and articles of association require that at least five clear&#160;days&#8217; notice will be given of any general meeting. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Class A Ordinary Shares subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;480, &#8220;Distinguishing Liabilities from Equity.&#8221; If the Company seeks shareholder approval of the Business Combination, a majority of the issued and outstanding shares voted must be voted in favor of the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Pursuant to the Company&#8217;s amended and restated memorandum and articles of association, if it has not completed its initial Business Combination within 24 months from the closing of the Initial Public Offering, it will as promptly as reasonably possible but not more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of amounts not previously released to the Company for permitted withdrawals and up to $<ix:nonFraction name="paii:InterestToPayDissolutionExpenses" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7731">100,000</ix:nonFraction> of interest to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete its initial Business Combination within 24 months from the closing of the Initial Public Offering. However, if the Sponsor or management team acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the prescribed time period. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 94; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5787"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:BasisOfAccounting" contextRef="cref_619992257" escape="true" id="ixv-5792"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="paii:GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5799"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Going Concern, Liquidity and Capital Resources</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, the Company had a cash balance of $<ix:nonFraction name="us-gaap:Cash" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7732">442,500</ix:nonFraction>. Following the closing of the Initial Public Offering, the Company&#8217;s liquidity needs are satisfied through using net proceeds from the Initial Public Offering and the sale of Private Placement Warrants for existing accounts payable, identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the Company&#8217;s estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination or because it becomes obligated to redeem a significant number of its Public Shares upon completion of an initial Business Combination, in which case the Company may issue additional securities or incur debt in connection with such initial Business Combination. In addition, in order to finance transaction costs in connection with an initial Business Combination, the Company&#8217;s officers, directors and initial shareholders may, but are not obligated to, provide it with loans up to $<ix:nonFraction name="paii:WorkingCapitalLoans" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7733">1,500,000</ix:nonFraction> as the Company may require (&#8220;Working Capital Loans&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects to incur additional significant costs in pursuit of its financing and acquisition plans, including the proposed business combination. The Company has until 24 months from the IPO to complete a Business Combination or cease all operations other than those required for the purpose of liquidation. In connection with management&#8217;s evaluation of the Company&#8217;s ability to continue as a going concern in accordance with FASB ASC Topic 205-40, &#8220;Presentation of Financial Statements &#8211; Going Concern,&#8221; the Company&#8217;s liquidity concerns raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the date the audited financial statements are available to be issued. The Company intends to satisfy its liquidity needs through the Working Capital Loans that may be provided by its officers, directors and initial shareholders. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to satisfy its obligations.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="paii:EmergingGrowthCompanyStatusPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5809"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Emerging Growth Company Status</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or the &#8220;Securities Act&#8221;, as modified by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act&#160;of&#160;2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 95; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="cref_619992257" escape="true" id="ixv-5827"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"></span><span style="font-weight: bold;">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5837"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Cash and Cash Equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7734">442,500</ix:nonFraction> in cash and <span style="-sec-ix-hidden:fc_1532244282">no</span> cash equivalents as of December 31, 2025.<span style="font-weight: bold;">&#160;</span> </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="paii:MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5846"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Marketable Securities Held in Trust Account</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the assets held in the Trust Account were invested in money market funds that invest solely in U.S. treasury securities.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5854"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Class A Ordinary Shares Subject to Possible Redemption</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s Class A Ordinary Shares that were sold as part of the units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Class A Ordinary Shares in connection with the Company&#8217;s liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies ordinary shares subject to redemption outside of permanent (deficit) equity as the redemption provisions are not solely within the control of the Company. Each Unit consists of one Class A Ordinary Share and one-half of one Public Warrant. As such, the initial carrying value of Class A Ordinary Shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The Class A Ordinary Shares are subject to ASC 480-10-S99 and are currently not redeemable as the redemption is contingent upon the occurrence of events mentioned above. According to ASC 480-10-S99-15, no subsequent adjustment is needed if it is not probable that the instrument will become redeemable.<ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="cref_619992257" continuedAt="continuation_1734160265" escape="true" id="ixv-7735"> The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table:</ix:nonNumeric> </p><ix:continuation id="continuation_1734160265"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Gross proceeds</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="cref_73988315" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7736">200,411,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Less:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Class A Ordinary Shares issuance costs</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="paii:ClassAOrdinarySharesIssuanceCosts" contextRef="cref_73988315" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7737">12,512,442</ix:nonFraction></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9pt">Fair value of Public Warrants at issuance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_73988315" unitRef="uref_200602150" scale="0" decimals="0" sign="-" format="ixt:num-dot-decimal" id="ixv-7738">3,724,648</ix:nonFraction></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Plus:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Remeasurement of Class A Ordinary Shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="cref_73988315" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7739">19,838,837</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Class A Ordinary Shares subject to possible redemption at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="cref_1879775354" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7740">204,013,247</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td> </tr> </tbody></table></ix:continuation></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="cref_619992257" escape="true" id="ixv-5913"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Fair Value Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 96; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5927"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Fair Value Measurement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the price that would be received for sale of an asset or paid for in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> There were no investments, assets or liabilities requiring fair value measurement as of December 31, 2025 except marketable securities held in Trust Account of $<ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="cref_638126375" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7741">204,013,247</ix:nonFraction>, which is determined to be a Level 1 measurement. </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5957"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Derivative Financial Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluates its equity-linked financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounted for the Public Warrants issued in connection with the Initial Public Offering and the Private Placement Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the instruments continue to be classified in equity. The over-allotment option was deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and would be accounted for as a liability pursuant to ASC 480. The over-allotment option was partially exercised on July 24, 2025, and the over-allotment liability recorded by Company was reversed.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="paii:OfferingCostsPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5965"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Offering Costs</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the units between Class A Ordinary Shares and warrants, prorate, allocating the Initial Public Offering proceeds to the assigned value of the warrants and to the Class A Ordinary Shares. Offering costs allocated to the Class A Ordinary Shares were charged to temporary equity and offering costs allocated to the Public and Private Placement Warrants were charged to shareholders&#8217; deficit as Public and Private Placement Warrants, after management&#8217;s evaluation, are accounted for under equity treatment.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="paii:SubscriptionReceivablePolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5971"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Subscription Receivable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company records stock issuances at the effective date. If the subscription is not funded upon issuance, the Company records a subscription receivable as an asset on a balance sheet, except when subscription receivable is not received prior to the issuance of financial statements at a reporting date in satisfaction of the requirements under ASC 505-10-45-2, in which case, the subscription is reclassified as a contra account to stockholders&#8217; deficit on the balance sheet.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5977"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes under ASC Topic&#160;740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statements and tax basis of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 97; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> ASC Topic&#160;740 clarifies the accounting for uncertainty in income taxes recognized in an entity&#8217;s financial statements and prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are <span style="-sec-ix-hidden:fc_1353994326">no</span> significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#8217;s tax provision was zero for the periods presented.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-5997"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Net Income Per Ordinary Share</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company complies with accounting and disclosure requirements of ASC 260, &#8220;Earnings Per Share.&#8221; Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary shares outstanding during the period. For the period from May 1, 2025 (inception) through December 31, 2025, the Company did not consider the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase Public Shares in the calculation of diluted income per ordinary share, since their inclusion is contingent on a future event.<ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="cref_619992257" continuedAt="continuation_2065823040" escape="true" id="ixv-7742"> A reconciliation of the net income per ordinary share is stated below.</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:continuation id="continuation_2065823040"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The<br/> Period&#160;From<br/> May&#160;1, <br/> 2025<br/> (Inception)<br/> Through <br/> December 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Basic Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="cref_1891084432" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7743">1,971,714</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_1891084432" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7744">13,598,470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_1891084432" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7745">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="cref_116935946" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7746">1,002,149</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="cref_116935946" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7747">6,911,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_116935946" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7748">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Diluted Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="cref_1891084432" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7749">1,963,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_1891084432" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7750">13,598,470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_1891084432" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7751">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="cref_116935946" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7752">1,010,383</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="cref_116935946" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7753">6,997,607</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Diluted net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_116935946" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7754">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:continuation></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 98; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="cref_619992257" escape="true" id="ixv-6204"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal Deposit Insurance Corporation coverage of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7755">250,000</ix:nonFraction>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows. </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="paii:WarrantsPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6211"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in the statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants are not precluded from equity classification, and will be accounted for as such on the date of issuance.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="cref_619992257" escape="true" id="ixv-6221"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Share-Based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for Founder Shares issued to its independent directors in accordance with SEC Staff Accounting Bulletin 5T and ASC 718, &#8220;Compensation-Stock Compensation.&#8221; The fair value of the Founder Shares issued in this arrangement was determined using the implied stock price as of the date of the Initial Public Offering of the Company&#8217;s Class A Ordinary Shares and the probability of the success of the initial Business Combination.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6228"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric>  <ix:nonNumeric name="paii:InitialPublicOfferingTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6234"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 3&#8212;INITIAL PUBLIC OFFERING</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The registration statement for the Company&#8217;s Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, the Company consummated the Initial Public Offering of <ix:nonFraction name="paii:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="cref_1673988012" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7756">17,500,000</ix:nonFraction> Units, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="cref_1673988012" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7757">175,000,000</ix:nonFraction>. On July 24, 2025, the Underwriters partially exercised their over-allotment option to purchase an additional <ix:nonFraction name="paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues" contextRef="cref_1057160995" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7758">2,541,150</ix:nonFraction> Units at a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_726704442" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7759">10.00</ix:nonFraction> per Unit, generating additional gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="cref_1057160995" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7760">25,411,500</ix:nonFraction>. The Underwriters forfeited their option to purchase an additional <ix:nonFraction name="paii:SharesIssuedSharesShareBasedPaymentArrangementForfeited" contextRef="cref_474135015" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7761">83,850</ix:nonFraction> Units. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 99; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Each Unit consists of one Class A Ordinary Share and one-half of one redeemable Public Warrant. Each whole warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1284032524" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7762">11.50</ix:nonFraction> per share, subject to adjustment as described, and only whole warranty is exercisable. The warrants will become exercisable <ix:nonNumeric name="paii:ExercisableWarrantsTerm" contextRef="cref_1330416410" format="ixt-sec:durday" id="ixv-7763">30</ix:nonNumeric>&#160;days after the completion of the Company&#8217;s initial Business Combination and will expire five&#160;years after the completion of the Company&#8217;s initial Business Combination, or earlier upon redemption or liquidation. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1273128513" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7764">5,050,000</ix:nonFraction> Private Placement Warrants to the Sponsor, at a purchase price of $<ix:nonFraction name="paii:ClassOfWarrantsAndRightsIssuedPricePerWarrant" contextRef="cref_745494576" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7765">1.00</ix:nonFraction> per Private Placement Warrant, generating gross proceeds to the Company of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7766">5,050,000</ix:nonFraction>. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Each Private Placement Warrant is exercisable for one Class A Ordinary Share at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_259502220" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7767">11.50</ix:nonFraction> per share. If the initial Business Combination is not completed within 24 months from the closing of the Initial Public Offering, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis and will expire five years after the completion of the Company&#8217;s initial Business Combination or earlier upon redemption or liquidation. As the Sponsor will agree, subject to limited exceptions, not to transfer, assign or sell any of the Private Placement Warrants (including their underlying securities) until <ix:nonNumeric name="paii:ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" contextRef="cref_1330416410" format="ixt-sec:durday" id="ixv-7768">30</ix:nonNumeric> days after the completion of the initial Business Combination. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p></ix:exclude></ix:nonNumeric>  <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6256"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 4&#8212;RELATED PARTY TRANSACTIONS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Founder Shares</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On May&#160;5, 2025, the Sponsor made a capital contribution of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="cref_1609389963" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7769">25,000</ix:nonFraction>, or approximately $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_2136458884" unitRef="uref_246701486" scale="0" decimals="3" format="ixt:num-dot-decimal" id="ixv-7770">0.003</ix:nonFraction> per share, to cover certain of the Company&#8217;s expenses, for which the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_1609389963" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7771">7,255,952</ix:nonFraction> Founder Shares to the Sponsor. The Founder Shares included up to <ix:nonFraction name="paii:NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" contextRef="cref_1609389963" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7772">946,428</ix:nonFraction> of the Founder Shares subject to forfeiture by the Sponsor for no consideration to the extent the Underwriters&#8217; over-allotment was not fully exercised. The Underwriters had 45 days after the closing of the Initial Public Offering to exercise their over-allotment option. On July 24, 2025, the Underwriters partially exercised their over-allotment option as part of the Initial Public Offering. As such, <ix:nonFraction name="paii:NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" contextRef="cref_820702892" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7773">30,231</ix:nonFraction> Founder Shares were forfeited by the Sponsor. All share and per share data has been retroactively restated. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In June 2025, the Sponsor transferred&#160;<ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="cref_1830146596" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7774">30,000</ix:nonFraction>&#160;of the Company&#8217;s Founder Shares to each of the Company&#8217;s three independent directors. These&#160;<ix:nonFraction name="paii:NumberOfSharesNotSubjectToForfeiture" contextRef="cref_606805414" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7775">90,000</ix:nonFraction>&#160;Founder Shares were not subject to forfeiture. The allocation of the Founder Shares to the directors is in the scope of ASC 718. Under ASC 718, share-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Company used the implied stock price as of the date of the Initial Public Offering of the Company&#8217;s Class A Ordinary Shares and the probability of the success of the initial Business Combination. The fair value of the&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="cref_1595368894" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7776">90,000</ix:nonFraction>&#160;Founder Shares granted to the Company&#8217;s directors was $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" contextRef="cref_1844658907" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7777">216,637</ix:nonFraction>&#160;or $<ix:nonFraction name="paii:GrantedPricePerShare" contextRef="cref_1595368894" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7778">2.41</ix:nonFraction>&#160;per share. The Founder Shares were granted subject to a performance condition, the performance of the duties of an independent director through and the occurrence of an initial Business Combination. Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under ASC 718. The Company determined the performance conditions are not considered probable, and, therefore,&#160;<span style="-sec-ix-hidden:fc_912153279">no</span>&#160;share-based compensation expense was recognized as of December 31, 2025. As of December 31, 2025, the unrecognized stock compensation expense was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" id="fc_1026132719" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal">216,637</ix:nonFraction>. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 100; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Founder Shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A Ordinary Shares included in the Units sold in the Initial Public Offering, and holders of Founder Shares have the same shareholder rights as Public Shareholders, except that (i) the Founder Shares are subject to certain transfer restrictions, as described in more detail below, (ii) the Founder Shares are entitled to registration rights, (iii) the Company&#8217;s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (A) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Company&#8217;s initial Business Combination, (B) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the Company&#8217;s amended and restated memorandum and articles of association (1) to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem <ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" contextRef="cref_329624284" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7780">100</ix:nonFraction>% of the Company&#8217;s Public Shares if the Company has not consummated an initial Business Combination within 24 months from the closing of the Initial Public Offering, (2) with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial Business Combination activity, (3) waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete the Company&#8217;s initial Business Combination within the 24 months from the closing of the Initial Public Offering, although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the initial Business Combination within such time period and to liquidating distributions from assets outside the Trust Account and (4) vote any Founder Shares held by them and any Public Shares purchased during or after the Initial Public Offering (including in open market and privately negotiated transactions) in favor of the initial Business Combination (including any proposals recommended by the Company&#8217;s board of directors in connection with such Business Combination) (except with respect to any Public Shares which may not be voted in favor of approving the Business Combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations or guidance relating thereto), (iv) the Founder Shares are automatically convertible into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Company&#8217;s initial Business Combination or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in the amended and restated memorandum and articles of association, and (v) prior to the closing of the Company&#8217;s initial Business Combination, only holders of Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing in a jurisdiction outside the Cayman Islands (including any special resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Founder Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the initial Business Combination or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares, or any other equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to or in connection with the closing of the initial Business Combination, the ratio at which Class B ordinary shares convert into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, <ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" contextRef="cref_1272538016" unitRef="uref_193655120" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-7781">26.5</ix:nonFraction>% of the sum of (i) the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering (including any Class A Ordinary Shares issued pursuant to the Underwriters&#8217; over-allotment option and excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor and the Underwriters), plus (ii) all Class A Ordinary Shares and equity-linked securities issued or deemed issued in connection with the Company&#8217;s initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Company&#8217;s Sponsor or any of its affiliates or to the Company&#8217;s officers and directors upon conversion of Working Capital Loans) minus (iii) any redemptions of Class A Ordinary Shares by Public Shareholders in connection with an initial Business Combination; provided that such conversion of Founder Shares will never occur on a less than one-for-one basis. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s initial shareholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (i)&#160;one year after the completion of the initial Business Combination and (ii)&#160;the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company&#8217;s shareholders having the right to exchange their Class A Ordinary Shares for cash, securities or other property (except to certain permitted transferees and under certain circumstances). Notwithstanding the foregoing, if the last sale price of the Class A Ordinary Shares equals or exceeds $<ix:nonFraction name="paii:CommonStockStockPriceTrigger" contextRef="cref_61013207" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7782">12.00</ix:nonFraction> per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="paii:CommonStockThresholdTradingDays" contextRef="cref_1940925763" format="ixt-sec:durday" id="ixv-7783">20</ix:nonNumeric>&#160;trading days within any <ix:nonNumeric name="paii:CommonStockThresholdConsecutiveTradingDays" contextRef="cref_1940925763" format="ixt-sec:durday" id="ixv-7784">30</ix:nonNumeric>-trading&#160;day period commencing at least <ix:nonNumeric name="paii:NumberOfDaysAfterInitialBusinessCombination" contextRef="cref_1940925763" format="ixt-sec:durday" id="ixv-7785">150</ix:nonNumeric>&#160;days after the completion of the Company&#8217;s initial Business Combination, the Founder Shares will be released from this lock-up. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 101; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Promissory Note&#8212;Related Party</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Sponsor has agreed to loan the Company an aggregate of up to $<ix:nonFraction name="paii:AggregateUnsecuredPromissoryAmount" contextRef="cref_1093598802" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7786">300,000</ix:nonFraction> under an unsecured promissory to be used for a portion of the expenses in connection with the Initial Public Offering. The loan was non-interest bearing, unsecured and due at the earlier of December 31, 2025 or the closing of the Initial Public Offering. As of the Initial Public Offering date of July 18, 2025, the $<ix:nonFraction name="paii:PromissoryNotePayableFullyUtilizedAfterIPO" contextRef="cref_1462063775" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7787">300,000</ix:nonFraction> note was fully utilized by the Company. In connection with the private sale of <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="cref_1549419295" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7788">5,050,000</ix:nonFraction> warrants as described above in Note 4, the Company settled the outstanding note through the issuance of <ix:nonFraction name="paii:IssuanceOfPrivatePlacementWarrantsWithRelatedParty" contextRef="cref_1626106670" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7789">300,000</ix:nonFraction> Private Placement Warrants to the related party. The <ix:nonFraction name="paii:IssuanceOfPrivatePlacementWarrantsWithRelatedParty" contextRef="cref_525945823" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7790">300,000</ix:nonFraction> Private Placement Warrants are included in the total of <ix:nonFraction name="paii:InitialPublicOfferings" contextRef="cref_525945823" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7791">5,050,000</ix:nonFraction> in connection with the Initial Public Offering. The Company determined that the carrying value and fair value of the note are the same as the fair value of the Private Placement Warrants given in exchange for the note. As of December 31, 2025, there are <span style="-sec-ix-hidden:fc_1028152249">no</span> amounts outstanding under the note and the note is no longer available to be drawn.<span style="font-weight: bold;">&#160;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Share Subscription Receivable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On July 19, 2025, in connection with the sale of the Private Placement Warrants, the Sponsor should have deposited $<ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="cref_1113090420" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7792">353,445</ix:nonFraction> of the net proceeds into the Company&#8217;s bank account. This amount still has not been received as of December 31, 2025. The Company has accounted for the amount due as a share subscription receivable within shareholders&#8217; deficit. The amount is non-interest bearing, due on demand and expected to be settled in the near term. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Private Placement Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On July 18, 2025, the Sponsor purchased an aggregate <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1549419295" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7793">5,050,000</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1549419295" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7794">1.00</ix:nonFraction> per whole Private Placement Warrant in a private placement that occurred simultaneously with the closing of the Initial Public Offering. Each whole Private Placement Warrant is exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="cref_1549419295" unitRef="uref_779585586" scale="0" decimals="0" format="ixt-sec:numwordsen" id="ixv-7795">one</ix:nonFraction> whole Class A Ordinary Share at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_1950299307" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7796">11.50</ix:nonFraction> per share. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the initial Business Combination is not completed within 24&#160;months from the closing of the Initial Public Offering, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis and will expire <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="cref_2109124231" format="ixt-sec:durwordsen" id="ixv-7797">five&#160;years</ix:nonNumeric> after the completion of the Company&#8217;s initial Business Combination or earlier upon redemption or liquidation. As the Sponsor will agree, subject to limited exceptions, not to transfer, assign or sell any of the Private Placement Warrants (including their underlying securities) until <ix:nonNumeric name="paii:ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" contextRef="cref_333300986" format="ixt-sec:durday" id="ixv-7798">30</ix:nonNumeric>&#160;days after the completion of the initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Administrative Support Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Commencing on the effective date of the Initial Public Offering, the Company entered into an agreement with the Sponsor to pay an aggregate of $<ix:nonFraction name="paii:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7799">35,000</ix:nonFraction> per month for office space, utilities and secretarial and administrative support. Upon completion of the initial Business Combination or its liquidation, the Company will cease paying these monthly fees. For the period from May 1, 2025 (inception) through December 31, 2025, the Company recognized $<ix:nonFraction name="us-gaap:AdministrativeFeesExpense" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7800">192,500</ix:nonFraction> in administrative fees. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Working Capital Loans</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#8217;s Sponsor or an affiliate of its Sponsor or certain of its officers and directors may, but are not obligated to, loan the Company funds as may be required on a non-interest bearing basis. If the Company completes its initial Business Combination, the Company would repay such loaned amounts. In the event that the initial Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay such loaned amounts but no proceeds held in the Trust Account would be used for such repayment. Up to $<ix:nonFraction name="paii:MaximumLoansConvertibleIntoWarrants" contextRef="cref_2109124231" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7801">1,500,000</ix:nonFraction> of such loans may be convertible into Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_2109124231" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7802">1.00</ix:nonFraction> per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. The terms of such loans by the Company&#8217;s Sponsor or its affiliates, or its officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, <span style="-sec-ix-hidden:fc_936727067">no</span> such Working Capital Loans were outstanding. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 102; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6330"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 5&#8212;COMMITMENTS AND CONTINGENCIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks and Uncertainties</span></p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict, the Israel-Hamas war and the conflict between the United States and Israel and Iran, as well as recent developments to U.S. tariff policies. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the U.S., the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. &#8192;The invasion of Ukraine by Russia, the Israel-Hamas war, the conflict between the United States and Israel and Iran and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the Israel-Hamas war, and the conflict between the United States and Israel and Iran and subsequent sanctions or related actions or the ongoing trade and tariff policy changes by the U.S. or other countries could adversely affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Registration Rights</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the (i) Founder Shares, which were issued in the Private Placement prior to the closing of the Initial Public Offering, (ii) Private Placement Warrants and the Class A Ordinary Shares underlying such Private Placement Warrants and (iii) Private Placement Warrants that may be issued upon conversion of Working Capital Loans will have registration rights to require the Company to register a sale of any of the Company&#8217;s securities held by them and any other securities of the Company acquired by them prior to the consummation of the Company&#8217;s initial Business Combination pursuant to a registration rights agreement signed on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to the Company&#8217;s completion of the Company&#8217;s initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Underwriting Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On July 18, 2025, the Company paid a cash discount of <ix:nonFraction name="paii:PercentageOfCashDiscountOnInitialPublicOffering" contextRef="cref_1491172312" unitRef="uref_193655120" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-7803">1.5</ix:nonFraction>% of the per Unit Initial Public Offering price on the base Units sold in the Offering (or $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="cref_1491172312" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7804">2,625,000</ix:nonFraction> in aggregate) to the Underwriters at the closing of the Initial Public Offering, with an additional fee of <ix:nonFraction name="paii:PercentageOfAdditionalFeeOnInitialPublicOffering" contextRef="cref_1491172312" unitRef="uref_193655120" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-7805">4.5</ix:nonFraction>% of the gross Initial Public Offering proceeds with respect to the base Units sold in the Offering (and <ix:nonFraction name="paii:PercentageOfInitialPublicOfferingSoldToUnderwriters" contextRef="cref_1491172312" unitRef="uref_193655120" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-7806">6.0</ix:nonFraction>% of the per Unit Initial Public Offering price on the Units sold pursuant to the Underwriters&#8217; over-allotment option) payable only upon the Company&#8217;s completion of its initial Business Combination (the &#8220;Deferred Discount&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 103; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> A Deferred Discount of $<ix:nonFraction name="paii:DeferredDiscount" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7807">9,399,690</ix:nonFraction>, including the partial exercise of the over-allotment option, will become payable to the Underwriters from the amounts held in the Trust Account solely in the event the Company completes its initial Business Combination. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude></ix:nonNumeric>  <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6366"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 6&#8212;SHAREHOLDERS&#8217; DEFICIT</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <span style="font-weight: bold;">Preference Shares&#8212;</span>The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="cref_1692716169" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7808">1,000,000</ix:nonFraction> preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="cref_1692716169" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7809">0.0001</ix:nonFraction> per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December 31, 2025, there were <span style="-sec-ix-hidden:fc_899188066"><span style="-sec-ix-hidden:fc_174561091">no</span></span> preference shares issued or outstanding. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <span style="font-weight: bold;">Class A Ordinary Shares&#8212;</span>The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_1879775354" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7810">200,000,000</ix:nonFraction> Class A Ordinary Shares at par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_1879775354" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7811">0.0001</ix:nonFraction> each. Holders of the Company&#8217;s Class A Ordinary Shares are entitled to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="cref_73988315" id="ixv-7812">one</ix:nonNumeric> vote for each share. As of December 31, 2025, there were <span style="-sec-ix-hidden:fc_492491914"><span style="-sec-ix-hidden:fc_459141205">no</span></span> Class A Ordinary Shares issued or outstanding (excluding <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="cref_1879775354" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7813">20,041,150</ix:nonFraction> shares subject to possible redemption). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <span style="font-weight: bold;">Class&#160;B Ordinary Shares&#8212;</span>The Company is authorized to issue a total of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_1901841206" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7814">20,000,000</ix:nonFraction> Class&#160;B ordinary shares at par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_1901841206" unitRef="uref_246701486" scale="0" decimals="4" format="ixt:num-dot-decimal" id="ixv-7815">0.0001</ix:nonFraction> each. On May&#160;5, 2025, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_770479516" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7816">7,255,952</ix:nonFraction> Class&#160;B ordinary shares to the Sponsor (the &#8220;Founder Shares&#8221;) for $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="cref_770479516" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7817">25,000</ix:nonFraction>, or approximately $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_1318038427" unitRef="uref_246701486" scale="0" decimals="3" format="ixt:num-dot-decimal" id="ixv-7818">0.003</ix:nonFraction> per share, which included an aggregate of up to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="cref_1104949232" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7819">946,428</ix:nonFraction> shares that were subject to forfeiture to the extent that the Underwriters&#8217; over-allotment option was not exercised in full or in part. In June 2025, the Sponsor transferred&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_874887864" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7820">30,000</ix:nonFraction>&#160;of the Company&#8217;s Founder Shares to each of the Company&#8217;s three independent directors. On July 24, 2025, the Underwriters partially exercised their over-allotment option and forfeited their right remaining Units under the over-allotment option. As a result, the Sponsor forfeited <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="cref_2120962183" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7821">30,231</ix:nonFraction> Class B ordinary shares. As of December 31, 2025, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="cref_1901841206" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7822"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="cref_1901841206" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7823">7,225,721</ix:nonFraction></ix:nonFraction> Class&#160;B ordinary shares issued and outstanding. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Class&#160;B ordinary shares will automatically convert into Class A Ordinary Shares at the time of the Company&#8217;s initial Business Combination (with such conversion taking place immediately prior to, simultaneously with, or immediately following the time of the initial Business Combination, as may be determined by the Company&#8217;s directors) or earlier at the option of the holder on a one-for-one basis (subject to adjustment for share subdivisions, share dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares, or equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which Class&#160;B ordinary shares convert into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class&#160;B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issued and issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, <ix:nonFraction name="paii:ConvertibleStockConversionRatio1" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-7824">26.5</ix:nonFraction>% of the sum of (i)&#160;the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering (including any Class A Ordinary Shares issued pursuant to the Underwriters&#8217; over-allotment option but excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor), plus (ii)&#160;all Class A Ordinary Shares and equity-linked securities issued or deemed issued in connection with the Company&#8217;s initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Company&#8217;s Sponsor or any of its affiliates or to the Company&#8217;s officers and directors upon conversion of working capital loans) minus (iii)&#160;any redemptions of Class A Ordinary Shares by Public Shareholders prior to or in connection with an initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the Company enters into an initial Business Combination, it may (depending on the terms of such an initial Business Combination) be required to increase the number of Class A Ordinary Shares which the Company is authorized to issue at the same time as the Company&#8217;s shareholder votes on the initial Business Combination to the extent the Company seeks shareholder approval in connection with the initial Business Combination. Holders of the Company&#8217;s ordinary shares are entitled to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="cref_1330416410" id="ixv-7825">one</ix:nonNumeric> vote for each ordinary share (except as otherwise expressed in the Company&#8217;s amended and restated memorandum and articles of association). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <span style="font-weight: bold;">Warrants&#8212;</span>As of December 31, 2025, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1062301092" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7826">15,070,575</ix:nonFraction> warrants outstanding (<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1486745643" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7827">10,020,575</ix:nonFraction> Public Warrants and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_779585586" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7828">5,050,000</ix:nonFraction> Private Placement Warrants). Each whole warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1284032524" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7829">11.50</ix:nonFraction> per share, subject to adjustment as described herein. Only whole warrants are exercisable. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 104; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span>&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will not be obligated to issue any Class A Ordinary Shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A Ordinary Shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue a Class A Ordinary Share upon exercise of a warrant unless the Class A Ordinary Share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a Unit containing such warrant will have paid the full purchase price for the Unit solely for the Class A Ordinary Share underlying such unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The warrants will become exercisable <ix:nonNumeric name="paii:WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" contextRef="cref_73988315" format="ixt-sec:durday" id="ixv-7830">30</ix:nonNumeric> days after the completion of the Company&#8217;s initial Business Combination, which may be within <ix:nonNumeric name="paii:InitialBusinessCombinationTerm" contextRef="cref_22280331" format="ixt-sec:durwordsen" id="ixv-7831">one year</ix:nonNumeric> of the Initial Public Offering. However, because the warrants will be exercisable until their expiration date of up to <ix:nonNumeric name="paii:WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" contextRef="cref_87236569" format="ixt-sec:durwordsen" id="ixv-7832">five years</ix:nonNumeric> after the completion of the initial Business Combination, in order to comply with the requirements of Section 10(a)(3) of the Securities Act following the consummation of the initial Business Combination, under the terms of the warrant agreement, the Company has agreed that, as soon as practicable, but in no event later than <ix:nonNumeric name="paii:ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" contextRef="cref_668677484" format="ixt-sec:durday" id="ixv-7833">20</ix:nonNumeric> business days, after the closing of its initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement or a new registration statement covering the registration under the Securities Act of the Class A Ordinary Shares issuable upon exercise of the warrants and thereafter will use its commercially reasonable efforts to cause the same to become effective within <ix:nonNumeric name="paii:ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" contextRef="cref_1618928315" format="ixt-sec:durday" id="ixv-7834">60</ix:nonNumeric> business days following its initial Business Combination and to maintain a current prospectus relating to the Class A Ordinary Shares issuable upon exercise of the warrants until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A Ordinary Shares issuable upon exercise of the warrants is not effective by the sixtieth (60) business day after the closing of the Company&#8217;s initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Company&#8217;s Class A Ordinary Shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <span style="font-weight: bold;"><i>Redemption of warrants for cash when the price per Class A Ordinary Share equals or exceeds $<ix:nonFraction name="paii:RedemptionOfPublicWarrants" contextRef="cref_1284032524" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7835">18.00</ix:nonFraction></i></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may redeem the outstanding Public Warrants for cash:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify"><span style="font-family: Symbol"></span>in whole and not in part;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#9679;</td> <td style="text-align: justify"><span style="font-family: Symbol"></span>at a price of $<ix:nonFraction name="paii:ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" contextRef="cref_157283163" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7836">0.01</ix:nonFraction> per warrant; upon not less than <ix:nonNumeric name="paii:ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" contextRef="cref_1330416410" format="ixt-sec:durday" id="ixv-7837">30</ix:nonNumeric>&#160;days&#8217; prior written notice of redemption (the &#8220;<ix:nonNumeric name="paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" contextRef="cref_1330416410" format="ixt-sec:durday" id="ixv-7838">30</ix:nonNumeric>-day redemption period&#8221;); and &#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#9679;</td> <td style="text-align: justify"><span style="font-family: Symbol"></span>if, and only if, the last reported sale price of the Class A Ordinary Shares equals or exceeds $<ix:nonFraction name="paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" contextRef="cref_1292095244" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7839">18.00</ix:nonFraction> per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" contextRef="cref_157283163" format="ixt-sec:durday" id="ixv-7840">20</ix:nonNumeric>&#160;trading days within a <ix:nonNumeric name="paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" contextRef="cref_157283163" format="ixt-sec:durday" id="ixv-7841">30</ix:nonNumeric>&#160;trading day period ending on the third&#160;trading day prior to the date on which the Company send the notice of redemption to the warrant holders</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the Class A Ordinary Shares issuable upon exercise of the warrants is effective and a current prospectus relating to those Class A Ordinary Shares is available throughout such 30&#160;trading day period and the 30&#160;day redemption period. If and when the Public Warrants become redeemable by the Company, it may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. The Company has established the last of the redemption criterion discussed above to prevent a&#160;redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of the Class A Ordinary Shares may fall below the $<ix:nonFraction name="paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" contextRef="cref_1292095244" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7842">18.00</ix:nonFraction> redemption trigger price (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) as well as the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1062301092" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7843">11.50</ix:nonFraction> (for whole shares) warrant exercise price after the redemption notice is issued. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 105; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Anti-dilution adjustments</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If (x) the Company issues additional Class A Ordinary Shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $<ix:nonFraction name="paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" contextRef="cref_1879775354" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7844">9.20</ix:nonFraction> per Class A Ordinary Shares (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <ix:nonFraction name="paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7845">60</ix:nonFraction>% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and the volume weighted average trading price of the Class A Ordinary Shares during the <ix:nonNumeric name="paii:CommonStockThresholdTradingDay" contextRef="cref_73988315" format="ixt-sec:durday" id="ixv-7846">20</ix:nonNumeric> trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction name="paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" contextRef="cref_333300986" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7847">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="paii:PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7848">115</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price, and the $<ix:nonFraction name="paii:ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" contextRef="cref_1330416410" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7849">18.00</ix:nonFraction> per share redemption trigger price will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="paii:PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" contextRef="cref_1330416410" unitRef="uref_193655120" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-7850">180</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Private Placement Warrants (including the Class A Ordinary Shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants sold as part of the units in the Initial Public Offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company accounts for the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1062301092" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7851">15,070,575</ix:nonFraction> warrants issued in connection with the Initial Public Offering (including <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1486745643" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7852">10,020,575</ix:nonFraction> Public Warrants and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_779585586" unitRef="uref_779585586" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7853">5,050,000</ix:nonFraction> Private Placement Warrants) in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p></ix:exclude></ix:nonNumeric>  <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6460"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7&#8212;SEGMENT INFORMATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC Topic&#160;280, &#8220;Segment Reporting,&#8221; establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#8217;s chief operating officer decision maker (&#8220;CODM&#8221;), or group, in deciding how to allocate resources and assess performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <ix:nonNumeric name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription" contextRef="cref_1330416410" id="ixv-6467">The Company&#8217;s CODM has been identified as the <span style="-sec-ix-hidden:fc_832639951">Chief Financial Officer</span>, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="cref_1330416410" unitRef="uref_599377219" scale="0" decimals="0" format="ixt-sec:numwordsen" id="ixv-7854">one</ix:nonFraction> reportable segment.</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the statements of operations as net income or loss. The measure of segment assets is reported on the balance sheet as total assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 106; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude><ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6479"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income or loss and total assets, which include the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of<br/> December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Marketable securities held in Trust Account</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="cref_333300986" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7855">204,013,247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The <br/> Period&#160;From<br/> May&#160;1,<br/> 2025 <br/> (Inception) <br/> Through <br/> December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">General and administrative expenses</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7856">628,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividends and interest earned on marketable securities held in the Trust Account</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="cref_1330416410" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7857">3,601,747</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative costs are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete an offering and eventually a Business Combination within the Business Combination period. The CODM also reviews general and administrative expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. General and administrative expenses, as reported on the statement of operations, are the significant segment expenses provided to the CODM on a regular basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other segment items included in net income or loss are reported on the statement of operations and described within their respective disclosures.</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude></ix:nonNumeric>  <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6530"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 8&#8212;FAIR VALUE MEASUREMENT</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6534"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 by level within the fair value hierarchy:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Assets:</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">Marketable securities held in Trust Account</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="cref_1093905091" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7858">204,013,247</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_1886441502">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_2088902046">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Public Warrants were valued using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The value of the Public Warrants as of the IPO date was $<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="cref_200602150" unitRef="uref_200602150" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-7859">3,724,648</ix:nonFraction> or $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_246701486" unitRef="uref_246701486" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7860">0.37</ix:nonFraction> per warrant. The Public Warrants have been classified within shareholders&#8217; deficit and will not require remeasurement after issuance. <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="cref_619992257" continuedAt="continuation_663624867" escape="true" id="ixv-7861">The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Warrants as of the Initial Public Offering date using level 3 inputs:</ix:nonNumeric> </p><ix:continuation id="continuation_663624867"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 18,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Market price of public stock</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1064750139" unitRef="uref_193655120" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7862">9.81</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Term (years)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1075758566" unitRef="uref_193655120" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-7863">6.50</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free rate</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1779705651" unitRef="uref_193655120" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-7864">3.77</ix:nonFraction></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1680536946" unitRef="uref_193655120" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-7865">0.00</ix:nonFraction></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_1954112812" unitRef="uref_193655120" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-7866">9.11</ix:nonFraction></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Probability of merger</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="cref_193655120" unitRef="uref_193655120" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-7867">25.00</ix:nonFraction></td><td style="text-align: left">%</td> </tr> </tbody></table></ix:continuation><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p></ix:exclude></ix:nonNumeric>  <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="cref_619992257" escape="true" id="ixv-6628"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9&#8212;SUBSEQUENT EVENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company evaluated subsequent events and transactions that occurred after the balance sheet date through March 30, 2026, the date that the financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p></ix:exclude></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-22</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"></span></p><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>ea028245801ex4-5.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 4.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><I>The following
description of Pyrophyte Acquisition Corp. II&rsquo;s (the &ldquo;Company,&rdquo; &ldquo;we&rdquo; or &ldquo;us&rdquo;) securities is
a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company&rsquo;s amended
and restated memorandum and articles of association (the &ldquo;Amended and Restated Memorandum and Articles of Association&rdquo;), which
is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this exhibit is a part. We encourage you to read
the Amended and Restated Memorandum and Articles of Association and the applicable provisions of the Companies Act (As Revised) of the
Cayman Islands (the &ldquo;Companies Act&rdquo;) for additional information. Terms not otherwise defined herein shall have the meaning
assigned to them in the Annual Report on Form 10-K of which this Exhibit 4.5 is a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Pursuant to our
Amended and Restated Memorandum and Articles of Association, we are authorized to issue up to 221,000,000 ordinary shares, $0.0001 par
value each, including 200,000,000 Class A Ordinary Shares and 20,000,000 Class B ordinary shares, par value $0.0001 per share (&ldquo;Class
B ordinary shares&rdquo;), as well as 1,000,000 preference shares, $0.0001 par value each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">As of December
31, 2025, Pyrophyte Acquisition Corp. II has three classes of securities registered under Section 12 of the Exchange Act of 1934 (the
&ldquo;Exchange Act&rdquo;): (1) our Units; (2) our Class A Ordinary Shares; and (3) our Public Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Public Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Each Unit consists
of one Class A Ordinary Share and one-half of one redeemable Public Warrant. Each whole Public Warrant entitles the holder thereof to
purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustments. Pursuant to the warrant agreement, dated July
16, 2025 by and between the Company and Continental Stock Transfer &amp; Trust Company (&ldquo;Continental&rdquo;), as warrant agent (the
&ldquo;Warrant Agreement&rdquo;), a warrant holder may exercise its warrants only for a whole number of the Company&rsquo;s Class A Ordinary
Shares. This means only a whole warrant may be exercised at any given time by a warrant holder. For example, if a warrant holder holds
one-half of one warrant to purchase a Class A Ordinary Share, such warrant will not be exercisable. If a warrant holder holds two-halves
of one warrant, such whole warrant will be exercisable for one Class A Ordinary Share at a price of $11.50 per share. The Class A Ordinary
Shares and Public Warrants comprising the Units began separate trading on September 8, 2026. Holders have the option to continue to hold
Units or separate their Units into the component securities. Holders will need to have their brokers contact our transfer agent in order
to separate the Units into Class A Ordinary Shares and Public Warrants. No fractional Public Warrants will be issued upon separation of
the Units and only whole Public Warrants will trade. Accordingly, unless you purchased at least two Units, you will not be able to receive
or trade a whole Public Warrant. Additionally, the Units that have not already been separated will automatically separate into their component
parts in connection with the completion of our initial Business Combination and will no longer be listed thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Ordinary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">As of December
31, 2025, there were 27,266,871 ordinary shares outstanding, consisting of 20,041,150 Class A Ordinary Shares and 7,225,721 Class B ordinary
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Ordinary shareholders
of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of Class A Ordinary Shares
and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders except
as required by law. Unless specified in our Amended and Restated Memorandum and Articles of Association, or as required by applicable
provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of our ordinary shares that are
represented in person or by proxy and are voted is required to approve any such matter voted on by our shareholders. Approval of certain
actions will require a special resolution under Cayman Islands law, and pursuant to our Amended and Restated Memorandum and Articles of
Association passed by the affirmative vote of at least two-thirds of our ordinary shares which are represented in person or represented
by proxy and are voted at a general meeting of the Company; such actions include amending our Amended and Restated Memorandum and Articles
of Association and approving a statutory merger or consolidation with another company. Prior to the closing of our initial Business Combination,
only holders of Class B ordinary shares will be entitled to vote on continuing the Company in a jurisdiction outside the Cayman Islands
(including any special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents
of the Company, in each case, as a result of the Company approving a transfer by way of continuation in a jurisdiction outside the Cayman
Islands). Our shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally
available therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Because our Amended
and Restated Memorandum and Articles of Association authorize the issuance of up to 200,000,000 Class A Ordinary Shares, if we were to
enter into a Business Combination, we may (depending on the terms of such a Business Combination) be required to increase the number of
Class A Ordinary Shares which we are authorized to issue at the same time as our shareholders vote on the Business Combination to the
extent we seek shareholder approval in connection with our initial Business Combination.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In accordance
with the NYSE corporate governance requirements, we are not required to hold an annual meeting until no later than one year after our
first fiscal year end following our listing on the NYSE. There is no requirement under the Companies Act for us to hold annual or extraordinary
general meetings or appoint directors. We may not hold an annual general meeting to appoint new directors prior to the consummation of
our initial Business Combination. Our board of directors is divided into three classes with only one class of directors being elected
in each year and each class (except for those directors appointed prior to our first annual general meeting) serving a three-year term.
There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares
voted for the appointment of directors can appoint all of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We will provide
our Public Shareholders with the opportunity to redeem, regardless of whether they abstain, vote for, or against, our initial Business
Combination, all or a portion of their Public Shares upon the completion of our initial Business Combination at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation
of our initial Business Combination, including interest earned on the funds held in the Trust Account (which interest shall be net of
taxes paid or payable), divided by the number of then outstanding Public Shares, subject to the limitations described herein. The amount
in the Trust Account is initially anticipated to be $10.00 per Public Share. The per share amount we will distribute to investors who
properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the Underwriters. Our Sponsor,
officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights
with respect to any Founder Shares and Public Shares they hold in connection with the completion of our initial Business Combination.
Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction with their
initial Business Combinations and provide for related redemptions of Public Shares for cash upon completion of such initial Business Combinations
even when a vote is not required by law, if a shareholder vote is not required by law and we do not decide to hold a shareholder vote
for business or other legal reasons, we will, pursuant to our Amended and Restated Memorandum and Articles of Association, conduct the
redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents with the SEC prior to completing our initial
Business Combination. Our Amended and Restated Memorandum and Articles of Association require these tender offer documents to contain
substantially the same financial and other information about our initial Business Combination and the redemption rights as is required
under the SEC&rsquo;s proxy rules. If, however, a shareholder approval of the transaction is required by law, or we decide to obtain shareholder
approval for business or other legal reasons, we will, like many special purpose acquisition companies, offer to redeem shares in conjunction
with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we
will complete our initial Business Combination only if we receive an ordinary resolution under Cayman Islands law, passed by the affirmative
vote of at least a majority of the votes cast by the shareholders of the issued shares represented in person or represented by proxy and
are voted at a general meeting of the Company. However, if our initial Business Combination is structured as a statutory merger or consolidation
with another company under Cayman Islands law, the approval of our initial Business Combination will require a special resolution passed
by the affirmative vote of at least two-thirds of our ordinary shares which are represented in person or by proxy and are voted at a general
meeting of the Company. However, the participation of our Sponsor, officers, directors, advisors or their affiliates in privately-negotiated
transactions, if any, could result in the approval of our initial Business Combination even if a majority of our Public Shareholders vote,
or indicate their intention to vote, against such initial Business Combination. For purposes of seeking approval of an ordinary resolution,
non-votes will have no effect on the approval of our initial Business Combination once a quorum is obtained. Our Amended and Restated
Memorandum and Articles of Association require that at least five days&rsquo; notice will be given of any general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If we seek shareholder
approval of our initial Business Combination and we do not conduct redemptions in connection with our initial Business Combination pursuant
to the tender offer rules, our Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together
with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &ldquo;group&rdquo;
(as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to Excess Shares, without
our prior consent. However, we would not be restricting our shareholders&rsquo; ability to vote all of their shares (including Excess
Shares) for or against our initial Business Combination. Our shareholders&rsquo; inability to redeem the Excess Shares will reduce their
influence over our ability to complete our initial Business Combination, and such shareholders could suffer a material loss in their investment
if they sell such Excess Shares on the open market. Additionally, such shareholders will not receive redemption distributions with respect
to the Excess Shares if we complete our initial Business Combination. And, as a result, such shareholders will continue to hold that number
of shares exceeding 15% and, in order to dispose such shares would be required to sell their shares in open market transactions, potentially
at a loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If we seek shareholder
approval in connection with our initial Business Combination, our initial shareholders, Sponsor, officers and directors have agreed to
vote any Founder Shares they hold and any Public Shares purchased during or after the Initial Public Offering in favor of our initial
Business Combination. As a result, in addition to our initial shareholders&rsquo; Founder Shares, we would need 6,407,716, or approximately
32.0% of the 20,041,150 Public Shares sold in the Initial Public Offering to be voted in favor of an initial Business Combination in order
to have our initial Business Combination approved (assuming all outstanding shares are voted and the parties to the letter agreement do
not acquire any Class A Ordinary Shares). Assuming that only the holders of one-third of our issued and outstanding ordinary shares, representing
a quorum under our Amended and Restated Memorandum and Articles of Association, vote their shares at a general meeting of the Company,
we will not need any Public Shares in addition to our Founder Shares to be voted in favor of an initial Business Combination in order
to approve an initial Business Combination. However, if our initial Business Combination is structured as a statutory merger or consolidation
with another company under Cayman Islands law, the approval of our initial Business Combination will require a special resolution, passed
by the affirmative vote of at least two-thirds of the votes cast by the shareholders of the issued shares represented in person or represented
by proxy and entitled to vote on such matter at a general meeting of the Company and are voted at a general meeting of the Company. Additionally,
each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction
or whether they were a Public Shareholder on the record date for the general meeting held to approve the proposed transaction.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Pursuant to our
Amended and Restated Memorandum and Articles of Association, if we are unable to complete our initial Business Combination within the
Completion Window, we will, as promptly as reasonably possible but no more than ten business days thereafter, redeem the Public Shares,
at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on
the funds held in the Trust Account (which interest shall be net of amounts not previously released to us for permitted withdrawals and
up to $100,000 of interest to pay liquidation expenses), divided by the number of then outstanding Public Shares, which redemption will
constitute full and complete payment and completely extinguish Public Shareholders&rsquo; rights as shareholders (including the right
to receive further liquidation distribution or other distributions, if any), subject to our obligations under Cayman Islands law to provide
for claims of creditors and the requirements of other applicable law. Our Sponsor, officers and directors have entered into a letter agreement
with us, pursuant to which they have agreed to waive their rights to liquidating distributions from the Trust Account with respect to
their Founder Shares if we fail to complete our initial Business Combination within the Completion Window, although they will be entitled
to liquidating distributions from assets outside the Trust Account. However, if our Sponsor or management team acquire Public Shares in
or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account and to liquidating distributions
from assets outside the Trust Account with respect to such Public Shares if we fail to complete our initial Business Combination within
the prescribed time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In the event
of a liquidation, dissolution or winding up of the Company after a Business Combination, our shareholders are entitled to share ratably
in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of
shares, if any, having preference over the ordinary shares. Our shareholders have no preemptive or other subscription rights. There are
no sinking fund provisions applicable to the ordinary shares, except that we will provide our Public Shareholders with the opportunity
to redeem their Public Shares for cash at a per share price equal to the aggregate amount then on deposit in the Trust Account, including
interest earned on the funds held in the Trust Account (which interest shall be net of taxes paid or payable), divided by the number of
then outstanding Public Shares, upon the completion of our initial Business Combination, subject to the limitations described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Founder Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The Founder Shares
are designated as Class B ordinary shares and, except as described below, are identical to the Class A Ordinary Shares included in the
Units sold in the Initial Public Offering, and holders of Founder Shares have the same shareholder rights as Public Shareholders, except
that (i) the Founder Shares are subject to certain transfer restrictions, as described in more detail below, (ii) the Founder Shares are
entitled to registration rights, (iii) our Sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to (A) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion
of our initial Business Combination, (B) waive their redemption rights with respect to their Founder Shares and Public Shares in connection
with a shareholder vote to approve an amendment to our Amended and Restated Memorandum and Articles of Association (A) to modify the substance
or timing of our obligation to allow redemption in connection with our initial Business Combination or to redeem 100% of our Public Shares
if we have not consummated an initial Business Combination within the Completion Window or (B) with respect to any other material provisions
relating to shareholders&rsquo; rights or pre-initial Business Combination activity, (C) waive their rights to liquidating distributions
from the Trust Account with respect to their Founder Shares if we fail to complete our initial Business Combination within the Completion
Window, although they will be entitled to liquidating distributions from the Trust Account and to liquidating distributions from assets
outside the Trust Account with respect to any Public Shares they hold if we fail to complete our initial Business Combination within such
time period and (D) vote any Founder Shares held by them and any Public Shares purchased during or after the Initial Public Offering (including
in open market and privately-negotiated transactions) in favor of our initial Business Combination, (iv) the Founder Shares are automatically
convertible into Class A Ordinary Shares concurrently with or immediately following the consummation of our initial Business Combination,
or earlier at the option of the holders thereof, on a one-for-one basis, subject to adjustment as described herein and in our Amended
and Restated Memorandum and Articles of Association, and (v) prior to the closing of our initial Business Combination, only holders of
Class B ordinary shares will be entitled to vote on continuing the Company in a jurisdiction outside the Cayman Islands (including any
special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents of the Company,
in each case, as a result of the Company approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The Founder Shares
will automatically convert into Class A Ordinary Shares at the time of the consummation of our initial Business Combination, or earlier
at the option of the holders thereof, on a one-for-one basis, subject to adjustment for share splits, share dividends, reorganizations,
recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares
or equity-linked securities are issued or deemed issued in connection with our initial Business Combination, the number of Class A Ordinary
Shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 26.5% of the total number
of Class A Ordinary Shares outstanding after such conversion (after giving effect to any redemptions of Class A Ordinary Shares by Public
Shareholders and not including the Class A Ordinary Shares underlying the Private Placement Units), including the total number of Class
A Ordinary Shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or
deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any
Class A Ordinary Shares or equity-linked securities or rights exercisable for or convertible into Class A Ordinary Shares issued, or to
be issued, to any seller in the initial Business Combination and any Private Placement Units issued to our Sponsor, officers or directors
upon conversion of working capital loans, <I>provided that</I> such conversion of Founder Shares will never occur on a less than one-for-one
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">With certain
limited exceptions, the Founder Shares are not transferable, assignable or salable (except to our officers and directors and other persons
or entities affiliated with our Sponsor, each of whom will be subject to the same transfer restrictions) until the earlier to occur of
(i) one year after the completion of our initial Business Combination or (ii) the date following the completion of our initial Business
Combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders
having the right to exchange their Class A Ordinary Shares for cash, securities or other property. Any permitted transferees will be subject
to the same restrictions and other agreements of our initial shareholders with respect to any Founder Shares.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Notwithstanding
the foregoing, if (1) the closing price of our Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing
at least 150 days after our initial Business Combination or (2) if we consummate a transaction after our initial Business Combination
which results in our shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares
will be released from the lock-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Register of Members</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Under Cayman Islands law, we must keep a register of members
and there will be entered therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the names and addresses of the members, a statement of the
shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of each member and the voting rights
of the shares of each member;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">whether voting rights are attached to the share in issue;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the date on which the name of any person was entered on the
register as a member; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the date on which any person ceased to be a member.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Under Cayman
Islands law, the register of members of our Company is prima facie evidence of the matters set out therein (i.e. the register of members
will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members
will be deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The shareholders
recorded in the register of members will be deemed to have legal title to the shares set against their name. However, there are certain
limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members
reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained
by a company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application
for an order for rectification of the register of members were made in respect of our ordinary shares, then the validity of such shares
may be subject to re-examination by a Cayman Islands court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Preference Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Our Amended and
Restated Memorandum and Articles of Association authorize 1,000,000 preference shares and provide that preference shares may be issued
from time to time in one or more series. Our board of directors is authorized to fix the voting rights, if any, designations, powers,
preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof,
applicable to the shares of each series. Our board of directors will be able to, without shareholder approval, issue preference shares
with voting and other rights that could adversely affect the voting power and other rights of the holders of the ordinary shares and could
have anti-takeover effects. The ability of our board of directors to issue preference shares without shareholder approval could have the
effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preference shares
outstanding at the date hereof. Although we do not currently intend to issue any preference shares, we cannot assure you that we will
not do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Public Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Each whole warrant
entitles the registered holder to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment as discussed
below, at any time commencing 30 days after the completion of our initial Business Combination, <I>provided that </I>we have an effective
registration statement under the Securities Act covering the Class A Ordinary Shares issuable upon exercise of the warrants and a current
prospectus relating to them is available (or we permit holders to exercise their warrants on a cashless basis under the circumstances
specified in the Warrant Agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue
sky, laws of the state of residence of the holder. Pursuant to the Warrant Agreement, a warrant holder may exercise its warrants only
for a whole number of Class A Ordinary Shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No
fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. Accordingly, unless
you purchased at least two Units, you will not be able to receive or trade a whole Public Warrant. The warrants will expire five years
after the completion of our initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We will not be
obligated to deliver any Class A Ordinary Shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant
exercise unless a registration statement under the Securities Act with respect to the Class A Ordinary Shares underlying the warrants
is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect
to registration. No warrant will be exercisable and we will not be obligated to issue a Class A Ordinary Share upon exercise of a warrant
unless the Class A Ordinary Share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the
securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately
preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant
and such warrant may have no value and expire worthless. In no event will we be required to net cash settle any warrant. In the event
that a registration statement is not effective for the exercised warrants, the purchaser of a Unit containing such warrant will have paid
the full purchase price for the Unit solely for the Class A Ordinary Share underlying such Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We registered
the Class A Ordinary Shares issuable upon exercise of the warrants in the registration statement filed in connection with our Initial
Public Offering because the warrants will become exercisable 30 days after the completion of our initial Business Combination. However,
because the warrants will be exercisable until their expiration date of up to five years after the completion of our initial Business
Combination, in order to comply with the requirements of Section 10(a)(3) of the Securities Act following the consummation of our initial
Business Combination under the terms of the Warrant Agreement, we have agreed, that as soon as practicable, but in no event later than
20 business days after the closing of our initial Business Combination, we will use our commercially reasonable efforts to file with the
SEC a post-effective amendment to the registration statement in connection with the Initial Public Offering or a new registration statement
covering the registration, under the Securities Act, of the Class A Ordinary Shares issuable upon exercise of the warrants and thereafter
will use our commercially reasonable efforts to cause the same to become effective within 60 business days following our initial Business
Combination and to maintain a current prospectus relating to the Class A Ordinary Shares issuable upon exercise of the warrants until
the expiration of the warrants in accordance with the provisions of the Warrant Agreement. If a registration statement covering the Class
A Ordinary Shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of our initial Business
Combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have
failed to maintain an effective registration statement, exercise warrants on a &ldquo;cashless basis&rdquo; in accordance with Section
3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if our Class A Ordinary Shares are at the time of any exercise
of a warrant not listed on a national securities exchange such that they satisfy the definition of a &ldquo;covered security&rdquo; under
Section 18(b)(1) of the Securities Act, we may, at our option, require holders of Public Warrants who exercise their warrants to do so
on a &ldquo;cashless basis&rdquo; in accordance with Section 3(a)(9) of the Securities Act and, in the event we so elect, we will not
be required to file or maintain in effect a registration statement.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Redemption of Warrants for Cash</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Once the warrants become exercisable, we may call the Public
Warrants for redemption for cash:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">in whole and not in part;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at a price of $0.01 per Public Warrant;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">upon not less than 30 days&rsquo; prior written notice of
redemption (the &ldquo;30-day measurement period&rdquo;); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">if, and only if, the closing price of the ordinary shares
equals or exceeds $18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like
and for certain issuances of Class A Ordinary Shares and equity-linked securities for capital raising purposes in connection with the
closing of our initial Business Combination) for any 20 trading days within a 30-trading day period ending on the third trading day before
we send to the notice of redemption to the warrant holders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If and when the
Public Warrants become redeemable by us for cash, we may not exercise our redemption right if the issuance of ordinary shares upon exercise
of the Public Warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect
such registration or qualification. We will use our best efforts to register or qualify such ordinary shares under the blue sky laws of
the state of residence in those states in which Public Warrants were offered by us in the Initial Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We have established
the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant
premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the Public Warrants,
each warrant holder will be entitled to exercise his, her or its Public Warrant prior to the scheduled redemption date. However, the price
of the Class A Ordinary Shares may fall below the $18.00 redemption trigger price (as adjusted for share splits, share capitalizations,
reorganizations, recapitalizations and the like and for certain issuances of Class A Ordinary Shares and equity-linked securities for
capital raising purposes in connection with the closing of our initial Business Combination) as well as the $11.50 warrant exercise price
after the redemption notice is issued.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Redemption Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If we call the
Public Warrants for redemption as described above under &ldquo;- <I>Redemption of Warrants for Cash</I>&rdquo;, our management will have
the option to require any holder that wishes to exercise his, her or its Public Warrant to do so on a &ldquo;cashless basis.&rdquo; In
determining whether to require all holders to exercise their Public Warrants on a &ldquo;cashless basis,&rdquo; our management will consider,
among other factors, our cash position, the number of Public Warrants that are outstanding and the dilutive effect on our shareholders
of issuing the maximum number of Class A Ordinary Shares issuable upon the exercise of our Public Warrants. If our management takes advantage
of this option, all holders of Public Warrants would pay the exercise price by surrendering their Public Warrants for that number of Class
A Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Class A Ordinary Shares underlying the Public
Warrants, multiplied by the excess of the &ldquo;fair market value&rdquo; of our Class A Ordinary Shares (defined below) over the exercise
price of the Public Warrants by (y) the fair market value. The &ldquo;fair market value&rdquo; will mean the average closing price of
the Class A Ordinary Shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of warrants. If our management takes advantage of this option, the notice of redemption will contain the information
necessary to calculate the number of Class A Ordinary Shares to be received upon exercise of the warrants, including the &ldquo;fair market
value&rdquo; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen
the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the
exercise of the warrants after our initial Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">A holder of a
warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise
such warrant, to the extent that after giving effect to such exercise, such person (together with such person&rsquo;s affiliates), to
the warrant agent&rsquo;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as specified by the
holder) of the Class A Ordinary Shares outstanding immediately after giving effect to such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Anti-dilution Adjustments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If the number
of outstanding Class A Ordinary Shares is increased by a share capitalization payable in Class A Ordinary Shares, or by a split-up of
ordinary shares or other similar event, then, on the effective date of such share capitalization, split-up or similar event, the number
of Class A Ordinary Shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary
shares. A rights offering to holders of ordinary shares entitling holders to purchase Class A Ordinary Shares at a price less than the
&ldquo;Historical Fair Market Value&rdquo; (as defined below) will be deemed a share capitalization of a number of Class A Ordinary Shares
equal to the product of (i) the number of Class A Ordinary Shares actually sold in such rights offering (or issuable under any other equity
securities sold in such rights offering that are convertible into or exercisable for Class A Ordinary Shares) and (ii) one (1) minus the
quotient of (x) the price per Class A Ordinary Share paid in such rights offering and (y) the Historical Fair Market Value. For these
purposes (i) if the rights offering is for securities convertible into or exercisable for Class A Ordinary Shares, in determining the
price payable for Class A Ordinary Shares, there will be taken into account any consideration received for such rights, as well as any
additional amount payable upon exercise or conversion and (ii) &ldquo;Historical Fair Market Value&rdquo; means the volume weighted average
price of Class A Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the first date
on which the Class A Ordinary Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive
such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In addition,
if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other
assets to the holders of Class A Ordinary Shares on account of such Class A Ordinary Shares (or other securities into which the warrants
are convertible), other than (a) as described above, (b) certain ordinary cash dividends, (c) to satisfy the redemption rights of the
holders of Class A Ordinary Shares in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of
the holders of Class A Ordinary Shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles
of Association (A) to modify the substance or timing of the Company&rsquo;s obligation to allow redemption in connection with the Company&rsquo;s
initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete the Business Combination within the
period set forth in the Memorandum and Articles of Association or (B) with respect to any other material provisions relating to shareholders&rsquo;
rights or pre-initial Business Combination activity or (e) in connection with the redemption of our Public Shares upon our failure to
complete our initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective
date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class A Ordinary
Share in respect of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If the number
of outstanding Class A Ordinary Shares is decreased by a consolidation, combination, reverse share split or reclassification of Class
A Ordinary Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification
or similar event, the number of Class A Ordinary Shares issuable on exercise of each warrant will be decreased in proportion to such decrease
in outstanding Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Whenever the
number of Class A Ordinary Shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant
exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the
numerator of which will be the number of Class A Ordinary Shares purchasable upon the exercise of the warrants immediately prior to
such adjustment, and (y) the denominator of which will be the number of Class A Ordinary Shares so purchasable immediately
thereafter.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In addition,
if (x) we issue additional Class A Ordinary Shares or equity-linked securities for capital raising purposes in connection with the closing
of our initial Business Combination at a Newly Issued Price of less than $9.20 per Class A Ordinary Shares, (y) the aggregate gross proceeds
from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial
Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the Market Value
of the Class A Ordinary Shares is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to
be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described
under &ldquo;- <I>Redemption of Warrants for Cash</I>&rdquo; will be adjusted (to the nearest cent) to be equal to 180% of the higher
of the Market Value and the Newly Issued Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In case of any
reclassification or reorganization of the outstanding Class A Ordinary Shares (other than those described above or that solely affects
the par value of such Class A Ordinary Shares), or in the case of any merger or consolidation of us with or into another corporation (other
than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization
of our outstanding Class A Ordinary Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or
other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants
will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and
in lieu of the Class A Ordinary Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented
thereby, the kind and amount of Class A Ordinary Shares or other securities or property (including cash) receivable upon such reclassification,
reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would
have received if such holder had exercised their warrants immediately prior to such event (the &ldquo;Alternative Issuance&rdquo;). If
less than 70% of the consideration receivable by the holders of Class A Ordinary Shares in such a transaction is payable in the form of
Class A Ordinary Shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established
over- the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of
the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price
will be reduced as specified in the Warrant Agreement based on the Black-Scholes Warrant Value (as defined in the Warrant Agreement) of
the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary
transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the
full potential value of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Registered Form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The warrants
were issued in registered form under a Warrant Agreement between Continental, as warrant agent, and us. The Warrant Agreement provides
that the terms of the warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or to correct
any defective provision or mistake, (ii) adjusting the provisions relating to cash dividends on ordinary shares as contemplated by and
in accordance with the Warrant Agreement, (iii) adding or changing any provisions with respect to matters or questions arising under the
Warrant Agreement as the parties to the Warrant Agreement may deem necessary or desirable and that the parties deem to not adversely affect
the rights of the registered holders of the warrants or (iv) to provide for the delivery of the Alternative Issuance, <I>provided that
</I>the approval by the holders of at least 50% of the then-outstanding Public Warrants is required to make any change that adversely
affects the interests of the registered holders of Public Warrants, and, solely with respect to any amendment to the terms of the Private
Placement Warrants, 50% of the then outstanding Private Placement Warrants (including the vote or written consent of the Underwriters).
You should review a copy of the Warrant Agreement, for a complete description of the terms and conditions applicable to the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Exercise Mechanics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The warrants
may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with
the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the
exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants
being exercised. The warrant holders do not have the rights or privileges of holders of ordinary shares and any voting rights until they
exercise their warrants and receive Class A Ordinary Shares. After the issuance of Class A Ordinary Shares upon exercise of the warrants,
each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">No fractional
shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional
interest in a share, we will, upon exercise, round down to the nearest whole number the number of Class A Ordinary Shares to be issued
to the warrant holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Governing Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We have agreed
that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement
will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New
York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or
claim. See &ldquo;<I>Risk Factors - Our warrant agreement designates the courts of the State of New York or the United States District
Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated
by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our
Company.</I>&rdquo; This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any
claim for which the federal district courts of the United States of America are the sole and exclusive forum.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Private Placement Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The Private Placement
Warrants (including the Class A Ordinary Shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable
or salable until 30 days after the completion of our initial Business Combination (except to our officers and directors and other persons
or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants have terms and provisions
that are identical to those of Public Warrants. All modifications or amendments of the Private Placement Warrants or the Warrant Agreement
related to the Private Placement Warrants, including any modification or amendment to increase the warrant price or shorten the exercise
period (including, for the avoidance of doubt, the forfeiture or cancellation of any Private Placement Warrants), will require 50% of
the number of then outstanding Private Placement Warrants (including the vote or written consent of the Underwriters).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We have not paid
any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of our Business Combination.
The payment of cash dividends following the completion of our initial Business Combination will be within the discretion of our board
of directors at such time and will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition
subsequent to completion of our initial Business Combination. There is no certainty that we will be in a position to, or decide to, pay
cash dividends after completing our initial Business Combination. Further, if we incur any indebtedness in connection with our initial
Business Combination, our ability to declare dividends following the completion of our initial Business Combination may be limited by
restrictive covenants we may agree to in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our Transfer Agent and Warrant Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The transfer
agent for our ordinary shares and warrant agent for our warrants is Continental. We have agreed to indemnify Continental in its roles
as transfer agent and warrant agent, its agents and each of its shareholders, directors, officers and employees against all claims and
losses that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to any gross
negligence or intentional misconduct of the indemnified person or entity. Continental has agreed that it has no right of set-off or any
right, title, interest or claim of any kind to, or to any monies in, the Trust Account, and has irrevocably waived any right, title, interest
or claim of any kind to, or to any monies in, the Trust Account that it may have now or in the future. Accordingly, any indemnification
provided will only be able to be satisfied, or a claim will only be able to be pursued, solely against us and our assets outside the Trust
Account and not against any monies in the Trust Account or interest earned thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Certain Differences in Corporate Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Cayman Islands
companies are governed by the Companies Act. The Companies Act is modeled on English Law but does not follow recent English Law statutory
enactments, and differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the
material differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in
the United States and their shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><I>Mergers and
Similar Arrangements</I>. In certain circumstances, the Companies Act allows for mergers or consolidations between two Cayman Islands
companies, or between a Cayman Islands exempted company and a company incorporated in another jurisdiction (<I>provided that </I>is facilitated
by the laws of that other jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Where the merger
or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of merger or consolidation
containing certain prescribed information. That plan or merger or consolidation must then be authorized by either (a) a special resolution
(usually the affirmative vote of at least two-thirds of the votes cast by the shareholders of the issued shares present in person or represented
by proxy and entitled to vote on such matter at a general meeting of the company and are voted at a general meeting of the company) of
the shareholders of each company; or (b) such other authorization, if any, as may be specified in such constituent company&rsquo;s articles
of association. No shareholder resolution is required for a merger between a parent company (i.e., a company that owns at least 90% of
the issued shares of each class in a subsidiary company) and its subsidiary company. The consent of each holder of a fixed or floating
security interest of a constituent company must be obtained, unless the court waives such requirement. If the Cayman Islands Registrar
of Companies is satisfied that the requirements of the Companies Act (which includes certain other formalities) have been complied with,
the Registrar of Companies will register the plan of merger or consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Where the merger
or consolidation involves a foreign company, the procedure is similar, save that with respect to the foreign company, the directors of
the Cayman Islands exempted company are required to make a declaration to the effect that, having made due enquiry, they are of the opinion
that the requirements set out below have been met: (i) that the merger or consolidation is permitted or not prohibited by the constitutional
documents of the foreign company and by the laws of the jurisdiction in which the foreign company is incorporated, and that those laws
and any requirements of those constitutional documents have been or will be complied with; (ii) that no petition or other similar proceeding
has been filed and remains outstanding or order made or resolution adopted to wind up or liquidate the foreign company in any jurisdictions;
(iii) that no receiver, trustee, administrator or other similar person has been appointed in any jurisdiction and is acting in respect
of the foreign company, its affairs or its property or any part thereof; (iv) that no scheme, order, compromise or other similar arrangement
has been entered into or made in any jurisdiction whereby the rights of creditors of the foreign company are and continue to be suspended
or restricted.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0in; text-align: justify; text-indent: 0.25in">Where the surviving
company is the Cayman Islands exempted company, the directors of the Cayman Islands exempted company are further required to make a declaration
to the effect that, having made due inquiry, they are of the opinion that the requirements set out below have been met: (i) that the
foreign company is able to pay its debts as they fall due and that the merger or consolidated is <I>bona fide </I>and not intended to
defraud unsecured creditors of the foreign company; (ii) that in respect of the transfer of any security interest granted by the foreign
company to the surviving or consolidated company (a) consent or approval to the transfer has been obtained, released or waived; (b) the
transfer is permitted by and has been approved in accordance with the constitutional documents of the foreign company; and (c) the laws
of the jurisdiction of the foreign company with respect to the transfer have been or will be complied with; (iii) that the foreign company
will, upon the merger or consolidation becoming effective, cease to be incorporated, registered or exist under the laws of the relevant
foreign jurisdiction; and (iv) that there is no other reason why it would be against the public interest to permit the merger or consolidation.
The arrangement in question must be approved by a majority in number of each class of shareholders and creditors with whom the arrangement
is to be made and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case
may be, that are present and voting either in person or by proxy at an annual general meeting, or extraordinary general meeting summoned
for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of
the Cayman Islands. While a dissenting shareholder would have the right to express to the court the view that the transaction should
not be approved, the court can be expected to approve the arrangement if it satisfies itself that:&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">we are not proposing to act illegally or beyond the scope
of our corporate authority and the statutory provisions as to majority vote have been complied with;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            shareholders have been fairly represented at the general meeting in question;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            arrangement is such as a businessman would reasonably approve; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            arrangement is not one that would more properly be sanctioned under some other provision
                                            of the Companies Act or that would amount to a &ldquo;fraud on the minority.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If a scheme of
arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable to appraisal
rights (providing rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily
be available to dissenting shareholders of United States corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><I>Squeeze-out
Provisions</I>. When a takeover offer is made and accepted by holders of 90% of the shares to whom the offer relates is made within four
months, the offeror may, within a two-month period, require the holders of the remaining shares to transfer such shares on the terms of
the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed unless there is evidence
of fraud, bad faith, collusion or inequitable treatment of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Further, transactions
similar to a merger, reconstruction and/or an amalgamation may in some circumstances be achieved through means other than these statutory
provisions, such as a share capital exchange, asset acquisition or control, or through contractual arrangements, of an operating business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><I>Shareholders&rsquo;
Suits</I>. Maples and Calder (Cayman) LLP (&ldquo;Maples&rdquo;), our Cayman Islands legal counsel, is not aware of any reported class
action having been brought in a Cayman Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman
Islands courts have confirmed the availability for such actions. In most cases, we will be the proper plaintiff in any claim based on
a breach of duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">However, based
both on Cayman Islands authorities and on English authorities, which would in all likelihood be of persuasive authority and be applied
by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
company is acting, or proposing to act, illegally or beyond the scope of its authority;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes
which have actually been obtained; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">those
who control the company are perpetrating a &ldquo;fraud on the minority.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">A shareholder
may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about to be infringed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><I>Enforcement
of Civil Liabilities</I>. The Cayman Islands has a different body of securities laws as compared to the United States and provides less
protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the Federal courts of the United States.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We have been
advised by Maples, our Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against
us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United
States or any state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the
civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Where the above
procedures are adopted, the Companies Act provides for a right of dissenting shareholders to be paid a payment of the fair value of his
shares upon their dissenting to the merger or consolidation if they follow a prescribed procedure. In essence, that procedure is as follows
(a) the shareholder must give his written objection to the merger or consolidation to the constituent company before the vote on the merger
or consolidation, including a statement that the shareholder proposes to demand payment for his shares if the merger or consolidation
is authorized by the vote; (b) within 20 days following the date on which the merger or consolidation is approved by the shareholders,
the constituent company must give written notice to each shareholder who made a written objection; (c) a shareholder must within 20 days
following receipt of such notice from the constituent company, give the constituent company a written notice of his intention to dissent
including, among other details, a demand for payment of the fair value of his shares; (d) within seven days following the date of the
expiration of the period set out in paragraph (b) above or seven days following the date on which the plan of merger or consolidation
is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to
each dissenting shareholder to purchase his shares at a price that the company determines is the fair value and if the company and the
shareholder agree the price within 30 days following the date on which the offer was made, the company must pay the shareholder such amount;
and (e) if the company and the shareholder fail to agree a price within such 30 day period, within 20 days following the date on which
such 30 day period expires, the company (and any dissenting shareholder) must file a petition with the Cayman Islands Grand Court to determine
the fair value and such petition must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements
as to the fair value of their shares have not been reached by the company. At the hearing of that petition, the court has the power to
determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined
to be the fair value. Any dissenting shareholder whose name appears on the list filed by the company may participate fully in all proceedings
until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances,
for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized
interdealer quotation system at the relevant date or where the consideration for such shares to be contributed are shares of any company
listed on a national securities exchange or shares of the surviving or consolidated company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Moreover, Cayman
Islands law has separate statutory provisions that facilitate the reconstruction or amalgamation of companies in certain circumstances,
schemes of arrangement will generally be more suited for complex mergers or other transactions involving widely held companies, commonly
referred to in the Cayman Islands as a &ldquo;scheme of arrangement&rdquo; which may be tantamount to a merger. In the event that a merger
was sought pursuant to a scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures
typically required to consummate a merger in the United States), imposed by those provisions are penal in nature. In those circumstances,
although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman
Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits
based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for
which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment
must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman
Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement
of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be
held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought
elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><I>Special Considerations
for Exempted Companies</I>. We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes
between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business
mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially
the same as for an ordinary company except for the exemptions and privileges listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company does not have to file an annual return of its shareholders with the Registrar of Companies;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company&rsquo;s register of members is not open to inspection;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company does not have to hold an annual general meeting;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company may issue shares with no par value;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20
years in the first instance);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company may register as a limited duration company; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
exempted company may register as a segregated portfolio company.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">&ldquo;Limited
liability&rdquo; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the
company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper
purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Amended and Restated Memorandum and Articles
of Association</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The Business
Combination Article of our Amended and Restated Memorandum and Articles of Association contains provisions designed to provide certain
rights and protections relating to the Initial Public Offering that will apply to us until the completion of our initial Business Combination.
These provisions cannot be amended without a special resolution. As a matter of Cayman Islands law, a resolution is deemed to be a special
resolution where it has been approved by either (i) at least two-thirds (or any higher threshold specified in a company&rsquo;s articles
of association) of a company&rsquo;s shareholders at a general meeting for which notice specifying the intention to propose the resolution
as a special resolution has been given; or (ii) if so authorized by a company&rsquo;s articles of association, by a unanimous written
resolution of all of the company&rsquo;s shareholders. Our Amended and Restated Memorandum and Articles of Association provide that special
resolutions must be approved either by at least two-thirds of our shareholders (i.e., the lowest threshold permissible under Cayman Islands
law), or by a unanimous written resolution of all of our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Our initial shareholders,
who, as of December 31, 2025, collectively beneficially own 26.5% of our ordinary shares, may participate in any vote to amend our Amended
and Restated Memorandum and Articles of Association and will have the discretion to vote in any manner they choose. Specifically, our
Amended and Restated Memorandum and Articles of Association provide, among other things, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                            we are unable to complete our initial Business Combination within the Completion Window,
                                            we will, as promptly as reasonably possible but no more than ten business days thereafter,
                                            redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount
                                            then on deposit in the Trust Account, including interest earned on the funds held in the
                                            Trust Account (which interest shall be net of taxes paid or payable and up to $100,000 of
                                            interest to pay liquidation expenses), divided by the number of then outstanding Public Shares,
                                            which redemption will constitute full and complete payment and completely extinguish Public
                                            Shareholders&rsquo; rights as shareholders (including the right to receive further liquidating
                                            distributions or other distributions, if any), subject to our obligations under Cayman Islands
                                            law to provide for claims of creditors the requirements of other applicable law;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
                                            to our initial Business Combination, we may not, except in connection with the conversion
                                            of Class B ordinary shares into Class A Ordinary Shares where the holders of such shares
                                            have waived any rights to receive funds from the Trust Account, issue additional securities
                                            that would entitle the holders thereof to (i) receive funds from the Trust Account or (ii)
                                            vote on our initial Business Combination;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                            a shareholder vote on our initial Business Combination is not required by law and we do not
                                            decide to hold a shareholder vote for business or other legal reasons, we will offer to redeem
                                            our Public Shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will
                                            file tender offer documents with the SEC prior to completing our initial Business Combination
                                            which contain substantially the same financial and other information about our initial Business
                                            Combination and the redemption rights as is required under Regulation 14A of the Exchange
                                            Act;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NYSE
                                            rules require that we must consummate an initial Business Combination with one or more operating
                                            businesses or assets with a fair market value equal to at least 80% of the net assets held
                                            in the Trust Account (excluding the amount of any deferred underwriting commissions and taxes
                                            paid or payable on the income earned on the Trust Account) at the time of our signing a definitive
                                            agreement in connection with our initial Business Combination;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            our shareholders approve an amendment to our Amended and Restated Memorandum and Articles
                                            of Association (A) to modify the substance or timing of our obligation to allow redemption
                                            in connection with our initial Business Combination or to redeem 100% of our Public Shares
                                            if we do not complete our initial Business Combination within the Completion Window, or (B)
                                            with respect to any other material provisions relating to shareholders&rsquo; rights or pre-initial
                                            Business Combination activity, we will provide our Public Shareholders with the opportunity
                                            to redeem all or a portion of their Class A Ordinary Shares upon such approval at a per-share
                                            price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account,
                                            including interest (which interest shall be net of taxes paid or payable), divided by the
                                            number of then outstanding Public Shares, subject to the limitations described herein;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            will not effectuate our initial Business Combination solely with another blank check company
                                            or a similar company with nominal operations; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Only
                                            holders of our Class B ordinary shares have the right to vote on appointing or removing directors
                                            or continuing our Company in a jurisdiction outside the Cayman Islands (as further described
                                            herein), prior to the consummation of our initial Business Combination.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Our Amended and Restated Memorandum
and Articles of Association provide that unless we consent in writing to the selection of an alternative forum, the courts of the Cayman
Islands shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with our Amended and Restated Memorandum
and Articles of Association or otherwise related in any way to each shareholder&rsquo;s shareholding in us, including but not limited
to (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of any fiduciary or other
duty owed by any of our current or former director, officer or other employee to us or our shareholders, (iii) any action asserting a
claim arising pursuant to any provision of the Companies Act or our Amended and Restated Memorandum and Articles of Association, or (iv)
any action asserting a claim against us governed by the internal affairs doctrine (as such concept is recognized under the laws of the
United States of America) and that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of the Cayman Islands
over all such claims or disputes. Our Amended and Restated Memorandum and Articles of Association also provide that, without prejudice
to any other rights or remedies that we may have, each of our shareholders acknowledges that damages alone would not be an adequate remedy
for any breach of the selection of the courts of the Cayman Islands as exclusive forum and that accordingly we shall be entitled, without
proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach
of the selection of the courts of the Cayman Islands as exclusive forum. The forum selection provision in our Amended and Restated Memorandum
and Articles of Association does not apply to actions or suits brought to enforce any liability or duty created by the Securities Act,
Exchange Act or any claim for which the federal district courts of the United States of America are, as a matter of the laws of the United
States of America, the sole and exclusive forum for determination of such a claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The Companies
Act permits a company incorporated in the Cayman Islands to amend its memorandum and articles of association with the approval of a special
resolution. A company&rsquo;s articles of association may specify that the approval of a higher majority is required but, provided the
approval of the required majority is obtained, any Cayman Islands exempted company may amend its memorandum and articles of association
regardless of whether its memorandum and articles of association provide otherwise. Accordingly, although we could amend any of the provisions
relating to our proposed offering, structure and business plan which are contained in our Amended and Restated Memorandum and Articles
of Association, we view all of these provisions as binding obligations to our shareholders and neither we, nor our officers or directors,
will take any action to amend or waive any of these provisions unless we provide dissenting Public Shareholders with the opportunity to
redeem their Public Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Anti-Money Laundering-Cayman Islands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If any person
resident in the Cayman Islands knows or suspects or has reasonable grounds for knowing or suspecting that another person is engaged in
criminal conduct or money-laundering or is involved with terrorism or terrorist financing and property and the information for that knowledge
or suspicion came to their attention in the course of business in the regulated sector, or other trade, profession, business or employment,
the person will be required to report such knowledge or suspicion to (i) the Financial Reporting Authority of the Cayman Islands, pursuant
to the Proceeds of Crime Act (As Revised) of the Cayman Islands if the disclosure relates to criminal conduct or money laundering, or
(ii) a police officer of the rank of constable or higher, or the Financial Reporting Authority, pursuant to the Terrorism Act (As Revised)
of the Cayman Islands, if the disclosure relates to involvement with terrorism or terrorist financing and property. Such a report shall
not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Cayman Islands Data Protection</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We have certain
duties under the Data Protection Act (As Revised) of the Cayman Islands (the &ldquo;DPA&rdquo;) based on internationally accepted principles
of data privacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Privacy Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Introduction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">This privacy
notice puts our shareholders on notice that through your investment in the company you will provide us with certain personal information
which constitutes personal data within the meaning of the DPA (&ldquo;personal data&rdquo;). In the following discussion, the &ldquo;company&rdquo;
refers to us and our affiliates and/or delegates, except where the context requires otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Investor Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We will collect,
use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably
expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately
required to conduct our activities of on an ongoing basis or to comply with legal and regulatory obligations to which we are subject.
We will only transfer personal data in accordance with the requirements of the DPA, and will apply appropriate technical and organizational
information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental
loss, destruction or damage to the personal data.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In our use of
this personal data, we will be characterized as a &ldquo;data controller&rdquo; for the purposes of the DPA, while our affiliates and
service providers who may receive this personal data from us in the conduct of our activities may either act as our &ldquo;data processors&rdquo;
for the purposes of the DPA or may process personal information for their own lawful purposes in connection with services provided to
us. We may also obtain personal data from other public sources. Personal data includes, without limitation, the following information
relating to a shareholder and/or any individuals connected with a shareholder as an investor: name, residential address, email address,
contact details, corporate contact information, signature, nationality, place of birth, date of birth, tax identification, credit history,
correspondence records, passport number, bank account details, source of funds details and details relating to the shareholder&rsquo;s
investment activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Who this Affects</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">If you are a
natural person, this will affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such
as trusts or exempted limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation
your investment in the company, this will be relevant for those individuals and you should transmit the content of this Privacy Notice
to such individuals or otherwise advise them of its content.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">How the Company May Use Your Personal Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The company, as the data controller, may collect, store
and use personal data for lawful purposes, including, in particular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">where this is necessary for the performance of our rights
and obligations under any purchase agreements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">where this is necessary for compliance with a legal and regulatory
obligation to which we are subject (such as compliance with anti-money laundering and FATCA/CRS requirements); and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">where this is necessary for the purposes of our legitimate
interests and such interests are not overridden by your interests, fundamental rights or freedoms.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Should we wish
to use personal data for other specific purposes (including, if applicable, any purpose that requires your consent), we will contact you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Why We May Transfer Your Personal Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">In certain circumstances,
we may be legally obliged to share personal data and other information with respect to your shareholding with the relevant regulatory
authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information
with foreign authorities, including tax authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We anticipate
disclosing personal data to persons who provide services to us and their respective affiliates (which may include certain entities located
outside the United States, the Cayman Islands or the European Economic Area), who will process your personal data on our behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Data Protection Measures We Take</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Any transfer
of personal data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in accordance with the
requirements of the DPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We and our duly
authorized affiliates and/or delegates shall apply appropriate technical and organizational information security measures designed to
protect against unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal
data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">We shall notify
you of any personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those
data subjects to whom the relevant personal data relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Certain Anti-Takeover Provisions of our Amended and
Restated Memorandum and Articles of Association</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Our Amended and
Restated Memorandum and Articles of Association provide that our board of directors will be classified into three classes of directors.
As a result, in most circumstances, a person can gain control of our board only by successfully engaging in a proxy contest at two or
more annual meetings. Our authorized but unissued Class A Ordinary Shares and preference shares are available for future issuances without
shareholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital,
acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Class A Ordinary Shares and preference
shares could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger
or otherwise.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Securities Eligible for Future Sale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">As of December
31, 2025, there were 20,041,150 Class A Ordinary Shares issued or outstanding and 7,225,721 Class B ordinary shares outstanding. All of
the outstanding Founder Shares and all of the outstanding Private Placement Warrants (5,050,000 Private Placement Warrants) will be restricted
securities under Rule 144, in that they were issued in private transactions not involving a public offering, and the Founder Shares and
Private Placement Warrants, are subject to transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Rule 144</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Rule 144 is not
available for the resale of securities initially issued by shell companies (other than Business Combination related shell companies) or
issuers that have been at any time previously a shell company, such as the Company. However, Rule 144 also includes an important exception
to this prohibition if the following conditions are met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
issuer of the securities that was formerly a shell company has ceased to be a shell company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12
months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form 8-K;
and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">at
least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as
an entity that is not a shell company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">When and if Rule
144 becomes available for the resale of the Company&rsquo;s securities, a person who has beneficially owned restricted shares or warrants
for at least six months would be entitled to sell their securities <I>provided that </I>(i) such person is not deemed to have been one
of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are subject to the Exchange Act
periodic reporting requirements for at least three months before the sale and have filed all required reports under Section 13 or 15(d)
of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Persons who have
beneficially owned restricted shares or warrants for at least six months but who are our affiliates at the time of, or at any time during
the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within
any three-month period only a number of securities that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">1% of the total number of ordinary shares then outstanding;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.45pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            average weekly reported trading volume of the Class A Ordinary Shares during the four calendar
                                            weeks preceding the filing of a notice on Form 144 with respect to the sale</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Sales by our
affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public
information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Registration Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">The holders of
the (i) Founder Shares, (ii) Private Placement Warrants and the Class A Ordinary Shares underlying such Private Placement Warrants and
(iii) Private Placement Warrants that may be issued upon conversion of working capital loans will have registration rights to require
us to register a sale of any of our securities held by them prior to the consummation of our initial Business Combination pursuant to
a registration rights agreement. Pursuant to the registration rights agreement, and assuming up to $1,500,000 of working capital loans
are converted into Private Placement Warrants, we will be obligated to register up to 13,775,721 Class A Ordinary Shares and 6,550,000
warrants. The number of Class A Ordinary Shares includes (i) 7,225,721 Class A Ordinary Shares to be issued upon conversion of the Founder
Shares, (ii) 5,050,000 Class A Ordinary Shares underlying the Private Placement Warrants and (iii) 1,500,000 Class A Ordinary Shares underlying
the Private Placement Warrants issued upon conversion of working capital loans. The number of warrants includes 5,050,000 Private Placement
Warrants and up to 1,500,000 Private Placement Warrants issued upon conversion of working capital loans. The holders of these securities
are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have
certain &ldquo;piggy- back&rdquo; registration rights with respect to registration statements filed subsequent to our completion of our
initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Listing of Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Our Units, Class
A Ordinary Shares, and Public Warrants are listed on the NYSE under the symbols &ldquo;PAII.U,&rdquo; &ldquo;PAII&rdquo; and &ldquo;PAII
WS,&rdquo; respectively.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ea028245801ex19-1.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: right"><B>Exhibit 19.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PYROPHYTE ACQUISITION CORP. II<BR>
POLICY REGARDING INSIDER TRADING AND<BR>
DISSEMINATION OF INSIDE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Effective July 16, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>I.</B></TD><TD STYLE="text-align: justify"><B><U>INTRODUCTION</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy Regarding Insider
Trading and Dissemination of Inside Information (this &ldquo;<B><I>Policy</I></B>&rdquo;) describes the policy of Pyrophyte Acquisition
Corp. II (the &ldquo;<B><I>Company</I></B>&rdquo;) regarding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            trading of securities while you are in possession of Inside Information (as defined below)
                                            (<B><I>&ldquo;insider trading&rdquo;</I></B>) about the Company or any other company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">other
                                            misuse of material non-public information (<B><I>&ldquo;Inside Information&rdquo;</I></B>)
                                            of the Company or any other company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your obligations and potential
liability under securities laws dealing with insider trading abuses are also outlined below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy provides an overview
of the most significant aspects involved in insider trading. Every director, officer and employee of the Company must read and retain
this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>II.</B></TD><TD STYLE="text-align: justify"><B><U>STATEMENT OF THE POLICY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">No director, officer, employee or other Insider (as defined
below) shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">trade
                                            in securities of the Company or any other company while in possession of Inside Information
                                            concerning the Company or such other company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">disseminate
                                            Inside Information of the Company or any other company to others (except for legitimate Company
                                            purposes in accordance with Company communications policies; <U>provided</U> that the disclosing
                                            person reasonably does not expect the recipient to trade in securities, or disseminate the
                                            information to others who may trade in securities, while in possession of such Inside Information);
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">engage
                                            in any other action or conduct to take advantage of Inside Information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prohibited dissemination
of Inside Information includes the disclosure through written, oral or electronic means to all persons or entities, including friends,
family members, business contacts or others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even the appearance of improper
conduct must be avoided to preserve the Company&rsquo;s reputation for adhering to high ethical standards of conduct. Accordingly, conduct
which merely suggests the possibility of insider trading may be deemed by the Company, in its sole discretion, to be a violation of this
Policy.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>III.</B></TD><TD STYLE="text-align: justify"><B><U>FEDERAL LAW PROHIBITING INSIDER TRADING</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule 10b-5 under the Securities
Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), has been determined by the courts to prohibit trading
by an Insider (as defined below) of any securities (debt or equity) of a company on the basis of Inside Information about such company.
Liability under Rule 10b-5 can apply to trading in the Company&rsquo;s securities or the securities of <U>any</U> other company if one
is in possession of Inside Information about the company whose securities are traded. <B>The prohibition against insider trading applies
to the Company&rsquo;s officers, directors, employees and other Insiders at all times regardless of whether or not the Company is observing
a scheduled or special &ldquo;blackout&rdquo; period.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Liability under Rule 10b-5
may attach not only to Insiders who trade while in possession of Inside Information, but also, under certain circumstances, to (i) Insiders
who disclose or tip Inside Information (tippers) to third parties without trading themselves, and (ii) third parties (such as relatives,
business associates or friends) who have received Inside Information from Insiders (tippees) and trade while in possession of that Inside
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>IV.</B></TD><TD STYLE="text-align: justify"><B><U>THE CONSEQUENCES OF INSIDER TRADING</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals who trade on material
non-public information (or tip information to others) can be subject to an array of civil and criminal penalties. Violations are taken
very seriously by the U.S. Securities and Exchange Commission, the federal agency responsible for enforcing the law in this area. Potential
sanctions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">disgorgement
                                            of profits gained or losses avoided and interest thereon;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            civil penalty of up to three times the profit gained or loss avoided;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            bar from acting as an officer or director of a publicly traded company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            criminal fine (no matter how small the profit or the lack thereof) of up to $1 million; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            jail term of up to ten years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These penalties can apply
even if the individual is not a director, officer or senior manager. In addition to the potentially severe civil and criminal penalties
for violation of the insider trading laws, violation of this Policy may result in the imposition of Company sanctions, including dismissal.
A conviction or finding of liability for insider trading can also result in individuals being banned generally from employment in the
securities or financial industries or other employment, and even a mere allegation of insider trading can result in severe harm to one&rsquo;s
professional and personal reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A transaction that may be
necessary or seem justifiable for independent reasons (including a need to raise money for a personal financial emergency) is neither
an exception to this Policy nor a safeguard against prosecution for violation of insider trading laws.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a company (as well as
possibly any supervisory person) that fails to take appropriate steps to prevent illegal trading, a civil penalty of the greater of $1
million or three times the profit gained or loss avoided as a result of an employee&rsquo;s violation and a criminal fine of up to $2.5
million may be imposed. There are also likely to be stockholder lawsuits and adverse publicity arising from such illegal conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>V.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B> <U>WHO IS AN &ldquo;INSIDER&rdquo; FOR PURPOSES OF THE INSIDER TRADING PROHIBITIONS?</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An <B><I>&ldquo;Insider&rdquo;
</I></B>for purposes of insider trading law is <U>any person</U> who possesses Inside Information; the status results from such possession
and not simply a person&rsquo;s position, if any, with the Company. Accordingly, Insiders subject to liability for insider trading are
not solely those executive officers and directors who are required to report their securities transactions of Company ordinary shares
under Section 16 of the Exchange Act and who are also often referred to as &ldquo;insiders&rdquo; for purposes of that law. The category
of potential Insiders for purposes of insider trading law includes not only the Company&rsquo;s directors, officers and employees, but
also outside professional advisors and business consultants who have access to Inside Information prior to its public release and absorption
by the securities markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>VI.</B></TD><TD STYLE="text-align: justify"><B><U>PERSONS COVERED BY THE POLICY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy covers the directors,
officers and employees of the Company, and outside professional advisors and business consultants of the Company who have access to Inside
Information of the Company, as well as their Family Members and Controlled Entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Family Members&rdquo;
</I></B>include a person&rsquo;s spouse, partner, financially dependent children, relative, or other members of such person&rsquo;s immediate
household to whose support such person contributes or whose investments such person controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Controlled Entities&rdquo;
</I></B>include any legal entities controlled by a person, such as any corporations, partnerships, or trusts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>VII.</B></TD><TD STYLE="text-align: justify"><B><U>INDIVIDUAL RESPONSIBILITY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Persons subject to this Policy
have ethical and legal obligations to maintain the confidentiality of Inside Information and to not trade while in possession of Inside
Information. Each individual is responsible for making sure that he or she complies with this Policy, and that any Family Member or Controlled
Entity also complies with this policy. In all cases, the responsibility for determining whether an individual is in possession of Inside
Information rests with that individual, and any action on the part of the Company, the Administrator (as defined under the caption &ldquo;Administration
of the Policy&rdquo;) or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice
or insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary
action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described above in more detail under
the heading &ldquo;The Consequences of Insider Trading.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>VIII.</B></TD><TD STYLE="text-align: justify"><B><U>TRANSACTIONS COVERED BY THIS POLICY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading covered by this
Policy includes all types of transactions and securities, including ordinary shares, options or warrants to purchase ordinary shares,
or any other type of securities, including (but not limited to) preferred stock, convertible debentures, as well as derivative securities
that are issued by third parties, such as exchange-traded put or call options or swaps relating to securities of the Company or another
company with respect to which an Insider possesses Inside Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>IX.</B></TD><TD STYLE="text-align: justify"><B><U>WHAT IS MATERIAL NON-PUBLIC INFORMATION?</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Material information
</I></B>is any information that a reasonable investor would consider important in arriving at a decision to buy, sell or hold the securities
of a company and/or would view its disclosure as significantly altering the total mix of information otherwise made available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Non-Public information </I></B>is information
that is not generally known to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Examples</U>. Examples
of non-public information that generally would be regarded as material and thus Inside Information include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">financial
                                            information, such as revenues, expenses, earnings, new sales or investment returns;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">information
                                            about a transaction that will affect the financial condition or performance of the company
                                            in a significant manner, such as a pending or proposed merger, acquisition, tender offer,
                                            sale of assets, or disposition of a subsidiary, or entering into or terminating a significant
                                            contract;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">earnings
                                            estimates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            stock split or the offering of additional securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">major
                                            litigation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
                                            in senior management;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">major
                                            new products; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            gain or loss of a substantial customer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Either positive or negative
information may be material. The foregoing list is not exhaustive; other types of information may be material at any particular time,
depending upon all the circumstances.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>X.</B></TD><TD STYLE="text-align: justify"><B><U>TRADING</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy permits an Insider
to trade securities beginning at the close of regular trading on the second full Trading Day after all Inside Information has been disclosed
to the public through general release to the national news media, which will provide the securities markets a sufficient opportunity to
absorb and evaluate the information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Trading Day</I></B>&rdquo;
means a day on which the principal U.S. stock exchange on which shares of the Company&rsquo;s ordinary shares are then listed is open
for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, if Inside Information
(including quarterly or annual earnings) is disclosed at (a) 8:00 a.m., Eastern Time, on a Monday, then trading may commence after 4:00
p.m., Eastern Time, on Tuesday, (b) 10:00 a.m., Eastern Time, on Monday, then trading may commence after 4:00 p.m., Eastern Time, on Wednesday
or (c) 5:00 p.m., Eastern Time, on Monday, then trading may commence after 4:00 p.m., Eastern Time, on Wednesday.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer to the paragraph
below captioned &ldquo;Additional Procedures&rdquo; for additional restrictions on trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>XI.</B></TD><TD STYLE="text-align: justify"><B><U>TRANSACTIONS NOT SUBJECT TO THIS POLICY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>A. Bona Fide
Gifts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bona fide gifts are not transactions
subject to this Policy, unless the person making the gift has reason to believe that the recipient intends to sell the Company securities
while the person making the gift is aware of Inside Information or during a blackout period to which the person making the gift is subject;
<U>provided</U> that bona fide gifts of Company securities by directors, officers who have been designated by the Company&rsquo;s Board
of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;) as &ldquo;officers&rdquo; for purposes of Section 16 of the Exchange Act (collectively
with the directors, &ldquo;<B><I>Section 16 Reporting Persons</I></B>&rdquo;) and certain other employees who may be designated by the
Administrator from time to time (&ldquo;<B><I>Designated Individuals</I></B>&rdquo;) are subject to the pre-clearance procedures set forth
below under the caption &ldquo;Additional Procedures.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>B. Option
Exercises</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy does not apply
to the exercise of an employee option acquired pursuant to the Company&rsquo;s plans, or to the exercise of a tax withholding right pursuant
to which a person has elected to have the Company withhold stock subject to an option to satisfy tax withholding requirements; <U>provided</U>
that such exercises by Section 16 Reporting Persons and Designated Individuals are subject to the pre-clearance procedures set forth below
under the caption &ldquo;Additional Procedures.&rdquo; This Policy does apply, however, to any sale of stock as part of a broker-assisted
cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an
option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>C. Restricted
Stock Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy does not
apply to the exercise of a tax withholding right pursuant to which you elect to have the Company withhold stock to satisfy tax
withholding requirements upon the vesting of any restricted stock; <U>provided</U> that such exercise by Section 16 Reporting
Persons and Designated Individuals is subject to the pre-clearance procedures set forth below under the caption &ldquo;Additional
Procedures.&rdquo; This Policy does apply, however, to any market sale of restricted stock.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I></I></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>D. Mutual
Funds</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transactions in mutual funds
that are invested in securities of the Company or another company with respect to which an Insider possesses Inside Information are not
transactions subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>E. Other Similar
Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any other purchase of Company
securities from the Company or sales of Company securities to the Company are not subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>F. Rule 10b5-1
Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities trading pursuant
to contracts, plans or instructions complying with the requirements of Rule 10b5-1(c)(1) under the Exchange Act (&ldquo;<B><I>Rule 10b5-1
Plans</I></B>&rdquo;) and entered into in good faith while the person entering into the Rule 10b5-1 Plan is not in possession of Inside
Information is not subject to this Policy, <U>provided</U> that the adoption and maintenance of any such Rule 10b5-1 Plan by such person
must be approved by the Administrator and must comply with the requirements of Rule 10b5-1(c)(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>XII.</B></TD><TD STYLE="text-align: justify"><B><U>SPECIAL AND PROHIBITED TRANSACTIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has determined
that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy
engage in certain types of transactions. Therefore any persons covered by this Policy must comply with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>A. Hedging
Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hedging or monetization transactions
can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable
forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit a director, officer or employee to continue to
own Company securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When
that occurs, the director, officer or employee may no longer have the same objectives as the Company&rsquo;s other stockholders. Therefore,
directors, officers and employees, as well as their Family Members and Controlled Entities, are prohibited from engaging in any such transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>B. Margin
Accounts and Pledged Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to avoid a
margin sale or foreclosure sale at a time when a pledgor, who is a Company director, officer or employee, or their Family Members or
Controlled Entities, is aware of Inside Information or otherwise is not permitted to trade Company securities due to a blackout
period, no Company director, officer or employee, or their Family Members or Controlled Entities, may hold Company securities in a
margin account or otherwise pledge (or hypothecate) Company securities as collateral for a loan without first obtaining prior
approval from the Administrator. Pre-clearance is required for such transactions because Company securities held in a margin account
may be sold by the broker without the customer&rsquo;s consent if the customer fails to meet a margin call and Company securities
pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Any Company
director, officer or employee, or their Family Members or Controlled Entities, preparing to pledge Company securities or hold such
securities in a margin account must submit a request for approval to the Administrator at least two weeks prior to the proposed
execution of documents evidencing the proposed pledge or margin account. In its request, such Company director, officer or employee,
or their Family Members or Controlled Entities, shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">enclose
                                            copies of the governing documents evidencing the proposed pledge or margin account, which
                                            governing documents must provide such person with the opportunity to substitute or provide
                                            additional collateral or to repay the loan before the pledged Company securities may be sold;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">undertake
                                            to the Company (in form and manner satisfactory to the Administrator and the Company) (i)
                                            to maintain adequate financial capacity to repay the loan or cover the margin call, as applicable,
                                            without resort to the pledged Company securities and (ii) to substitute or provide additional
                                            collateral or repay the loan in the event of a borrower default or margin call, as applicable,
                                            at a time when such person is aware of Inside Information or otherwise is not permitted to
                                            trade Company securities due to a blackout period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above is not meant to
restrict the rehypothecation or lending of securities held in a brokerage account; <U>provided</U> that the securities are permitted to
be held in such account in accordance with this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>XIII.</B></TD><TD STYLE="text-align: justify"><B><U>ADDITIONAL PROCEDURES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has established
additional procedures in order to assist the Company in the administration of this Policy, to facilitate compliance with laws prohibiting
insider trading while in possession of Inside Information, and to avoid the appearance of any impropriety. These additional procedures
are applicable only to those individuals described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>A. <I>Pre-Clearance Procedures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16 Reporting Persons
and Designated Individuals, as well as their Family Members and Controlled Entities, may not engage in any transaction in Company securities
without first obtaining pre-clearance of the transaction from the Administrator in order to determine compliance with this Policy, insider
trading laws, Section 16 of the Exchange Act and Rule 144 promulgated under the Securities Act of 1933, as amended (&ldquo;<B><I>Rule
144</I></B>&rdquo;). A person requesting pre-clearance should submit the request to the Administrator (and, in the case of a request by
the Chief Executive Officer, also notify the Chairman of the Nominating and Corporate Governance Committee) at least two business days
in advance of the proposed transaction. The Administrator may determine not to permit the transaction if it is not in compliance this
Policy, insider trading laws, Section 16 of the Exchange Act or Rule 144. If a person seeks pre-clearance and permission to engage in
the transaction is denied, then he or she should refrain from initiating any transaction in Company securities, and should not inform
any other person of the restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a request for pre-clearance
is made, the requestor should carefully consider whether he or she may be aware of any Inside Information about the Company, and should
describe fully those circumstances to the Administrator. If the requestor is a Section 16 insider, the requestor should also indicate
whether he or she has effected any non-exempt &ldquo;opposite-way&rdquo; transactions within the past six months, and should be prepared
to report the proposed transaction on an appropriate Form 4 or Form 5. The requestor should also be prepared to comply with Rule 144 and
file Form 144, if necessary, at the time of any sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>B. <I>Special Blackout Periods</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, an event
may occur that is material to the Company and is known by only a few directors, officers and/or employees. So long as the event remains
material and nonpublic, the persons with knowledge of the event who are designated by the Administrator may not trade Company securities.
In that situation, the Administrator may notify these persons that they should not trade in the Company&rsquo;s securities, without disclosing
the reason for the restriction. The existence of an event-specific blackout period or extension of a blackout period may not be announced
to the Company as a whole, and should not be communicated to any other person. Even if the Administrator has not designated you as a person
who should not trade due to an event-specific restriction, you should not trade while aware of Inside Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>XIV.</B></TD><TD STYLE="text-align: justify"><B><U>POST-TERMINATION TRANSACTIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an individual is in possession
of Inside Information or subject to any blackout period or other Company-imposed trading restrictions when his or her service terminates,
that individual may not trade in Company securities until that information has become public, is no longer material or such blackout period
or Company-imposed trading restriction has expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>XV.</B></TD><TD STYLE="text-align: justify"><B><U>ADMINISTRATION OF THIS POLICY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s principal
financial officer, or in his absence the Chairman of the Nominating and Corporate Governance Committee, or with respect to matters involving
the Company&rsquo;s principal financial officer, the Chairman of the Nominating and Corporate Governance Committee (the &ldquo;<B><I>Administrator</I></B>&rdquo;),
shall be responsible for administration of this Policy, including the matters for which the Administrator is specifically designated herein
as administering or deciding and all other matters. All determinations and interpretations by the Administrator shall be subject to review
by the Nominating and Corporate Governance Committee, whose determinations shall be final.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>XVI.</B></TD><TD><B><U>COMPANY ASSISTANCE / REPORTING OF VIOLATIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who has any questions
about this Policy or about specific transactions may obtain additional guidance from the Administrator. You should contact the Administrator
immediately if you know or have reason to believe that this Policy has been or is about to be violated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ea028245801ex31-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES
EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Bernard J. Duroc-Danner, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Pyrophyte
Acquisition Corp. II;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">(Paragraph omitted pursuant to Exchange Act Rules 13a-14(a)
and 15d-15(a));</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">Date: March 30, 2026</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Bernard J. Duroc-Danner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Bernard J. Duroc-Danner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer and Director </I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ea028245801ex31-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES
EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Sten Gustafson, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Pyrophyte
Acquisition Corp. II;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">(Paragraph omitted pursuant to Exchange Act Rules 13a-14(a)
and 15d-15(a));</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 30, 2026</P></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Sten Gustafson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Sten Gustafson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Financial Officer and Director</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ea028245801ex32-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Pyrophyte
Acquisition Corp. II (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December&nbsp;31, 2025, as filed with the Securities
and Exchange Commission (the &ldquo;Report&rdquo;), I, Bernard J. Duroc-Danner, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">Date: March 30, 2026</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Bernard J. Duroc-Danner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Bernard J. Duroc-Danner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer and Director</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ea028245801ex32-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Pyrophyte
Acquisition Corp. II (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December&nbsp;31, 2025, as filed with the Securities
and Exchange Commission (the &ldquo;Report&rdquo;), I, Sten Gustafson, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">Date: March 30, 2026</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Sten Gustafson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Sten Gustafson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Chief Financial Officer and Director</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>ea028245801ex97-1.htm
<DESCRIPTION>POLICY RELATING TO THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 97.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PYROPHYTE ACQUISITION CORP. II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POLICY FOR THE<BR>
RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">A.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OVERVIEW</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">In accordance with the applicable
rules of the New York Stock Exchange Listed Company Manual (the <B><I>&ldquo;NYSE Rules&rdquo;</I></B>), Section 10D and Rule 10D-1 of
the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;) (&ldquo;<B><I>Rule 10D-1</I></B>&rdquo;),
the Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;) of Pyrophyte Acquisition Corp. II (the &ldquo;<B><I>Company</I></B>&rdquo;)
has adopted this Policy (the &ldquo;<B><I>Policy</I></B>&rdquo;) to provide for the recovery of erroneously awarded Incentive-based Compensation
from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">B.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of an Accounting Restatement, the Company will reasonably promptly recover the Erroneously Awarded Compensation Received in
accordance with NYSE Rules and Rule 10D-1 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After an Accounting Restatement,
the Compensation Committee (if composed entirely of independent directors, or in the absence of such a committee, a majority of independent
directors serving on the Board) (the &ldquo;<B><I>Committee</I></B>&rdquo;) shall determine the amount of&#9;any Erroneously Awarded Compensation
Received by each Executive Officer and shall promptly notify each Executive Officer with a written notice containing the amount of any
Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Incentive-based Compensation
based on (or derived from) the Company&rsquo;s stock price or total shareholder return, where the amount of Erroneously Awarded Compensation
is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount to be repaid or returned
shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company&rsquo;s
stock price or total shareholder return upon which the Incentive-based Compensation was Received; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall maintain documentation
of the determination of such reasonable estimate and provide the relevant documentation as required to the NYSE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Committee shall have discretion
to determine the appropriate means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances. Notwithstanding
the foregoing, except as set forth in Section B(2) below, in no event may the Company accept an amount that is less than the amount of
Erroneously Awarded Compensation in satisfaction of an Executive Officer&rsquo;s obligations hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that the Executive
Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations
established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously
Awarded Compensation that is subject to recovery under this Policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that an Executive
Officer fails to repay all Erroneously Awarded Compensation to the Company when due, the Company shall take all actions reasonable and
appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall
be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering
such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee
(which, as specified above, is composed entirely of independent directors or in the absence of such a committee, a majority of the independent
directors serving on the Board) determines that recovery would be impracticable <I>and </I>any of the following two conditions are met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Committee has determined
that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making
this determination, the Company must make a reasonable attempt to recover the Erroneously Awarded Compensation, documented such attempt(s)
and provided such documentation to the NYSE; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery would likely cause
an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the
requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">C.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REQUIREMENTS</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">The Company shall
file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission (&ldquo;<B><I>SEC</I></B>&rdquo;)
filings and rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">D.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROHIBITION OF INDEMNIFICATION</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">The Company shall
not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid,
returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company&rsquo;s enforcement of its rights
under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted,
paid or awarded to an Executive Officer from the application of this Policy or that waives the Company&rsquo;s right to recovery of any
Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective
Date of this Policy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">E.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMINISTRATION AND INTERPRETATION</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">This Policy shall be administered
by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">The Committee
is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration
of this Policy and for the Company&rsquo;s compliance with NYSE Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation,
rule or interpretation of the SEC or NYSE promulgated or issued in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">F.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDMENT; TERMINATION</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">The Committee
may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything
in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would
(after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to
violate any federal securities laws, SEC rule or NYSE rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 32.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">G.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER RECOVERY RIGHTS</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 36.3pt">This Policy shall
be binding and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or NYSE,
their beneficiaries, heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied
to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement
or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement
by the Executive Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu
of, any other remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant
to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement
or other arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 36.3pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">H.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">For purposes of this Policy,
the following capitalized terms shall have the meanings set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Accounting Restatement</I></B>&rdquo; means an
accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities
laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to
the previously issued financial statements (a &ldquo;Big R&rdquo; restatement), or that would result in a material misstatement if the
error were corrected in the current period or left uncorrected in the current period (a &ldquo;little r&rdquo; restatement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Clawback Eligible Incentive Compensation</I></B>&rdquo;
means all Incentive-based Compensation Received by an Executive Officer (i) on or after the effective date of the applicable NYSE rules,
(ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance
period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded
Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities
exchange or a national securities association, and (v) during the applicable Clawback Period (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Clawback
Period</I></B>&rdquo; means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding
the Restatement Date (as defined below), and if the Company changes its fiscal year, any transition period of less than nine months within
or immediately following those three completed fiscal years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Erroneously
Awarded Compensation</I></B>&rdquo; means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount
of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received
had it been determined based on the restated amounts, computed without regard to any taxes paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Executive
Officer</I></B>&rdquo; means each individual who is currently or was previously designated as an &ldquo;officer&rdquo; of the Company
as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes
of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of
Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting
officer, the controller).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Financial
Reporting Measures</I></B>&rdquo; means measures that are determined and presented in accordance with the accounting principles used in
preparing the Company&rsquo;s financial statements, and all other measures that are derived wholly or in part from such measures. Stock
price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return)
shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure
need not be presented in the Company&rsquo;s financial statements or included in a filing with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Incentive-based
Compensation</I></B>&rdquo; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a
Financial Reporting Measure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>NYSE</I></B>&rdquo;
means the New York Stock Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Received</I></B>&rdquo;
means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received
in the Company&rsquo;s fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award
is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(10) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Restatement
Date</I></B>&rdquo; means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized
to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare
an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting
Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 16, 2025.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATTESTATION AND ACKNOWLEDGEMENT OF POLICY FOR
THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By my signature below, I acknowledge and agree
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
have received and read the attached Policy for the Recovery of Erroneously Awarded Compensation of Pyrophyte Acquisition Corp. II (this
&ldquo;<B><I>Policy</I></B>&rdquo;).</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation,
by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
hereby waive any right to the indemnification, insurance or advancement of expenses by the Company with respect to any Erroneously Awarded
Compensation in accordance with Section D of this Policy.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 15%">Signature:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Printed Name:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Date:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>paii-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><xs:schema targetNamespace="http://pyrophyteacquisitioncorp2.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:paii="http://pyrophyteacquisitioncorp2.com/20251231" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025">
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xs:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="paii-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="paii-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="paii-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="paii-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple" />
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/Cover" id="Cover">
        <link:definition>995300 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation" id="AuditInformation">
        <link:definition>995301 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" id="BalanceSheet">
        <link:definition>995302 - Statement - Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals" id="BalanceSheetParentheticals">
        <link:definition>995303 - Statement - Balance Sheet (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" id="StatementofOperations">
        <link:definition>995304 - Statement - Statement of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals" id="StatementofOperationsParentheticals">
        <link:definition>995305 - Statement - Statement of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit" id="StatementofChangesinShareholdersDeficit">
        <link:definition>995306 - Statement - Statement of Changes in Shareholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals" id="StatementofChangesinShareholdersDeficitParentheticals">
        <link:definition>995307 - Statement - Statement of Changes in Shareholders&#8217; Deficit (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows" id="StatementofCashFlows">
        <link:definition>995308 - Statement - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations" id="OrganizationandBusinessOperations">
        <link:definition>995309 - Disclosure - Organization and Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies" id="SummaryofSignificantAccountingPolicies">
        <link:definition>995310 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering" id="InitialPublicOffering">
        <link:definition>995311 - Disclosure - Initial Public Offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995312 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies" id="CommitmentsandContingencies">
        <link:definition>995313 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit" id="ShareholdersDeficit">
        <link:definition>995314 - Disclosure - Shareholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation" id="SegmentInformation">
        <link:definition>995315 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement" id="FairValueMeasurement">
        <link:definition>995316 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995317 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure" id="CybersecurityRiskManagementandStrategyDisclosure">
        <link:definition>995318 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies" id="AccountingPoliciesbyPolicyPolicies">
        <link:definition>996319 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996320 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables" id="SegmentInformationTables">
        <link:definition>996321 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
        <link:definition>996322 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails" id="OrganizationandBusinessOperationsDetails">
        <link:definition>996323 - Disclosure - Organization and Business Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996324 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" id="SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails">
        <link:definition>996325 - Disclosure - Summary of Significant Accounting Policies - Schedule of Class A Ordinary Shares Subject to Possible Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" id="SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails">
        <link:definition>996326 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails" id="InitialPublicOfferingDetails">
        <link:definition>996327 - Disclosure - Initial Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <link:definition>996328 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
        <link:definition>996329 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails" id="ShareholdersDeficitDetails">
        <link:definition>996330 - Disclosure - Shareholders&#8217; Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails" id="SegmentInformationDetails">
        <link:definition>996331 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails" id="SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails">
        <link:definition>996332 - Disclosure - Segment Information - Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails" id="FairValueMeasurementDetails">
        <link:definition>996333 - Disclosure - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" id="FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>996334 - Disclosure - Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" id="FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails">
        <link:definition>996335 - Disclosure - Fair Value Measurement - Schedule of Valuation of the Public Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="paii_RedeemableClassAOrdinarySharesMember" name="RedeemableClassAOrdinarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_ClassBNonredeemableOrdinarySharesMember" name="ClassBNonredeemableOrdinarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_SubscriptionReceivablePolicyTextBlock" name="SubscriptionReceivablePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_OfferingCostsPolicyTextBlock" name="OfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" name="MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" name="GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_CommonStockThresholdTradingDays" name="CommonStockThresholdTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_FounderSharesMember" name="FounderSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_GrantedPricePerShare" name="GrantedPricePerShare" type="dtr:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_InitialBusinessCombinationMember" name="InitialBusinessCombinationMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_InitialPublicOfferings" name="InitialPublicOfferings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty" name="IssuanceOfPrivatePlacementWarrantsWithRelatedParty" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_MaximumLoansConvertibleIntoWarrants" name="MaximumLoansConvertibleIntoWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_NumberOfDaysAfterInitialBusinessCombination" name="NumberOfDaysAfterInitialBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfSharesNotSubjectToForfeiture" name="NumberOfSharesNotSubjectToForfeiture" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" name="NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PromissoryNotePayableFullyUtilizedAfterIPO" name="PromissoryNotePayableFullyUtilizedAfterIPO" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_PromissoryNoteRelatedPartyMember" name="PromissoryNoteRelatedPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="paii_RelatedPartyTransactionsDetailsTable" name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_SponsorMember" name="SponsorMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_WorkingCapitalLoanOutstanding" name="WorkingCapitalLoanOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_WorkingCapitalLoans" name="WorkingCapitalLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" name="ClassOfWarrantsAndRightsIssuedPricePerWarrant" type="dtr:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ExercisableWarrantsTerm" name="ExercisableWarrantsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_InitialPublicOfferingAbstract" name="InitialPublicOfferingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_InitialPublicOfferingDetailsTable" name="InitialPublicOfferingDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" name="SharesIssuedSharesShareBasedPaymentArrangementForfeited" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" name="ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_UnitsIssuedDuringPeriodSharesNewIssues" name="UnitsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" name="ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" name="ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" name="ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_CommonStockThresholdTradingDay" name="CommonStockThresholdTradingDay" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ConvertibleStockConversionRatio1" name="ConvertibleStockConversionRatio1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_FounderShareMember" name="FounderShareMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_InitialBusinessCombinationTerm" name="InitialBusinessCombinationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" name="PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" name="WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" name="NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" name="NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" name="StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" name="UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" name="PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" name="PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PublicWarrantsMember" name="PublicWarrantsMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_RedemptionOfPublicWarrants" name="RedemptionOfPublicWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="paii_ShareholdersDeficitDetailsTable" name="ShareholdersDeficitDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" name="ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" name="ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" name="WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassAOrdinarySharesParValue00001PerShareMember" name="ClassAOrdinarySharesParValue00001PerShareMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" name="WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_DeferredUnderwritingFeesPayableNoncurrent" name="DeferredUnderwritingFeesPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_ShareSubscriptionReceivable" name="ShareSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" name="StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" name="FormationAndOperatingExpensesPaidInExchangeForFounderShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty" name="PrepaidExpensePaidThroughPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees" name="StockIssuedDuringPeriodValuePaidUnderwritersFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" name="StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable" name="StockIssuedDuringPeriodValueShareSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" name="PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" name="ClassAOrdinarySharesSubjectToPossibleRedemptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants" name="StockIssuedDuringPeriodValueFairValueOfPublicWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares" name="OfferingCostsPaidThroughTheIssuanceOfFounderShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" name="StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_ClassAOrdinarySharesIssuanceCosts" name="ClassAOrdinarySharesIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" name="ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_ProbabilityOfMergerMember" name="ProbabilityOfMergerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" name="AdditionalUnitsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_InterestToPayDissolutionExpenses" name="InterestToPayDissolutionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" name="MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" name="MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NetProceedsAmount" name="NetProceedsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_NewlyAdjustedIssueSharePrice" name="NewlyAdjustedIssueSharePrice" type="dtr:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfSharesInEachUnit" name="NumberOfSharesInEachUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_OrganizationandBusinessOperationsDetailsTable" name="OrganizationandBusinessOperationsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_PriceIssuedPerShare" name="PriceIssuedPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_AggregateUnsecuredPromissoryAmount" name="AggregateUnsecuredPromissoryAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" name="ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="paii_CommonStockStockPriceTrigger" name="CommonStockStockPriceTrigger" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_CommonStockThresholdConsecutiveTradingDays" name="CommonStockThresholdConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PublicWarrantMember" name="PublicWarrantMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="paii_SharesRedemptionObligationPercentage" name="SharesRedemptionObligationPercentage" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_TransactionCosts" name="TransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_UpforntUnderwritingFees" name="UpforntUnderwritingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_USTreasuryGovernmentBillsMaturityTerm" name="USTreasuryGovernmentBillsMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_YearOfInception" name="YearOfInception" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PercentageOfCashDiscountOnInitialPublicOffering" name="PercentageOfCashDiscountOnInitialPublicOffering" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters" name="PercentageOfInitialPublicOfferingSoldToUnderwriters" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_DeferredDiscount" name="DeferredDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="paii_PercentageOfAdditionalFeeOnInitialPublicOffering" name="PercentageOfAdditionalFeeOnInitialPublicOffering" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" name="PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_InitialPublicOfferingTextBlock" name="InitialPublicOfferingTextBlock" type="dtr:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" name="NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" name="NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="paii_DeferredUnderwritingFeesPayable" name="DeferredUnderwritingFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>paii-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofCashFlows" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#BalanceSheet" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofOperations" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" />
  <link:calculationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" xlink:label="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareSubscriptionReceivable" xlink:label="paii_ShareSubscriptionReceivable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="107.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent" />
    <link:calculationArc xlink:type="arc" order="119.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="120.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="paii_DeferredUnderwritingFeesPayableNoncurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="paii_ShareSubscriptionReceivable" />
    <link:calculationArc xlink:type="arc" order="5.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:calculationArc xlink:type="arc" order="6.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeOther" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>paii-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails" xlink:href="paii-20251231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails" xlink:href="paii-20251231.xsd#InitialPublicOfferingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails" xlink:href="paii-20251231.xsd#ShareholdersDeficitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals" xlink:href="paii-20251231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/Cover" xlink:href="paii-20251231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" xlink:href="paii-20251231.xsd#BalanceSheet" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails" xlink:href="paii-20251231.xsd#FairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit" xlink:href="paii-20251231.xsd#StatementofChangesinShareholdersDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" xlink:href="paii-20251231.xsd#StatementofOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" xlink:href="paii-20251231.xsd#FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails" xlink:href="paii-20251231.xsd#OrganizationandBusinessOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:href="paii-20251231.xsd#FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals" xlink:href="paii-20251231.xsd#StatementofOperationsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals" xlink:href="paii-20251231.xsd#StatementofChangesinShareholdersDeficitParentheticals" xlink:type="simple" />
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1721" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1728" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1729" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_1725" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesIssuanceCosts" xlink:label="paii_ClassAOrdinarySharesIssuanceCosts_1735" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" xlink:label="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1722" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1896" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1731" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_1733" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1722_default" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" />
    <link:definitionArc xlink:type="arc" order="146.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" xlink:to="us-gaap_StatementClassOfStockAxis_1721" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1728" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1729" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" xlink:to="paii_ClassAOrdinarySharesIssuanceCosts_1735" />
    <link:definitionArc xlink:type="arc" order="145.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" />
    <link:definitionArc xlink:type="arc" order="147.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1721" xlink:to="us-gaap_ClassOfStockDomain_1722" />
    <link:definitionArc xlink:type="arc" order="276.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1722" xlink:to="us-gaap_CommonClassAMember_1896" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1731" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_1733" />
    <link:definitionArc xlink:type="arc" order="147.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1721" xlink:to="us-gaap_ClassOfStockDomain_1722_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1747" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1748" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1741" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1969" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1968" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1751" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_1967" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1750" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_1745" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_1966" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1749" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1742" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RedeemableClassAOrdinarySharesMember" xlink:label="paii_RedeemableClassAOrdinarySharesMember_1743" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassBNonredeemableOrdinarySharesMember" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_1744" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1742_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract_1966" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1747" />
    <link:definitionArc xlink:type="arc" order="324.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_1967" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" />
    <link:definitionArc xlink:type="arc" order="326.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1748" />
    <link:definitionArc xlink:type="arc" order="160.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" xlink:to="us-gaap_StatementClassOfStockAxis_1741" />
    <link:definitionArc xlink:type="arc" order="159.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems_1745" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" />
    <link:definitionArc xlink:type="arc" order="323.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1968" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1969" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1751" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1746" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_1967" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1968" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract_1966" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1751" />
    <link:definitionArc xlink:type="arc" order="322.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems_1745" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_1967" />
    <link:definitionArc xlink:type="arc" order="327.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" xlink:to="us-gaap_EarningsPerShareDiluted_1750" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems_1745" xlink:to="us-gaap_EarningsPerShareBasicAbstract_1966" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" xlink:to="us-gaap_EarningsPerShareBasic_1749" />
    <link:definitionArc xlink:type="arc" order="161.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1741" xlink:to="us-gaap_ClassOfStockDomain_1742" />
    <link:definitionArc xlink:type="arc" order="162.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1742" xlink:to="paii_RedeemableClassAOrdinarySharesMember_1743" />
    <link:definitionArc xlink:type="arc" order="163.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1742" xlink:to="paii_ClassBNonredeemableOrdinarySharesMember_1744" />
    <link:definitionArc xlink:type="arc" order="161.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1741" xlink:to="us-gaap_ClassOfStockDomain_1742_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdTradingDays" xlink:label="paii_CommonStockThresholdTradingDays_1806" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FounderSharesMember" xlink:label="paii_FounderSharesMember_1801" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_GrantedPricePerShare" xlink:label="paii_GrantedPricePerShare_1228" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialBusinessCombinationMember" xlink:label="paii_InitialBusinessCombinationMember_1215" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferings" xlink:label="paii_InitialPublicOfferings_1237" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty" xlink:label="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_1813" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MaximumLoansConvertibleIntoWarrants" xlink:label="paii_MaximumLoansConvertibleIntoWarrants_1819" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfDaysAfterInitialBusinessCombination" xlink:label="paii_NumberOfDaysAfterInitialBusinessCombination_1808" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesNotSubjectToForfeiture" xlink:label="paii_NumberOfSharesNotSubjectToForfeiture_1939" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_1804" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PromissoryNotePayableFullyUtilizedAfterIPO" xlink:label="paii_PromissoryNotePayableFullyUtilizedAfterIPO_1810" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PromissoryNoteRelatedPartyMember" xlink:label="paii_PromissoryNoteRelatedPartyMember_1809" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_1818" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RelatedPartyTransactionsDetailsTable" xlink:label="paii_RelatedPartyTransactionsDetailsTable_1194" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1218" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WorkingCapitalLoanOutstanding" xlink:label="paii_WorkingCapitalLoanOutstanding_1652" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense_1779" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1229" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1214" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_1230" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1200" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1811" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1812" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1239" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1815" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1814" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1202" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1201" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="us-gaap_CommonStockOtherValueOutstanding_1234" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_1227" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1869" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1196" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1225" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_1226" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1221" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1213" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AggregateUnsecuredPromissoryAmount" xlink:label="paii_AggregateUnsecuredPromissoryAmount_1233" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" xlink:label="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_1817" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockStockPriceTrigger" xlink:label="paii_CommonStockStockPriceTrigger_1805" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdConsecutiveTradingDays" xlink:label="paii_CommonStockThresholdConsecutiveTradingDays_1807" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit_1870" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1197" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_1198" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1217" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1799" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1800" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_1219" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1199" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1803" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1195" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_1235" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_1816" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1214_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1200_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1812_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1196_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1217_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1800_default" />
    <link:definitionArc xlink:type="arc" order="205.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_CommonStockThresholdTradingDays_1806" />
    <link:definitionArc xlink:type="arc" order="202.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain_1800" xlink:to="paii_FounderSharesMember_1801" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_GrantedPricePerShare_1228" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_1214" xlink:to="paii_InitialBusinessCombinationMember_1215" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_InitialPublicOfferings_1237" />
    <link:definitionArc xlink:type="arc" order="211.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_1813" />
    <link:definitionArc xlink:type="arc" order="217.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_MaximumLoansConvertibleIntoWarrants_1819" />
    <link:definitionArc xlink:type="arc" order="207.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_NumberOfDaysAfterInitialBusinessCombination_1808" />
    <link:definitionArc xlink:type="arc" order="301.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_NumberOfSharesNotSubjectToForfeiture_1939" />
    <link:definitionArc xlink:type="arc" order="203.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_1804" />
    <link:definitionArc xlink:type="arc" order="209.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_PromissoryNotePayableFullyUtilizedAfterIPO_1810" />
    <link:definitionArc xlink:type="arc" order="208.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain_1800" xlink:to="paii_PromissoryNoteRelatedPartyMember_1809" />
    <link:definitionArc xlink:type="arc" order="216.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_1818" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_RelatedPartyTransactionsDetailsTable_1194" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain_1217" xlink:to="paii_SponsorMember_1218" />
    <link:definitionArc xlink:type="arc" order="36.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_WorkingCapitalLoanOutstanding_1652" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_AdministrativeFeesExpense_1779" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1229" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis_1213" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1214" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_1230" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1199" xlink:to="us-gaap_ClassOfStockDomain_1200" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1811" />
    <link:definitionArc xlink:type="arc" order="210.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1811" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1812" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1239" />
    <link:definitionArc xlink:type="arc" order="213.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1815" />
    <link:definitionArc xlink:type="arc" order="212.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1814" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1200" xlink:to="us-gaap_CommonClassAMember_1202" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1200" xlink:to="us-gaap_CommonClassBMember_1201" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_CommonStockOtherValueOutstanding_1234" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_1227" />
    <link:definitionArc xlink:type="arc" order="252.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1869" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1195" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1196" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1225" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_1226" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_SharesIssuedPricePerShare_1221" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_BusinessAcquisitionAxis_1213" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_AggregateUnsecuredPromissoryAmount_1233" />
    <link:definitionArc xlink:type="arc" order="215.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_1817" />
    <link:definitionArc xlink:type="arc" order="204.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_CommonStockStockPriceTrigger_1805" />
    <link:definitionArc xlink:type="arc" order="206.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_CommonStockThresholdConsecutiveTradingDays_1807" />
    <link:definitionArc xlink:type="arc" order="253.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_EscrowDeposit_1870" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1196" xlink:to="us-gaap_IPOMember_1197" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1812" xlink:to="us-gaap_PrivatePlacementMember_1198" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" xlink:to="us-gaap_RelatedPartyDomain_1217" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_RelatedPartyTransactionAxis_1799" />
    <link:definitionArc xlink:type="arc" order="201.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis_1799" xlink:to="us-gaap_RelatedPartyTransactionDomain_1800" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_StatementClassOfStockAxis_1199" />
    <link:definitionArc xlink:type="arc" order="39.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1803" />
    <link:definitionArc xlink:type="arc" order="38.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1802" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1195" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_WarrantsAndRightsOutstanding_1235" />
    <link:definitionArc xlink:type="arc" order="214.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_1816" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis_1213" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1214_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1199" xlink:to="us-gaap_ClassOfStockDomain_1200_default" />
    <link:definitionArc xlink:type="arc" order="210.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1811" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1812_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1195" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1196_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" xlink:to="us-gaap_RelatedPartyDomain_1217_default" />
    <link:definitionArc xlink:type="arc" order="201.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis_1799" xlink:to="us-gaap_RelatedPartyTransactionDomain_1800_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="us-gaap_AssetsHeldInTrustCurrent_1847" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SummaryOfSignificantAccountingPoliciesTable" xlink:label="paii_SummaryOfSignificantAccountingPoliciesTable_1848" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WorkingCapitalLoans" xlink:label="paii_WorkingCapitalLoans_1965" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_1163" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_1712" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_1790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1851" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_1852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_1783" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850_default" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_AssetsHeldInTrustCurrent_1847" />
    <link:definitionArc xlink:type="arc" order="243.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="paii_SummaryOfSignificantAccountingPoliciesTable_1848" />
    <link:definitionArc xlink:type="arc" order="321.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="paii_WorkingCapitalLoans_1965" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_Cash_1163" />
    <link:definitionArc xlink:type="arc" order="244.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_SummaryOfSignificantAccountingPoliciesTable_1848" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_1712" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_CashFDICInsuredAmount_1790" />
    <link:definitionArc xlink:type="arc" order="246.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850" xlink:to="us-gaap_FairValueInputsLevel1Member_1851" />
    <link:definitionArc xlink:type="arc" order="245.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_UnrecognizedTaxBenefits_1783" />
    <link:definitionArc xlink:type="arc" order="245.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1138" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1639" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1130" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1643" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1146" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_1787" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InterestToPayDissolutionExpenses" xlink:label="paii_InterestToPayDissolutionExpenses_1160" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" xlink:label="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_1155" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" xlink:label="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_1154" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NetProceedsAmount" xlink:label="paii_NetProceedsAmount_1153" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NewlyAdjustedIssueSharePrice" xlink:label="paii_NewlyAdjustedIssueSharePrice_1159" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesInEachUnit" xlink:label="paii_NumberOfSharesInEachUnit_1642" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OrganizationandBusinessOperationsDetailsTable" xlink:label="paii_OrganizationandBusinessOperationsDetailsTable_1129" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceIssuedPerShare" xlink:label="paii_PriceIssuedPerShare_1786" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember_1647" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1133" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1134" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1141" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_1151" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1132" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_1157" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1644" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1139" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantMember" xlink:label="paii_PublicWarrantMember_1135" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1645" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesRedemptionObligationPercentage" xlink:label="paii_SharesRedemptionObligationPercentage_1158" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareSubscriptionReceivable" xlink:label="paii_ShareSubscriptionReceivable_1864" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_TransactionCosts" xlink:label="paii_TransactionCosts_1148" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_1137" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UpforntUnderwritingFees" xlink:label="paii_UpforntUnderwritingFees_1788" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_USTreasuryGovernmentBillsMaturityTerm" xlink:label="paii_USTreasuryGovernmentBillsMaturityTerm_1865" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_YearOfInception" xlink:label="paii_YearOfInception_1945" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_1152" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1640" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1147" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1131" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_1156" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1134_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1640_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1131_default" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_SharesIssuedPricePerShare_1138" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_StatementClassOfStockAxis_1639" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1130" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1643" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1146" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_DeferredUnderwritingFeesPayableNoncurrent_1787" />
    <link:definitionArc xlink:type="arc" order="34.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_InterestToPayDissolutionExpenses_1160" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_1155" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_1154" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_NetProceedsAmount_1153" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_NewlyAdjustedIssueSharePrice_1159" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_NumberOfSharesInEachUnit_1642" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_OrganizationandBusinessOperationsDetailsTable_1129" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_PriceIssuedPerShare_1786" />
    <link:definitionArc xlink:type="arc" order="103.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1131" xlink:to="paii_PrivatePlacementWarrantsMember_1647" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1133" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1133" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1134" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1141" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1646" />
    <link:definitionArc xlink:type="arc" order="101.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1640" xlink:to="us-gaap_CommonClassAMember_1641" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_DeferredOfferingCosts_1151" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1131" xlink:to="us-gaap_IPOMember_1132" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_OtherAssets_1157" />
    <link:definitionArc xlink:type="arc" order="102.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1131" xlink:to="us-gaap_OverAllotmentOptionMember_1644" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1139" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1134" xlink:to="paii_PublicWarrantMember_1135" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1645" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_SharesRedemptionObligationPercentage_1158" />
    <link:definitionArc xlink:type="arc" order="248.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_ShareSubscriptionReceivable_1864" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_TransactionCosts_1148" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_UnitsIssuedDuringPeriodSharesNewIssues_1137" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_UpforntUnderwritingFees_1788" />
    <link:definitionArc xlink:type="arc" order="249.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_USTreasuryGovernmentBillsMaturityTerm_1865" />
    <link:definitionArc xlink:type="arc" order="307.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_YearOfInception_1945" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_Cash_1152" />
    <link:definitionArc xlink:type="arc" order="100.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1639" xlink:to="us-gaap_ClassOfStockDomain_1640" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1147" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1130" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1131" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_SaleOfStockPricePerShare_1156" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1133" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1134_default" />
    <link:definitionArc xlink:type="arc" order="100.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1639" xlink:to="us-gaap_ClassOfStockDomain_1640_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1130" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1131_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1797" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ExercisableWarrantsTerm" xlink:label="paii_ExercisableWarrantsTerm_1187" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingDetailsTable" xlink:label="paii_InitialPublicOfferingDetailsTable_1168" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember_1796" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1792" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" xlink:label="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_1843" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_1183" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1174" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1182" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1179" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1180" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1620" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1795" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1175" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1171" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_1623" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1615" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1798" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1170" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1186" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1173" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1169" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1793" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1791" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1174_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1180_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1170_default" />
    <link:definitionArc xlink:type="arc" order="199.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1797" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_ExercisableWarrantsTerm_1187" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_InitialPublicOfferingDetailsTable_1168" />
    <link:definitionArc xlink:type="arc" order="92.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1170" xlink:to="paii_PrivatePlacementWarrantsMember_1796" />
    <link:definitionArc xlink:type="arc" order="196.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1792" />
    <link:definitionArc xlink:type="arc" order="242.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_1843" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_UnitsIssuedDuringPeriodSharesNewIssues_1183" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1173" xlink:to="us-gaap_ClassOfStockDomain_1174" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1179" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1179" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1180" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1620" />
    <link:definitionArc xlink:type="arc" order="197.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1795" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1174" xlink:to="us-gaap_CommonClassAMember_1175" />
    <link:definitionArc xlink:type="arc" order="90.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1170" xlink:to="us-gaap_IPOMember_1171" />
    <link:definitionArc xlink:type="arc" order="89.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1170" xlink:to="us-gaap_PrivatePlacementMember_1623" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1615" />
    <link:definitionArc xlink:type="arc" order="200.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1798" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1169" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1170" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_SharesIssuedPricePerShare_1186" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_StatementClassOfStockAxis_1173" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1169" />
    <link:definitionArc xlink:type="arc" order="197.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1180" xlink:to="us-gaap_WarrantMember_1793" />
    <link:definitionArc xlink:type="arc" order="195.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1791" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1173" xlink:to="us-gaap_ClassOfStockDomain_1174_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1179" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1180_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1169" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1170_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" xlink:label="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_1825" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" xlink:label="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_1840" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_1734" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1827" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1829" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_1838" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" xlink:label="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_1834" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdTradingDay" xlink:label="paii_CommonStockThresholdTradingDay_1832" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ConvertibleStockConversionRatio1" xlink:label="paii_ConvertibleStockConversionRatio1_1820" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FounderShareMember" xlink:label="paii_FounderShareMember_1279" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialBusinessCombinationTerm" xlink:label="paii_InitialBusinessCombinationTerm_1308" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_1835" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" xlink:label="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_1822" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_1285" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_1294" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_1830" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_1831" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember_1291" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember_1290" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RedemptionOfPublicWarrants" xlink:label="paii_RedemptionOfPublicWarrants_1726" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareholdersDeficitDetailsTable" xlink:label="paii_ShareholdersDeficitDetailsTable_1258" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1282" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" xlink:label="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_1824" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" xlink:label="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_1823" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" xlink:label="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_1821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1295" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1302" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_1297" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1262" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1293" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1299" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1627" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1628" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1278" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1280" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1281" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1260" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1873" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1283" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1298" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1301" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1259" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_1872" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1289" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1270" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1269" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1267" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1268" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1284" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1292" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1287" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1288" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1649" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1836" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1837" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1265" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1266" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1296" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_1839" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1278_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1281_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1260_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1268_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1284_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1288_default" />
    <link:definitionArc xlink:type="arc" order="223.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_1825" />
    <link:definitionArc xlink:type="arc" order="238.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_1840" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_1734" />
    <link:definitionArc xlink:type="arc" order="225.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1827" />
    <link:definitionArc xlink:type="arc" order="227.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1829" />
    <link:definitionArc xlink:type="arc" order="236.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_1838" />
    <link:definitionArc xlink:type="arc" order="232.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_1834" />
    <link:definitionArc xlink:type="arc" order="230.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_CommonStockThresholdTradingDay_1832" />
    <link:definitionArc xlink:type="arc" order="218.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ConvertibleStockConversionRatio1_1820" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain_1278" xlink:to="paii_FounderShareMember_1279" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_InitialBusinessCombinationTerm_1308" />
    <link:definitionArc xlink:type="arc" order="233.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_1835" />
    <link:definitionArc xlink:type="arc" order="220.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_1822" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1260" xlink:to="us-gaap_OverAllotmentOptionMember_1261" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1284" xlink:to="us-gaap_PreferredStockMember_1285" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_1294" />
    <link:definitionArc xlink:type="arc" order="228.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_1830" />
    <link:definitionArc xlink:type="arc" order="229.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_1831" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1288" xlink:to="paii_PrivatePlacementWarrantsMember_1291" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1288" xlink:to="paii_PublicWarrantsMember_1290" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_RedemptionOfPublicWarrants_1726" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ShareholdersDeficitDetailsTable_1258" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain_1281" xlink:to="paii_SponsorMember_1282" />
    <link:definitionArc xlink:type="arc" order="222.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_1824" />
    <link:definitionArc xlink:type="arc" order="221.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_1823" />
    <link:definitionArc xlink:type="arc" order="219.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_1821" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockSharesAuthorized_1295" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockSharesIssued_1302" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockSharesOutstanding_1303" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockVotingRights_1297" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1260" xlink:to="us-gaap_IPOMember_1262" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockSharesAuthorized_1293" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1299" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockSharesIssued_1627" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockSharesOutstanding_1628" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" xlink:to="us-gaap_RelatedPartyDomain_1278" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_RelatedPartyTransactionAxis_1280" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis_1280" xlink:to="us-gaap_RelatedPartyTransactionDomain_1281" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1260" />
    <link:definitionArc xlink:type="arc" order="256.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1873" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_SharesIssuedPricePerShare_1300" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_StatementClassOfStockAxis_1283" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1298" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1301" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1259" />
    <link:definitionArc xlink:type="arc" order="255.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_1872" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1288" xlink:to="us-gaap_WarrantMember_1289" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1268" xlink:to="srt_MaximumMember_1270" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1268" xlink:to="srt_MinimumMember_1269" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="srt_RangeAxis_1267" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_1267" xlink:to="srt_RangeMember_1268" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1283" xlink:to="us-gaap_ClassOfStockDomain_1284" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1287" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1287" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1288" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1649" />
    <link:definitionArc xlink:type="arc" order="234.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1836" />
    <link:definitionArc xlink:type="arc" order="235.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1837" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1284" xlink:to="us-gaap_CommonClassAMember_1265" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1284" xlink:to="us-gaap_CommonClassBMember_1266" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1296" />
    <link:definitionArc xlink:type="arc" order="237.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_1839" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" xlink:to="us-gaap_RelatedPartyDomain_1278_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis_1280" xlink:to="us-gaap_RelatedPartyTransactionDomain_1281_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1260_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_1267" xlink:to="srt_RangeMember_1268_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1283" xlink:to="us-gaap_ClassOfStockDomain_1284_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1287" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1288_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1040" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_1941" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_1942" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1900" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" xlink:label="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_1940" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1029" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1030" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1031" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1037" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1038" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1039" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1028" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1032" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_1674" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1899" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1027" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1903" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_1033" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1034" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1035" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1036" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_1673" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1901" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1902" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_1675" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1029_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1899_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1902_default" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockSharesOutstanding_1040" />
    <link:definitionArc xlink:type="arc" order="303.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_1941" />
    <link:definitionArc xlink:type="arc" order="304.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_1942" />
    <link:definitionArc xlink:type="arc" order="279.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain_1899" xlink:to="paii_SponsorMember_1900" />
    <link:definitionArc xlink:type="arc" order="302.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_1940" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1028" xlink:to="us-gaap_ClassOfStockDomain_1029" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1029" xlink:to="us-gaap_CommonClassAMember_1030" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1029" xlink:to="us-gaap_CommonClassBMember_1031" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1037" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockSharesAuthorized_1038" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockSharesIssued_1039" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_StatementClassOfStockAxis_1028" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_1674" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" />
    <link:definitionArc xlink:type="arc" order="278.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" xlink:to="us-gaap_RelatedPartyDomain_1899" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_StatementTable_1027" />
    <link:definitionArc xlink:type="arc" order="282.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1902" xlink:to="us-gaap_OverAllotmentOptionMember_1903" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_1033" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockSharesAuthorized_1034" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockSharesIssued_1035" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockSharesOutstanding_1036" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_1673" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1901" />
    <link:definitionArc xlink:type="arc" order="281.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1901" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1902" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_1675" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1028" xlink:to="us-gaap_ClassOfStockDomain_1029_default" />
    <link:definitionArc xlink:type="arc" order="278.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" xlink:to="us-gaap_RelatedPartyDomain_1899_default" />
    <link:definitionArc xlink:type="arc" order="281.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1901" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1902_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1004" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1008" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1003" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1023" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_1018" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1672" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1006" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1007" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_1020" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_1679" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_1024" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_1017" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1013" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_1019" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_1660" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_1678" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareSubscriptionReceivable" xlink:label="paii_ShareSubscriptionReceivable_1860" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_1859" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1015" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_1677" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_1022" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_1021" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_1011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1009" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_1662" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_1658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_1664" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_1659" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1005" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_1636" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1005_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1003" xlink:to="us-gaap_StatementClassOfStockAxis_1004" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_StatementTable_1003" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_StockholdersEquity_1023" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_StockholdersEquityAbstract_1018" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1672" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1005" xlink:to="us-gaap_CommonClassAMember_1006" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1005" xlink:to="us-gaap_CommonClassBMember_1007" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_CommonStockValue_1020" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="us-gaap_Liabilities_1679" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_1024" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1013" xlink:to="us-gaap_LiabilitiesCurrent_1017" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="us-gaap_LiabilitiesCurrentAbstract_1013" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_PreferredStockValue_1019" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract_1658" xlink:to="us-gaap_PrepaidExpenseCurrent_1660" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="paii_DeferredUnderwritingFeesPayableNoncurrent_1678" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="paii_ShareSubscriptionReceivable_1860" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1013" xlink:to="us-gaap_AccountsPayableCurrent_1859" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1013" xlink:to="us-gaap_AccruedLiabilitiesCurrent_1015" />
    <link:definitionArc xlink:type="arc" order="129.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract_1009" xlink:to="us-gaap_PrepaidExpenseNoncurrent_1677" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_1022" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_AdditionalPaidInCapital_1021" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_Assets_1011" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_AssetsAbstract_1009" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract_1658" xlink:to="us-gaap_AssetsCurrent_1662" />
    <link:definitionArc xlink:type="arc" order="111.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract_1009" xlink:to="us-gaap_AssetsCurrentAbstract_1658" />
    <link:definitionArc xlink:type="arc" order="117.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract_1009" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_1664" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract_1658" xlink:to="us-gaap_Cash_1659" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1004" xlink:to="us-gaap_ClassOfStockDomain_1005" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="us-gaap_CommitmentsAndContingencies_1636" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1004" xlink:to="us-gaap_ClassOfStockDomain_1005_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/Cover" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" xlink:label="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_1323" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_1414" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_1430" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_1349" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_1858" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_1404" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_1418" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_1421" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_1406" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_1854" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_1853" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_1855" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_1450" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_1468" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_1471" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_1460" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesParValue00001PerShareMember" xlink:label="paii_ClassAOrdinarySharesParValue00001PerShareMember_1324" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" xlink:label="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_1325" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1322" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1326" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1327" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1321" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_1856" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_1384" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_1383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_1331" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_1328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_1382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_1857" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_1344" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_1332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_1441" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_1442" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_1443" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_1446" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_1444" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_1405" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_1467" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_1413" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_1419" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_1420" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_1650" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_1377" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_1449" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_1409" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_1343" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1322_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_1323" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityFilerCategory_1414" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityIncorporationStateCountryCode_1430" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityInteractiveDataCurrent_1349" />
    <link:definitionArc xlink:type="arc" order="36.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityPublicFloat_1858" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityRegistrantName_1404" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityShellCompany_1418" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntitySmallBusiness_1421" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityTaxIdentificationNumber_1406" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityVoluntaryFilers_1854" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityWellKnownSeasonedIssuer_1853" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_IcfrAuditorAttestationFlag_1855" />
    <link:definitionArc xlink:type="arc" order="43.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_LocalPhoneNumber_1450" />
    <link:definitionArc xlink:type="arc" order="44.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_Security12bTitle_1468" />
    <link:definitionArc xlink:type="arc" order="46.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_SecurityExchangeName_1471" />
    <link:definitionArc xlink:type="arc" order="45.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_TradingSymbol_1460" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="paii_ClassAOrdinarySharesParValue00001PerShareMember_1324" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_1325" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1321" xlink:to="us-gaap_ClassOfStockDomain_1322" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="us-gaap_CommonClassAMember_1326" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="us-gaap_CommonClassBMember_1327" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable_1328" xlink:to="us-gaap_StatementClassOfStockAxis_1321" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_1856" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentFiscalPeriodFocus_1384" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentFiscalYearFocus_1383" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentInformationTable_1328" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentPeriodEndDate_1382" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_1857" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentTransitionReport_1344" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentType_1332" />
    <link:definitionArc xlink:type="arc" order="37.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressAddressLine1_1441" />
    <link:definitionArc xlink:type="arc" order="38.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressAddressLine2_1442" />
    <link:definitionArc xlink:type="arc" order="39.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressCityOrTown_1443" />
    <link:definitionArc xlink:type="arc" order="41.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressPostalZipCode_1446" />
    <link:definitionArc xlink:type="arc" order="40.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressStateOrProvince_1444" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityCentralIndexKey_1405" />
    <link:definitionArc xlink:type="arc" order="47.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityCommonStockSharesOutstanding_1467" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityCurrentReportingStatus_1413" />
    <link:definitionArc xlink:type="arc" order="34.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityEmergingGrowthCompany_1419" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityExTransitionPeriod_1420" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityFileNumber_1650" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_AmendmentFlag_1377" />
    <link:definitionArc xlink:type="arc" order="42.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_CityAreaCode_1449" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_CurrentFiscalYearEndDate_1409" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentAnnualReport_1343" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1321" xlink:to="us-gaap_ClassOfStockDomain_1322_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" xlink:label="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_1700" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1052" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_1782" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1067" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1063" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValuePaidUnderwritersFees" xlink:label="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_1699" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" xlink:label="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_1696" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember_1861" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable" xlink:label="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_1862" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_1054" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants" xlink:label="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_1702" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_1703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1056" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1066" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1064" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" xlink:label="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_1698" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1694" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_1695" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1058" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1060" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1057" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1059" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1061" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1065" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1051" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1053" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_1055" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1704" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1707" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1056_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1060_default" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_1700" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1051" xlink:to="us-gaap_StatementEquityComponentsAxis_1052" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_1782" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockholdersEquity_1067" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_SharesOutstanding_1063" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_1699" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_1696" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1056" xlink:to="us-gaap_ReceivablesFromStockholderMember_1861" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_1862" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1056" xlink:to="us-gaap_AdditionalPaidInCapitalMember_1054" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_1702" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_1703" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_EquityComponentDomain_1056" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_NetIncomeLoss_1066" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1064" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_1698" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1694" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_1695" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1060" xlink:to="us-gaap_CommonClassAMember_1058" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1057" xlink:to="us-gaap_ClassOfStockDomain_1060" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1051" xlink:to="us-gaap_StatementClassOfStockAxis_1057" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1060" xlink:to="us-gaap_CommonClassBMember_1059" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1065" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StatementTable_1051" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1056" xlink:to="us-gaap_CommonStockMember_1053" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1056" xlink:to="us-gaap_RetainedEarningsMember_1055" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1704" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1056" xlink:to="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1707" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_EquityComponentDomain_1056_default" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1057" xlink:to="us-gaap_ClassOfStockDomain_1060_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_1952" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1953" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1954" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1955" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1956" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1957" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1960" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1963" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember_1964" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1954_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1957_default" />
    <link:definitionArc xlink:type="arc" order="308.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" xlink:to="us-gaap_ClassOfWarrantOrRightTable_1952" />
    <link:definitionArc xlink:type="arc" order="309.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1952" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1953" />
    <link:definitionArc xlink:type="arc" order="310.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1953" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1954" />
    <link:definitionArc xlink:type="arc" order="311.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1954" xlink:to="us-gaap_IPOMember_1955" />
    <link:definitionArc xlink:type="arc" order="312.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1952" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1956" />
    <link:definitionArc xlink:type="arc" order="313.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1956" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1957" />
    <link:definitionArc xlink:type="arc" order="316.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1960" />
    <link:definitionArc xlink:type="arc" order="319.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1963" />
    <link:definitionArc xlink:type="arc" order="320.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1957" xlink:to="paii_PublicWarrantsMember_1964" />
    <link:definitionArc xlink:type="arc" order="310.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1953" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1954_default" />
    <link:definitionArc xlink:type="arc" order="313.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1956" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1957_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1911" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1913" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1919" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1921" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1922" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1918" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1914" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1915" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1912" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1917" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1909" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1920" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1910" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1911_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1914_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1917_default" />
    <link:definitionArc xlink:type="arc" order="284.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1910" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1911" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_StatementClassOfStockAxis_1913" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1921" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1922" />
    <link:definitionArc xlink:type="arc" order="291.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain_1917" xlink:to="paii_SponsorMember_1918" />
    <link:definitionArc xlink:type="arc" order="287.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1913" xlink:to="us-gaap_ClassOfStockDomain_1914" />
    <link:definitionArc xlink:type="arc" order="288.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1914" xlink:to="us-gaap_CommonClassBMember_1915" />
    <link:definitionArc xlink:type="arc" order="285.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1911" xlink:to="us-gaap_OverAllotmentOptionMember_1912" />
    <link:definitionArc xlink:type="arc" order="290.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" xlink:to="us-gaap_RelatedPartyDomain_1917" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="us-gaap_StatementTable_1909" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1920" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1910" />
    <link:definitionArc xlink:type="arc" order="284.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1910" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1911_default" />
    <link:definitionArc xlink:type="arc" order="287.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1913" xlink:to="us-gaap_ClassOfStockDomain_1914_default" />
    <link:definitionArc xlink:type="arc" order="290.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" xlink:to="us-gaap_RelatedPartyDomain_1917_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_1946" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1046" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_1665" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1048" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1666" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1670" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_1657" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1044" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1667" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1668" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1669" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1047" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_1043" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1045" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassBNonredeemableOrdinarySharesMember" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_1671" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1669_default" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_InterestIncomeOther_1946" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1046" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_1665" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_EarningsPerShareDiluted_1048" />
    <link:definitionArc xlink:type="arc" order="118.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_StatementTable_1666" />
    <link:definitionArc xlink:type="arc" order="122.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1669" xlink:to="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1670" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_OperatingIncomeLoss_1657" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_NetIncomeLoss_1044" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1666" xlink:to="us-gaap_StatementClassOfStockAxis_1668" />
    <link:definitionArc xlink:type="arc" order="121.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1668" xlink:to="us-gaap_ClassOfStockDomain_1669" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_EarningsPerShareBasic_1047" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_GeneralAndAdministrativeExpense_1043" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1045" />
    <link:definitionArc xlink:type="arc" order="123.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1669" xlink:to="paii_ClassBNonredeemableOrdinarySharesMember_1671" />
    <link:definitionArc xlink:type="arc" order="121.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1668" xlink:to="us-gaap_ClassOfStockDomain_1669_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1888" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_1889" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1881" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1878" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1885" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_1886" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_1887" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1879" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_1880" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1879_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883_default" />
    <link:definitionArc xlink:type="arc" order="269.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1881" xlink:to="us-gaap_AssetsAbstract_1888" />
    <link:definitionArc xlink:type="arc" order="270.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract_1888" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_1889" />
    <link:definitionArc xlink:type="arc" order="258.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1881" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_1878" />
    <link:definitionArc xlink:type="arc" order="266.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" xlink:to="us-gaap_FairValueInputsLevel1Member_1885" />
    <link:definitionArc xlink:type="arc" order="267.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" xlink:to="us-gaap_FairValueInputsLevel2Member_1886" />
    <link:definitionArc xlink:type="arc" order="268.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" xlink:to="us-gaap_FairValueInputsLevel3Member_1887" />
    <link:definitionArc xlink:type="arc" order="260.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1878" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1879" />
    <link:definitionArc xlink:type="arc" order="264.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" />
    <link:definitionArc xlink:type="arc" order="261.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_1879" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_1880" />
    <link:definitionArc xlink:type="arc" order="260.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1878" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1879_default" />
    <link:definitionArc xlink:type="arc" order="264.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1772" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1766" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1765" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_1774" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_1769" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_1767" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_1770" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_1768" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1771" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1776" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1775" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember_1777" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ProbabilityOfMergerMember" xlink:label="paii_ProbabilityOfMergerMember_1773" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1766_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1776_default" />
    <link:definitionArc xlink:type="arc" order="188.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1771" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1772" />
    <link:definitionArc xlink:type="arc" order="182.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis_1765" xlink:to="us-gaap_MeasurementInputTypeDomain_1766" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" xlink:to="us-gaap_MeasurementInputTypeAxis_1765" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputSharePriceMember_1774" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_1769" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_1767" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputExpectedTermMember_1770" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_1768" />
    <link:definitionArc xlink:type="arc" order="180.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1771" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" />
    <link:definitionArc xlink:type="arc" order="190.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1775" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1776" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1775" />
    <link:definitionArc xlink:type="arc" order="191.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1776" xlink:to="paii_PublicWarrantsMember_1777" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="paii_ProbabilityOfMergerMember_1773" />
    <link:definitionArc xlink:type="arc" order="182.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis_1765" xlink:to="us-gaap_MeasurementInputTypeDomain_1766_default" />
    <link:definitionArc xlink:type="arc" order="190.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1775" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1776_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1932" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1937" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1938" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1928" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1930" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1931" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1934" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1927" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1933" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1929" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1935" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1925" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1936" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1930_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1927_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1933_default" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1932" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1937" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1938" />
    <link:definitionArc xlink:type="arc" order="294.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain_1927" xlink:to="paii_SponsorMember_1928" />
    <link:definitionArc xlink:type="arc" order="296.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis_1929" xlink:to="us-gaap_ClassOfStockDomain_1930" />
    <link:definitionArc xlink:type="arc" order="297.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain_1930" xlink:to="us-gaap_CommonClassBMember_1931" />
    <link:definitionArc xlink:type="arc" order="300.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1933" xlink:to="us-gaap_OverAllotmentOptionMember_1934" />
    <link:definitionArc xlink:type="arc" order="293.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" xlink:to="us-gaap_RelatedPartyDomain_1927" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" />
    <link:definitionArc xlink:type="arc" order="299.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1932" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1933" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_StatementClassOfStockAxis_1929" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="us-gaap_StatementTable_1925" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1936" />
    <link:definitionArc xlink:type="arc" order="296.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis_1929" xlink:to="us-gaap_ClassOfStockDomain_1930_default" />
    <link:definitionArc xlink:type="arc" order="293.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" xlink:to="us-gaap_RelatedPartyDomain_1927_default" />
    <link:definitionArc xlink:type="arc" order="299.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1932" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1933_default" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" order="0" priority="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>paii-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RedeemableClassAOrdinarySharesMember" xlink:label="paii_RedeemableClassAOrdinarySharesMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassBNonredeemableOrdinarySharesMember" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsPolicyTextBlock" xlink:label="paii_WarrantsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SubscriptionReceivablePolicyTextBlock" xlink:label="paii_SubscriptionReceivablePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OfferingCostsPolicyTextBlock" xlink:label="paii_OfferingCostsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" xlink:label="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="paii_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdTradingDays" xlink:label="paii_CommonStockThresholdTradingDays" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FounderSharesMember" xlink:label="paii_FounderSharesMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_GrantedPricePerShare" xlink:label="paii_GrantedPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialBusinessCombinationMember" xlink:label="paii_InitialBusinessCombinationMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferings" xlink:label="paii_InitialPublicOfferings" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty" xlink:label="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MaximumLoansConvertibleIntoWarrants" xlink:label="paii_MaximumLoansConvertibleIntoWarrants" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfDaysAfterInitialBusinessCombination" xlink:label="paii_NumberOfDaysAfterInitialBusinessCombination" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesNotSubjectToForfeiture" xlink:label="paii_NumberOfSharesNotSubjectToForfeiture" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PromissoryNotePayableFullyUtilizedAfterIPO" xlink:label="paii_PromissoryNotePayableFullyUtilizedAfterIPO" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PromissoryNoteRelatedPartyMember" xlink:label="paii_PromissoryNoteRelatedPartyMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RelatedPartyTransactionsDetailsTable" xlink:label="paii_RelatedPartyTransactionsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WorkingCapitalLoanOutstanding" xlink:label="paii_WorkingCapitalLoanOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="us-gaap_CommonStockOtherValueOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="us-gaap_AssetsHeldInTrustCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SummaryOfSignificantAccountingPoliciesTable" xlink:label="paii_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WorkingCapitalLoans" xlink:label="paii_WorkingCapitalLoans" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ExercisableWarrantsTerm" xlink:label="paii_ExercisableWarrantsTerm" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingAbstract" xlink:label="paii_InitialPublicOfferingAbstract" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingDetailsTable" xlink:label="paii_InitialPublicOfferingDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" xlink:label="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" xlink:label="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" xlink:label="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" xlink:label="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdTradingDay" xlink:label="paii_CommonStockThresholdTradingDay" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ConvertibleStockConversionRatio1" xlink:label="paii_ConvertibleStockConversionRatio1" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FounderShareMember" xlink:label="paii_FounderShareMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialBusinessCombinationTerm" xlink:label="paii_InitialBusinessCombinationTerm" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" xlink:label="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" xlink:label="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" xlink:label="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RedemptionOfPublicWarrants" xlink:label="paii_RedemptionOfPublicWarrants" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareholdersDeficitDetailsTable" xlink:label="paii_ShareholdersDeficitDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" xlink:label="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" xlink:label="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" xlink:label="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesParValue00001PerShareMember" xlink:label="paii_ClassAOrdinarySharesParValue00001PerShareMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" xlink:label="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareSubscriptionReceivable" xlink:label="paii_ShareSubscriptionReceivable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLineItems" xlink:label="dei_AuditorLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" xlink:label="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" xlink:label="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty" xlink:label="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValuePaidUnderwritersFees" xlink:label="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" xlink:label="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable" xlink:label="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" xlink:label="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants" xlink:label="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares" xlink:label="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" xlink:label="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesIssuanceCosts" xlink:label="paii_ClassAOrdinarySharesIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" xlink:label="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ProbabilityOfMergerMember" xlink:label="paii_ProbabilityOfMergerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InterestToPayDissolutionExpenses" xlink:label="paii_InterestToPayDissolutionExpenses" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" xlink:label="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" xlink:label="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NetProceedsAmount" xlink:label="paii_NetProceedsAmount" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NewlyAdjustedIssueSharePrice" xlink:label="paii_NewlyAdjustedIssueSharePrice" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesInEachUnit" xlink:label="paii_NumberOfSharesInEachUnit" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OrganizationandBusinessOperationsDetailsTable" xlink:label="paii_OrganizationandBusinessOperationsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceIssuedPerShare" xlink:label="paii_PriceIssuedPerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AggregateUnsecuredPromissoryAmount" xlink:label="paii_AggregateUnsecuredPromissoryAmount" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" xlink:label="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockStockPriceTrigger" xlink:label="paii_CommonStockStockPriceTrigger" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdConsecutiveTradingDays" xlink:label="paii_CommonStockThresholdConsecutiveTradingDays" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantMember" xlink:label="paii_PublicWarrantMember" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesRedemptionObligationPercentage" xlink:label="paii_SharesRedemptionObligationPercentage" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_TransactionCosts" xlink:label="paii_TransactionCosts" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UpforntUnderwritingFees" xlink:label="paii_UpforntUnderwritingFees" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_USTreasuryGovernmentBillsMaturityTerm" xlink:label="paii_USTreasuryGovernmentBillsMaturityTerm" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_YearOfInception" xlink:label="paii_YearOfInception" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:label="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfCashDiscountOnInitialPublicOffering" xlink:label="paii_PercentageOfCashDiscountOnInitialPublicOffering" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfInitialPublicOfferingSoldToUnderwriters" xlink:label="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredDiscount" xlink:label="paii_DeferredDiscount" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfAdditionalFeeOnInitialPublicOffering" xlink:label="paii_PercentageOfAdditionalFeeOnInitialPublicOffering" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingTextBlock" xlink:label="paii_InitialPublicOfferingTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayable" xlink:label="paii_DeferredUnderwritingFeesPayable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_RedeemableClassAOrdinarySharesMember" xlink:to="paii_RedeemableClassAOrdinarySharesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassBNonredeemableOrdinarySharesMember" xlink:to="paii_ClassBNonredeemableOrdinarySharesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_WarrantsPolicyTextBlock" xlink:to="paii_WarrantsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_SubscriptionReceivablePolicyTextBlock" xlink:to="paii_SubscriptionReceivablePolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_OfferingCostsPolicyTextBlock" xlink:to="paii_OfferingCostsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" xlink:to="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" xlink:to="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="paii_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_CommonStockThresholdTradingDays" xlink:to="paii_CommonStockThresholdTradingDays_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_FounderSharesMember" xlink:to="paii_FounderSharesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_GrantedPricePerShare" xlink:to="paii_GrantedPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InitialBusinessCombinationMember" xlink:to="paii_InitialBusinessCombinationMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InitialPublicOfferings" xlink:to="paii_InitialPublicOfferings_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty" xlink:to="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_MaximumLoansConvertibleIntoWarrants" xlink:to="paii_MaximumLoansConvertibleIntoWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfDaysAfterInitialBusinessCombination" xlink:to="paii_NumberOfDaysAfterInitialBusinessCombination_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfSharesNotSubjectToForfeiture" xlink:to="paii_NumberOfSharesNotSubjectToForfeiture_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" xlink:to="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PromissoryNotePayableFullyUtilizedAfterIPO" xlink:to="paii_PromissoryNotePayableFullyUtilizedAfterIPO_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PromissoryNoteRelatedPartyMember" xlink:to="paii_PromissoryNoteRelatedPartyMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_RelatedPartyTransactionsDetailsTable" xlink:to="paii_RelatedPartyTransactionsDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_SponsorMember" xlink:to="paii_SponsorMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_WorkingCapitalLoanOutstanding" xlink:to="paii_WorkingCapitalLoanOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherValueOutstanding" xlink:to="us-gaap_CommonStockOtherValueOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustCurrent" xlink:to="us-gaap_AssetsHeldInTrustCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_SummaryOfSignificantAccountingPoliciesTable" xlink:to="paii_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_WorkingCapitalLoans" xlink:to="paii_WorkingCapitalLoans_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" xlink:to="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ExercisableWarrantsTerm" xlink:to="paii_ExercisableWarrantsTerm_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InitialPublicOfferingAbstract" xlink:to="paii_InitialPublicOfferingAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InitialPublicOfferingDetailsTable" xlink:to="paii_InitialPublicOfferingDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PrivatePlacementWarrantsMember" xlink:to="paii_PrivatePlacementWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" xlink:to="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" xlink:to="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="paii_UnitsIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" xlink:to="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" xlink:to="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" xlink:to="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_CommonStockThresholdTradingDay" xlink:to="paii_CommonStockThresholdTradingDay_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ConvertibleStockConversionRatio1" xlink:to="paii_ConvertibleStockConversionRatio1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_FounderShareMember" xlink:to="paii_FounderShareMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InitialBusinessCombinationTerm" xlink:to="paii_InitialBusinessCombinationTerm_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" xlink:to="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" xlink:to="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" xlink:to="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" xlink:to="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" xlink:to="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" xlink:to="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PublicWarrantsMember" xlink:to="paii_PublicWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_RedemptionOfPublicWarrants" xlink:to="paii_RedemptionOfPublicWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ShareholdersDeficitDetailsTable" xlink:to="paii_ShareholdersDeficitDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" xlink:to="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" xlink:to="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" xlink:to="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassAOrdinarySharesParValue00001PerShareMember" xlink:to="paii_ClassAOrdinarySharesParValue00001PerShareMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" xlink:to="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:to="paii_DeferredUnderwritingFeesPayableNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ShareSubscriptionReceivable" xlink:to="paii_ShareSubscriptionReceivable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLineItems" xlink:to="dei_AuditorLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" xlink:to="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" xlink:to="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty" xlink:to="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees" xlink:to="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" xlink:to="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable" xlink:to="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" xlink:to="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" xlink:to="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants" xlink:to="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares" xlink:to="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" xlink:to="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassAOrdinarySharesIssuanceCosts" xlink:to="paii_ClassAOrdinarySharesIssuanceCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" xlink:to="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ProbabilityOfMergerMember" xlink:to="paii_ProbabilityOfMergerMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" xlink:to="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InterestToPayDissolutionExpenses" xlink:to="paii_InterestToPayDissolutionExpenses_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" xlink:to="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" xlink:to="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NetProceedsAmount" xlink:to="paii_NetProceedsAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NewlyAdjustedIssueSharePrice" xlink:to="paii_NewlyAdjustedIssueSharePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfSharesInEachUnit" xlink:to="paii_NumberOfSharesInEachUnit_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable" xlink:to="paii_OrganizationandBusinessOperationsDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PriceIssuedPerShare" xlink:to="paii_PriceIssuedPerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_AggregateUnsecuredPromissoryAmount" xlink:to="paii_AggregateUnsecuredPromissoryAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" xlink:to="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_CommonStockStockPriceTrigger" xlink:to="paii_CommonStockStockPriceTrigger_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_CommonStockThresholdConsecutiveTradingDays" xlink:to="paii_CommonStockThresholdConsecutiveTradingDays_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PublicWarrantMember" xlink:to="paii_PublicWarrantMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_SharesRedemptionObligationPercentage" xlink:to="paii_SharesRedemptionObligationPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_TransactionCosts" xlink:to="paii_TransactionCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_UpforntUnderwritingFees" xlink:to="paii_UpforntUnderwritingFees_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_USTreasuryGovernmentBillsMaturityTerm" xlink:to="paii_USTreasuryGovernmentBillsMaturityTerm_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_YearOfInception" xlink:to="paii_YearOfInception_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:to="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PercentageOfCashDiscountOnInitialPublicOffering" xlink:to="paii_PercentageOfCashDiscountOnInitialPublicOffering_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters" xlink:to="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_DeferredDiscount" xlink:to="paii_DeferredDiscount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PercentageOfAdditionalFeeOnInitialPublicOffering" xlink:to="paii_PercentageOfAdditionalFeeOnInitialPublicOffering_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" xlink:to="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_InitialPublicOfferingTextBlock" xlink:to="paii_InitialPublicOfferingTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="paii_DeferredUnderwritingFeesPayable" xlink:to="paii_DeferredUnderwritingFeesPayable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement of Class A ordinary shares to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A ordinary shares subject to possible redemption at September 30, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Ordinary Shares subject to possible redemption, $0.0001 par value; 20,041,150 ordinary shares at $10.08 per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Class A Ordinary Shares Subject to Possible Redemption [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plus:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Other Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Valuation of the Public Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator: Weighted Average Share Outstanding, Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic weighted average shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator: Weighted Average Share Outstanding, Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted weighted average shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Ordinary Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income allocable to Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income allocable to Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator: Net income allocable to Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator: Net income allocable to Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Ordinary Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Ordinary Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RedeemableClassAOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Class A Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-Redeemable Class B Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Non-Redeemable Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class B non-redeemable ordinary shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for its warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SubscriptionReceivablePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SubscriptionReceivablePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Receivable [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SubscriptionReceivablePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for subscription receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_OfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_OfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_OfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities Held in Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Held In Trust Account [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for marketable securities held in trust account.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern, Liquidity and Capital Resources</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern, Liquidity and Capital Resources [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for basis of accounting going concern, liquidity and capital resources.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of accounting policy for emerging growth company status.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum number of trading days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Threshold Trading Days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, threshold trading days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_GrantedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_GrantedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_GrantedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Granted price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialBusinessCombinationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Business Combination [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialBusinessCombinationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Business Combination Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offerings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of private palcement warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Private Placement Warrants With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The shares represent issuance of private palcement warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MaximumLoansConvertibleIntoWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum loans convertible into warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MaximumLoansConvertibleIntoWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum amount which a potential loan could have repaid through issuance of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfDaysAfterInitialBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum number of days after initial Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfDaysAfterInitialBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days After Initial Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfDaysAfterInitialBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesNotSubjectToForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Not Subject to Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesNotSubjectToForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares not subject to forfeiture.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares to be forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares To Be Forfeited If Overallotment Option Is Not Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares to be forfeited if overallotment option is not exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PromissoryNotePayableFullyUtilizedAfterIPO_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fully utilized after the IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PromissoryNotePayableFullyUtilizedAfterIPO_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note Payable Fully Utilized After IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PromissoryNotePayableFullyUtilizedAfterIPO_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount represent fully utilized after the IPO.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PromissoryNoteRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note Related Party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses per month</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party Per Month</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The contractual monthly amount to be paid for support services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RelatedPartyTransactionsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sponsor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsor Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WorkingCapitalLoanOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital loans, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WorkingCapitalLoanOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital Loan, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WorkingCapitalLoanOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of working capital loan, outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Administrative fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Administrative Fees Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of initial business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Achieved in Stages, Preacquisition and Acquired Equity Interests in Acquiree, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary share at a price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per warrant (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrant exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of aggregate share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private sale of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Class A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class B Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Class B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockOtherValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockOtherValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Other Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount granted to directors (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrustCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities held in trust account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrustCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset, Held-in-Trust, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per unit (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Shares issued price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares in each unit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WorkingCapitalLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WorkingCapitalLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital Loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WorkingCapitalLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of working capital loans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal deposit insurance corporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, FDIC Insured Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants And Rights Issued Price Per Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants and rights issued, price per warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ExercisableWarrantsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable warrants term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ExercisableWarrantsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercisable Warrants Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ExercisableWarrantsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercisable warrant term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferingDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining underwriters forfeited shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares (or other type of equity) forfeited during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold number of trading days For determining share price from date of business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Number Of Trading Days For Determining Share Price From Date Of Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of trading days for completion of business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of units sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Units Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the units issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shareholder's Deficit [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate amount (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redemption price per warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redemption price per share or per unit of warrants or rights outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum threshold written notice period for redemption of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right MinimumThreshold Written Notice Period For Redemption Of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum threshold period during which a written notice is required for redemption of warrants, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redemption trigger price (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold consecutive trading days for redemption of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold trading days for redemption of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price trigger for redemption of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Redemption Of Warrants Or Right Stock Price Trigger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Target share price of warrants or rights for redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Target Share Price of Warrants or Rights For Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, target share price of warrants or rights for redemption.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdTradingDay_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum number of trading days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdTradingDay_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Threshold Trading Day</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdTradingDay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents threshold trading days of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ConvertibleStockConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ratio to be applied to the stock in the conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ConvertibleStockConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The ratio to be applied to the stock in a conversion of convertible stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_FounderShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_FounderShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founder Share Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialBusinessCombinationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialBusinessCombinationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Business Combination Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialBusinessCombinationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial business combination term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of warrant exercise price adjusted to price received in new issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Warrants Exercise Price Adjusted to Price Received in New Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of warrant exercise price adjusted to price received in new issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants exercisable term from closing of ipo</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The warrants exercisable term from the closing of the initial public offering, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Over-Allotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders&#8217; deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares subjected to forfeiture if over allotment options is not exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares subjected to forfeiture if over allotment options is not exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Units Subjected to Forfeiture if Over Allotment Option Is Partially Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of units subjected to forfeiture if over allotment options is partially exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares, Share Based Compensations Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares (or other type of equity) forfeited during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Units Each Consisting Of One Class AOrdinary Share00001 Par Value And Onehalf Of One Redeemable Warrant Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders&#8217; Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#8217; DEFICIT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price threshold of newly issued stock to cause adjustment of exercise warrant price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price threshold of newly issued stock to cause adjustment of exercise warrant price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of equity proceeds from issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price, Percentage of Equity Proceeds From Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price of threshold of newly issued stock to cause adjustment of exercise warrant price, percentage of equity proceeds from issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RedemptionOfPublicWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redemption of Public Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_RedemptionOfPublicWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redemption of public warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ShareholdersDeficitDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholder's Deficit (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold period for effective within statement after business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold period for effective within statement after business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold period for filling registration statement after business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the threshold period for filling registration statement after business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable term after the completion of a business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercisable Term After The Completion Of A Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The warrants exercisable term after the completion of a business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares vote</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders&#8217; Deficit [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesParValue00001PerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A ordinary shares, par value $0.0001 per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesParValue00001PerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class AOrdinary Shares Par Value00001 Per Share Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Each Whole Warrant Exercisable For One Class AOrdinary Share At An Exercise Price Of1150 Per Share Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred underwriting fees payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred underwriting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Underwriting Fees Payable Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred underwriting commission.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share subscription receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share subscription receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of share subscription receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance - long term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities held in Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset, Held-in-Trust, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 5)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies (Note 5)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred underwriting fees payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Deferred Underwriting Fees Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value deferred underwriting fees payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Formation and operating expenses paid in exchange for Founder Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of formation and operating expenses paid in exchange for founder shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs paid through promissory note - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Paid Through Promissory Note Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expense paid through promissory note - related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash - end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash - beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Remeasurement of Class A ordinary shares to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paid underwriters fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Paid Underwriters Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value paid underwriters fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Proceeds from the Sale of Class A Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Proceeds from the Sale of Class A Units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income on cash account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Dividends and interest earned on marketable securities held in the Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividends and interest earned on marketable securities held in the Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest and Dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Measurement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares subject to possible redemption, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables from Stockholder [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share subscription receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Subscription Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of share subscription receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Warrants issued through forgiveness of promissory note - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of private placement warrants issued through forgiveness of promissory note - related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A ordinary shares subject to possible redemption [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of Public Warrants, at issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Fair Value of Public Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value fair value of public warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocated value of transaction costs to Class A Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class B ordinary shares to sponsor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Capital contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares issued value (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering costs paid through the issuance of Founder Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of offering costs paid through the issuance of Founder Shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of Units (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Proceeds from the Sale of Class A Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Shares Proceeds from the Sale of Class A Units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of Class B ordinary shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of forfeited shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of Class B ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Granted, Value, Share-Based Payment Arrangement, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A ordinary shares issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassAOrdinarySharesIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of class A ordinary shares issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Class A Ordinary Shares Subject to Possible Redemption [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of Public Warrants at issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of public warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market assumptions used in valuation of public warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market price of public stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (years) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Valuation of the Public Warrants [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Valuation of the Public Warrants [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ProbabilityOfMergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Probability of Merger [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income Per Ordinary Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per Class B Ordinary Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional units issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the additional units issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InterestToPayDissolutionExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest to pay liquidation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InterestToPayDissolutionExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest To Pay Dissolution Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InterestToPayDissolutionExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest to pay dissolution expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding voting securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Ownership Percentage To Be Acquired For Not To Be Registered As An Investment Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum ownership percentage to be acquired for not to be registered as an investment company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Fair Market Value Of Business Acquisition To Trust Account Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of fair market value of business acquisition to trust account balance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NetProceedsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NetProceedsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NetProceedsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of net proceeds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NewlyAdjustedIssueSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NewlyAdjustedIssueSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Newly Adjusted Issue Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NewlyAdjustedIssueSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Newly adjusted issue share price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesInEachUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesInEachUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Shares In Each Unit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_OrganizationandBusinessOperationsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Business Operations (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceIssuedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceIssuedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Issued Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PriceIssuedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Per share issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Business Operations [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Business Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_AggregateUnsecuredPromissoryAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate unsecured promissory amount (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_AggregateUnsecuredPromissoryAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Unsecured Promissory Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_AggregateUnsecuredPromissoryAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate unsecured promissory amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading period after completion of business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Blackout Trading Period After Completion of Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading period after completion of business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock trigger price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Stock Price Trigger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock trigger price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consecutive trading day threshold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Threshold Consecutive Trading Days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_CommonStockThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of consecutive trading days used to observe the share price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PublicWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PublicWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrant Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SharesRedemptionObligationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of public shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SharesRedemptionObligationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Redemption Obligation Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_SharesRedemptionObligationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares redemption obligation percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UpforntUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UpforntUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfornt Underwriting Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_UpforntUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount represemt upfornt underwriting fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_USTreasuryGovernmentBillsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity term of treasury government bills</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_USTreasuryGovernmentBillsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S Treasury Government Bills Maturity Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_USTreasuryGovernmentBillsMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity term of treasury government bills.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_YearOfInception_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year Of Inception</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_YearOfInception_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of inception</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds of warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sold per unit (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Accounting Practices [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EscrowDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposited amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EscrowDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Escrow Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information, Operating Income (Loss) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfCashDiscountOnInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cash discount on initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfCashDiscountOnInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Cash Discount On Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfCashDiscountOnInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of discount on initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of initial public offering sold to underwriters</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Initial Public Offering Sold To Underwriters</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of initial public offering sold to underwriters.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Ordinary shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Class B ordinary shares to sponsor (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred discount (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of deferred discount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfAdditionalFeeOnInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of additional fee on initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfAdditionalFeeOnInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Additional Fee On Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfAdditionalFeeOnInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of additional fee on initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preference shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preference shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares subject to possible redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares subject to possible redemption, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities held in Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of warrant exercise price adjusted to price received in new issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Warrants Exercise Price Adjusted To Price Received In New Issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of warrant exercise price adjusted to price received in new issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ORGANIZATION AND BUSINESS OPERATIONS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Offering costs paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares subject to possible redemption, per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Redemption Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INITIAL PUBLIC OFFERING</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_InitialPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELATED PARTY TRANSACTIONS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares subjected to forfeiture if over allotment options is not exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Subjected To Forfeiture If Over Allotment Option Is Not Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares subjected to forfeiture if over allotment options is not exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Units Subjected To Forfeiture If Over Allotment Options Is Partially Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units subjected to forfeiture if over allotment options is partially exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of units subjected to forfeiture if over allotment options is partially exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Investment of cash into Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred underwriting fees payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred underwriting fees payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="paii_DeferredUnderwritingFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred underwriting fees payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of Private Placement Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Other Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of Private Placement Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS&#8217; DEFICIT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEGMENT INFORMATION</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of the Net Income Per Ordinary Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Class A Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>paii-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#Cover" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/Cover" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#AuditInformation" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#BalanceSheet" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#BalanceSheetParentheticals" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofOperations" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofOperationsParentheticals" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofChangesinShareholdersDeficit" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofChangesinShareholdersDeficitParentheticals" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#StatementofCashFlows" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#OrganizationandBusinessOperations" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPolicies" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#InitialPublicOffering" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#RelatedPartyTransactions" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#CommitmentsandContingencies" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#ShareholdersDeficit" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SegmentInformation" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#FairValueMeasurement" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SubsequentEvents" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#CybersecurityRiskManagementandStrategyDisclosure" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#AccountingPoliciesbyPolicyPolicies" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SegmentInformationTables" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#FairValueMeasurementTables" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#OrganizationandBusinessOperationsDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#InitialPublicOfferingDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#RelatedPartyTransactionsDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#CommitmentsandContingenciesDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#ShareholdersDeficitDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SegmentInformationDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#FairValueMeasurementDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="paii-20251231.xsd#FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" roleURI="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" />
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1721" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1728" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1729" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_1725" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesIssuanceCosts" xlink:label="paii_ClassAOrdinarySharesIssuanceCosts_1735" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable" xlink:label="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1719" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1722" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1896" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1731" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_1733" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="146.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" xlink:to="us-gaap_StatementClassOfStockAxis_1721" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1728" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1729" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="150.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" xlink:to="us-gaap_TemporaryEquityLineItems_1725" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract_1737" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" xlink:to="paii_ClassAOrdinarySharesIssuanceCosts_1735" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="145.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1719" xlink:to="paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable_1720" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="147.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1721" xlink:to="us-gaap_ClassOfStockDomain_1722" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="276.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1722" xlink:to="us-gaap_CommonClassAMember_1896" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_1736" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1731" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_1725" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_1733" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1760" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1761" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1874" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1760" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1761" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1760" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1874" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_1758" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1757" />
    <link:presentationArc xlink:type="arc" order="176.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1757" xlink:to="us-gaap_FairValueDisclosuresTextBlock_1758" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1747" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1748" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1741" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1969" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1968" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1751" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_1967" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1750" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_1745" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_1966" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1749" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1739" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1742" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RedeemableClassAOrdinarySharesMember" xlink:label="paii_RedeemableClassAOrdinarySharesMember_1743" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassBNonredeemableOrdinarySharesMember" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_1744" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_1966" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1747" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="324.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_1967" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="326.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1748" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="160.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" xlink:to="us-gaap_StatementClassOfStockAxis_1741" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="159.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1739" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="323.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1968" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1969" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1751" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1746" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_1967" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1968" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_1966" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract_1751" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="322.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_1745" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_1967" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="327.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1970" xlink:to="us-gaap_EarningsPerShareDiluted_1750" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="164.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1740" xlink:to="us-gaap_EarningsPerShareBasicLineItems_1745" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_1745" xlink:to="us-gaap_EarningsPerShareBasicAbstract_1966" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1752" xlink:to="us-gaap_EarningsPerShareBasic_1749" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="161.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1741" xlink:to="us-gaap_ClassOfStockDomain_1742" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="162.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1742" xlink:to="paii_RedeemableClassAOrdinarySharesMember_1743" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="163.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1742" xlink:to="paii_ClassBNonredeemableOrdinarySharesMember_1744" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_1622" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_1120" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_1117" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_1113" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1112" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsPolicyTextBlock" xlink:label="paii_WarrantsPolicyTextBlock_1624" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SubscriptionReceivablePolicyTextBlock" xlink:label="paii_SubscriptionReceivablePolicyTextBlock_1866" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OfferingCostsPolicyTextBlock" xlink:label="paii_OfferingCostsPolicyTextBlock_1789" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock" xlink:label="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock_1706" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock_1971" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="paii_EmergingGrowthCompanyStatusPolicyTextBlock_1115" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_1621" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1119" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_1118" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_1617" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1626" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1625" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_1618" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_1116" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_ConcentrationRiskCreditRisk_1622" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_DerivativesPolicyTextBlock_1120" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_1117" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_BasisOfAccounting_1113" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="paii_WarrantsPolicyTextBlock_1624" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="paii_SubscriptionReceivablePolicyTextBlock_1866" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="paii_OfferingCostsPolicyTextBlock_1789" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock_1706" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock_1971" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="paii_EmergingGrowthCompanyStatusPolicyTextBlock_1115" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_1621" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1119" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_1118" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_1617" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1626" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1625" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_1618" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1112" xlink:to="us-gaap_UseOfEstimates_1116" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdTradingDays" xlink:label="paii_CommonStockThresholdTradingDays_1806" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FounderSharesMember" xlink:label="paii_FounderSharesMember_1801" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_GrantedPricePerShare" xlink:label="paii_GrantedPricePerShare_1228" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialBusinessCombinationMember" xlink:label="paii_InitialBusinessCombinationMember_1215" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferings" xlink:label="paii_InitialPublicOfferings_1237" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty" xlink:label="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_1813" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MaximumLoansConvertibleIntoWarrants" xlink:label="paii_MaximumLoansConvertibleIntoWarrants_1819" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfDaysAfterInitialBusinessCombination" xlink:label="paii_NumberOfDaysAfterInitialBusinessCombination_1808" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesNotSubjectToForfeiture" xlink:label="paii_NumberOfSharesNotSubjectToForfeiture_1939" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_1804" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PromissoryNotePayableFullyUtilizedAfterIPO" xlink:label="paii_PromissoryNotePayableFullyUtilizedAfterIPO_1810" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PromissoryNoteRelatedPartyMember" xlink:label="paii_PromissoryNoteRelatedPartyMember_1809" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_1818" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RelatedPartyTransactionsDetailsTable" xlink:label="paii_RelatedPartyTransactionsDetailsTable_1194" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1218" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WorkingCapitalLoanOutstanding" xlink:label="paii_WorkingCapitalLoanOutstanding_1652" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense_1779" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1229" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1214" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_1230" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1200" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1811" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1812" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1239" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1815" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1814" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1202" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1201" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="us-gaap_CommonStockOtherValueOutstanding_1234" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_1227" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1869" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1193" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1196" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1225" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_1226" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1221" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1213" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AggregateUnsecuredPromissoryAmount" xlink:label="paii_AggregateUnsecuredPromissoryAmount_1233" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination" xlink:label="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_1817" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockStockPriceTrigger" xlink:label="paii_CommonStockStockPriceTrigger_1805" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdConsecutiveTradingDays" xlink:label="paii_CommonStockThresholdConsecutiveTradingDays_1807" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit_1870" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1197" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_1198" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1217" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1799" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1800" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_1219" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1199" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1803" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1195" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_1235" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_1816" />
    <link:presentationArc xlink:type="arc" order="205.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_CommonStockThresholdTradingDays_1806" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="202.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_1800" xlink:to="paii_FounderSharesMember_1801" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_GrantedPricePerShare_1228" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_1214" xlink:to="paii_InitialBusinessCombinationMember_1215" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_InitialPublicOfferings_1237" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="211.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty_1813" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="217.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_MaximumLoansConvertibleIntoWarrants_1819" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="207.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_NumberOfDaysAfterInitialBusinessCombination_1808" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="301.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_NumberOfSharesNotSubjectToForfeiture_1939" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="203.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised_1804" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="209.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_PromissoryNotePayableFullyUtilizedAfterIPO_1810" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="208.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_1800" xlink:to="paii_PromissoryNoteRelatedPartyMember_1809" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="216.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_1818" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1193" xlink:to="paii_RelatedPartyTransactionsDetailsTable_1194" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_1217" xlink:to="paii_SponsorMember_1218" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="36.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_WorkingCapitalLoanOutstanding_1652" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_AdministrativeFeesExpense_1779" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1229" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_1213" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1214" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage_1230" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1199" xlink:to="us-gaap_ClassOfStockDomain_1200" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1811" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="210.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1811" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1812" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1239" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="213.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1815" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="212.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1814" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1200" xlink:to="us-gaap_CommonClassAMember_1202" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1200" xlink:to="us-gaap_CommonClassBMember_1201" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_CommonStockOtherValueOutstanding_1234" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_1227" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="252.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1869" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1195" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1196" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1225" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_1226" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_SharesIssuedPricePerShare_1221" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_BusinessAcquisitionAxis_1213" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_AggregateUnsecuredPromissoryAmount_1233" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="215.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination_1817" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="204.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_CommonStockStockPriceTrigger_1805" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="206.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="paii_CommonStockThresholdConsecutiveTradingDays_1807" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="253.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_EscrowDeposit_1870" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1196" xlink:to="us-gaap_IPOMember_1197" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1812" xlink:to="us-gaap_PrivatePlacementMember_1198" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1216" xlink:to="us-gaap_RelatedPartyDomain_1217" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_RelatedPartyTransactionAxis_1799" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="201.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_1799" xlink:to="us-gaap_RelatedPartyTransactionDomain_1800" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_RelatedPartyTransactionLineItems_1219" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_StatementClassOfStockAxis_1199" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="39.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1803" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="38.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1802" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_RelatedPartyTransactionsDetailsTable_1194" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1195" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_WarrantsAndRightsOutstanding_1235" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="214.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_1219" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_1816" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="us-gaap_AssetsHeldInTrustCurrent_1847" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SummaryOfSignificantAccountingPoliciesTable" xlink:label="paii_SummaryOfSignificantAccountingPoliciesTable_1848" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WorkingCapitalLoans" xlink:label="paii_WorkingCapitalLoans_1965" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1162" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_1163" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_1712" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_1790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1851" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesLineItems" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_1852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_1783" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_AssetsHeldInTrustCurrent_1847" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="243.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1162" xlink:to="paii_SummaryOfSignificantAccountingPoliciesTable_1848" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="321.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="paii_WorkingCapitalLoans_1965" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_Cash_1163" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="244.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_SummaryOfSignificantAccountingPoliciesTable_1848" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_1712" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_CashFDICInsuredAmount_1790" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="246.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850" xlink:to="us-gaap_FairValueInputsLevel1Member_1851" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="245.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1849" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1850" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="247.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_SummaryOfSignificantAccountingPoliciesTable_1848" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems_1852" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems_1852" xlink:to="us-gaap_UnrecognizedTaxBenefits_1783" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1138" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1639" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1130" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1643" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1146" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_1787" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InterestToPayDissolutionExpenses" xlink:label="paii_InterestToPayDissolutionExpenses_1160" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany" xlink:label="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_1155" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance" xlink:label="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_1154" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NetProceedsAmount" xlink:label="paii_NetProceedsAmount_1153" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NewlyAdjustedIssueSharePrice" xlink:label="paii_NewlyAdjustedIssueSharePrice_1159" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesInEachUnit" xlink:label="paii_NumberOfSharesInEachUnit_1642" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OrganizationandBusinessOperationsDetailsTable" xlink:label="paii_OrganizationandBusinessOperationsDetailsTable_1129" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceIssuedPerShare" xlink:label="paii_PriceIssuedPerShare_1786" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember_1647" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1133" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1134" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1141" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_1151" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1132" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1128" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_1157" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1644" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1139" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantMember" xlink:label="paii_PublicWarrantMember_1135" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1645" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesRedemptionObligationPercentage" xlink:label="paii_SharesRedemptionObligationPercentage_1158" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareSubscriptionReceivable" xlink:label="paii_ShareSubscriptionReceivable_1864" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_TransactionCosts" xlink:label="paii_TransactionCosts_1148" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_1137" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UpforntUnderwritingFees" xlink:label="paii_UpforntUnderwritingFees_1788" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_USTreasuryGovernmentBillsMaturityTerm" xlink:label="paii_USTreasuryGovernmentBillsMaturityTerm_1865" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_YearOfInception" xlink:label="paii_YearOfInception_1945" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_1152" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1640" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1147" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1131" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_1156" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_SharesIssuedPricePerShare_1138" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_StatementClassOfStockAxis_1639" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1130" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1643" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1146" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_DeferredUnderwritingFeesPayableNoncurrent_1787" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="34.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_InterestToPayDissolutionExpenses_1160" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany_1155" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance_1154" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_NetProceedsAmount_1153" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_NewlyAdjustedIssueSharePrice_1159" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_NumberOfSharesInEachUnit_1642" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1128" xlink:to="paii_OrganizationandBusinessOperationsDetailsTable_1129" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_PriceIssuedPerShare_1786" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="103.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1131" xlink:to="paii_PrivatePlacementWarrantsMember_1647" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1133" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1133" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1134" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1141" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1646" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_OrganizationandBusinessOperationsDetailsTable_1129" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="101.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1640" xlink:to="us-gaap_CommonClassAMember_1641" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_DeferredOfferingCosts_1151" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1131" xlink:to="us-gaap_IPOMember_1132" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_OtherAssets_1157" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="102.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1131" xlink:to="us-gaap_OverAllotmentOptionMember_1644" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1139" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1134" xlink:to="paii_PublicWarrantMember_1135" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1645" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_SharesRedemptionObligationPercentage_1158" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="248.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_ShareSubscriptionReceivable_1864" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_TransactionCosts_1148" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_UnitsIssuedDuringPeriodSharesNewIssues_1137" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_UpforntUnderwritingFees_1788" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="249.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_USTreasuryGovernmentBillsMaturityTerm_1865" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="307.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="paii_YearOfInception_1945" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_Cash_1152" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="100.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1639" xlink:to="us-gaap_ClassOfStockDomain_1640" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1147" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1130" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1131" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1136" xlink:to="us-gaap_SaleOfStockPricePerShare_1156" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant" xlink:label="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1797" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ExercisableWarrantsTerm" xlink:label="paii_ExercisableWarrantsTerm_1187" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingAbstract" xlink:label="paii_InitialPublicOfferingAbstract_1167" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingDetailsTable" xlink:label="paii_InitialPublicOfferingDetailsTable_1168" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember_1796" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited" xlink:label="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1792" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination" xlink:label="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_1843" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_UnitsIssuedDuringPeriodSharesNewIssues_1183" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1174" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1182" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1179" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1180" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1620" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1795" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1175" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1171" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_1623" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1615" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1798" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1170" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1186" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1173" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1169" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1793" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1791" />
    <link:presentationArc xlink:type="arc" order="199.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant_1797" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_ExercisableWarrantsTerm_1187" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_InitialPublicOfferingAbstract_1167" xlink:to="paii_InitialPublicOfferingDetailsTable_1168" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="92.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1170" xlink:to="paii_PrivatePlacementWarrantsMember_1796" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="196.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited_1792" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="242.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination_1843" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_UnitsIssuedDuringPeriodSharesNewIssues_1183" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1173" xlink:to="us-gaap_ClassOfStockDomain_1174" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_ClassOfStockLineItems_1182" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1179" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1179" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1180" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1620" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="197.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1795" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1174" xlink:to="us-gaap_CommonClassAMember_1175" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="90.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1170" xlink:to="us-gaap_IPOMember_1171" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="89.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1170" xlink:to="us-gaap_PrivatePlacementMember_1623" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1615" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="200.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1798" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1169" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1170" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="us-gaap_SharesIssuedPricePerShare_1186" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_StatementClassOfStockAxis_1173" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_InitialPublicOfferingDetailsTable_1168" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1169" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="197.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1180" xlink:to="us-gaap_WarrantMember_1793" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="195.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1182" xlink:to="paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues_1791" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1244" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1252" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfCashDiscountOnInitialPublicOffering" xlink:label="paii_PercentageOfCashDiscountOnInitialPublicOffering_1251" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfInitialPublicOfferingSoldToUnderwriters" xlink:label="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters_1254" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredDiscount" xlink:label="paii_DeferredDiscount_1255" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfAdditionalFeeOnInitialPublicOffering" xlink:label="paii_PercentageOfAdditionalFeeOnInitialPublicOffering_1253" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1244" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_1252" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1244" xlink:to="paii_PercentageOfCashDiscountOnInitialPublicOffering_1251" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1244" xlink:to="paii_PercentageOfInitialPublicOfferingSoldToUnderwriters_1254" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1244" xlink:to="paii_DeferredDiscount_1255" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1244" xlink:to="paii_PercentageOfAdditionalFeeOnInitialPublicOffering_1253" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant" xlink:label="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_1825" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant" xlink:label="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_1840" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_1734" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1827" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1829" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger" xlink:label="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_1838" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption" xlink:label="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_1834" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_CommonStockThresholdTradingDay" xlink:label="paii_CommonStockThresholdTradingDay_1832" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ConvertibleStockConversionRatio1" xlink:label="paii_ConvertibleStockConversionRatio1_1820" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FounderShareMember" xlink:label="paii_FounderShareMember_1279" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialBusinessCombinationTerm" xlink:label="paii_InitialBusinessCombinationTerm_1308" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_1835" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering" xlink:label="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_1822" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_1285" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_1294" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_1830" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance" xlink:label="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_1831" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsMember" xlink:label="paii_PrivatePlacementWarrantsMember_1291" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember_1290" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_RedemptionOfPublicWarrants" xlink:label="paii_RedemptionOfPublicWarrants_1726" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareholdersDeficitDetailsTable" xlink:label="paii_ShareholdersDeficitDetailsTable_1258" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1282" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination" xlink:label="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_1824" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination" xlink:label="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_1823" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination" xlink:label="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_1821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1295" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1302" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_1297" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1257" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1262" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1293" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1299" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1627" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1628" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1278" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1280" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1281" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1260" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1873" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_1300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1283" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1298" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1301" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1259" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_1872" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_1289" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1270" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1269" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1267" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1268" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1284" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1292" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1287" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1288" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1649" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1836" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1837" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1265" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1266" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1296" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances" xlink:label="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_1839" />
    <link:presentationArc xlink:type="arc" order="223.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant_1825" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="238.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant_1840" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice_1734" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="225.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_1827" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="227.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_1829" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="236.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger_1838" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="232.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption_1834" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="230.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_CommonStockThresholdTradingDay_1832" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="218.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ConvertibleStockConversionRatio1_1820" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_1278" xlink:to="paii_FounderShareMember_1279" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_InitialBusinessCombinationTerm_1308" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="233.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance_1835" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="220.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering_1822" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1260" xlink:to="us-gaap_OverAllotmentOptionMember_1261" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1284" xlink:to="us-gaap_PreferredStockMember_1285" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_1294" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="228.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice_1830" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="229.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance_1831" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1288" xlink:to="paii_PrivatePlacementWarrantsMember_1291" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1288" xlink:to="paii_PublicWarrantsMember_1290" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_RedemptionOfPublicWarrants_1726" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1257" xlink:to="paii_ShareholdersDeficitDetailsTable_1258" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_1281" xlink:to="paii_SponsorMember_1282" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="222.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination_1824" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="221.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination_1823" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="219.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination_1821" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockSharesAuthorized_1295" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockSharesIssued_1302" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockSharesOutstanding_1303" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockVotingRights_1297" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1260" xlink:to="us-gaap_IPOMember_1262" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockSharesAuthorized_1293" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1299" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockSharesIssued_1627" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_PreferredStockSharesOutstanding_1628" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" xlink:to="us-gaap_RelatedPartyDomain_1278" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_RelatedPartyTransactionAxis_1280" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_1280" xlink:to="us-gaap_RelatedPartyTransactionDomain_1281" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1277" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1260" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="256.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1873" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_SharesIssuedPricePerShare_1300" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_StatementClassOfStockAxis_1283" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1298" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1301" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1259" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="255.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_1872" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1288" xlink:to="us-gaap_WarrantMember_1289" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1268" xlink:to="srt_MaximumMember_1270" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1268" xlink:to="srt_MinimumMember_1269" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="srt_RangeAxis_1267" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_1267" xlink:to="srt_RangeMember_1268" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1283" xlink:to="us-gaap_ClassOfStockDomain_1284" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_ClassOfStockLineItems_1292" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="paii_ShareholdersDeficitDetailsTable_1258" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1287" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1287" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1288" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1649" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="234.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1836" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="235.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1837" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1284" xlink:to="us-gaap_CommonClassAMember_1265" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1284" xlink:to="us-gaap_CommonClassBMember_1266" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1296" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="237.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1292" xlink:to="paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances_1839" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1040" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_1941" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_1942" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1900" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited" xlink:label="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_1940" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1029" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1030" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1031" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1037" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1038" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1039" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1026" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1028" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1032" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_1674" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1899" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1027" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1903" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_1033" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_1034" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_1035" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_1036" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_1673" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1901" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1902" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_1675" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockSharesOutstanding_1040" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="303.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised_1941" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="304.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised_1942" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="279.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_1899" xlink:to="paii_SponsorMember_1900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="302.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited_1940" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1028" xlink:to="us-gaap_ClassOfStockDomain_1029" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1029" xlink:to="us-gaap_CommonClassAMember_1030" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1029" xlink:to="us-gaap_CommonClassBMember_1031" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1037" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockSharesAuthorized_1038" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_CommonStockSharesIssued_1039" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_StatementClassOfStockAxis_1028" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_StatementLineItems_1032" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_1674" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="278.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1898" xlink:to="us-gaap_RelatedPartyDomain_1899" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1026" xlink:to="us-gaap_StatementTable_1027" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="282.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1902" xlink:to="us-gaap_OverAllotmentOptionMember_1903" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_1033" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockSharesAuthorized_1034" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockSharesIssued_1035" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_PreferredStockSharesOutstanding_1036" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_1673" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1027" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1901" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="281.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1901" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1902" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1032" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_1675" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1004" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1008" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1002" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1003" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1023" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_1018" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1672" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1006" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1007" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_1020" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_1679" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_1024" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_1017" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1013" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_1019" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_1660" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayableNoncurrent" xlink:label="paii_DeferredUnderwritingFeesPayableNoncurrent_1678" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ShareSubscriptionReceivable" xlink:label="paii_ShareSubscriptionReceivable_1860" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_1859" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1015" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_1677" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_1022" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_1021" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_1011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1009" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_1662" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_1658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_1664" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_1659" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1005" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_1636" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1003" xlink:to="us-gaap_StatementClassOfStockAxis_1004" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1003" xlink:to="us-gaap_StatementLineItems_1008" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_StatementTable_1003" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_StockholdersEquity_1023" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_StockholdersEquityAbstract_1018" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1672" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1005" xlink:to="us-gaap_CommonClassAMember_1006" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1005" xlink:to="us-gaap_CommonClassBMember_1007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_CommonStockValue_1020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="us-gaap_Liabilities_1679" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_1024" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1013" xlink:to="us-gaap_LiabilitiesCurrent_1017" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="us-gaap_LiabilitiesCurrentAbstract_1013" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_PreferredStockValue_1019" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1658" xlink:to="us-gaap_PrepaidExpenseCurrent_1660" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="paii_DeferredUnderwritingFeesPayableNoncurrent_1678" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="paii_ShareSubscriptionReceivable_1860" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1013" xlink:to="us-gaap_AccountsPayableCurrent_1859" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1013" xlink:to="us-gaap_AccruedLiabilitiesCurrent_1015" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="129.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_1009" xlink:to="us-gaap_PrepaidExpenseNoncurrent_1677" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_1022" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1018" xlink:to="us-gaap_AdditionalPaidInCapital_1021" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_Assets_1011" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1008" xlink:to="us-gaap_AssetsAbstract_1009" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1658" xlink:to="us-gaap_AssetsCurrent_1662" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="111.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_1009" xlink:to="us-gaap_AssetsCurrentAbstract_1658" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="117.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_1009" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_1664" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1658" xlink:to="us-gaap_Cash_1659" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1004" xlink:to="us-gaap_ClassOfStockDomain_1005" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_1012" xlink:to="us-gaap_CommitmentsAndContingencies_1636" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/Cover" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember" xlink:label="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_1323" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_1414" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_1430" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_1349" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_1858" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_1404" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_1418" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_1421" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_1406" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_1854" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_1853" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_1855" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_1450" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_1468" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_1471" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_1460" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesParValue00001PerShareMember" xlink:label="paii_ClassAOrdinarySharesParValue00001PerShareMember_1324" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember" xlink:label="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_1325" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1322" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1326" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1327" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1321" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_1856" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_1384" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_1383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_1331" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_1328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_1382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_1857" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_1344" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_1332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_1441" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_1442" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_1443" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_1446" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_1444" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_1405" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_1467" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_1413" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_1419" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_1420" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_1650" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_1377" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_1449" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract_1320" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_1409" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_1343" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember_1323" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityFilerCategory_1414" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityIncorporationStateCountryCode_1430" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityInteractiveDataCurrent_1349" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="36.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityPublicFloat_1858" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityRegistrantName_1404" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityShellCompany_1418" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntitySmallBusiness_1421" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityTaxIdentificationNumber_1406" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityVoluntaryFilers_1854" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityWellKnownSeasonedIssuer_1853" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_IcfrAuditorAttestationFlag_1855" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="43.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_LocalPhoneNumber_1450" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="44.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_Security12bTitle_1468" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="46.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_SecurityExchangeName_1471" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="45.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_TradingSymbol_1460" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="paii_ClassAOrdinarySharesParValue00001PerShareMember_1324" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember_1325" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1321" xlink:to="us-gaap_ClassOfStockDomain_1322" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="us-gaap_CommonClassAMember_1326" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1322" xlink:to="us-gaap_CommonClassBMember_1327" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_1328" xlink:to="us-gaap_StatementClassOfStockAxis_1321" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_1856" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentFiscalPeriodFocus_1384" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentFiscalYearFocus_1383" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_1328" xlink:to="dei_DocumentInformationLineItems_1331" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1320" xlink:to="dei_DocumentInformationTable_1328" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentPeriodEndDate_1382" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_1857" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentTransitionReport_1344" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentType_1332" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="37.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressAddressLine1_1441" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="38.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressAddressLine2_1442" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="39.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressCityOrTown_1443" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="41.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressPostalZipCode_1446" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="40.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityAddressStateOrProvince_1444" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityCentralIndexKey_1405" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="47.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityCommonStockSharesOutstanding_1467" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityCurrentReportingStatus_1413" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="34.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityEmergingGrowthCompany_1419" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityExTransitionPeriod_1420" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_EntityFileNumber_1650" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_AmendmentFlag_1377" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="42.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_CityAreaCode_1449" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_CurrentFiscalYearEndDate_1409" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1331" xlink:to="dei_DocumentAnnualReport_1343" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_1491" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLineItems" xlink:label="dei_AuditorLineItems_1479" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_1492" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName_1490" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock_1493" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_1479" xlink:to="dei_AuditorFirmId_1491" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_1479" xlink:to="dei_AuditorLocation_1492" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_1479" xlink:to="dei_AuditorName_1490" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_1479" xlink:to="dei_AuditorOpinionTextBlock_1493" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable" xlink:label="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_1700" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1052" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1050" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_1782" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1067" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1063" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValuePaidUnderwritersFees" xlink:label="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_1699" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits" xlink:label="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_1696" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember_1861" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable" xlink:label="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_1862" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_1054" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants" xlink:label="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_1702" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_1703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1056" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1066" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_1064" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1068" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits" xlink:label="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_1698" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1694" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_1695" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_1058" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1060" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1062" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1057" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1059" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1061" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1065" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1051" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1053" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_1055" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1704" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1707" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable_1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1051" xlink:to="us-gaap_StatementEquityComponentsAxis_1052" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_1782" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockholdersEquity_1067" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_SharesOutstanding_1063" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValuePaidUnderwritersFees_1699" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits_1696" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_ReceivablesFromStockholderMember_1861" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable_1862" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_AdditionalPaidInCapitalMember_1054" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants_1702" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_1703" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_EquityComponentDomain_1056" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_NetIncomeLoss_1066" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_1064" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_SharesOutstanding_1068" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits_1698" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1694" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_1695" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1057" xlink:to="us-gaap_CommonClassAMember_1058" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1057" xlink:to="us-gaap_ClassOfStockDomain_1060" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockholdersEquity_1062" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1051" xlink:to="us-gaap_StatementClassOfStockAxis_1057" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1057" xlink:to="us-gaap_CommonClassBMember_1059" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1051" xlink:to="us-gaap_StatementLineItems_1061" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_1065" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1050" xlink:to="us-gaap_StatementTable_1051" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_CommonStockMember_1053" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="us-gaap_RetainedEarningsMember_1055" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1061" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1704" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1052" xlink:to="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1707" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares" xlink:label="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares_1684" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty" xlink:label="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty_1085" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_1692" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1688" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_1686" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1685" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1078" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1071" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1072" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1081" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_1077" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_1076" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_1947" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_1948" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_1863" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty" xlink:label="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty_1841" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1073" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1080" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1079" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares" xlink:label="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares_1897" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_1697" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_1687" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_DeferredUnderwritingFeesPayable" xlink:label="paii_DeferredUnderwritingFeesPayable_1086" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1690" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity_1689" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_1070" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_1082" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1073" xlink:to="paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares_1684" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_1082" xlink:to="paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty_1085" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1688" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_1692" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1688" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1685" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_1686" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1685" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1071" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_1078" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1071" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1071" xlink:to="us-gaap_NetIncomeLoss_1072" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1081" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_1076" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_1077" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1071" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_1076" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1073" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_1947" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_1076" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_1948" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_1076" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_1863" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_1082" xlink:to="paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty_1841" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1071" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1073" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1080" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1079" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_1082" xlink:to="paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares_1897" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1688" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_1697" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1685" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_1687" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_1082" xlink:to="paii_DeferredUnderwritingFeesPayable_1086" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1688" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1690" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1688" xlink:to="us-gaap_ProceedsFromOtherEquity_1689" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1070" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_1082" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_1952" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1953" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1954" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_1955" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1956" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1957" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1951" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1960" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_1963" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember_1964" />
    <link:presentationArc xlink:type="arc" order="308.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1951" xlink:to="us-gaap_ClassOfWarrantOrRightTable_1952" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="309.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1952" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1953" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="310.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1953" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1954" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="311.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1954" xlink:to="us-gaap_IPOMember_1955" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="312.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1952" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1956" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="313.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1956" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1957" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="315.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1952" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="316.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1960" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="319.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1959" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_1963" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="320.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1957" xlink:to="paii_PublicWarrantsMember_1964" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1911" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1913" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1919" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1921" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1922" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1918" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1914" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1915" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_1908" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1912" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1917" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1909" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1920" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1910" />
    <link:presentationArc xlink:type="arc" order="284.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1910" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1911" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_StatementClassOfStockAxis_1913" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_StatementLineItems_1919" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1921" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1922" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="291.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_1917" xlink:to="paii_SponsorMember_1918" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="287.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1913" xlink:to="us-gaap_ClassOfStockDomain_1914" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="288.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1914" xlink:to="us-gaap_CommonClassBMember_1915" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="285.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1911" xlink:to="us-gaap_OverAllotmentOptionMember_1912" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="290.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" xlink:to="us-gaap_RelatedPartyDomain_1917" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1916" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1908" xlink:to="us-gaap_StatementTable_1909" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1919" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1920" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1909" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1910" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_1946" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_1042" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1046" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_1665" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1048" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1666" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember" xlink:label="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1670" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_1657" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1044" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1667" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1668" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1669" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1047" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_1043" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1045" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ClassBNonredeemableOrdinarySharesMember" xlink:label="paii_ClassBNonredeemableOrdinarySharesMember_1671" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_InterestIncomeOther_1946" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1046" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_1665" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_EarningsPerShareDiluted_1048" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="118.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1042" xlink:to="us-gaap_StatementTable_1666" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="122.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1669" xlink:to="paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember_1670" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_OperatingIncomeLoss_1657" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_NetIncomeLoss_1044" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1666" xlink:to="us-gaap_StatementLineItems_1667" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1666" xlink:to="us-gaap_StatementClassOfStockAxis_1668" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="121.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1668" xlink:to="us-gaap_ClassOfStockDomain_1669" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_EarningsPerShareBasic_1047" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_GeneralAndAdministrativeExpense_1043" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1667" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1045" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="123.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1669" xlink:to="paii_ClassBNonredeemableOrdinarySharesMember_1671" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1892" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1893" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_1894" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_1895" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_1943" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_1944" />
    <link:presentationArc xlink:type="arc" order="272.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1892" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="273.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1893" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="274.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_1894" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="275.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_1895" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="305.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_1943" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="306.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1891" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_1944" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1888" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_1889" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1876" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1881" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1878" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1885" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_1886" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_1887" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1879" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_1880" />
    <link:presentationArc xlink:type="arc" order="269.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1881" xlink:to="us-gaap_AssetsAbstract_1888" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="270.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_1888" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_1889" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1881" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="258.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1876" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1877" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_1878" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="266.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" xlink:to="us-gaap_FairValueInputsLevel1Member_1885" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="267.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" xlink:to="us-gaap_FairValueInputsLevel2Member_1886" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="268.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" xlink:to="us-gaap_FairValueInputsLevel3Member_1887" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="260.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1878" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1879" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="264.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1882" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1883" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="261.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_1879" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_1880" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1772" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1766" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1765" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_1774" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_1769" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_1767" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_1770" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_1768" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_1763" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1771" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1776" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1775" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_PublicWarrantsMember" xlink:label="paii_PublicWarrantsMember_1777" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_ProbabilityOfMergerMember" xlink:label="paii_ProbabilityOfMergerMember_1773" />
    <link:presentationArc xlink:type="arc" order="188.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1771" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1772" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="182.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_1765" xlink:to="us-gaap_MeasurementInputTypeDomain_1766" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" xlink:to="us-gaap_MeasurementInputTypeAxis_1765" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputSharePriceMember_1774" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_1769" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_1767" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputExpectedTermMember_1770" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_1768" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="180.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract_1763" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1771" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="190.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1775" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1776" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1764" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1775" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="191.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1776" xlink:to="paii_PublicWarrantsMember_1777" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_1766" xlink:to="paii_ProbabilityOfMergerMember_1773" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1123" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1122" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1122" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1123" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:label="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1125" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_1126" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_1949" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_1844" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1125" xlink:to="us-gaap_GeneralAndAdministrativeExpense_1126" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1125" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_1949" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1125" xlink:to="us-gaap_MarketableSecurities_1844" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_1318" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1713" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1315" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_1317" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_1316" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_1717" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_1717" xlink:to="us-gaap_NumberOfReportableSegments_1318" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="139.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1315" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1713" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_1717" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_1317" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_1717" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_1316" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="143.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1713" xlink:to="us-gaap_SegmentReportingInformationLineItems_1717" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1932" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised" xlink:label="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1937" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised" xlink:label="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1938" />
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_SponsorMember" xlink:label="paii_SponsorMember_1928" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1930" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_1931" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_1934" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1927" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1933" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1929" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1935" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1924" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1925" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1936" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1932" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised_1937" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised_1938" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="294.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_1927" xlink:to="paii_SponsorMember_1928" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="296.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_1929" xlink:to="us-gaap_ClassOfStockDomain_1930" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="297.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_1930" xlink:to="us-gaap_CommonClassBMember_1931" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="300.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1933" xlink:to="us-gaap_OverAllotmentOptionMember_1934" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="293.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" xlink:to="us-gaap_RelatedPartyDomain_1927" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1926" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="299.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1932" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1933" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_StatementClassOfStockAxis_1929" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1925" xlink:to="us-gaap_StatementLineItems_1935" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1924" xlink:to="us-gaap_StatementTable_1925" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1935" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1936" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1088" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1089" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1088" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1089" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1091" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_1092" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1091" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_1092" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="paii-20251231.xsd#paii_InitialPublicOfferingTextBlock" xlink:label="paii_InitialPublicOfferingTextBlock_1095" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_1094" />
    <link:presentationArc xlink:type="arc" order="240.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_1094" xlink:to="paii_InitialPublicOfferingTextBlock_1095" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1097" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1098" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1097" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1098" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1101" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1100" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1103" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_1104" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1103" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_1104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1106" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_1107" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1106" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_1107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1109" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_1110" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1109" xlink:to="us-gaap_SubsequentEventsTextBlock_1110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1709" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1711" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_1710" />
    <link:presentationArc xlink:type="arc" order="137.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1709" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1711" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="136.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1709" xlink:to="us-gaap_TemporaryEquityTableTextBlock_1710" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PYROPHYTE ACQUISITION CORP. II<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002069238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3262 Westheimer Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">701-4243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember', window );">Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-half of one redeemable warrant<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PAII.U<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_ClassAOrdinarySharesParValue00001PerShareMember', window );">Class A ordinary shares, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Ordinary Shares, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PAII<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember', window );">Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PAII WS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,041,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,225,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_ClassAOrdinarySharesParValue00001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_ClassAOrdinarySharesParValue00001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Opinion on the Financial Statements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance sheet of Pyrophyte Acquisition Corp. II (the &#8220;Company&#8221;) as of December 31, 2025 and the related statements of operations, changes in shareholder&#8217;s deficit and cash flows for the period from May 1, 2025 (Inception) through December 31, 2025, and the related notes to the financial statements (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of Pyrophyte Acquisition Corp. II as of December 31, 2025 and the results of its operations and its cash flows for the period from May 1, 2025 (Inception) through December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet<br></strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 442,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">301,930<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">744,430<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">204,013,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid insurance - long term</a></td>
<td class="nump">45,228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">204,802,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">38,948<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">63,948<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_DeferredUnderwritingFeesPayableNoncurrent', window );">Deferred underwriting fees payable</a></td>
<td class="nump">9,399,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,463,638<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ShareSubscriptionReceivable', window );">Share subscription receivable</a></td>
<td class="num">(353,445)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,321,258)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; deficit</a></td>
<td class="num">(8,673,980)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders&#8217; Deficit</a></td>
<td class="nump">204,802,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A Ordinary Shares subject to possible redemption, $0.0001 par value; 20,041,150 ordinary shares at $10.08 per share</a></td>
<td class="nump">204,013,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, value</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, value</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number includes an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_DeferredUnderwritingFeesPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_DeferredUnderwritingFeesPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ShareSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of share subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ShareSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Ordinary shares subject to possible redemption, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Ordinary shares subject to possible redemption, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,041,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Ordinary shares subject to possible redemption, per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,225,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,225,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares | Sponsor</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited', window );">Stock Issued During Period Shares, Share Based Compensations Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares | Over-Allotment Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised', window );">Number of shares subjected to forfeiture if over allotment options is not exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">946,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised', window );">Number of Units Subjected to Forfeiture if Over Allotment Option Is Partially Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,850<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number includes an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subjected to forfeiture if over allotment options is not exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units subjected to forfeiture if over allotment options is partially exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Operations<br></strong></div></th>
<th class="th" colspan="2">8 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 628,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(628,213)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividends and interest earned on marketable securities held in the Trust Account</a></td>
<td class="nump">3,601,747<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income on cash account</a></td>
<td class="nump">329<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,973,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic | shares</a></td>
<td class="nump">13,598,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted | shares</a></td>
<td class="nump">13,598,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_ClassBNonredeemableOrdinarySharesMember', window );">Class B Non-Redeemable Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic | shares</a></td>
<td class="nump">6,911,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted | shares</a></td>
<td class="nump">6,997,607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number excludes                                             an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment                                             option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters                                             partially exercised their over-allotment option and forfeited their right to purchase the                                             remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited                                             30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_ClassBNonredeemableOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_ClassBNonredeemableOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Operations (Parentheticals) - Class B Ordinary Shares - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 24, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares forfeited</a></td>
<td class="nump">30,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised', window );">Number of shares subjected to forfeiture if over allotment options is not exercised</a></td>
<td class="nump">946,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised', window );">Number Of Units Subjected To Forfeiture If Over Allotment Options Is Partially Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subjected to forfeiture if over allotment options is not exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units subjected to forfeiture if over allotment options is partially exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Shareholders&#8217; Deficit - 8 months ended Dec. 31, 2025 - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Class A Ordinary Shares Subject to Possible Redemption</div></th>
<th class="th" colspan="2">
<div>Ordinary Shares </div>
<div>Class A</div>
</th>
<th class="th" colspan="2">
<div>Ordinary Shares </div>
<div>Class B</div>
</th>
<th class="th" colspan="2"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Share Subscription Receivable</div></th>
<th class="th" colspan="2"><div>Accumulated Deficit</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Apr. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Apr. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class B ordinary shares to sponsor</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class B ordinary shares to sponsor (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,255,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited', window );">Forfeiture of Class B ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeiture of Class B ordinary shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(30,231)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits', window );">Proceeds from the sale of Units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 200,411,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits', window );">Proceeds from the sale of Units (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,041,150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodValuePaidUnderwritersFees', window );">Paid underwriters fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,625,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable', window );">Deferred underwriting fees payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,399,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants', window );">Fair value of Public Warrants, at issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,724,648)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,724,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,724,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Allocated value of transaction costs to Class A Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(487,752)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(255,209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(255,209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from the sale of Private Placement Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,050,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,050,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable', window );">Share subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(353,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(353,445)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Remeasurement of Class A ordinary shares to redemption value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,838,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,543,716)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,295,121)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19,838,837)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,973,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,973,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 204,013,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 723<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (353,445)<span></span>
</td>
<td class="num">$ (8,321,258)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (8,673,980)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,041,150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,225,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number includes an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Proceeds from the Sale of Class A Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value deferred underwriting fees payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value fair value of public warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodValuePaidUnderwritersFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value paid underwriters fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodValuePaidUnderwritersFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Proceeds from the Sale of Class A Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of share subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Shareholders&#8217; Deficit (Parentheticals) - Class B Ordinary Shares - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 24, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares forfeited</a></td>
<td class="nump">30,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised', window );">Number of shares subjected to forfeiture if over allotment options is not exercised</a></td>
<td class="nump">946,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised', window );">Number of units subjected to forfeiture if over allotment options is partially exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subjected to forfeiture if over allotment options is not exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units subjected to forfeiture if over allotment options is partially exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,973,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividends and interest earned on marketable securities held in the Trust Account</a></td>
<td class="num">(3,601,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares', window );">Formation and operating expenses paid in exchange for Founder Shares</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(347,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">38,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(906,094)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Investment of cash into Trust Account</a></td>
<td class="num">(200,411,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(200,411,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from sale of Units</a></td>
<td class="nump">200,411,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of Private Placement Warrants</a></td>
<td class="nump">4,396,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs paid</a></td>
<td class="num">(3,047,961)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">201,760,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">442,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash - beginning of period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash - end of period</a></td>
<td class="nump">442,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty', window );">Private Placement Warrants issued through forgiveness of promissory note - related party</a></td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares', window );">Offering costs paid through the issuance of Founder Shares</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty', window );">Offering costs paid through promissory note - related party</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_DeferredUnderwritingFeesPayable', window );">Deferred underwriting fees payable</a></td>
<td class="nump">$ 9,399,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_DeferredUnderwritingFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fees payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_DeferredUnderwritingFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of formation and operating expenses paid in exchange for founder shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering costs paid through the issuance of Founder Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expense paid through promissory note - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of private placement warrants issued through forgiveness of promissory note - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="fin_006" style="display: inline-block;"></span>NOTE 1&#8212; ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pyrophyte Acquisition Corp.&#160;II (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on May&#160;1, 2025. The Company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business Combination&#8221;). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any Business Combination target with respect to an initial Business Combination with the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, the Company had not yet commenced operations. All activity for the period from May&#160;1, 2025 (inception) through December 31, 2025 relates to the Company&#8217;s formation and initial public offering (the &#8220;Initial Public Offering&#8221;). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering and sale of Private Placement Warrants (defined below). The Company has selected December&#160;31 as its fiscal year end. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The registration statement for the Company&#8217;s Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, the Company consummated its Initial Public Offering of 17,500,000 units (the &#8220;Units&#8221;). The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $175,000,000, which is described in Note 3. Each Unit consists of one Class A ordinary share, par value $0.0001 per share (the &#8220;Class A Ordinary Shares&#8221;) and one-half of one redeemable warrant (each whole warrant, a &#8220;Public Warrant&#8221;) of the Company. Each Public Warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment. The Company granted UBS Securities LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the &#8220;Underwriters&#8221;) in the Initial Public Offering a 45-day option to purchase up to 2,625,000 additional Units to cover over-allotments, if any. On July 24, 2025, the Underwriters partially exercised their over-allotment option to purchase an additional 2,541,150 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $25,411,500. The Underwriters forfeited their option to purchase the remaining 83,850 Units under their over-allotment option. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of 5,050,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a purchase price of $1.00 per Private Placement Warrant (the &#8220;Private Placement&#8221;) to Pyrophyte Acquisition II LLC (the &#8220;Sponsor&#8221;) and the Company&#8217;s independent directors, generating gross proceeds to the Company of $5,050,000. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Transaction costs amounted to $12,767,651, including $9,399,690 in deferred underwriting fees, $2,625,000 in upfront underwriting fees, and $742,961 in other offering costs related to the Initial Public Offering. In addition, cash of $1,500,000 (including share subscription receivable of $353,445) was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As a result of the Initial Public Offering and subsequent partial exercise of the over-allotment option, a total of $200,411,500 of the net proceeds from the Initial Public Offering and the sale of the over-allotment option units was deposited in a U.S.-based Trust Account maintained by Continental Stock Transfer &amp; Trust Company, acting as trustee (the &#8220;Trust Account&#8221;). Except with respect to interest earned on the funds in the Trust Account that may be released to the Company to pay its taxes, the proceeds from the Initial Public Offering held in the Trust Account will not be released until the earlier of (i) the consummation of the initial Business Combination and (ii) the distribution of the Trust Account proceeds as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses. <span style="font-size: 10pt">&#160;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The proceeds held in the Trust Account are invested only in U.S. government treasury bills with a maturity of one hundred eighty-five (185) days or less or in money market funds that meet certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;) and that invest only in direct U.S. government obligations or in an interest bearing demand deposit account. Funds will remain in the Trust Account until the earlier of (i) the consummation of the initial Business Combination or (ii) the distribution of the Trust Account proceeds as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete a Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held and taxes paid or payable on the income earned on the Trust Account) at the time of the signing of an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Upon the closing of the Initial Public Offering, an aggregate of $10.00 per Unit sold in the Initial Public Offering was held in a Trust Account as cash and will be invested only in U.S.&#160;government treasury obligations with a maturity of 185&#160;days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, which invest only in direct U.S.&#160;government treasury obligations, or held as cash; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the initial Business Combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that it holds investments in the Trust Account, the Company may, at any time (based on the management team&#8217;s ongoing assessment of all factors related to the potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in cash or in an interest or non-interest bearing demand deposit account at a U.S.&#160;chartered commercial bank with consolidated assets of $100&#160;billion or more selected by the trustee that is reasonably satisfactory to the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to pay the Company&#8217;s taxes, the proceeds from the Initial Public Offering and the sale of the Private Placement Warrants will not be released from the Trust Account until the earliest to occur of (i)&#160;the completion of the Company&#8217;s initial Business Combination (including the release of funds to pay any amounts due to any public shareholders who properly exercise their redemption rights in connection therewith), (ii)&#160;the redemption of any public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company&#8217;s amended and restated memorandum and articles of association (A)&#160;in a manner that would affect the substance or timing of the Company&#8217;s obligation to redeem 100% of its public shares if it does not complete an initial Business Combination within 24&#160;months from the closing of the Initial Public Offering or (B)&#160;with respect to any other material provision relating to the rights of holders of Class A Ordinary Shares (the &#8220;Public Shareholders&#8221;) or pre-initial Business Combination activity or (iii)&#160;the redemption of the Company&#8217;s public shares if it is unable to complete a Business Combination within 24&#160;months from the closing of Initial Public Offering, subject to applicable law. If the Company does not complete an initial Business Combination within 24&#160;months from the closing of the Initial Public Offering, the Company and the Underwriters have agreed that (1)&#160;the Underwriters will forfeit any rights or claims to their deferred underwriting discounts and commissions, including any accrued interest thereon, then in the Trust Account; and (2)&#160;that the deferred Underwriters&#8217; discounts and commissions will be distributed on a pro rata basis, together with any accrued interest thereon (which interest shall be net of taxes paid or payable) to the Public Shareholders. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company will provide its Public Shareholders with the opportunity to redeem, regardless of whether they abstain, vote for, or vote against the Company&#8217;s initial Business Combination, all or a portion of their Public Shares in connection with the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two&#160;business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account (net of taxes paid or payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations and on the conditions described herein. The amount in the Trust Account is initially anticipated to be $10.00 per Public Share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the Underwriters. The Company&#8217;s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their redemption rights with respect to their Founder Shares (as defined in Note 4) and Public Shares in connection with the completion of the Company&#8217;s initial Business Combination. Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction with their initial Business Combinations and provide for related redemptions of Public Shares for cash upon completion of such initial Business Combinations even when a vote is not required by law, if a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, it will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;), and file tender offer documents with the SEC prior to completing its initial Business Combination. The Company&#8217;s amended and restated memorandum and articles of association require these tender offer documents to contain substantially the same financial and other information about the initial Business Combination and the redemption rights as is required under the SEC&#8217;s proxy rules. If, however, a shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, it will, like many special purpose acquisition companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval, it will complete its initial Business Combination only if it obtains the approval of an ordinary resolution under Cayman Islands law and its amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. However, if the Company&#8217;s initial Business Combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of its initial Business Combination will require the approval of a special resolution, which requires the affirmative vote of at least two-thirds of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. However, the participation of the Company&#8217;s Sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions, if any, could result in the approval of an initial Business Combination even if a majority of the Public Shareholders vote, or indicate their intention to vote, against such initial Business Combination. For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of the initial Business Combination once a quorum is obtained. The Company&#8217;s amended and restated memorandum and articles of association require that at least five clear&#160;days&#8217; notice will be given of any general meeting. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Class A Ordinary Shares subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;480, &#8220;Distinguishing Liabilities from Equity.&#8221; If the Company seeks shareholder approval of the Business Combination, a majority of the issued and outstanding shares voted must be voted in favor of the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Pursuant to the Company&#8217;s amended and restated memorandum and articles of association, if it has not completed its initial Business Combination within 24 months from the closing of the Initial Public Offering, it will as promptly as reasonably possible but not more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of amounts not previously released to the Company for permitted withdrawals and up to $100,000 of interest to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete its initial Business Combination within 24 months from the closing of the Initial Public Offering. However, if the Sponsor or management team acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the prescribed time period. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2&#8212;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Going Concern, Liquidity and Capital Resources</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, the Company had a cash balance of $442,500. Following the closing of the Initial Public Offering, the Company&#8217;s liquidity needs are satisfied through using net proceeds from the Initial Public Offering and the sale of Private Placement Warrants for existing accounts payable, identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the Company&#8217;s estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination or because it becomes obligated to redeem a significant number of its Public Shares upon completion of an initial Business Combination, in which case the Company may issue additional securities or incur debt in connection with such initial Business Combination. In addition, in order to finance transaction costs in connection with an initial Business Combination, the Company&#8217;s officers, directors and initial shareholders may, but are not obligated to, provide it with loans up to $1,500,000 as the Company may require (&#8220;Working Capital Loans&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects to incur additional significant costs in pursuit of its financing and acquisition plans, including the proposed business combination. The Company has until 24 months from the IPO to complete a Business Combination or cease all operations other than those required for the purpose of liquidation. In connection with management&#8217;s evaluation of the Company&#8217;s ability to continue as a going concern in accordance with FASB ASC Topic 205-40, &#8220;Presentation of Financial Statements &#8211; Going Concern,&#8221; the Company&#8217;s liquidity concerns raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the date the audited financial statements are available to be issued. The Company intends to satisfy its liquidity needs through the Working Capital Loans that may be provided by its officers, directors and initial shareholders. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to satisfy its obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Emerging Growth Company Status</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or the &#8220;Securities Act&#8221;, as modified by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act&#160;of&#160;2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"></span><span style="font-weight: bold;">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Cash and Cash Equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $442,500 in cash and <span style="-sec-ix-hidden:fc_1532244282">no</span> cash equivalents as of December 31, 2025.<span style="font-weight: bold;">&#160;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Marketable Securities Held in Trust Account</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the assets held in the Trust Account were invested in money market funds that invest solely in U.S. treasury securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Class A Ordinary Shares Subject to Possible Redemption</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s Class A Ordinary Shares that were sold as part of the units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Class A Ordinary Shares in connection with the Company&#8217;s liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies ordinary shares subject to redemption outside of permanent (deficit) equity as the redemption provisions are not solely within the control of the Company. Each Unit consists of one Class A Ordinary Share and one-half of one Public Warrant. As such, the initial carrying value of Class A Ordinary Shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The Class A Ordinary Shares are subject to ASC 480-10-S99 and are currently not redeemable as the redemption is contingent upon the occurrence of events mentioned above. According to ASC 480-10-S99-15, no subsequent adjustment is needed if it is not probable that the instrument will become redeemable. The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Gross proceeds</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,411,500</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Less:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Class A Ordinary Shares issuance costs</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(12,512,442</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9pt">Fair value of Public Warrants at issuance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(3,724,648</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Plus:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Remeasurement of Class A Ordinary Shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,838,837</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Class A Ordinary Shares subject to possible redemption at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">204,013,247</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Fair Value Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Fair Value Measurement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the price that would be received for sale of an asset or paid for in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> There were no investments, assets or liabilities requiring fair value measurement as of December 31, 2025 except marketable securities held in Trust Account of $204,013,247, which is determined to be a Level 1 measurement. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Derivative Financial Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluates its equity-linked financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounted for the Public Warrants issued in connection with the Initial Public Offering and the Private Placement Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the instruments continue to be classified in equity. The over-allotment option was deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and would be accounted for as a liability pursuant to ASC 480. The over-allotment option was partially exercised on July 24, 2025, and the over-allotment liability recorded by Company was reversed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Offering Costs</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the units between Class A Ordinary Shares and warrants, prorate, allocating the Initial Public Offering proceeds to the assigned value of the warrants and to the Class A Ordinary Shares. Offering costs allocated to the Class A Ordinary Shares were charged to temporary equity and offering costs allocated to the Public and Private Placement Warrants were charged to shareholders&#8217; deficit as Public and Private Placement Warrants, after management&#8217;s evaluation, are accounted for under equity treatment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Subscription Receivable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company records stock issuances at the effective date. If the subscription is not funded upon issuance, the Company records a subscription receivable as an asset on a balance sheet, except when subscription receivable is not received prior to the issuance of financial statements at a reporting date in satisfaction of the requirements under ASC 505-10-45-2, in which case, the subscription is reclassified as a contra account to stockholders&#8217; deficit on the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes under ASC Topic&#160;740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statements and tax basis of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> ASC Topic&#160;740 clarifies the accounting for uncertainty in income taxes recognized in an entity&#8217;s financial statements and prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are <span style="-sec-ix-hidden:fc_1353994326">no</span> significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#8217;s tax provision was zero for the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Net Income Per Ordinary Share</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company complies with accounting and disclosure requirements of ASC 260, &#8220;Earnings Per Share.&#8221; Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary shares outstanding during the period. For the period from May 1, 2025 (inception) through December 31, 2025, the Company did not consider the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase Public Shares in the calculation of diluted income per ordinary share, since their inclusion is contingent on a future event. A reconciliation of the net income per ordinary share is stated below. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The<br/> Period&#160;From<br/> May&#160;1, <br/> 2025<br/> (Inception)<br/> Through <br/> December 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Basic Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,971,714</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,598,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">1,002,149</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,911,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Diluted Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,963,480</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,598,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">1,010,383</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">6,997,607</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Diluted net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in the statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants are not precluded from equity classification, and will be accounted for as such on the date of issuance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Share-Based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for Founder Shares issued to its independent directors in accordance with SEC Staff Accounting Bulletin 5T and ASC 718, &#8220;Compensation-Stock Compensation.&#8221; The fair value of the Founder Shares issued in this arrangement was determined using the implied stock price as of the date of the Initial Public Offering of the Company&#8217;s Class A Ordinary Shares and the probability of the success of the initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Initial Public Offering<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_InitialPublicOfferingTextBlock', window );">INITIAL PUBLIC OFFERING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 3&#8212;INITIAL PUBLIC OFFERING</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The registration statement for the Company&#8217;s Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, the Company consummated the Initial Public Offering of 17,500,000 Units, generating gross proceeds of $175,000,000. On July 24, 2025, the Underwriters partially exercised their over-allotment option to purchase an additional 2,541,150 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $25,411,500. The Underwriters forfeited their option to purchase an additional 83,850 Units. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Each Unit consists of one Class A Ordinary Share and one-half of one redeemable Public Warrant. Each whole warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment as described, and only whole warranty is exercisable. The warrants will become exercisable 30&#160;days after the completion of the Company&#8217;s initial Business Combination and will expire five&#160;years after the completion of the Company&#8217;s initial Business Combination, or earlier upon redemption or liquidation. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of an aggregate of 5,050,000 Private Placement Warrants to the Sponsor, at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $5,050,000. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Each Private Placement Warrant is exercisable for one Class A Ordinary Share at a price of $11.50 per share. If the initial Business Combination is not completed within 24 months from the closing of the Initial Public Offering, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis and will expire five years after the completion of the Company&#8217;s initial Business Combination or earlier upon redemption or liquidation. As the Sponsor will agree, subject to limited exceptions, not to transfer, assign or sell any of the Private Placement Warrants (including their underlying securities) until 30 days after the completion of the initial Business Combination. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 4&#8212;RELATED PARTY TRANSACTIONS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Founder Shares</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On May&#160;5, 2025, the Sponsor made a capital contribution of $25,000, or approximately $0.003 per share, to cover certain of the Company&#8217;s expenses, for which the Company issued 7,255,952 Founder Shares to the Sponsor. The Founder Shares included up to 946,428 of the Founder Shares subject to forfeiture by the Sponsor for no consideration to the extent the Underwriters&#8217; over-allotment was not fully exercised. The Underwriters had 45 days after the closing of the Initial Public Offering to exercise their over-allotment option. On July 24, 2025, the Underwriters partially exercised their over-allotment option as part of the Initial Public Offering. As such, 30,231 Founder Shares were forfeited by the Sponsor. All share and per share data has been retroactively restated. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In June 2025, the Sponsor transferred&#160;30,000&#160;of the Company&#8217;s Founder Shares to each of the Company&#8217;s three independent directors. These&#160;90,000&#160;Founder Shares were not subject to forfeiture. The allocation of the Founder Shares to the directors is in the scope of ASC 718. Under ASC 718, share-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Company used the implied stock price as of the date of the Initial Public Offering of the Company&#8217;s Class A Ordinary Shares and the probability of the success of the initial Business Combination. The fair value of the&#160;90,000&#160;Founder Shares granted to the Company&#8217;s directors was $216,637&#160;or $2.41&#160;per share. The Founder Shares were granted subject to a performance condition, the performance of the duties of an independent director through and the occurrence of an initial Business Combination. Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under ASC 718. The Company determined the performance conditions are not considered probable, and, therefore,&#160;<span style="-sec-ix-hidden:fc_912153279">no</span>&#160;share-based compensation expense was recognized as of December 31, 2025. As of December 31, 2025, the unrecognized stock compensation expense was $216,637. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Founder Shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A Ordinary Shares included in the Units sold in the Initial Public Offering, and holders of Founder Shares have the same shareholder rights as Public Shareholders, except that (i) the Founder Shares are subject to certain transfer restrictions, as described in more detail below, (ii) the Founder Shares are entitled to registration rights, (iii) the Company&#8217;s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (A) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Company&#8217;s initial Business Combination, (B) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the Company&#8217;s amended and restated memorandum and articles of association (1) to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem 100% of the Company&#8217;s Public Shares if the Company has not consummated an initial Business Combination within 24 months from the closing of the Initial Public Offering, (2) with respect to any other material provisions relating to shareholders&#8217; rights or pre-initial Business Combination activity, (3) waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete the Company&#8217;s initial Business Combination within the 24 months from the closing of the Initial Public Offering, although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the initial Business Combination within such time period and to liquidating distributions from assets outside the Trust Account and (4) vote any Founder Shares held by them and any Public Shares purchased during or after the Initial Public Offering (including in open market and privately negotiated transactions) in favor of the initial Business Combination (including any proposals recommended by the Company&#8217;s board of directors in connection with such Business Combination) (except with respect to any Public Shares which may not be voted in favor of approving the Business Combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations or guidance relating thereto), (iv) the Founder Shares are automatically convertible into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Company&#8217;s initial Business Combination or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in the amended and restated memorandum and articles of association, and (v) prior to the closing of the Company&#8217;s initial Business Combination, only holders of Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing in a jurisdiction outside the Cayman Islands (including any special resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Founder Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the initial Business Combination or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares, or any other equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to or in connection with the closing of the initial Business Combination, the ratio at which Class B ordinary shares convert into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, 26.5% of the sum of (i) the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering (including any Class A Ordinary Shares issued pursuant to the Underwriters&#8217; over-allotment option and excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor and the Underwriters), plus (ii) all Class A Ordinary Shares and equity-linked securities issued or deemed issued in connection with the Company&#8217;s initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Company&#8217;s Sponsor or any of its affiliates or to the Company&#8217;s officers and directors upon conversion of Working Capital Loans) minus (iii) any redemptions of Class A Ordinary Shares by Public Shareholders in connection with an initial Business Combination; provided that such conversion of Founder Shares will never occur on a less than one-for-one basis. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s initial shareholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (i)&#160;one year after the completion of the initial Business Combination and (ii)&#160;the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company&#8217;s shareholders having the right to exchange their Class A Ordinary Shares for cash, securities or other property (except to certain permitted transferees and under certain circumstances). Notwithstanding the foregoing, if the last sale price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20&#160;trading days within any 30-trading&#160;day period commencing at least 150&#160;days after the completion of the Company&#8217;s initial Business Combination, the Founder Shares will be released from this lock-up. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Promissory Note&#8212;Related Party</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Sponsor has agreed to loan the Company an aggregate of up to $300,000 under an unsecured promissory to be used for a portion of the expenses in connection with the Initial Public Offering. The loan was non-interest bearing, unsecured and due at the earlier of December 31, 2025 or the closing of the Initial Public Offering. As of the Initial Public Offering date of July 18, 2025, the $300,000 note was fully utilized by the Company. In connection with the private sale of 5,050,000 warrants as described above in Note 4, the Company settled the outstanding note through the issuance of 300,000 Private Placement Warrants to the related party. The 300,000 Private Placement Warrants are included in the total of 5,050,000 in connection with the Initial Public Offering. The Company determined that the carrying value and fair value of the note are the same as the fair value of the Private Placement Warrants given in exchange for the note. As of December 31, 2025, there are <span style="-sec-ix-hidden:fc_1028152249">no</span> amounts outstanding under the note and the note is no longer available to be drawn.<span style="font-weight: bold;">&#160;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Share Subscription Receivable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On July 19, 2025, in connection with the sale of the Private Placement Warrants, the Sponsor should have deposited $353,445 of the net proceeds into the Company&#8217;s bank account. This amount still has not been received as of December 31, 2025. The Company has accounted for the amount due as a share subscription receivable within shareholders&#8217; deficit. The amount is non-interest bearing, due on demand and expected to be settled in the near term. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Private Placement Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On July 18, 2025, the Sponsor purchased an aggregate 5,050,000 Private Placement Warrants at a price of $1.00 per whole Private Placement Warrant in a private placement that occurred simultaneously with the closing of the Initial Public Offering. Each whole Private Placement Warrant is exercisable for one whole Class A Ordinary Share at a price of $11.50 per share. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the initial Business Combination is not completed within 24&#160;months from the closing of the Initial Public Offering, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis and will expire five&#160;years after the completion of the Company&#8217;s initial Business Combination or earlier upon redemption or liquidation. As the Sponsor will agree, subject to limited exceptions, not to transfer, assign or sell any of the Private Placement Warrants (including their underlying securities) until 30&#160;days after the completion of the initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Administrative Support Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Commencing on the effective date of the Initial Public Offering, the Company entered into an agreement with the Sponsor to pay an aggregate of $35,000 per month for office space, utilities and secretarial and administrative support. Upon completion of the initial Business Combination or its liquidation, the Company will cease paying these monthly fees. For the period from May 1, 2025 (inception) through December 31, 2025, the Company recognized $192,500 in administrative fees. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Working Capital Loans</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#8217;s Sponsor or an affiliate of its Sponsor or certain of its officers and directors may, but are not obligated to, loan the Company funds as may be required on a non-interest bearing basis. If the Company completes its initial Business Combination, the Company would repay such loaned amounts. In the event that the initial Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay such loaned amounts but no proceeds held in the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into Private Placement Warrants at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. The terms of such loans by the Company&#8217;s Sponsor or its affiliates, or its officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, <span style="-sec-ix-hidden:fc_936727067">no</span> such Working Capital Loans were outstanding. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 5&#8212;COMMITMENTS AND CONTINGENCIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks and Uncertainties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict, the Israel-Hamas war and the conflict between the United States and Israel and Iran, as well as recent developments to U.S. tariff policies. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the U.S., the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. &#8192;The invasion of Ukraine by Russia, the Israel-Hamas war, the conflict between the United States and Israel and Iran and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the Israel-Hamas war, and the conflict between the United States and Israel and Iran and subsequent sanctions or related actions or the ongoing trade and tariff policy changes by the U.S. or other countries could adversely affect the Company&#8217;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Registration Rights</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the (i) Founder Shares, which were issued in the Private Placement prior to the closing of the Initial Public Offering, (ii) Private Placement Warrants and the Class A Ordinary Shares underlying such Private Placement Warrants and (iii) Private Placement Warrants that may be issued upon conversion of Working Capital Loans will have registration rights to require the Company to register a sale of any of the Company&#8217;s securities held by them and any other securities of the Company acquired by them prior to the consummation of the Company&#8217;s initial Business Combination pursuant to a registration rights agreement signed on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to the Company&#8217;s completion of the Company&#8217;s initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Underwriting Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On July 18, 2025, the Company paid a cash discount of 1.5% of the per Unit Initial Public Offering price on the base Units sold in the Offering (or $2,625,000 in aggregate) to the Underwriters at the closing of the Initial Public Offering, with an additional fee of 4.5% of the gross Initial Public Offering proceeds with respect to the base Units sold in the Offering (and 6.0% of the per Unit Initial Public Offering price on the Units sold pursuant to the Underwriters&#8217; over-allotment option) payable only upon the Company&#8217;s completion of its initial Business Combination (the &#8220;Deferred Discount&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> A Deferred Discount of $9,399,690, including the partial exercise of the over-allotment option, will become payable to the Underwriters from the amounts held in the Trust Account solely in the event the Company completes its initial Business Combination. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Shareholders&#8217; Deficit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; DEFICIT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 6&#8212;SHAREHOLDERS&#8217; DEFICIT</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <span style="font-weight: bold;">Preference Shares&#8212;</span>The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December 31, 2025, there were <span style="-sec-ix-hidden:fc_899188066"><span style="-sec-ix-hidden:fc_174561091">no</span></span> preference shares issued or outstanding. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <span style="font-weight: bold;">Class A Ordinary Shares&#8212;</span>The Company is authorized to issue 200,000,000 Class A Ordinary Shares at par value of $0.0001 each. Holders of the Company&#8217;s Class A Ordinary Shares are entitled to one vote for each share. As of December 31, 2025, there were <span style="-sec-ix-hidden:fc_492491914"><span style="-sec-ix-hidden:fc_459141205">no</span></span> Class A Ordinary Shares issued or outstanding (excluding 20,041,150 shares subject to possible redemption). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <span style="font-weight: bold;">Class&#160;B Ordinary Shares&#8212;</span>The Company is authorized to issue a total of 20,000,000 Class&#160;B ordinary shares at par value of $0.0001 each. On May&#160;5, 2025, the Company issued 7,255,952 Class&#160;B ordinary shares to the Sponsor (the &#8220;Founder Shares&#8221;) for $25,000, or approximately $0.003 per share, which included an aggregate of up to 946,428 shares that were subject to forfeiture to the extent that the Underwriters&#8217; over-allotment option was not exercised in full or in part. In June 2025, the Sponsor transferred&#160;30,000&#160;of the Company&#8217;s Founder Shares to each of the Company&#8217;s three independent directors. On July 24, 2025, the Underwriters partially exercised their over-allotment option and forfeited their right remaining Units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. As of December 31, 2025, there were 7,225,721 Class&#160;B ordinary shares issued and outstanding. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Class&#160;B ordinary shares will automatically convert into Class A Ordinary Shares at the time of the Company&#8217;s initial Business Combination (with such conversion taking place immediately prior to, simultaneously with, or immediately following the time of the initial Business Combination, as may be determined by the Company&#8217;s directors) or earlier at the option of the holder on a one-for-one basis (subject to adjustment for share subdivisions, share dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares, or equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which Class&#160;B ordinary shares convert into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class&#160;B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issued and issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 26.5% of the sum of (i)&#160;the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering (including any Class A Ordinary Shares issued pursuant to the Underwriters&#8217; over-allotment option but excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor), plus (ii)&#160;all Class A Ordinary Shares and equity-linked securities issued or deemed issued in connection with the Company&#8217;s initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Company&#8217;s Sponsor or any of its affiliates or to the Company&#8217;s officers and directors upon conversion of working capital loans) minus (iii)&#160;any redemptions of Class A Ordinary Shares by Public Shareholders prior to or in connection with an initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the Company enters into an initial Business Combination, it may (depending on the terms of such an initial Business Combination) be required to increase the number of Class A Ordinary Shares which the Company is authorized to issue at the same time as the Company&#8217;s shareholder votes on the initial Business Combination to the extent the Company seeks shareholder approval in connection with the initial Business Combination. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each ordinary share (except as otherwise expressed in the Company&#8217;s amended and restated memorandum and articles of association). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <span style="font-weight: bold;">Warrants&#8212;</span>As of December 31, 2025, there were 15,070,575 warrants outstanding (10,020,575 Public Warrants and 5,050,000 Private Placement Warrants). Each whole warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment as described herein. Only whole warrants are exercisable. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will not be obligated to issue any Class A Ordinary Shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A Ordinary Shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue a Class A Ordinary Share upon exercise of a warrant unless the Class A Ordinary Share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a Unit containing such warrant will have paid the full purchase price for the Unit solely for the Class A Ordinary Share underlying such unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The warrants will become exercisable 30 days after the completion of the Company&#8217;s initial Business Combination, which may be within one year of the Initial Public Offering. However, because the warrants will be exercisable until their expiration date of up to five years after the completion of the initial Business Combination, in order to comply with the requirements of Section 10(a)(3) of the Securities Act following the consummation of the initial Business Combination, under the terms of the warrant agreement, the Company has agreed that, as soon as practicable, but in no event later than 20 business days, after the closing of its initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement or a new registration statement covering the registration under the Securities Act of the Class A Ordinary Shares issuable upon exercise of the warrants and thereafter will use its commercially reasonable efforts to cause the same to become effective within 60 business days following its initial Business Combination and to maintain a current prospectus relating to the Class A Ordinary Shares issuable upon exercise of the warrants until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A Ordinary Shares issuable upon exercise of the warrants is not effective by the sixtieth (60) business day after the closing of the Company&#8217;s initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Company&#8217;s Class A Ordinary Shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <span style="font-weight: bold;"><i>Redemption of warrants for cash when the price per Class A Ordinary Share equals or exceeds $18.00</i></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may redeem the outstanding Public Warrants for cash:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify"><span style="font-family: Symbol"></span>in whole and not in part;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#9679;</td> <td style="text-align: justify"><span style="font-family: Symbol"></span>at a price of $0.01 per warrant; upon not less than 30&#160;days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;); and &#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#9679;</td> <td style="text-align: justify"><span style="font-family: Symbol"></span>if, and only if, the last reported sale price of the Class A Ordinary Shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) for any 20&#160;trading days within a 30&#160;trading day period ending on the third&#160;trading day prior to the date on which the Company send the notice of redemption to the warrant holders</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the Class A Ordinary Shares issuable upon exercise of the warrants is effective and a current prospectus relating to those Class A Ordinary Shares is available throughout such 30&#160;trading day period and the 30&#160;day redemption period. If and when the Public Warrants become redeemable by the Company, it may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. The Company has established the last of the redemption criterion discussed above to prevent a&#160;redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of the Class A Ordinary Shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Anti-dilution adjustments</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If (x) the Company issues additional Class A Ordinary Shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A Ordinary Shares (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and the volume weighted average trading price of the Class A Ordinary Shares during the 20 trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Private Placement Warrants (including the Class A Ordinary Shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants sold as part of the units in the Initial Public Offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company accounts for the 15,070,575 warrants issued in connection with the Initial Public Offering (including 10,020,575 Public Warrants and 5,050,000 Private Placement Warrants) in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7&#8212;SEGMENT INFORMATION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC Topic&#160;280, &#8220;Segment Reporting,&#8221; establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#8217;s chief operating officer decision maker (&#8220;CODM&#8221;), or group, in deciding how to allocate resources and assess performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s CODM has been identified as the <span style="-sec-ix-hidden:fc_832639951">Chief Financial Officer</span>, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reportable segment. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the statements of operations as net income or loss. The measure of segment assets is reported on the balance sheet as total assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income or loss and total assets, which include the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of<br/> December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Marketable securities held in Trust Account</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">204,013,247</td><td style="width: 1%; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The <br/> Period&#160;From<br/> May&#160;1,<br/> 2025 <br/> (Inception) <br/> Through <br/> December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">General and administrative expenses</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">628,213</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividends and interest earned on marketable securities held in the Trust Account</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">3,601,747</td><td style="text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative costs are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete an offering and eventually a Business Combination within the Business Combination period. The CODM also reviews general and administrative expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. General and administrative expenses, as reported on the statement of operations, are the significant segment expenses provided to the CODM on a regular basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other segment items included in net income or loss are reported on the statement of operations and described within their respective disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 8&#8212;FAIR VALUE MEASUREMENT</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 by level within the fair value hierarchy:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Assets:</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">Marketable securities held in Trust Account</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">204,013,247</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_1886441502">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_2088902046">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Public Warrants were valued using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The value of the Public Warrants as of the IPO date was $3,724,648 or $0.37 per warrant. The Public Warrants have been classified within shareholders&#8217; deficit and will not require remeasurement after issuance. The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Warrants as of the Initial Public Offering date using level 3 inputs: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 18,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Market price of public stock</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9.81</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Term (years)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free rate</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">3.77</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">9.11</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Probability of merger</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">25.00</td><td style="text-align: left">%</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9&#8212;SUBSEQUENT EVENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company evaluated subsequent events and transactions that occurred after the balance sheet date through March 30, 2026, the date that the financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">As a blank check company, we have no operations and therefore do not have any operations of our own that face cybersecurity threats. However, we do depend on the digital technologies of third parties, and as noted in &#8220;<i>Item 1A. Risk Factors</i>&#8221; of this Form 10-K, any sophisticated and deliberate attacks on, or security breaches in, systems or infrastructure or the cloud that we utilize, including those of third parties, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. Because of our reliance on the technologies of third parties, we also depend upon the personnel and the processes of third parties to protect against cybersecurity threats, and we have no personnel or processes of our own for this purpose. Our board of directors oversees risk for our Company, and prior to filings with the SEC, our board of directors reviews our risk factors, including the descriptions of the risks we face from cybersecurity threats, as described in &#8220;<i>Item 1A. Risk Factors</i>&#8221; of this Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">our board of directors reviews our risk factors, including the descriptions of the risks we face from cybersecurity threats, as described in &#8220;<i>Item 1A. Risk Factors</i>&#8221; of this Form 10-K.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">board of directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">we have no operations and therefore do not have any operations of our own that face cybersecurity threats.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,973,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock', window );">Going Concern, Liquidity and Capital Resources</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Going Concern, Liquidity and Capital Resources</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December 31, 2025, the Company had a cash balance of $442,500. Following the closing of the Initial Public Offering, the Company&#8217;s liquidity needs are satisfied through using net proceeds from the Initial Public Offering and the sale of Private Placement Warrants for existing accounts payable, identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the initial Business Combination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the Company&#8217;s estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination or because it becomes obligated to redeem a significant number of its Public Shares upon completion of an initial Business Combination, in which case the Company may issue additional securities or incur debt in connection with such initial Business Combination. In addition, in order to finance transaction costs in connection with an initial Business Combination, the Company&#8217;s officers, directors and initial shareholders may, but are not obligated to, provide it with loans up to $1,500,000 as the Company may require (&#8220;Working Capital Loans&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects to incur additional significant costs in pursuit of its financing and acquisition plans, including the proposed business combination. The Company has until 24 months from the IPO to complete a Business Combination or cease all operations other than those required for the purpose of liquidation. In connection with management&#8217;s evaluation of the Company&#8217;s ability to continue as a going concern in accordance with FASB ASC Topic 205-40, &#8220;Presentation of Financial Statements &#8211; Going Concern,&#8221; the Company&#8217;s liquidity concerns raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the date the audited financial statements are available to be issued. The Company intends to satisfy its liquidity needs through the Working Capital Loans that may be provided by its officers, directors and initial shareholders. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to satisfy its obligations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Emerging Growth Company Status</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or the &#8220;Securities Act&#8221;, as modified by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act&#160;of&#160;2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"></span><span style="font-weight: bold;">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Cash and Cash Equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $442,500 in cash and <span style="-sec-ix-hidden:fc_1532244282">no</span> cash equivalents as of December 31, 2025.<span style="font-weight: bold;">&#160;</span> </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock', window );">Marketable Securities Held in Trust Account</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Marketable Securities Held in Trust Account</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the assets held in the Trust Account were invested in money market funds that invest solely in U.S. treasury securities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Class A Ordinary Shares Subject to Possible Redemption</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company&#8217;s Class A Ordinary Shares that were sold as part of the units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Class A Ordinary Shares in connection with the Company&#8217;s liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#8217;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies ordinary shares subject to redemption outside of permanent (deficit) equity as the redemption provisions are not solely within the control of the Company. Each Unit consists of one Class A Ordinary Share and one-half of one Public Warrant. As such, the initial carrying value of Class A Ordinary Shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The Class A Ordinary Shares are subject to ASC 480-10-S99 and are currently not redeemable as the redemption is contingent upon the occurrence of events mentioned above. According to ASC 480-10-S99-15, no subsequent adjustment is needed if it is not probable that the instrument will become redeemable. The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Gross proceeds</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,411,500</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Less:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Class A Ordinary Shares issuance costs</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(12,512,442</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9pt">Fair value of Public Warrants at issuance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(3,724,648</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Plus:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Remeasurement of Class A Ordinary Shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,838,837</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Class A Ordinary Shares subject to possible redemption at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">204,013,247</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Fair Value Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Fair Value Measurement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the price that would be received for sale of an asset or paid for in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify">&#160;</td> <td style="width: 0.25in; text-align: justify">&#9679;</td> <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> There were no investments, assets or liabilities requiring fair value measurement as of December 31, 2025 except marketable securities held in Trust Account of $204,013,247, which is determined to be a Level 1 measurement. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Derivative Financial Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluates its equity-linked financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounted for the Public Warrants issued in connection with the Initial Public Offering and the Private Placement Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the instruments continue to be classified in equity. The over-allotment option was deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and would be accounted for as a liability pursuant to ASC 480. The over-allotment option was partially exercised on July 24, 2025, and the over-allotment liability recorded by Company was reversed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_OfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Offering Costs</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering.&#8221; Deferred offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 470-20, &#8220;Debt with Conversion and Other Options,&#8221; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the units between Class A Ordinary Shares and warrants, prorate, allocating the Initial Public Offering proceeds to the assigned value of the warrants and to the Class A Ordinary Shares. Offering costs allocated to the Class A Ordinary Shares were charged to temporary equity and offering costs allocated to the Public and Private Placement Warrants were charged to shareholders&#8217; deficit as Public and Private Placement Warrants, after management&#8217;s evaluation, are accounted for under equity treatment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_SubscriptionReceivablePolicyTextBlock', window );">Subscription Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Subscription Receivable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company records stock issuances at the effective date. If the subscription is not funded upon issuance, the Company records a subscription receivable as an asset on a balance sheet, except when subscription receivable is not received prior to the issuance of financial statements at a reporting date in satisfaction of the requirements under ASC 505-10-45-2, in which case, the subscription is reclassified as a contra account to stockholders&#8217; deficit on the balance sheet.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes under ASC Topic&#160;740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statements and tax basis of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> ASC Topic&#160;740 clarifies the accounting for uncertainty in income taxes recognized in an entity&#8217;s financial statements and prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are <span style="-sec-ix-hidden:fc_1353994326">no</span> significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#8217;s tax provision was zero for the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Per Ordinary Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Net Income Per Ordinary Share</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company complies with accounting and disclosure requirements of ASC 260, &#8220;Earnings Per Share.&#8221; Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary shares outstanding during the period. For the period from May 1, 2025 (inception) through December 31, 2025, the Company did not consider the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase Public Shares in the calculation of diluted income per ordinary share, since their inclusion is contingent on a future event. A reconciliation of the net income per ordinary share is stated below. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The<br/> Period&#160;From<br/> May&#160;1, <br/> 2025<br/> (Inception)<br/> Through <br/> December 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Basic Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,971,714</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,598,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">1,002,149</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,911,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Diluted Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,963,480</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,598,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">1,010,383</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">6,997,607</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Diluted net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Warrants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in the statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants are not precluded from equity classification, and will be accounted for as such on the date of issuance.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Share-Based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for Founder Shares issued to its independent directors in accordance with SEC Staff Accounting Bulletin 5T and ASC 718, &#8220;Compensation-Stock Compensation.&#8221; The fair value of the Founder Shares issued in this arrangement was determined using the implied stock price as of the date of the Initial Public Offering of the Company&#8217;s Class A Ordinary Shares and the probability of the success of the initial Business Combination.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of accounting policy for emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting going concern, liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for marketable securities held in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_OfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_OfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_SubscriptionReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_SubscriptionReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/480/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"> The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Gross proceeds</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,411,500</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Less:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Class A Ordinary Shares issuance costs</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(12,512,442</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9pt">Fair value of Public Warrants at issuance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(3,724,648</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Plus:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Remeasurement of Class A Ordinary Shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,838,837</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Class A Ordinary Shares subject to possible redemption at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">204,013,247</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of the Net Income Per Ordinary Share</a></td>
<td class="text"> A reconciliation of the net income per ordinary share is stated below.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The<br/> Period&#160;From<br/> May&#160;1, <br/> 2025<br/> (Inception)<br/> Through <br/> December 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Basic Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,971,714</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,598,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">1,002,149</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,911,596</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Diluted Earnings Per Share</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Net income allocable to Redeemable Class A Ordinary Shares</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,963,480</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,598,470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Non-Redeemable Class B ordinary shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Numerator: Net income allocable to non-redeemable Class B Ordinary Shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net income allocable to non-redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">1,010,383</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Denominator: Weighted Average Non-Redeemable Class B ordinary shares</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">6,997,607</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Diluted net income per share, Class B non-redeemable ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When evaluating the Company&#8217;s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income or loss and total assets, which include the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of<br/> December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Marketable securities held in Trust Account</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">204,013,247</td><td style="width: 1%; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For The <br/> Period&#160;From<br/> May&#160;1,<br/> 2025 <br/> (Inception) <br/> Through <br/> December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">General and administrative expenses</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">628,213</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividends and interest earned on marketable securities held in the Trust Account</td><td>&#160;</td><td style="text-align: left">$</td><td style="text-align: right">3,601,747</td><td style="text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 by level within the fair value hierarchy:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Assets:</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">Marketable securities held in Trust Account</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">204,013,247</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_1886441502">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_2088902046">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Valuation of the Public Warrants</a></td>
<td class="text">The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Warrants as of the Initial Public Offering date using level 3 inputs:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 18,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Market price of public stock</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9.81</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Term (years)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free rate</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">3.77</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">9.11</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Probability of merger</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">25.00</td><td style="text-align: left">%</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited', window );">Remaining underwriters forfeited shares</a></td>
<td class="nump">83,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_TransactionCosts', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,767,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_DeferredUnderwritingFeesPayableNoncurrent', window );">Deferred underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_UpforntUnderwritingFees', window );">Underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NetProceedsAmount', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,411,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance', window );">Percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany', window );">Percentage of outstanding voting securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Assets amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_SharesRedemptionObligationPercentage', window );">Percentage of public shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NewlyAdjustedIssueSharePrice', window );">Public per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_InterestToPayDissolutionExpenses', window );">Interest to pay liquidation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ShareSubscriptionReceivable', window );">Share subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_USTreasuryGovernmentBillsMaturityTerm', window );">Maturity term of treasury government bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">185 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_YearOfInception', window );">Year Of Inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May&#160;1, 2025 (inception) through December 31, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantMember', window );">Public Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 25,411,500<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues', window );">Additional units issued</a></td>
<td class="nump">2,541,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sold per unit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PriceIssuedPerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues', window );">Additional units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Private sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant', window );">Warrants purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesInEachUnit', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PriceIssuedPerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per unit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the additional units issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants and rights issued, price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_DeferredUnderwritingFeesPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_DeferredUnderwritingFeesPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_InterestToPayDissolutionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest to pay dissolution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_InterestToPayDissolutionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum ownership percentage to be acquired for not to be registered as an investment company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of fair market value of business acquisition to trust account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NetProceedsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NetProceedsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NewlyAdjustedIssueSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Newly adjusted issue share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NewlyAdjustedIssueSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfSharesInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares In Each Unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfSharesInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PriceIssuedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PriceIssuedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ShareSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of share subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ShareSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_SharesRedemptionObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares redemption obligation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_SharesRedemptionObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_USTreasuryGovernmentBillsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity term of treasury government bills.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_USTreasuryGovernmentBillsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the units issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_UpforntUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represemt upfornt underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_UpforntUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_YearOfInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of inception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_YearOfInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 442,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_WorkingCapitalLoans', window );">Working capital loans</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Marketable securities held in trust account</a></td>
<td class="nump">$ 204,013,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_WorkingCapitalLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of working capital loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_WorkingCapitalLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-5<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Class A Ordinary Shares Subject to Possible Redemption (Details) - Class A Ordinary Shares [Member]<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Schedule of Class A Ordinary Shares Subject to Possible Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 200,411,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassAOrdinarySharesIssuanceCosts', window );">Class A ordinary shares issuance costs</a></td>
<td class="num">(12,512,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of Public Warrants at issuance</a></td>
<td class="num">(3,724,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract', window );"><strong>Plus:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Remeasurement of Class A ordinary shares to redemption value</a></td>
<td class="nump">19,838,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption at September 30, 2025</a></td>
<td class="nump">$ 204,013,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassAOrdinarySharesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of class A ordinary shares issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassAOrdinarySharesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details)<br></strong></div></th>
<th class="th" colspan="2">8 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_RedeemableClassAOrdinarySharesMember', window );">Redeemable Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract', window );"><strong>Numerator: Net income allocable to Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income allocable to Ordinary Shares | $</a></td>
<td class="nump">$ 1,971,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator: Weighted Average Share Outstanding, Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding | shares</a></td>
<td class="nump">13,598,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator: Net income allocable to Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income allocable to Ordinary Shares | $</a></td>
<td class="nump">$ 1,963,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator: Weighted Average Share Outstanding, Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding | shares</a></td>
<td class="nump">13,598,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=paii_ClassBNonredeemableOrdinarySharesMember', window );">Non-Redeemable Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract', window );"><strong>Numerator: Net income allocable to Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income allocable to Ordinary Shares | $</a></td>
<td class="nump">$ 1,002,149<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator: Weighted Average Share Outstanding, Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding | shares</a></td>
<td class="nump">6,911,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator: Net income allocable to Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income allocable to Ordinary Shares | $</a></td>
<td class="nump">$ 1,010,383<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator: Weighted Average Share Outstanding, Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding | shares</a></td>
<td class="nump">6,997,607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share | $ / shares</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number excludes                                             an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment                                             option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters                                             partially exercised their over-allotment option and forfeited their right to purchase the                                             remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited                                             30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_RedeemableClassAOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_RedeemableClassAOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=paii_ClassBNonredeemableOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=paii_ClassBNonredeemableOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Initial Public Offering (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ExercisableWarrantsTerm', window );">Exercisable warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited', window );">Remaining underwriters forfeited shares</a></td>
<td class="nump">83,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination', window );">Threshold number of trading days For determining share price from date of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ordinary share at a price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Private sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,070,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ordinary share at a price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited', window );">Remaining underwriters forfeited shares</a></td>
<td class="nump">83,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant', window );">Warrants purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 25,411,500<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues', window );">Additional units issued</a></td>
<td class="nump">2,541,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Private sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant', window );">Warrants purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member] | Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Initial Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the additional units issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants and rights issued, price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ExercisableWarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercisable warrant term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ExercisableWarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for completion of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the units issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=paii_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>May 05, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 19, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount', window );">Amount granted to directors (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_GrantedPricePerShare', window );">Granted price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherValueOutstanding', window );">Outstanding (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_WorkingCapitalLoanOutstanding', window );">Working capital loans, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Capital contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination', window );">Trading period after completion of business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth', window );">Expenses per month</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ordinary share at a price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty', window );">Issuance of private palcement warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of aggregate share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrant exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_MaximumLoansConvertibleIntoWarrants', window );">Maximum loans convertible into warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=paii_PromissoryNoteRelatedPartyMember', window );">Promissory Note Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_AggregateUnsecuredPromissoryAmount', window );">Aggregate unsecured promissory amount (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PromissoryNotePayableFullyUtilizedAfterIPO', window );">Fully utilized after the IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Founder shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember', window );">Sponsor [Member] | Private Placement Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Deposited amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember', window );">Sponsor [Member] | Founder Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Capital contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,255,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised', window );">Number of shares to be forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_CommonStockThresholdTradingDays', window );">Minimum number of trading days</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_CommonStockThresholdConsecutiveTradingDays', window );">Consecutive trading day threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfDaysAfterInitialBusinessCombination', window );">Minimum number of days after initial Business Combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesNotSubjectToForfeiture', window );">Number of Shares Not Subject to Forfeiture</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=paii_InitialBusinessCombinationMember', window );">Initial Business Combination [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage', window );">Percentage of initial business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares [Member] | Initial Business Combination [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage', window );">Percentage of initial business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Founder Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_CommonStockStockPriceTrigger', window );">Common stock trigger price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member] | Private Placement Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_InitialPublicOfferings', window );">Initial public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty', window );">Issuance of private palcement warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member] | Sponsor [Member] | Founder Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised', window );">Number of shares to be forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number includes an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_AggregateUnsecuredPromissoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate unsecured promissory amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_AggregateUnsecuredPromissoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading period after completion of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_CommonStockStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock trigger price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_CommonStockStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_CommonStockThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of consecutive trading days used to observe the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_CommonStockThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_CommonStockThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, threshold trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_CommonStockThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_GrantedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Granted price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_GrantedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_InitialPublicOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_InitialPublicOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares represent issuance of private palcement warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_MaximumLoansConvertibleIntoWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount which a potential loan could have repaid through issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_MaximumLoansConvertibleIntoWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfDaysAfterInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfDaysAfterInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfSharesNotSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares not subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfSharesNotSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares to be forfeited if overallotment option is not exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PromissoryNotePayableFullyUtilizedAfterIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represent fully utilized after the IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PromissoryNotePayableFullyUtilizedAfterIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contractual monthly amount to be paid for support services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_WorkingCapitalLoanOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital loan, outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_WorkingCapitalLoanOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 850<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of share of other common stock instruments held by shareholder. Includes, but is not limited to, exchangeable share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment made to pay deferred cash remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=paii_PromissoryNoteRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=paii_PromissoryNoteRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=paii_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=paii_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=paii_InitialBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=paii_InitialBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 18, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PercentageOfCashDiscountOnInitialPublicOffering', window );">Percentage of cash discount on initial public offering</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate amount (in Dollars)</a></td>
<td class="nump">$ 2,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PercentageOfAdditionalFeeOnInitialPublicOffering', window );">Percentage of additional fee on initial public offering</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PercentageOfInitialPublicOfferingSoldToUnderwriters', window );">Percentage of initial public offering sold to underwriters</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_DeferredDiscount', window );">Deferred discount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,399,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_DeferredDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deferred discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_DeferredDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PercentageOfAdditionalFeeOnInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional fee on initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PercentageOfAdditionalFeeOnInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PercentageOfCashDiscountOnInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount on initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PercentageOfCashDiscountOnInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PercentageOfInitialPublicOfferingSoldToUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of initial public offering sold to underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PercentageOfInitialPublicOfferingSoldToUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Deficit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>Jul. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Ordinary shares vote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Ordinary shares issued value (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ConvertibleStockConversionRatio1', window );">Ratio to be applied to the stock in the conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice', window );">Price threshold of newly issued stock to cause adjustment of exercise warrant price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance', window );">Percentage of equity proceeds from issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption', window );">Target share price of warrants or rights for redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance', window );">Percentage of warrant exercise price adjusted to price received in new issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances', window );">Percentage of warrant exercise price adjusted to price received in new issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant', window );">Minimum threshold written notice period for redemption of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant', window );">Redemption price per warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,070,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,070,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,020,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,020,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Ordinary shares vote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of shares in each unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination', window );">Warrants exercisable term after the completion of a business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice', window );">Price threshold of newly issued stock to cause adjustment of exercise warrant price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_CommonStockThresholdTradingDay', window );">Minimum number of trading days</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Number of shares subject to possible redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,041,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_RedemptionOfPublicWarrants', window );">Redemption of Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice', window );">Redemption trigger price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger', window );">Stock price trigger for redemption of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,225,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,225,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=paii_SponsorMember', window );">Sponsor [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of forfeited shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_FounderShareMember', window );">Founder Shares [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,255,952<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Ordinary shares issued value (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of shares in each unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination', window );">Threshold period for filling registration statement after business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Founder Shares [Member] | Class B Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">946,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of shares in each unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_InitialBusinessCombinationTerm', window );">Initial business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering', window );">Warrants exercisable term from closing of ipo</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder's Deficit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination', window );">Threshold period for effective within statement after business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This number includes an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum threshold period during which a written notice is required for redemption of warrants, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, target share price of warrants or rights for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_CommonStockThresholdTradingDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents threshold trading days of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_CommonStockThresholdTradingDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ConvertibleStockConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio to be applied to the stock in a conversion of convertible stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ConvertibleStockConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_InitialBusinessCombinationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial business combination term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_InitialBusinessCombinationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant exercise price adjusted to price received in new issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant exercise price adjusted to price received in new issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price threshold of newly issued stock to cause adjustment of exercise warrant price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of threshold of newly issued stock to cause adjustment of exercise warrant price, percentage of equity proceeds from issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_RedemptionOfPublicWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of public warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_RedemptionOfPublicWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for effective within statement after business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period for filling registration statement after business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The warrants exercisable term after the completion of a business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The warrants exercisable term from the closing of the initial public offering, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>paii_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=paii_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=paii_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=paii_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_FounderShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=paii_FounderShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment description</a></td>
<td class="text">The Company&#8217;s CODM has been identified as the Chief Financial Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reportable segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information, Operating Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">$ 204,013,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">628,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividends and interest earned on marketable securities held in the Trust Account</a></td>
<td class="nump">$ 3,601,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details) - IPO [Member] - Public Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of public warrants | $</a></td>
<td class="nump">$ 3,724,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">$ 204,013,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">204,013,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Valuation of the Public Warrants (Details) - Public Warrants [Member]<br></strong></div></th>
<th class="th"><div>Jul. 18, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Market price of public stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Valuation of the Public Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Market assumptions used in valuation of public warrants</a></td>
<td class="nump">9.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term (years) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Valuation of the Public Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Market assumptions used in valuation of public warrants</a></td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Valuation of the Public Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Market assumptions used in valuation of public warrants</a></td>
<td class="nump">0.0377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Valuation of the Public Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Market assumptions used in valuation of public warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Valuation of the Public Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Market assumptions used in valuation of public warrants</a></td>
<td class="nump">0.0911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=paii_ProbabilityOfMergerMember', window );">Probability of Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Valuation of the Public Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Market assumptions used in valuation of public warrants</a></td>
<td class="nump">0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=paii_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=paii_ProbabilityOfMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=paii_ProbabilityOfMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>101</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995300 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet</Role>
      <ShortName>Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Balance Sheet (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals</Role>
      <ShortName>Balance Sheet (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Statement of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations</Role>
      <ShortName>Statement of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Statement of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals</Role>
      <ShortName>Statement of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Statement - Statement of Changes in Shareholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit</Role>
      <ShortName>Statement of Changes in Shareholders??? Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Statement - Statement of Changes in Shareholders??? Deficit (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals</Role>
      <ShortName>Statement of Changes in Shareholders??? Deficit (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Statement - Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows</Role>
      <ShortName>Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations</Role>
      <ShortName>Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Initial Public Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering</Role>
      <ShortName>Initial Public Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Shareholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit</Role>
      <ShortName>Shareholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996319 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996320 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996321 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996322 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996323 - Disclosure - Organization and Business Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails</Role>
      <ShortName>Organization and Business Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996324 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996325 - Disclosure - Summary of Significant Accounting Policies - Schedule of Class A Ordinary Shares Subject to Possible Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Class A Ordinary Shares Subject to Possible Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996326 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996327 - Disclosure - Initial Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails</Role>
      <ShortName>Initial Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996328 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996329 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996330 - Disclosure - Shareholders??? Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails</Role>
      <ShortName>Shareholders??? Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996331 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996332 - Disclosure - Segment Information - Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails</Role>
      <ShortName>Segment Information - Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996333 - Disclosure - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails</Role>
      <ShortName>Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996334 - Disclosure - Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ea0282458-10k_pyrophyte2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996335 - Disclosure - Fair Value Measurement - Schedule of Valuation of the Public Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Valuation of the Public Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0282458-10k_pyrophyte2.htm">ea0282458-10k_pyrophyte2.htm</File>
    <File>paii-20251231.xsd</File>
    <File>paii-20251231_cal.xml</File>
    <File>paii-20251231_def.xml</File>
    <File>paii-20251231_lab.xml</File>
    <File>paii-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="262">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0282458-10k_pyrophyte2.htm": {
   "nsprefix": "paii",
   "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "ea0282458-10k_pyrophyte2.htm"
     ]
    },
    "schema": {
     "local": [
      "paii-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "paii-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "paii-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "paii-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "paii-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 172,
   "keyCustom": 83,
   "axisStandard": 11,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 15,
   "hidden": {
    "total": 95,
    "http://fasb.org/us-gaap/2025": 62,
    "http://pyrophyteacquisitioncorp2.com/20251231": 28,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 101,
   "entityCount": 1,
   "segmentCount": 41,
   "elementCount": 481,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 262,
    "http://xbrl.sec.gov/dei/2025": 48,
    "http://xbrl.sec.gov/cyd/2025": 6,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover",
     "longName": "995300 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation",
     "longName": "995301 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
     "longName": "995302 - Statement - Balance Sheet",
     "shortName": "Balance Sheet",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:Cash",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
     "longName": "995303 - Statement - Balance Sheet (Parentheticals)",
     "shortName": "Balance Sheet (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "uref_246701486",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1879775354",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "uref_246701486",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
     "longName": "995304 - Statement - Statement of Operations",
     "shortName": "Statement of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals",
     "longName": "995305 - Statement - Statement of Operations (Parentheticals)",
     "shortName": "Statement of Operations (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "cref_1953308297",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
      "unitRef": "uref_779585586",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "i",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
     "longName": "995306 - Statement - Statement of Changes in Shareholders\u2019 Deficit",
     "shortName": "Statement of Changes in Shareholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "cref_1257381007",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1257381007",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
     "longName": "995307 - Statement - Statement of Changes in Shareholders\u2019 Deficit (Parentheticals)",
     "shortName": "Statement of Changes in Shareholders\u2019 Deficit (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "cref_1953308297",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
      "unitRef": "uref_779585586",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "i",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows",
     "longName": "995308 - Statement - Statement of Cash Flows",
     "shortName": "Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1330416410",
      "name": "paii:FormationAndOperatingExpensesPaidInExchangeForFounderShares",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations",
     "longName": "995309 - Disclosure - Organization and Business Operations",
     "shortName": "Organization and Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies",
     "longName": "995310 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering",
     "longName": "995311 - Disclosure - Initial Public Offering",
     "shortName": "Initial Public Offering",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "paii:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "paii:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions",
     "longName": "995312 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies",
     "longName": "995313 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit",
     "longName": "995314 - Disclosure - Shareholders\u2019 Deficit",
     "shortName": "Shareholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation",
     "longName": "995315 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement",
     "longName": "995316 - Disclosure - Fair Value Measurement",
     "shortName": "Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SubsequentEvents",
     "longName": "995317 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure",
     "longName": "995318 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies",
     "longName": "996319 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996320 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables",
     "longName": "996321 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables",
     "longName": "996322 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_619992257",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
     "longName": "996323 - Disclosure - Organization and Business Operations (Details)",
     "shortName": "Organization and Business Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "cref_1491172312",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1330416410",
      "name": "paii:TransactionCosts",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996324 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:Cash",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails",
     "longName": "996325 - Disclosure - Summary of Significant Accounting Policies - Schedule of Class A Ordinary Shares Subject to Possible Redemption (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Class A Ordinary Shares Subject to Possible Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "cref_73988315",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_73988315",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails",
     "longName": "996326 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "cref_1891084432",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1891084432",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
     "longName": "996327 - Disclosure - Initial Public Offering (Details)",
     "shortName": "Initial Public Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "cref_1330416410",
      "name": "paii:ExercisableWarrantsTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "paii:InitialPublicOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1330416410",
      "name": "paii:ExercisableWarrantsTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "paii:InitialPublicOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
     "longName": "996328 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "cref_1595368894",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "uref_779585586",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1595368894",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "uref_779585586",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails",
     "longName": "996329 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "cref_1491172312",
      "name": "paii:PercentageOfCashDiscountOnInitialPublicOffering",
      "unitRef": "uref_193655120",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1491172312",
      "name": "paii:PercentageOfCashDiscountOnInitialPublicOffering",
      "unitRef": "uref_193655120",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
     "longName": "996330 - Disclosure - Shareholders\u2019 Deficit (Details)",
     "shortName": "Shareholders\u2019 Deficit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "uref_779585586",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails",
     "longName": "996331 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1330416410",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails",
     "longName": "996332 - Disclosure - Segment Information - Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets (Details)",
     "shortName": "Segment Information - Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
     "longName": "996333 - Disclosure - Fair Value Measurement (Details)",
     "shortName": "Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "cref_246701486",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "uref_246701486",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_200602150",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "996334 - Disclosure - Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "cref_333300986",
      "name": "us-gaap:AssetsHeldInTrustNoncurrent",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1093905091",
      "name": "us-gaap:AssetsHeldInTrustNoncurrent",
      "unitRef": "uref_200602150",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails",
     "longName": "996335 - Disclosure - Fair Value Measurement - Schedule of Valuation of the Public Warrants (Details)",
     "shortName": "Fair Value Measurement - Schedule of Valuation of the Public Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "cref_1064750139",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "uref_193655120",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1064750139",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "uref_193655120",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282458-10k_pyrophyte2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r596"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r596",
      "r812"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r726",
      "r727",
      "r728",
      "r729",
      "r785",
      "r815"
     ]
    },
    "paii_AdditionalUnitsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "AdditionalUnitsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional units issued",
        "documentation": "Represent the additional units issued during period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of Private Placement Warrants",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r17",
      "r45"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative fees",
        "label": "Administrative Fees Expense",
        "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r813",
      "r814"
     ]
    },
    "paii_AggregateUnsecuredPromissoryAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "AggregateUnsecuredPromissoryAmount",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate unsecured promissory amount (in Dollars)",
        "label": "Aggregate Unsecured Promissory Amount",
        "documentation": "Aggregate unsecured promissory amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r648",
      "r681"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r684"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r676",
      "r685",
      "r689",
      "r697"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r262",
      "r272"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r55",
      "r70",
      "r88",
      "r89",
      "r90",
      "r127",
      "r140",
      "r145",
      "r148",
      "r155",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r346",
      "r348",
      "r392",
      "r420",
      "r421",
      "r424",
      "r495",
      "r566",
      "r567",
      "r576",
      "r596",
      "r598",
      "r599",
      "r610",
      "r743",
      "r744",
      "r796"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current, Total",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r75",
      "r88",
      "r89",
      "r90",
      "r155",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r346",
      "r348",
      "r392",
      "r596",
      "r743",
      "r744",
      "r796"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Asset",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrustCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsHeldInTrustCurrent",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities held in trust account",
        "label": "Asset, Held-in-Trust, Current",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722"
     ]
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsHeldInTrustNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 107.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities held in Trust Account",
        "label": "Asset, Held-in-Trust, Noncurrent",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r634"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r634"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r634"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting [Text Block]",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r445",
      "r583",
      "r584",
      "r781",
      "r783",
      "r784"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r445",
      "r583",
      "r584",
      "r781",
      "r783",
      "r784"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of initial business combination",
        "label": "Business Combination, Achieved in Stages, Preacquisition and Acquired Equity Interests in Acquiree, Percentage",
        "documentation": "Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash",
        "terseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r427",
      "r470",
      "r490",
      "r596",
      "r598",
      "r599",
      "r610",
      "r717"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash - end of period",
        "periodStartLabel": "Cash - beginning of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r39",
      "r85"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r39"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r804"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassAOrdinarySharesIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassAOrdinarySharesIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A ordinary shares issuance costs",
        "documentation": "The amount of class A ordinary shares issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassAOrdinarySharesParValue00001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassAOrdinarySharesParValue00001PerShareMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A ordinary shares, par value $0.0001 per share",
        "label": "Class AOrdinary Shares Par Value00001 Per Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassAOrdinarySharesSubjectToPossibleRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassAOrdinarySharesSubjectToPossibleRedemptionMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A Ordinary Shares Subject to Possible Redemption",
        "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption",
        "label": "Class A ordinary shares subject to possible redemption [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassBNonredeemableOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassBNonredeemableOrdinarySharesMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-Redeemable Class B Ordinary Shares [Member]",
        "terseLabel": "Class B Non-Redeemable Ordinary Shares",
        "label": "Class B non-redeemable ordinary shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering [Abstract]",
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r71",
      "r72",
      "r73",
      "r88",
      "r90",
      "r114",
      "r115",
      "r122",
      "r124",
      "r129",
      "r130",
      "r155",
      "r173",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r185",
      "r186",
      "r188",
      "r189",
      "r191",
      "r195",
      "r198",
      "r199",
      "r202",
      "r205",
      "r212",
      "r392",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r482",
      "r503",
      "r525",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r716",
      "r723",
      "r724",
      "r730"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering [Line Items]",
        "verboseLabel": "Shareholder's Deficit [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r129",
      "r188",
      "r198",
      "r199",
      "r200",
      "r202",
      "r205",
      "r210",
      "r212",
      "r356",
      "r450",
      "r451",
      "r452",
      "r453",
      "r577",
      "r716",
      "r721",
      "r723"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "paii_ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading period after completion of business combination",
        "label": "Class of Warrant or Right, Blackout Trading Period After Completion of Business Combination",
        "documentation": "Trading period after completion of business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price per warrant",
        "documentation": "Redemption price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ordinary share at a price per share",
        "terseLabel": "Price per warrant (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r213"
     ]
    },
    "paii_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum threshold written notice period for redemption of warrants",
        "label": "Class Of Warrant Or Right MinimumThreshold Written Notice Period For Redemption Of Warrant",
        "documentation": "The minimum threshold period during which a written notice is required for redemption of warrants, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrant exercisable",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of aggregate share",
        "label": "Private sale of warrants",
        "verboseLabel": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price trigger for redemption of warrants",
        "label": "Class Of Warrant Or Right Redemption Of Warrants Or Right Stock Price Trigger",
        "documentation": "Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption trigger price (in Dollars per share)",
        "label": "Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price",
        "documentation": "Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days for redemption of warrants",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days",
        "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days for redemption of warrants",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days",
        "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "paii_ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target share price of warrants or rights for redemption",
        "label": "Class of Warrant or Right, Target Share Price of Warrants or Rights For Redemption",
        "documentation": "Class of warrant or right, target share price of warrants or rights for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ClassOfWarrantsAndRightsIssuedPricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ClassOfWarrantsAndRightsIssuedPricePerWarrant",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants purchase price",
        "label": "Class Of Warrants And Rights Issued Price Per Warrant",
        "documentation": "Class of warrants and rights issued, price per warrant."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Business Operations [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 5)",
        "label": "Commitments and Contingencies (Note 5)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r50",
      "r426",
      "r481"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r167",
      "r168",
      "r548",
      "r740",
      "r742"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A Ordinary Shares [Member]",
        "terseLabel": "Class A Ordinary Shares",
        "netLabel": "Class A",
        "label": "Class A Ordinary Shares",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Ordinary Shares [Member]",
        "terseLabel": "Class B Ordinary Shares",
        "netLabel": "Class B",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r726",
      "r727",
      "r729",
      "r785",
      "r811",
      "r815"
     ]
    },
    "us-gaap_CommonStockOtherValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockOtherValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in Dollars)",
        "label": "Common Stock, Other Value, Outstanding",
        "documentation": "Value of share of other common stock instruments held by shareholder. Includes, but is not limited to, exchangeable share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r482"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r482",
      "r501",
      "r815",
      "r816"
     ]
    },
    "paii_CommonStockStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "CommonStockStockPriceTrigger",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock trigger price",
        "label": "Common Stock, Stock Price Trigger",
        "documentation": "Common stock trigger price."
       }
      }
     },
     "auth_ref": []
    },
    "paii_CommonStockThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "CommonStockThresholdConsecutiveTradingDays",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading day threshold",
        "label": "Common Stock, Threshold Consecutive Trading Days",
        "documentation": "The number of consecutive trading days used to observe the share price."
       }
      }
     },
     "auth_ref": []
    },
    "paii_CommonStockThresholdTradingDay": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "CommonStockThresholdTradingDay",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum number of trading days",
        "label": "Common Stock, Threshold Trading Day",
        "documentation": "Represents threshold trading days of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "paii_CommonStockThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "CommonStockThresholdTradingDays",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum number of trading days",
        "label": "Common Stock, Threshold Trading Days",
        "documentation": "Common stock, threshold trading days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r186",
      "r194",
      "r429",
      "r596"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares vote",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391"
     ]
    },
    "paii_ConvertibleStockConversionRatio1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ConvertibleStockConversionRatio1",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ratio to be applied to the stock in the conversion",
        "documentation": "The ratio to be applied to the stock in a conversion of convertible stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r706"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r707"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r703"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r702"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r704"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r705"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r705"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount granted to directors (in Dollars)",
        "label": "Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount",
        "documentation": "Amount of commitment made to pay deferred cash remuneration."
       }
      }
     },
     "auth_ref": []
    },
    "paii_DeferredDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "DeferredDiscount",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred discount (in Dollars)",
        "label": "Deferred Discount",
        "documentation": "Represent the amount of deferred discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Offering costs",
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "paii_DeferredUnderwritingFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "DeferredUnderwritingFeesPayable",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred underwriting fees payable",
        "label": "Deferred underwriting fees payable",
        "documentation": "Deferred underwriting fees payable."
       }
      }
     },
     "auth_ref": []
    },
    "paii_DeferredUnderwritingFeesPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "DeferredUnderwritingFeesPayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred underwriting fees payable",
        "verboseLabel": "Deferred underwriting fees",
        "label": "Deferred Underwriting Fees Payable Noncurrent",
        "documentation": "Deferred underwriting commission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r94",
      "r110",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r634"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r634",
      "r677"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Ordinary Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net income per share",
        "terseLabel": "Basic net income per share",
        "label": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r82",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r114",
      "r122",
      "r123",
      "r124",
      "r126",
      "r184",
      "r261",
      "r288",
      "r344",
      "r371",
      "r372",
      "r419",
      "r436",
      "r557"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic Earnings Per Share",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Ordinary Share [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r122",
      "r124"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net income per share",
        "terseLabel": "Diluted net income per share",
        "label": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r82",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r114",
      "r122",
      "r123",
      "r124",
      "r126",
      "r184",
      "r261",
      "r288",
      "r344",
      "r371",
      "r372",
      "r419",
      "r436",
      "r557"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted Earnings Per Share",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income Per Ordinary Share",
        "label": "Net loss per Class B Ordinary Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r125"
     ]
    },
    "paii_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Growth Company Status",
        "label": "Emerging Growth Company Status Policy Text Block",
        "documentation": "The entire disclosure of accounting policy for emerging growth company status."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Deficit [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r60",
      "r61",
      "r62",
      "r79",
      "r80",
      "r81",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r128",
      "r156",
      "r157",
      "r166",
      "r183",
      "r214",
      "r261",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r343",
      "r344",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r435",
      "r439",
      "r440",
      "r441",
      "r458",
      "r525"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r648",
      "r681"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r645",
      "r678"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposited amount",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r549"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "paii_ExercisableWarrantsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ExercisableWarrantsTerm",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable warrants term",
        "label": "Exercisable Warrants Term",
        "documentation": "Exercisable warrant term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Public Warrants at issuance",
        "verboseLabel": "Fair value of public warrants",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurement [Line Items]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r383",
      "r590"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r383",
      "r590"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r786",
      "r787",
      "r791"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation of the Public Warrants [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r587",
      "r588",
      "r591"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r587",
      "r588",
      "r591"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation of the Public Warrants",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r591"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r383",
      "r384",
      "r389",
      "r411",
      "r412",
      "r413",
      "r552",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r590",
      "r591",
      "r595"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r590",
      "r789",
      "r792"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENT",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r418",
      "r590",
      "r592"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r216",
      "r221",
      "r223",
      "r375",
      "r383",
      "r389",
      "r411",
      "r552",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r590",
      "r595"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r216",
      "r221",
      "r223",
      "r225",
      "r375",
      "r376",
      "r383",
      "r389",
      "r412",
      "r552",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r590",
      "r595"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r389",
      "r413",
      "r552",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r590",
      "r591",
      "r595"
     ]
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation of the Public Warrants [Abstract]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r590",
      "r789",
      "r792"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r383",
      "r384",
      "r389",
      "r411",
      "r412",
      "r413",
      "r552",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r590",
      "r591",
      "r595"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r792"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r685"
     ]
    },
    "paii_FormationAndOperatingExpensesPaidInExchangeForFounderShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "FormationAndOperatingExpensesPaidInExchangeForFounderShares",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Formation and operating expenses paid in exchange for Founder Shares",
        "documentation": "The amount of formation and operating expenses paid in exchange for founder shares."
       }
      }
     },
     "auth_ref": []
    },
    "paii_FounderShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "FounderShareMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder Shares [Member]",
        "label": "Founder Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r505"
     ]
    },
    "paii_GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern, Liquidity and Capital Resources",
        "label": "Going Concern, Liquidity and Capital Resources [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting going concern, liquidity and capital resources."
       }
      }
     },
     "auth_ref": []
    },
    "paii_GrantedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "GrantedPricePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted price per share (in Dollars per share)",
        "label": "Granted Price Per Share",
        "documentation": "Granted price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r634"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsAttributableToParentAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator: Net income allocable to Ordinary Shares",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r449"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r676",
      "r685",
      "r689",
      "r697"
     ]
    },
    "paii_InitialBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InitialBusinessCombinationMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Business Combination [Member]",
        "label": "Initial Business Combination Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_InitialBusinessCombinationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InitialBusinessCombinationTerm",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial business combination",
        "label": "Initial Business Combination Term",
        "documentation": "Initial business combination term."
       }
      }
     },
     "auth_ref": []
    },
    "paii_InitialPublicOfferingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InitialPublicOfferingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "paii_InitialPublicOfferingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InitialPublicOfferingDetailsTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "paii_InitialPublicOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InitialPublicOfferingTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INITIAL PUBLIC OFFERING",
        "label": "Initial Public Offering Text Block",
        "documentation": "The entire disclosure for initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "paii_InitialPublicOfferings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InitialPublicOfferings",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering",
        "label": "Initial Public Offerings",
        "documentation": "Initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r701"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r701"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r701"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income on cash account",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "paii_InterestToPayDissolutionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "InterestToPayDissolutionExpenses",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest to pay liquidation expenses",
        "label": "Interest To Pay Dissolution Expenses",
        "documentation": "Interest to pay dissolution expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends and interest earned on marketable securities held in the Trust Account",
        "verboseLabel": "Dividends and interest earned on marketable securities held in the Trust Account",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "paii_IssuanceOfPrivatePlacementWarrantsWithRelatedParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "IssuanceOfPrivatePlacementWarrantsWithRelatedParty",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of private palcement warrants",
        "label": "Issuance Of Private Placement Warrants With Related Party",
        "documentation": "The shares represent issuance of private palcement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Total",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r88",
      "r89",
      "r90",
      "r155",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r347",
      "r348",
      "r349",
      "r392",
      "r480",
      "r559",
      "r576",
      "r610",
      "r743",
      "r796",
      "r797"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders\u2019 Deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r51",
      "r432",
      "r596",
      "r598",
      "r599",
      "r721",
      "r725",
      "r738",
      "r794"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r68",
      "r88",
      "r89",
      "r90",
      "r155",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r347",
      "r348",
      "r349",
      "r392",
      "r596",
      "r743",
      "r796",
      "r797"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationScheduleofSeveralKeyMetricsIncludedInNetIncomeorLossandTotalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities held in Trust Account",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r719"
     ]
    },
    "paii_MarketableSecuritiesHeldInTrustAccountPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "MarketableSecuritiesHeldInTrustAccountPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities Held in Trust Account",
        "label": "Marketable Securities Held In Trust Account [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for marketable securities held in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "paii_MaximumLoansConvertibleIntoWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "MaximumLoansConvertibleIntoWarrants",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum loans convertible into warrants",
        "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r169",
      "r170",
      "r171",
      "r172",
      "r227",
      "r254",
      "r255",
      "r256",
      "r274",
      "r378",
      "r416",
      "r437",
      "r438",
      "r444",
      "r472",
      "r473",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r573",
      "r577",
      "r585",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r745",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (years) [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r591",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market price of public stock [Member]",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r376",
      "r377",
      "r378",
      "r587",
      "r588",
      "r589",
      "r591"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r587",
      "r588",
      "r589",
      "r591"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r169",
      "r170",
      "r171",
      "r172",
      "r227",
      "r254",
      "r255",
      "r256",
      "r274",
      "r378",
      "r416",
      "r437",
      "r438",
      "r444",
      "r472",
      "r473",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r573",
      "r577",
      "r585",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r597",
      "r745",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "paii_MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding voting securities",
        "label": "Minimum Ownership Percentage To Be Acquired For Not To Be Registered As An Investment Company",
        "documentation": "Minimum ownership percentage to be acquired for not to be registered as an investment company."
       }
      }
     },
     "auth_ref": []
    },
    "paii_MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fair market value",
        "label": "Minimum Percentage Of Fair Market Value Of Business Acquisition To Trust Account Balance",
        "documentation": "Minimum percentage of fair market value of business acquisition to trust account balance."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation, Total",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation, Total",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net income",
        "totalLabel": "Net income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r41",
      "r53",
      "r62",
      "r66",
      "r76",
      "r77",
      "r81",
      "r88",
      "r89",
      "r90",
      "r93",
      "r98",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r120",
      "r155",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r187",
      "r190",
      "r196",
      "r261",
      "r288",
      "r344",
      "r372",
      "r392",
      "r434",
      "r502",
      "r523",
      "r524",
      "r554",
      "r555",
      "r556",
      "r608",
      "r743"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToParentDilutedAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator: Net income allocable to Ordinary Shares",
        "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income allocable to Ordinary Shares",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r83",
      "r102",
      "r103",
      "r104",
      "r105",
      "r111",
      "r112",
      "r121",
      "r124",
      "r187",
      "r190",
      "r196",
      "r344"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income allocable to Ordinary Shares",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r113",
      "r116",
      "r117",
      "r118",
      "r119",
      "r121",
      "r124"
     ]
    },
    "paii_NetProceedsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NetProceedsAmount",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Net Proceeds Amount",
        "documentation": "The amount of net proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NewlyAdjustedIssueSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NewlyAdjustedIssueSharePrice",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public per share (in Dollars per share)",
        "label": "Newly Adjusted Issue Share Price",
        "documentation": "Newly adjusted issue share price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r676",
      "r685"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "paii_NumberOfDaysAfterInitialBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfDaysAfterInitialBusinessCombination",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum number of days after initial Business Combination",
        "label": "Number of Days After Initial Business Combination",
        "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r571",
      "r733"
     ]
    },
    "paii_NumberOfSharesInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfSharesInEachUnit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares",
        "documentation": "Number Of Shares In Each Unit."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NumberOfSharesNotSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfSharesNotSubjectToForfeiture",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares Not Subject to Forfeiture",
        "documentation": "Number of shares not subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subjected to forfeiture if over allotment options is not exercised",
        "label": "Number Of Shares Subjected To Forfeiture If Over Allotment Option Is Not Exercised",
        "documentation": "Number of shares subjected to forfeiture if over allotment options is not exercised."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares subjected to forfeiture if over allotment options is not exercised",
        "documentation": "Number of shares subjected to forfeiture if over allotment options is not exercised."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares to be forfeited",
        "label": "Number Of Shares To Be Forfeited If Overallotment Option Is Not Exercised",
        "documentation": "Number of shares to be forfeited if overallotment option is not exercised."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Units Subjected to Forfeiture if Over Allotment Option Is Partially Exercised",
        "documentation": "Number of units subjected to forfeiture if over allotment options is partially exercised."
       }
      }
     },
     "auth_ref": []
    },
    "paii_NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Units Subjected To Forfeiture If Over Allotment Options Is Partially Exercised",
        "terseLabel": "Number of units subjected to forfeiture if over allotment options is partially exercised",
        "documentation": "Number of units subjected to forfeiture if over allotment options is partially exercised."
       }
      }
     },
     "auth_ref": []
    },
    "paii_OfferingCostsPaidThroughTheIssuanceOfFounderShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "OfferingCostsPaidThroughTheIssuanceOfFounderShares",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs paid through the issuance of Founder Shares",
        "documentation": "Represents the amount of offering costs paid through the issuance of Founder Shares."
       }
      }
     },
     "auth_ref": []
    },
    "paii_OfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "OfferingCostsPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering Costs",
        "label": "Offering Costs [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss), Total",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r554",
      "r556",
      "r560",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND BUSINESS OPERATIONS",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r63",
      "r64",
      "r65",
      "r446",
      "r447"
     ]
    },
    "paii_OrganizationandBusinessOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "OrganizationandBusinessOperationsDetailsTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Operations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets amount",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r69",
      "r423",
      "r567",
      "r598",
      "r599",
      "r610"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r683"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r686"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r686"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "verboseLabel": "Over-Allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment of cash into Trust Account",
        "label": "Payments for (Proceeds from) Investments, Total",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Offering costs paid",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "paii_PercentageOfAdditionalFeeOnInitialPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PercentageOfAdditionalFeeOnInitialPublicOffering",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of additional fee on initial public offering",
        "label": "Percentage Of Additional Fee On Initial Public Offering",
        "documentation": "Percentage of additional fee on initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PercentageOfCashDiscountOnInitialPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PercentageOfCashDiscountOnInitialPublicOffering",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cash discount on initial public offering",
        "label": "Percentage Of Cash Discount On Initial Public Offering",
        "documentation": "Percentage of discount on initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PercentageOfInitialPublicOfferingSoldToUnderwriters": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PercentageOfInitialPublicOfferingSoldToUnderwriters",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of initial public offering sold to underwriters",
        "label": "Percentage Of Initial Public Offering Sold To Underwriters",
        "documentation": "Percentage of initial public offering sold to underwriters."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of warrant exercise price adjusted to price received in new issuance",
        "label": "Percentage of Warrants Exercise Price Adjusted to Price Received in New Issuance",
        "documentation": "Percentage of warrant exercise price adjusted to price received in new issuance."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of warrant exercise price adjusted to price received in new issuance",
        "label": "Percentage Of Warrants Exercise Price Adjusted To Price Received In New Issuances",
        "documentation": "Percentage of warrant exercise price adjusted to price received in new issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r811",
      "r815"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preference shares, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r198"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preference shares, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r482"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preference shares issued",
        "terseLabel": "Preference shares, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r198"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preference shares outstanding",
        "terseLabel": "Preference shares, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r482",
      "r501",
      "r815",
      "r816"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r186",
      "r193",
      "r428",
      "r596"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r158",
      "r159",
      "r553"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 119.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance - long term",
        "label": "Prepaid Expense, Noncurrent, Total",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "paii_PrepaidExpensePaidThroughPromissoryNoteRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PrepaidExpensePaidThroughPromissoryNoteRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs paid through promissory note - related party",
        "label": "Prepaid Expense Paid Through Promissory Note Related Party",
        "documentation": "Prepaid expense paid through promissory note - related party."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PriceIssuedPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PriceIssuedPerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Price Issued Per Share",
        "documentation": "Per share issued."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price threshold of newly issued stock to cause adjustment of exercise warrant price",
        "label": "Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price",
        "documentation": "Price threshold of newly issued stock to cause adjustment of exercise warrant price."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of equity proceeds from issuance",
        "label": "Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price, Percentage of Equity Proceeds From Issuance",
        "documentation": "Price of threshold of newly issued stock to cause adjustment of exercise warrant price, percentage of equity proceeds from issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Warrant [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants issued through forgiveness of promissory note - related party",
        "documentation": "The amount of private placement warrants issued through forgiveness of promissory note - related party."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants [Member]",
        "label": "Private Placement Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_ProbabilityOfMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ProbabilityOfMergerMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probability of Merger [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/CommitmentsandContingenciesDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate amount (in Dollars)",
        "terseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Private Placement Warrants",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds of warrant",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Units",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "paii_PromissoryNotePayableFullyUtilizedAfterIPO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PromissoryNotePayableFullyUtilizedAfterIPO",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fully utilized after the IPO",
        "label": "Promissory Note Payable Fully Utilized After IPO",
        "documentation": "The amount represent fully utilized after the IPO."
       }
      }
     },
     "auth_ref": []
    },
    "paii_PromissoryNoteRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PromissoryNoteRelatedPartyMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Related Party [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "paii_PublicWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PublicWarrantMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrant [Member]",
        "label": "Public Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrants [Member]",
        "label": "Public Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r169",
      "r170",
      "r171",
      "r172",
      "r215",
      "r227",
      "r254",
      "r255",
      "r256",
      "r260",
      "r274",
      "r378",
      "r414",
      "r415",
      "r416",
      "r437",
      "r438",
      "r444",
      "r472",
      "r473",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r573",
      "r577",
      "r585",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r602",
      "r741",
      "r745",
      "r789",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r169",
      "r170",
      "r171",
      "r172",
      "r215",
      "r227",
      "r254",
      "r255",
      "r256",
      "r260",
      "r274",
      "r378",
      "r414",
      "r415",
      "r416",
      "r437",
      "r438",
      "r444",
      "r472",
      "r473",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r573",
      "r577",
      "r585",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r602",
      "r741",
      "r745",
      "r789",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803"
     ]
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Subscription Receivable",
        "label": "Receivables from Stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r645",
      "r678"
     ]
    },
    "paii_RedeemableClassAOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "RedeemableClassAOrdinarySharesMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Class A Ordinary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "paii_RedemptionOfPublicWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "RedemptionOfPublicWarrants",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Public Warrants",
        "documentation": "Redemption of public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r93",
      "r154",
      "r222",
      "r226",
      "r405",
      "r406",
      "r425",
      "r433",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r500",
      "r532",
      "r813"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r93",
      "r405",
      "r406",
      "r795"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r93",
      "r795"
     ]
    },
    "paii_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses per month",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party Per Month",
        "documentation": "The contractual monthly amount to be paid for support services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r93",
      "r154",
      "r405",
      "r406",
      "r407",
      "r506",
      "r507",
      "r510"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r93",
      "r154",
      "r222",
      "r226",
      "r405",
      "r406",
      "r425",
      "r433",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r500",
      "r532",
      "r795",
      "r813"
     ]
    },
    "paii_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r408",
      "r455",
      "r456",
      "r457",
      "r508",
      "r509",
      "r510",
      "r529",
      "r531"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r679"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r680"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r654",
      "r687"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r45",
      "r431",
      "r442",
      "r443",
      "r454",
      "r483",
      "r596"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r156",
      "r157",
      "r166",
      "r183",
      "r261",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r343",
      "r344",
      "r359",
      "r361",
      "r362",
      "r364",
      "r370",
      "r399",
      "r400",
      "r439",
      "r441",
      "r458",
      "r815"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder shares",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sold per unit (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ScheduleOfClassAOrdinarySharesSubjectToPossibleRedemptionTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Class A Ordinary Shares Subject to Possible Redemption [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Net Income Per Ordinary Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Ordinary Share [Table]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r122",
      "r124"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r565",
      "r572"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment description",
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r562",
      "r569"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r127",
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r561",
      "r563",
      "r564",
      "r566",
      "r568",
      "r570",
      "r571"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationOperatingIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Several Key Metrics Included In Net Income or Loss and Total Assets [Abstract]",
        "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeiture of Class B ordinary shares (in Shares)",
        "verboseLabel": "Number of forfeited shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r232",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "paii_ShareSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ShareSubscriptionReceivable",
     "crdr": "debit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share subscription receivable",
        "terseLabel": "Share subscription receivable",
        "label": "Share Subscription Receivable",
        "documentation": "Represents the amount of share subscription receivable."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ShareholdersDeficitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ShareholdersDeficitDetailsTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder's Deficit (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per unit (in Dollars per share)",
        "netLabel": "Shares issued price per share (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)",
        "label": "Number of shares in each unit",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "paii_SharesIssuedSharesShareBasedPaymentArrangementForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "SharesIssuedSharesShareBasedPaymentArrangementForfeited",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining underwriters forfeited shares",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "paii_SharesRedemptionObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "SharesRedemptionObligationPercentage",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of public shares",
        "label": "Shares Redemption Obligation Percentage",
        "documentation": "Shares redemption obligation percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption",
        "label": "Ordinary Shares Subject to Possible Redemption",
        "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "paii_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "SponsorMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsor [Member]",
        "verboseLabel": "Sponsor",
        "label": "Sponsor Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r71",
      "r72",
      "r73",
      "r88",
      "r90",
      "r114",
      "r115",
      "r122",
      "r124",
      "r129",
      "r130",
      "r155",
      "r173",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r185",
      "r186",
      "r188",
      "r189",
      "r191",
      "r195",
      "r198",
      "r199",
      "r202",
      "r205",
      "r212",
      "r392",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r482",
      "r503",
      "r525",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r716",
      "r723",
      "r724",
      "r730"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r32",
      "r33",
      "r60",
      "r61",
      "r62",
      "r79",
      "r80",
      "r81",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r128",
      "r156",
      "r157",
      "r166",
      "r183",
      "r214",
      "r261",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r343",
      "r344",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r435",
      "r439",
      "r440",
      "r441",
      "r458",
      "r525"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r128",
      "r185",
      "r186",
      "r188",
      "r191",
      "r400",
      "r417",
      "r448",
      "r459",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r504",
      "r505",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r555",
      "r556",
      "r603",
      "r813"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r128",
      "r154",
      "r185",
      "r186",
      "r188",
      "r191",
      "r400",
      "r417",
      "r448",
      "r459",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r504",
      "r505",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r555",
      "r556",
      "r603",
      "r813"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatutoryAccountingPracticesLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]",
        "label": "Statutory Accounting Practices [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r649",
      "r682"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeiture of Class B ordinary shares",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued",
        "netLabel": "Ordinary shares issued",
        "verboseLabel": "Issuance of Class B ordinary shares to sponsor (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r29",
      "r45",
      "r450",
      "r525",
      "r539"
     ]
    },
    "paii_StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of Units (in Shares)",
        "label": "Stock Issued During Period Shares Proceeds from the Sale of Class A Units",
        "documentation": "Stock Issued During Period Shares Proceeds from the Sale of Class A Units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares forfeited",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "paii_StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares, Share Based Compensations Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "paii_StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred underwriting fees payable",
        "label": "Stock Issued During Period Value Deferred Underwriting Fees Payable",
        "documentation": "Stock issued during period value deferred underwriting fees payable."
       }
      }
     },
     "auth_ref": []
    },
    "paii_StockIssuedDuringPeriodValueFairValueOfPublicWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodValueFairValueOfPublicWarrants",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Public Warrants, at issuance",
        "label": "Stock Issued During Period Value Fair Value of Public Warrants",
        "documentation": "Stock issued during period value fair value of public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class B ordinary shares to sponsor",
        "netLabel": "Capital contribution",
        "verboseLabel": "Ordinary shares issued value (in Dollars)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r29",
      "r45",
      "r458",
      "r525",
      "r539",
      "r609"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated value of transaction costs to Class A Ordinary Shares",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "paii_StockIssuedDuringPeriodValuePaidUnderwritersFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodValuePaidUnderwritersFees",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid underwriters fees",
        "label": "Stock Issued During Period Value Paid Underwriters Fees",
        "documentation": "Stock issued during period value paid underwriters fees."
       }
      }
     },
     "auth_ref": []
    },
    "paii_StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of Units",
        "label": "Stock Issued During Period Value Proceeds from the Sale of Class A Units",
        "documentation": "Stock Issued During Period Value Proceeds from the Sale of Class A Units."
       }
      }
     },
     "auth_ref": []
    },
    "paii_StockIssuedDuringPeriodValueShareSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "StockIssuedDuringPeriodValueShareSubscriptionReceivable",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share subscription receivable",
        "label": "Stock Issued During Period Value Share Subscription Receivable",
        "documentation": "Represents the amount of share subscription receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 deficit",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r42",
      "r484",
      "r501",
      "r526",
      "r527",
      "r596",
      "r610",
      "r721",
      "r724",
      "r725",
      "r738",
      "r794",
      "r815"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 deficit",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 DEFICIT",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r197",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r214",
      "r356",
      "r369",
      "r528",
      "r530",
      "r543"
     ]
    },
    "paii_SubscriptionReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "SubscriptionReceivablePolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Receivable",
        "label": "Subscription Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subscription receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficitParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperationsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "paii_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofChangesinShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Remeasurement of Class A ordinary shares to redemption value",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of Class A ordinary shares to redemption value",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r190",
      "r196"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheet",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A ordinary shares subject to possible redemption at September 30, 2025",
        "terseLabel": "Class A Ordinary Shares subject to possible redemption, $0.0001 par value; 20,041,150 ordinary shares at $10.08 per share",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r185",
      "r186",
      "r188",
      "r192",
      "r271",
      "r273",
      "r430"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Class A Ordinary Shares Subject to Possible Redemption [Line Items]",
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r188",
      "r189",
      "r191",
      "r195"
     ]
    },
    "us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofClassAOrdinarySharesSubjecttoPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plus:",
        "label": "Temporary Equity, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares subject to possible redemption, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares subject to possible redemption, per share",
        "label": "Temporary Equity, Redemption Price Per Share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/BalanceSheetParentheticals",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares subject to possible redemption",
        "terseLabel": "Ordinary shares subject to possible redemption, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r188"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Class A Ordinary Shares Subject to Possible Redemption",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ]
    },
    "paii_ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold number of trading days For determining share price from date of business combination",
        "label": "Threshold Number Of Trading Days For Determining Share Price From Date Of Business Combination",
        "documentation": "Number of trading days for completion of business combination."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold period for effective within statement after business combination",
        "documentation": "Threshold period for effective within statement after business combination."
       }
      }
     },
     "auth_ref": []
    },
    "paii_ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold period for filling registration statement after business combination",
        "documentation": "Represents the threshold period for filling registration statement after business combination."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "paii_TransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "TransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs amount",
        "label": "Transaction Costs",
        "documentation": "Transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "paii_USTreasuryGovernmentBillsMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "USTreasuryGovernmentBillsMaturityTerm",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity term of treasury government bills",
        "label": "U.S Treasury Government Bills Maturity Term",
        "documentation": "Maturity term of treasury government bills."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "paii_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant",
        "label": "Units Each Consisting Of One Class AOrdinary Share00001 Par Value And Onehalf Of One Redeemable Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_UnitsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units sold",
        "verboseLabel": "Number of units sold",
        "label": "Units Issued During Period Shares New Issues",
        "documentation": "Represent the units issued during period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r278",
      "r586"
     ]
    },
    "paii_UpforntUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "UpforntUnderwritingFees",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting fees",
        "label": "Upfornt Underwriting Fees",
        "documentation": "The amount represemt upfornt underwriting fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r131",
      "r132",
      "r133",
      "r134",
      "r420",
      "r422",
      "r558"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/InitialPublicOfferingDetails",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/FairValueMeasurementScheduleofValuationofthePublicWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market assumptions used in valuation of public warrants",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ]
    },
    "paii_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share",
        "label": "Warrants Each Whole Warrant Exercisable For One Class AOrdinary Share At An Exercise Price Of1150 Per Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "paii_WarrantsExercisableTermAfterTheCompletionOfABusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "WarrantsExercisableTermAfterTheCompletionOfABusinessCombination",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable term after the completion of a business combination",
        "label": "Warrants Exercisable Term After The Completion Of A Business Combination",
        "documentation": "The warrants exercisable term after the completion of a business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "paii_WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/ShareholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable term from closing of ipo",
        "documentation": "The warrants exercisable term from the closing of the initial public offering, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days"
       }
      }
     },
     "auth_ref": []
    },
    "paii_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Disclosure of accounting policy for its warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted weighted average shares outstanding",
        "terseLabel": "Weighted average shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r124"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator: Weighted Average Share Outstanding, Ordinary Shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/StatementofOperations",
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic weighted average shares outstanding",
        "terseLabel": "Weighted average shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r124"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerOrdinaryShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator: Weighted Average Share Outstanding, Ordinary Shares",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "paii_WorkingCapitalLoanOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "WorkingCapitalLoanOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital loans, outstanding",
        "label": "Working Capital Loan, Outstanding",
        "documentation": "Amount of working capital loan, outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "paii_WorkingCapitalLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "WorkingCapitalLoans",
     "crdr": "credit",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital loans",
        "label": "Working Capital Loans",
        "documentation": "Represents the amount of working capital loans."
       }
      }
     },
     "auth_ref": []
    },
    "paii_YearOfInception": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyrophyteacquisitioncorp2.com/20251231",
     "localname": "YearOfInception",
     "presentation": [
      "http://pyrophyteacquisitioncorp2.com/20251231/role/OrganizationandBusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Of Inception",
        "documentation": "Year of inception"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "850",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/480/tableOfContent"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-9"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001213900-26-036502-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-036502-xbrl.zip
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M.E1A5JVFJ:0"\;3!OMF)^5?OLMMQN]U>J]?9">JON;U@2[;:+:_I;512K%S
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M0RQBWHIKM>!LFKU'.88K,0:MQT]GK)J=#&%.^-A5<B$"^ [_O3"O=G[[^V"
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MM-Q#AM86DO-''=0_-Y"6ZV1)W530!P.L^9$6OHG1_D;^N>AYF/E?BQBT](:
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M$C:DBBB7<4>P/P]-CRV?0A"6AR]F1N'E<O;9DJNUM ,AT;$\Y@(R8<F=0G:
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MF5@\P82GTO;G$\[]N&;'U]9W&SI7EA(<C'Y3RD<52APZN#K:7)!%!NC)S22
M$ ,WJL2T0& 6'-T#V81EQFDS/(JNP*F#0I7I]N%0IS]K[L Y$I9)4\H(:93Y
MQK+B@)49*2$C>]04-P1F?8 EM7]>#;(N;&$LXU3R.9V0SZ:OS."G0BPST4+V
ML%_0L?NI>?\F1OL-=2^@#[WD#R'E@ZES?_I5;Q9$;6%)-&>Q%<AR/^ AUA>!
M+25*HY&.6.ZSC.:/ 11M!C7,+G(6J2^811H) ^G[CQASUZ28408FFTX46*32
M':$"CB:=U\U87DW,YP[AJ>*%82S1^ZV,$HHB54]%PI)AHF"A Q9BTN O]TJ?
MFTD@B8Q; U:@M15(C%W4'NG ;QA;>B>P7XH9"=UE&<7_7:_?E!S]5\T.UZF:
M5&T84%:H#:0CGC%Z923Y0%"^_DBH;[:EJ=:]VA'*+G^(*\5^MX?K3;@U[0C+
M]>DJB\\6H(XGXW#8X( FWN-;(9UBUZ R4@-7H_P]DU 1J:JS+O1UO+Z5QM6J
M3:',%)1<RZ@'U.66VC,-#('ON&*H:ZE#>]0;\SD0(W=,8%*4HDW2!J<(JX(P
M#>6NV-"$NP 15B8C-I=3+O!++FJ0$<M[=+C< P5-;LE)D8O\T2P>9J^&SF_X
MO0A-70E_O-_JFRY@+I4^4@E6-+.R83H%JL-D%*9"O3-$?4NME!M1\H7@[R44
M)I]"J;?2>L$,4HT*_PG%*XIZY_I2;QT<-":OV@]S*R'.4ADF*88,*OE,AC9I
M.%#4[[5FIA*39G;V#=0VF-N_IK#[2@7@F,= ND?('T$OPRWD^D?I]J]461NC
MIPE?>8X_$!)A;4MHA3\H@Y(U&9'E_"58N0SR:(O7L'.O;@H_BJXW@>FK9CT8
M*I7;7DRLKE>U,B(1,:.4,C*@X)..>I3\.A+G;\U2F&.+L[2D.JT  3@.8O3.
MDJ\JXE'FU RG 08R, =OZ*,P4F5I""BBD4/6*,"CR4QC62+#E<(ZF5%N"^@1
M";.B,(7SQIR $1@NW#6$B'R$09J,= CRD^L,T.4;\CNL%^$FEZ$&K'-N1.<9
M,!.BZ)A!'L!XD;@GF%H9B>!:E# \\>P*LT21R6+0@UVV/>Y7IU]_$I:D"SR%
M;V)F<SYQ+*(2@2)5BCA,2B=51%1G-N%/%L9HW35;>:_7F\J&KO'S((,">WY!
M:9("2M" #@)D,; 3H[Z2*8#14,@M+^\ME83-^_T7"$B*YBY@#G<R1TD+.K,0
M>O&$9!J>7S_;\AO)38RHO%IT%NR$,94DI[$*(4O]YP@69.%B]]37N"JPW#\$
MEM^W#H'EK:=C$]J#VMY\!N[S=\43I*&&^<8GLM]G\JS#RE\5"!3'B TX%3*,
M,"^Q!@;?Q'S@<*4!TI%.HP+]^_+C:17QW*@;EU)[16J8M20U[-C^>W(GE"9*
M F Q.@>8,*PVF] >Y<8"Y,K($V!-ND=1Q"7/EOP1R@ 20U*,!F)("<[)DH%'
M)BRFKFA S',L='D>>LD?ND,*OOK/)/UF7^)&6ZK)I[:G%5C/YS\O/^JN,/(4
MF+H:]=M\)W'VB_-5H9T5?38:^* EOOOHLC^XU+?5B_E5R-+]*OP%JY32-A#H
M(;%U10EB3V7$-KRBBX71?QAC7.778=%%7&IE]=) ,&*$O7+_ZE=O#_[PG:*D
MD\(,-1)Z=9%>4D9]*(%=F*G-(#Z023%3>L58G#9V0TL5#(NE*PU><JG/C;1Y
ML<0RBMC%&7$L!W[K.N:/=9G"J\4PG0O<<4FJP+?("6G)'-^@!'!AP'M+@)74
MJ*XP<:>J%VXHF\!)"$B.TW,3#\[W+NY.]7(EI$,0<A1(;KJ#O&/H0T/(D,-5
MVJFK=%6"*%N7@,H0HG01"7>)X,@Q_YYU+\I;)^S.>\25]D]W8J_:D+3FBD-M
MM=:K BH,3;@(EY?Q3[%O#8,UZ?APO2:=E5+TK7OHT;:A1V=EAQ[A!2 $;"2X
M/1[SYZ)-C]D:4!?SFEE^%F=X2LVZ:+I'#<)A&Q"&07"(:.1+KJ_!%QHVP@SC
MNE2H,T_>8"LY/G3I:S3Z<%5*O0H,!ZNHLBGEBR[16N6NF'XM3G**):@6[KD(
M20_A5A)<MH_/++,]D-\&">,RR*&HB4.I&I;@I6"C"2DPYQ85U15RQ8R^L!RE
M*28[F*9 LID**\LWOZ7&<GK_+,Y*%@P5A=N(L^4;7S4RWW)_MV+OBY945 9O
MRF1>U\@/(]DJCL-O;&PNIONWULOP5HX@-3RUY8-I@/(4JW5A#\(XUQ:M7AD^
M]E+]W-@))D%.__DNL0)77D$3FF# /NTC;CT!NR.'H&G1+B=\Z$IL5_J:[:F'
M\@M>(NK5]T7"2V:J+.!2PS(^_=(WW,)!%>S5W_7UH)(-O(D:Q\^Z@*"EMQH>
M(:O>(U1JQ-S0;S,)MU&GC!<U^(H7EF!1; D_SWBCI6Z$R/ITQ_0P5K X(%IT
MLGU@<CB)1Z_BB[',C5%<5Q?)4^>"<H^85>FGY=BMKU(CJ+J?VF'0;L6)V<H1
M&?>4(R)P6%F"P,%#*B]0JR4L.RW;2%'R$10@LOVABG6,=:DG&A^6L=W&/(#D
MHD@&30C01!)6I5$/8]A2>SYZ>"!B,(2HC(^:TK"@(HQ@*;30\\UHKZPP8'SE
MNTB'A*Z79V:72N["6%>CNAFZ4;NH8$+7(A J7ZQIH B*1B)MN @Q@V:V:NI@
MK%C7HU;6W)!' S;$'+3BO$N+ F2WR3?U.B9+&HZF6+3MY.]Y>;"OY/GD3!P"
MZO09PAM[&#,W<YW!D=OC?].X%NIT,UDC+SGN8+:9\Z"<%%GA68R&RIY%UTMF
M2=3/MNB^7#@3\7-J-%E&/,"X(M49:>U00NZBZ9[Y(^ROD0YD<Y)B(JB?6CS,
M?#=H4_F;J]8@C;%!&)PJR^XVB:8<L]8#/!,G\(E6DZ)R8T[+9^^#YK$KDU#K
M>P-74-/-1F'5D]&M8N,DEOX\HQ[L5</:G+PRNHV5V(NLK%-(L;I0+;,,:&B9
MWL,U>(Q+G)EEW"49V+"-#*!*K]X8-.;;)%TG=T+V>K)*G*7T.B,00U)-=JG1
MO5:XH%YF-".,<J9Z$,6:;^GV>,P&2EN#>Z$ZWR!L[W@:Z=XVLEHN-1NT:R2=
MZIL*K.ZBY*BV*:LR-*>RX]-Z2L;\>,_C9E_=Z&Y6W"6@9NNMH;9O$ONE*TTG
M[3C$(Z!TMO FX<Z'7/9?$8HES\:B^LB&_=*3[S<*S-CM;Q7=(73+>=-C"?_S
MFFASX;R*&3  P1@![3B-3IHH4NB4A]'M*8@XE=+^@TW.7C;E^G0[#-UKK$ 1
MEK!H"FY?%:A*;S%I5U*QR"S.#I>.:!!:X7@ZIB8<=TDJH>:U[)--/- ]A]T_
MI$VNQE\3@HJ<&B2.A9]FAI)J>(BD F0@]274C'J,S:<TQOC$- A)8RW$ /+;
MPF]Q_VHQRX0T,B9"&S40H+.HC-!G<M-790JYSB%5Z'U[[U.%]H^P2_GYX:C"
M6JBP&\T 63[*G%VF*HRBQ,\UZGTM#R(;#B51H,-N113:L*2-%D:U;['D6TR(
M^;'_C5AI$*(2BJR.]-N0NC)0R(_Q<W#0?TV37+)@Y9%'E3OU X-UFWU.,-[-
MK!#57_V%I1S[SX3MG:^T!JP?L ;F@*859JYJJ%?C[.8J_62\AB'^(U,R^CFN
M=H@,9LH]-C=/"2&,J5/3K!2_ECX$0O&=D!9A^D205R( 0J%,#6:5$'Q8;DFU
MH)'*JW)!A25QIV7E6JG1U _H8,?V5<FQL*:KZD=.Q# 7B_9ZI> 3D0VK2IIP
M&.."SH!KBXO(K'0U6;)%KAC/^YV4/TM\QRA#)M2TE*-I@9^)55O<7VQ'(Z,Z
M2E$OVU>)3";TKWT,.ZYL@M+0Q4&R\3#Q9],PH/P+Z7\KJ,>7IUVU_U<J?A@-
MI(U3LD N47=N56.1%HAK"90FK#K]2LP<#36W3G&-7<=IK)_V.\@H,1[??&0W
M*QFXZBC1V5G"3"ZX@,4]90AE1$LQU5HF#@Q8-AEGK; W(ASLIXP!QW)@%Q->
MX.4FSB).2Y-H5B.;=33#\!1R.76(S5]07OQN+_$2:I$LYRP".KZ*-^D@Z7Z"
MB2TZ7M!=9!NYPH0KSCDWFDDJ;_AMF.!MPJA?<;S]E_XK;?(GJ55V%+?EYZ/Z
MXZ\U)8L)(\RM"$I9SZ6QW28MN?Q9QY:MP^>)K>R1+@V+NX?HC(5SD[[F.52S
M)V#:)7]J:(9.3%%D/9CW\@Z-]H7.,-MTABV*E5@%;@O6!DWCH2XB6L?K6SXC
MY5#2T$Y%QW*CK:8N!U)I)W T!H&TA"*092S"R!/!6!$F6\4X;RP\1 DL^]\&
M-]Q^3IVRUD$.><7;FL*VN,'':U8=BH8?<!&,M/)5R&R5UJ/$#MA;)(O=-A?>
M7#,LOC"@:0*W&]JY@CD#W2=1,96\[/HM7]%#9O1NW85PM"&"K$H.Z_Z2HV3G
M4$Z$V1@Q!HLEO"YU&E:-#[$C:*!9-%]W1=*6).FG)-0#23XE>Y8I-!8BB,J4
M.K_H*6!4K!OF@*+B8&,)$5;1IPCT&[8NS9 MQX]4"M*JI1[8\.[1_ 9XL":I
M":%P9H3',)>05.LJ*;6^;DC;;(9L6"4>4.LY?F]=DI/!N^]\!/9ARX:^?6L=
M,,5VC42Q\J"DWG)IW*E,^+@@DQ4]1Y\2;,N%&]D[^D?#YB"725,SE6^HW&5%
M$K>U#G-KE VM(K,G!+&0O=D\7777I2NO4XFW[195+5!>:DFMNYS6RJ^*Q"B_
M'_61^T!G(2R4SLJ,D9X?0^WCU.3-I3/.&TALBY%.RFNT#D2Y?T1I6,)EY^5:
MI/8#GM4#+>TM+3&,:X&]MRY-_7RT2 9\C+0W77FUVJIBQ[DE17AP(-#])=!
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ML:R6Q9U*U<I+X((CE.N@XQQ%8?Q-!++\N:A((Q<?_Q"4\YCM#(:ST\2*]V\
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M-N6TX&B,)-Q;7K(IWH@@<,S 23N^L?]^P*""PH&-^!Z1_B4&0FC\%U$S30]
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M\6CHX9UN-D:\S:.-6)J*P,%,L.H1ORV]J0.D"YX 33_VVF_^59$ TD(NE!?
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M23)R@6N)>47T>?W-QZH%^_(:85007ZS75:O92^I@[\-*[UV6X)2N#RTR\'J
MA1JQ>M3RK41>)!L4.B%3$6U$M"S[8HRYAA> (19]*[134=S0UZV 9IBBM(X*
M0^$8,<BZ$Y;>6OP7/_+V%K3??^S\D9[AC7Y^6X.TA9.;WH),-7_L55-G.0$B
M_B?;9-3/*34GFS/?+VXOKRA4>>G%A&X42$SYJ&3;@L9%$R)$*&_XT<+2%475
M()_F/;01Y@'J&**@^Q&JA7:7_V)4R3J[96F0D+S%NJUT&3U.V:0@ 4)D4E*J
M0O=Z\AEOX ,CO!JXA5ESG0;U)\P<7UT!:T.K.63_2\R&+W,4Z!XM6)N7[-3M
M]'O*./0T=J0!&"WV,V.#?MN/F^),0(>"0XJC&2BC:AJ.W$@(5[<0?,.^0E=W
M66>W/D;!M=%MX6.@L)6>G9U%/C+C,VS%$.KC99,W?I[]J8HA.9,E!* /3LX$
MK5K\1MR@VP 7DRQ,I&\ 1[8KFNLQ3)+$*EQ]]PLO0@D_BG>989HA7UK<;GU
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MG&.MT>4:6NR *\0_L\D0 :\;7(X#N2<X'_'OOA 3. CH>O$<;BNY;:T$ON)
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M(^@B$&BC@11[ERK+4/VRTS3O\*F6U:)C/';OR<*BD92SKAS4127%$0ZSJRW
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M>&620TS/S4[6OO66]OUT 3F!.UQKQ[XM"&5KKLS?L/P2R)95X(SL!GDUS&+
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MA_;F-/E9,XU(\\P4?>Q^]?)[3:6[F\;&>+ZPPX<38YZ$>';<)'Q,YY([Q4\
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MN4X> ^ESHM6"^<+P$&24)&\SL0["$L:\BZS7B?6LRSC=^PE;$J?'!I:"T!H
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MW=<K 6HZL3$YM:[%]N,CB!G&!3D8X.8FXBP=\'-,J((*#BX!KV 1*+L3C$N
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MDKU-AK'/T%+L%QFF[Q^) B&(<]P\VQF1C#OOD*=5]Y#"TLH#[0I:!I(>&&=
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M7/A^_NS9N?#].9\'QD<1UALT/C*78)PF11]*77+5QW'2LVP13Y@3_8GF*,7
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M-S()IGL5/(#?A)W3Z92[9>E3;ES'>=CY-[<M-T)*P#7%(&G 4+,:G(>9%TN
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M-.J)@-U?K:/8D*WN1A3"F"J9-M:RO4+8*"L^9?11[5'D1"<?NXSUS\;^>YO
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M1G+JX\YLG%K'SPM5I:I\!ZI..C&*)-$59'M=]H(:-4,'2N [%"5("B>=X'>
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M5_M)Y6S_*[GC7HF%>*,MZ?>2XW.][&/J95^?ZV7/OWAZKI=]SN?A13V>I9+
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M__S_L_>FS6TCR=KH]_H5"$>?-Z0(2"/)EF6YIQ4AJ^UN];278WF.[]P;;TR
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M(F?.(<35=U.;50OEA4H(X:]:VR8-%LBT310!KL/G\%PVZ(+](X 453Q(B:L
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MZ<#BX?@79S5#..SUG,4NP&E[V/[P0K1I$V 0 J7#\5QS[[3*PK65^@*&9Z<
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MH/&^.$#+36L^HQP#\%5M>[)T/D$ZM;@ F.T?%!MJVNS;2$H5!R?ZO)06(_(
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M57=W;*,9CA!#:$LRHRO"_RUVT"ZB/V;Y/-I]S%4+V]%K_<L3Y8&X2KVF)8)
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MP6="VVZ_P=XW?FV42A2SE=/J-$N1A3ZU3NI(>UNP\:UX8JRTFPV8SLDX3KK
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MO,O^C%K2%TXCN$:Z7B +IG?\[AXNV/'L')E(X3\?T7J90&268G9_]=[WO$K
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MC-(!/"!G+P9C>?/F]V?X>N3&R\ [;$>SF38"I.0OR9RE,F*[RA>P4L3!L+!
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MC/J%8WL.Z[^A=]4:,)R;LPO"F]3)8) 0BG#3/E@OB$,/7 4C\Q>S [YUO(W
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MG62;DLOJ&AF<JH2"A*(#)F7-@&VJX92F9^TG\S2IC]HT)9Y!^6^ZFO1N!'5
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M7GN/N!_Z3+C:F(39Q"IL^UPQ7Q)V5[&5>(1R45R,K1'EM'!&?6LM4%?(V.W
MC92\.Y9Y6W),YK*R8+ WG5#K>BWULZN,#^"ETQ:92JI.?.Q90=Z7L&,)]"_\
M(G(7HV6>%=9%IRQ"E8[!,^!"PX63)E>4R[LK_+!RQ^R*C[3K7 +SM?5@[O$J
MAD;&([G,AELQ*6HQ84P0:B6&0=M?(T[FGGC55E52R.7OV<>G</I>S:C_+DC(
M! :1#D=/Y>9Z5XW>2,G4FZH<'K/2?I$GYP](IN$%;]/Q+P^&L)C_?KQ[>'BX
MM[=_\(#]]>:7!]G'YNDX^YB.MIIJECX MQG_=KEUL'_X\,&1W &@_OQ1'.'1
MY8O2D5!DBK2H/*8UD.XZM2DF:FV WPHD=@.E1IB29%)1>!T+N]&F!)4T+C.=
M54-L/!%'=9(+*6@IG8EJV]9 /5[0%DPPL=!%QL>L!;<6WD38JA;_7S)N)]*Y
M@7LLN ZW&:J#!'0&G/DY<L-QPYJ&8F:3LDD7..N\]:*I(G%=K-JA16!'_]U!
M:!"H1V]XV]%Q<,%V+VM$?.8YMP9^+M?M[F''C1O]*#;AGZ#$-?]41']F&C9A
MCV643@H;F#*MSJ3WK2W.23*'IT6G=0Z3KU$\0>FG=(N8')>1! [16EP5SW"(
M9*'MV/4ZZV%H6"T>"@=EX6ZX#H&R&^[T&NY.JD= 1F11:L[&P%? -7,!+KD]
MSN$DP3"H&N5=)8L 0XYXB-EV9*47R^U<R_&^9(T62D]R#FJP;NB2'\]RY.E/
M9GF#ID\R&ZE%@+%%"6O0BHA]R&#_804;R2VN/J%GH5FUJNU"D2"Z2F23R4>*
MV\K*3C$&WXC] &(1((L%II?;DP6?H><[,NSK(F]K@KFK1IH>X%(BZ(^W\*(J
M9^<7\L7R"KF(R!*@18O;BTEFD?RI2,^QK;US-/1V&+G+RF\H*?+)EX9,7__F
MCQZ,.M+9I/#I/]-ZV9KIOO/NUH2>A.$B0!OD)FT:SH$;-#(=?CR!LS@ZU[1E
M74[@QUD%)A8J^V&J%-C"+>C>0@,!T3S76'IIMWB^9)3WQ))ZW;L A@TL["]'
MES09UVRQ8L0ZCIJLR=/8!L[)0\B3;.)#ZAF%KJCX25EDS)^%6_^NPH2&T&'Q
M?=[U2G/35Q(('A49/4U>-IZ1VR!=%&LZ&6-RS)(J$_^WD1R:!ZBW#F93FIDD
M/S6"7Z?I!PK:8Z%!(-3!S.R!9^,'+H&DJ4L$ [=P]4PM&RH?S\$5)+P9.*<>
M_HF!KIJ 4L13C<4L&]DFFETT^WJ&>YOAH0&G##G*9@U9E^),AB.%@6YD_&N+
MXD]75@?<GX.R<#4XM6)0X-!1!6G 0': _")7?H!N,-]::,?.L"+15U%Z"(/D
M'<H.ANP9_<HZ?YQAK1O>NJ-9,R?WMD[='5X;<HKL : +G^H_\!%5*H5R^&>J
MX<@NRI*C*[! EQS40#RF<!IWCC&T+B(09CQE="_QO4^W$L: 3$:..@:9X K"
M!"?!Y=$%N4+&/BW.E,.UD'B+7H"Y 5_&""UV#_0^]'BCD829;@:Q7Y(106JP
M$2S-G+M<>:;/%94FV1N(# )W\_#\D@EN9'+%?L3*90@H.AO:D\[33'MT3P[-
M>^?]*1PB$-58&/#5@O#)A6'AT.O0_J9U*\F-5TH#QJ<$JP49T8"76S1B!;K,
M\N@FE_PG>5-V 98O^N=[Q\HTZ9-UFO3HX.$Z3?I]26T]1;-B],N#Y-\[>[L6
MH(=1J3R9/P4-@-C6K0%F2W]&*<<?'!'S\>[NML?#YJ=:[XE6]9.G"R'^V@0&
M!"8YN;XLY7 ST2<$25*T,:S!R\6CZ8B<1#(Z\9[TRW2UCG>Q7+=5H&O:!;H=
M1G6[8LC#IC9I,HDP"9%WEI6NPN%L1Z_"2E_34^F+?^-J7Q^YAE@[KX8XJ ,>
MIY(T5F]&>=_D#8'3FI>X\7Z-L&%+/:Q^CGN-*_$>;!&P-03AL\ZM6U$CK%\S
M0=\86R <WVJUHPV.<N?X=_$M&E#)]&^/%9U#!%A O.EJ(HVUEFS]AZX7Y>MS
M%A58'+KC+?>'W<,X&H#SACX91=WHZZT-M.L #M!6.=Z:@EY)&UL7'L1@VC7
ME'*1"B6!!*0723ZV,2X/1Q=-2X(YPCHUF(IL+(1-^=I<NFPT0W0G''BNMD0*
MR8SAS+K$QEMBZ>3>[GM)*R7970+\NGX.#/E-^ Q+HI-C\A5&K$9IOPSZ.B0V
MRI52B0?B"M+!A;5!1'V'K09?X3C:3::AS,@)9R>5PH_JJ5HWU8B;"NO@$K-N
MMNV%T349A\.CM.*H)&G!W6=*10X\X#&3Y#65U5*ZDTXX]3-SN16#RQ'*EUOB
M5KY?3-&VFM828PSB+1?)KK+T-G+3G5?2:&N'_<'1\;A)-8*,936>*C/+ 9P!
M*<.*"^KJ K$5$]1+VH]+?%"B@PC9([P?(SC:V.Y)0WJ]ZWH.QXH9/5DS$I):
M3PNXT?G<ZPR!!7(!NT3HZ<(_"\+5$CZ6%3,31( D(A6'4.:3W2#L-Y0L;33I
M()_#BT'V$;.L(A[$.+KT)CYO2H-<?E-[(&GC8:,E3(YY%"F32R8<IY(S3>O"
MV&AOS0?SSC5=/)CA[KK-V8Y.&P0#S I+<K'PZL""TJVA95;43 -2K%?AM=8!
MN0&&R4QP#BX.J\\HZV9KZ*E/O5CLZ]L0?8_MV,(X?.,BF 1K\@ZB)*$U,4'D
M0U_I^C;'PF3 $&86DAZTN#\VF7F:D4I'0%(?@@^/$A@#,PSF8&$$7G#SSN;@
MM?;J@CW]3ZF=.MNM,+QOWPCG]^-IRO?V0F2T"6V=H*2,&FY@(U)N1<[;<JV(
M^E#K4S)L6<= @]KJR,13SC>S-&.3Y!)J9"(:+&X@D:>!45X(33V/$;D[7(<J
MHTC/RX:,:@8T*)#(4]L^9PP#Z:RR-W8BJYV1=Z21J6)Y2 .D(ACU&)@[_/I#
MZ%I;X]\_63'..<01;H]+.<.\+Q4.%1BPY%+DW'D.CE#+BB5+VUE0[>B>%EF8
M#L%8N"AO+P16_R2!DF,R$F5T&Z5#BC(:3D$/4\$)LH]FS?3>*XGBC66C79HX
MA>7%(RU+95]JF*F1;&;92*R[9GBBI_^(:<7N_H\0E S".WLW"^_L;<-["(DT
MCUY?%;"P%]D4E^A$',!GM(X(733\N3"!!#WJWDJ/K3-GI#!9R+U1Z^^(F2W/
M2RH&9<>R3ANZ?T%Y^?@R!U'C>BA=7\07N/5G'Q!+EZLY&W\$3X!/7E+UW\.=
M.-K;V7L<F\%\S<7QO=8'4S*1P;MBL-IXU"#MW'^RCDN^^HMH_[^L+("'KC2
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M\Z9?<'D%IH4-_S&,;J>UJ\TF ?O##/]@&4;+L$P7>1Q(ZA.W#_P^>%:CF'Y
M3]-+T!Q)ODQFX_U!F.SS#V3LE/;NH>-8NIO:*F*)APN10Z&@]HRCYV6!6D&=
MFE1Z!U3^E5_" LQPB;F> )UH'*?CQ_F-%KZQC$GJC)4:8BW]I$9\Q7=ZPC;*
MK_=F&*VS>V@;IMZUZQFMX8FOC.FJY<V\F; ,[W4)MS1,,$K'I2Q&GI*X4'86
M]YI5,<_"K$$R/MXH2W1W#]N.HSL-6.(E!<XS) NXJG_YS#91,B7W8$=CF.TF
MFL6)R/9L]MQ_AR6=36A!Y^&DOSDN:!G@C./E,TQ;MYSVYCBA6@K,,T65E%I$
M"P43D8W9UT8A1CM];)%Z'RIIT\QG@OGCZI;5V3JE5""8&FFB_#JMAFRI**A>
M1C%5O+WP70OQD@.<A/4K(Y\7]%=OK\#L?NYC%Q":FV%1B\G'CF'I7<-=F$_Y
M^3<B[MHDZ5SW?"TGECN699WX"VK)9=3NLV]SI?^]O%WY[:QW=/;M[.;LY%K7
M+JZ^GIWWKO[4KG_O79U<:]<_COYQ<GR#O=.7%]?79T??3K2KDZ\GWR\Q1*5K
MO?.O[*._7WS[>G)U+?O43D[/CL]NWLP1-.#*)4A_+&OU6)D=V'M?W@S)&AG'
MS[6#N#V,U1A/:#F_N.G33*4\S^H1F[QD>]R@V]7"]F"X EUG^VR>ES;!X52B
MF?\> D%\I]]2*;51%G3 IG%UHT'0<0O,[M5$>Q0%L2G7?UM.W]T];-F-!-";
MD31?1=</E1 ^8F ("X1]?W-J;^VR!]S\X(O8^ ]EWZ>P;:X(-^W_MW8/N[K=
M[>JM[JN014N% )HRJR*U"J35VV', GFX&>YK(_<Y( M;]FLPQCZ\^"4O9$-7
M$GL@> <45LT>4[/6G3_I8Q)ACYJJW$]K-![4XIC]V._O!S_W[X,!+/O+L/]/
ML]V!!]EVISW7$;\QI?W!D:LS5X]'7AQK/>T"2\9Q>A6!$%"KX;]X ]$TC..
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M@/FN"RZ+_9P8V3LBYP<K523=6J;;=3K=BBSP.Z+6!Z>4<DK'LI@I_,$H36H
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MRSW)Y5]*V?SY?1G+-'J\7+]JMNRFB^KK*Q!EX$\&,5FG:&"!T0I.FQ=-@(+
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MZU?MXNJWWOG9_]>C1N3>^5?MZ,?UV?G)];5V<7ER1;^^7LGE+]Q&#OK:.""
MZQ6*G 7>>OD4A=/[)S!*>_U_SX*81HEKQV$T/6 +.CO3]M"%0M)9QJ_'3$;3
M3^:OGQ#(Q=-N1][D+ZU_[X/4X4*<NB\C'#2%9JZ'GSKVGF#AVED,GQ[$",XR
MGN(?Q3?@O=^])_96WK-]H*%FX._4'KTX^UAL*<.U36?PJYB\.Y\R#Q3MT>">
MW/F1KGF@E.\\UO6E<X0-T9:FL[XDT#YR]^(C OI%!VL]5*X78M3$P3@8>9%V
M.XL#BHO )F[A8M'?'X/D'G;CXP?'()SDI^  55H>B2\?IU\6A,WN')9!>#FQ
M/R(T&0U_&4_!WAB")"AZCI8 0^"^)@1IDW^2#O\5T0_P2UHJW"IP6V[]>V\T
MU#5_<@<RC&K_Z%6S6T1010 2BKG-XA@A:W3X(8(%C9X8;H_X26<DP&]6K8T^
M!+)IRL&#2-4'"(%3_#7ZO+*9U2C[$DFSF>N(R#E%\/9Z[A 'Q Y/F+L/QV/4
MD[()$\Z% <OP<.=3>DTH]\!*C J5"=G1?_I>=#$\@T<2F$^-W:R8NM;N8?[^
M:GN!>,XGZ0T78/=G%G/(O6-JZ5:V3<*[_6O,;6_1>RI89@I. ^PD%'ZX>M/.
M^&<NV6>$KUY\V1X#(!Z2]\Z?($5]8N2TAR+R'_S)S$<8I"0 ,@\3#H:$@FSD
M,Q$QI.M4Q<X@>1+Z&M![%/AQ4K *N0*@SGZZ M;9+GJLD1ST0M&@S?\<LEPS
M$8G^X:<I%\8$Q!2B\@P,2+C>@_0O)42CY]57J&E[ Q]T--:3^*/PL4"@26$F
M&(*QCFVBND#J#0-TOH#+0=#ZD\&!]@;O^PW!BMT%<<+N;NK+R&N;9_^R<T'U
M""XHJ"5L.F-Z\('8@!#3S);0J0)#S>P4"1>X[O%L/"8%BZ=0]CHX_0IOG&I2
MRP"\@(STI\+H8ZMM=SL=P[36!=75-NS=0[.-F;_"V \'.5/E!^TF*RWH5]HC
MW#ATL09XF3VX3 $+,O^M.J/0]QEI+GD8=B$Z6$ZK;9A.&1VLYG1P@ [&01$)
M$(H,=Z@+$80G?A>%(,*DP,A*YXI=5Q6/<NYBS"5X:S%RK"Q6XR);4+-@(5^
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MV[5:(*.<N5N\.L6-:4.]5=+0K7ER$UP[PY[[B%":@RD%\@=#C6Y6,9SLC^?
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M-F5#+,)CVHU.)&#=0WC)<P9-XH^QK1!>(6+UI&*P;E=I+QQZ?9QGPZR;.D\
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MKH5"-CH!O._U5V<N?!/[_E]Q(2GD9M/(3AVG\P0G1:P8D9DJ5H_.FZ0 2T"
M<#3CK1KX[AQPJA!NSY8U/#_H\[H46A/H=F)TT+8D"O$[HE *8\C_"D42&3_.
M=%$?_WC[Q$1])C;OP1'?^B@..%P1*?-!"(?(_18X:;!V8DKQX(K\B!UB(."_
M1R-@_(&.SV>'R^,\2@!.5"&*/'4>/DE6^@1+)"S@$K%LXBP20+:4B:2T$D.8
MI8"8BKDL8D/LFF0+4.8/4Y_CAEJ.XA6M4MYE>4E>OI23%C]L<)#VD_L@2HL/
M7]EADS@@WD??H\)LFS-L=;47WQL\!#':MZ% [D"RC0("*,4-L13<Z&E_XM^%
M2<#<G%0*2[ AU.V8=>$-<=QOR@F!RE,G.XELH/P]+ HM(,5U@<O;YUEOLO\H
MH\[2-^Q#(EY0:ZL=@%&=K3] 24E1W%IAIE/NFS$1\2^9^)-0E$R%\P2I5;(A
MQL(\[=^S,)I140>3K_Y@G=:%EZ2WA/H#X.->E!;4B& S7'^$U1"191H0)9*)
M.2Y^BX5A=  E624E!*'81P2F"1</X[8<4%/Y*RO?);\'GQH, R:/T\(=GR;/
M,R>DV&,K39M@AK2/+Z8<J#1N)5:^B&P@JU]C7,5#P7@48L7S'K>?3WO71S(?
M5OCYXW" U=X\.\N_UKN69K=V$TZ#/CLNIV/HPC+_&M X.S"@[O&!WP+O%JN0
M4&Q2@NB$-G[ ']/<F!%D*8D%SHF9DO@2-]KP:@]8.?>MSW\"N@Z]AS"J>M-;
MA/&^S-F<*Y1$.C<E!29\"HG4P&S@.49MV?2B,'X]\E#@9F)\+U-V YHA#E!1
MWX*7A.MCY?K@>:+A711SI7090]'>XWW@0CB =<3*:I5>>][2!-\!K^23KH3)
M\H'.%PLOKR+P6Y,K%,4PY-!$_D/ P+3*.IJI3-"/>&4*GOL@\AZ]$?.*&!QD
M513VC*_C)KSTGK[BU"ZFQ/E4KPU!E]@$RU<"8J$BH/,J(E'P1\837_F*@NC"
MG$Z5E^H34B62$-E%UIFP$=*00,:4SE=)48$H*4O$TT!NBEA(2FR0)=MEJYDT
M.C_-A?O+RWGB<G<S"3-!09[]!XK!R0\""O^F\0ZRDUBT!9LJ::'Y<@DT#K8G
MH,P.0:D0G:-G6>5<H\ASUNW$GJ11G*E86;O@GO>!.?&IL#);JRL:5>:CXI@8
ME,,.JBI0TAX)U1-\-G')/<FM:E6D9<$CF>BBDF8V+X/;YOD9%6]_-%!MA8;S
M4:$!V^Y^5&BLA+6KYYM=8Z\?^DZ3)'6M+BD4[,?/G%K6:2_':/DQ?W.X(YE9
MYKML!IG%9Y!=__C^O7?UIW9QJEV?_79^=GIVW#N_T7K'QQ<_SF_.SG_3+B^^
MG1V?G5QSK))U>DFU2\^@IH@2L=+#.L)2N8MA>E#+G4O76L&Y++MCV@,;<9-.
MSWN!H]A<L"8S@#/335(T:5-C+A71ACGZ!-TP"$<C+Q(9'+3K,7[ XN%I2 1<
M,7C>%)W;M($<_NY/^;-820)!4]&8PEB&2W[K]2XS8!+Y]$Z:_ %'#FM^1,Z:
MS)[:E.A!D;;?\GM'+MMO(8$M@NZ))M_(U +*]R8#/IS@RH_#6=3W8Q*:3\\4
MF3C >V-$H9UJ?*NZ)C=+1RIF,<C]OMD[VWQ6G,>J,VX9$,'R0)7K1VRT0>0[
MCE4"-7\:8H)(>,5+E,1+KW<D>68B$2Y8PUC@IW/;9_3\Y^'P5;1HH2OM_V2Q
M72$=Y7!N\-3PM.'TQ5-]C(![7'X6XK/ ,4\&)+.!N\![(?$+'T_C;55 +W.0
M&CKFL1[\$>\=H9(0L7WFL^-K1K07928F2)54Z-:\ "-9_B-3.'RLIU*L@6^4
M#2W2YV_R7-8G*#@E]P':#'=R*>#(\[O$+2*+)ZB>P3.I2TB]Q3Q.+IT@KY /
MWQF3:N87D"&=8AA.9=P\\74694J\OUBT%*3 %(R#+&=2Z4;F(&J*;> DJ4B:
MQ9G)F$DPJLN#N!,?$1H\U@C*,]*JD,3>30H0!7#8R-D!#>"CF&T:>L8BF2F;
MQTBS4L5*9/E3S3(/M._@\X5SH"/X]@F/2_$J'&6@"#>^,*T>4"PMT^M40QBL
MV_'[WBS&)>,_0^01'O,3R!D4/_<8G ISL928:+YR/2XJ\JM9!N776"RN+\9_
MJ)NGD*NZ9Q4&!#/6V(@Z\&^3HMK,!DGK#%8S!;(&C(Z,MMFJ*<;&1<V<=9LL
M#*_.UQ1DII9FPK[45(]Y$^1GC/2K!Z4KS01L0:/0PZ!M;3#_#P8ZS"VC;_BM
MS2AWNQ*%VHOG&$,DW87QSW<BC3S:2PH:^_:$KU+%0!F,/HM3LQNA7ACE[DH&
M)L\H2,0M3@4)@W]+S0;4X9F>/%Y*AU4>@\(9U_/37%D/>4&$^NSRHDE[)J85
MJ!6<6E#D*&.>/^!R'2L)94ECP?1O)>%#MSY_A=-0=ZK&N%557A_$DNU/HG0T
MF*"LPCHP!F719WY(40D!5@1HO>MCEM<'X]S==]*LOAI8P'>GQ0;7J9=-JS!_
MU;(^C\CT5YNV?&6Q%GG8$J_4NX(.G($T34M9E]SSD/4*L;G2'$&3QO7*TY=P
M&QYP5F4L(:-G;T6Q09;1&&8+70%FK3/0YKPU+^QW?&^AR-!4Q 8N5BD?&"2+
MB>P#[5R='\B35K>^/X&GLR)S,HW Y&?F$$_CLI2^SPSGD5+/$=]3D9@J"!'/
M478YJ]M64G<O&K7(-HH61R-.L#02=OQ;%#XF]WPKUP3ALHH 1,?89 !";$YC
MNY,GQ?;W9@,.F9M(,&M<DOF"'G>,'CR.*,54MO/FFDED#ABUY_$.[OD('<'&
MLC_QJ?)=VU9Q9V4YN^A@R'V7WDY?&%/E59KS_\=L/ 7Y$R7:!2A2J9"N\5>S
M:<&K+<.T,MT2_[@XNE:!;75>DTU2!;P;M&<?/$*WH$0YQ\[R?\J6#I*1#UZ$
MI1R@U:CCDL;+*PET5FT892I@T4L@I<@A$7(-0\)V+#Z4@%*Y7,_KLDB'F@"Y
MF<G:RY2E#*3^5J:WD3Q'\9\D5+^DU$A*)SUSTH[AR"BL%]UZ0/#]BY\C_ZF(
MV(:ER_XV;-H?A?$,@0.58@76&DM^T4\X=XH$X"+]2<PKMR<,PX.T$]")D5BV
M.&$K@=1 [/3RAU-4SR#@Q3PJ9[T-6'4(KQ)^XG74D[(U4;BAI!*/ZD+QUQ.L
M6_;Z]]@>R$>*S!7^< R9P1LLGCMEQ2UZEGU,P]J[_23!*C@GB5O(CRZNX'HZ
MT6J^GL!6J.?M@::\*IU :>HBEM6<S.(5,PC3%^UQ,"J=&ZRLC8\5.R<\'IN5
M5!R]DIF\*5>BDS7R"(V<2J21FT)L9N(/(H1;*H9EE=CRD9&$!56ZBT2N@]$/
MD=)(5%3=\87HP2PU>2#<JA)":5)R,D\8L]0H6L?B*PE670E! =S!,?K00>?.
M"K,V.8!'9KT%HG,Z)6ABNJSEO$$^]X0W-;#0(:N/%^O!AN8(Z!"2")[W?@0L
M&1Y,=AOLD>7[8&&1L2^M4MX(*>A*KV8E:<I1<%V#KP;%-O1Q:%H&1)J"P!PM
MD+0$ ?3D6#43LM Y=&J9,J>#\@:XM0+>D,M5<7KG[T;M]Y&T 45"X/__XE^-
M@KC</2MT*#(-.!D]^23 )T&D\H!:!7-.PLH_LT?A*824N>1GSO(&-0R,YQ;T
M:392I 7CM&Z6Q^M" 3 L !#%0?=9-5:Q3(J%2MCJ#.;:P67J5J6NIZK$R?TH
M<8)MF\;;JW%:/T;,RLMJ?L3^Q?!$I%V6\YNM5=0Z-=ZN.GA)[+*.)C^8[)/[
M?-/N-%CT:.N+$&"A+BLHI<$BF&PO9UXKJD6](5.E:<*.XK]@4PAGAYE**1HD
M\Y30S)@+5^%7U7@5*]E.';0ACQ?>D4%2\ITD#0UR+5<<%90EY?/+$>7\VH#R
MMLKG*#_.*G??'L]\9VG3]"@E$V0/7.*@JHF!?\T&=_B! ^V,+%K9Q5C4OB,!
M]<2[I$W.VS6Q#U6"!.GPHD2$T2/P1>@#_2#JS\8,6)1S&=4[^(.F/" :+93=
M84(>'(N(=Y?!M9AQ?$OT]L5J1;<MK^_B)643C$V#)AD+4%EUI,APACW>=-<"
M5C>!#;<).#8]BNO#;T9/NII=9JV\,7\5L\]4B@,]>1P!_4!Y:*_ 0"O505@9
M1$5E\3UV'3YX(R312D*Z]HNJIAP5C@7B/OU#V=J;53\9'U9<JIC2;_$]R-%]
MNB<J2KK(@H=1 &_$[F5EID!R'_F^2/Z)D0+DRTYG$=S"6*)_42V:GU(X[TW7
M3IC>7'6:4UZ=)F'?D8DR[(9#W?:#G_OWP0 .X,NP_T_3M2T+'M2Q=@\GH9A%
MF:<+1ZJ;J^\[6.Q*%[:O;+FT8<-P: 8%QEO2:-GO8,6?3=3I2BL1/4YK@Z(G
MW:<:%OR=MXIF6J*VLQ7@!8569<EK[1@K AB0HU0JAB7RR20X_4,9)BF'D*2A
MUM>LREDYUS5K#[T)OV,,"5%M4JCV8S*>XK-)^BN*AJSDSKG.)M5]"3#%==HL
M>RDLX73S[_[Z%:*JE-&21;/QRM%$)(0,P(0KM_;9%/*:,4D"JBT#!#+T/3+4
MF6= F$&Q+ ;* LE3\+UL?24XC\7U-+S$#T.U0X8^0![4/'8@KD,%&&OXEOH"
MQEQM$985.1UCWS3VK[O=;$&I!$B)4R">N IY10P4Q<)JL/H\G.ZN[6'.OA\D
MGP2P"B_04[XGAPS$,NW,9:;25HN'&(6C7/S^0#OQX'!H8A99G[QX&#VRXA/C
MZ+3^_KTW&HJ/<H[A-?4'V!.!AZYG2K5E^0W#D*D8=U #+?/(28!,UZ>Z3-D8
M,/#17A8U#H6GU3;V+8-;NR7OISZ$](BRA\Q108"BLP@3/J,G#GR)!;QD/\R?
M4!"K 1D)C4.S72*?=X,P/U<;,UPHW/MM^. K?N_\6O9-%RL%J*B,PL&)4@;%
MDBL^YCWDH :6OPYOO4QP@8UJXIW\U#*.%<K*E@XJ5=B-.""&@'.#WVBHED19
MVZ '=C__@6[;/TVP\T'&6BVW3'F!)^ *85B/<"1#*BH4I#_D&4-^(*(W)[[W
M:2!GH9G#$[98?1>,TD:Y8=H6@P3X,M^KSDT!=9NTF;)]OX2KRRS>OC\:3;&0
M=7)'GAC^#*JM+WX6"0661NEC=^$T]K]HXE^_ M\,DGM<H?'+KUK3U<+I_3VY
M#0=/L(Y(O.3!1\0=;R16S;(*O\+9]/^ZBQ#3 1<01E^TZ.YVSS(<W;([NN6Z
MG^AQ _$<OJ).YY<2*OP6A=0VP$3'WS\G@\/YKYN_I.0J^4#V\2-_F.P>_JWD
MT]W<IPGT8O>PVM.^Y$L\C<(Q8G$CBUX,L5DRG-!$QH([UK:[G8YMNNOSPL%9
M@X?ICFD6>N(+D4NA,%R3),*#7((A_K@/$C_+!84G_PU4^Q>QP.S+B[\YM\J2
MS_'CK/_@_ .7WW7U-2BT*OE=W\=E %-B8JC4/N,,QPK:BXBV&IKM5;1.T-IZ
M8F5L8>(B'..R5GH!,'3\W[O[S6\"3B.U=!?^WW&LVHLP3Z-/+\3XA>>.D[13
MBRQKR%%R0C# BQ^]$'^X0G)X>]*TN1B*%6[VY#N[A[;>MAR]Y70V<O +W_W\
ML;QZZ==4YE^.9A\R'^^^K/3 \I="D7#ECRG$YHO)L*6QA8S[2D(D3X#"MY91
MJZY,I\9T6/I)C:RPG)<#7EE$G9<W82XNEXJIC=AE.$VQJW> ,3IVNU8HE7#%
M2YIH\_&UXE!8?JD68Z4E?3_0;'.>79XX!2LK6<0"7.A,$VK\&OG,4:K8>HDO
M\=S'+L/NQSQXTZ/BCU["<./(TP\OO:B8V<U.N]MNN[;KK(W='0/=$$<W3%NW
MG,7YW6+\WN@@"J[ 9^Z^?B92L!R$ZLYO2S?8G"UU,92-CF<R^L,K");*)'1-
M>X.9!+)B:6.:LITW6S6 ,:]AQG O;!\M+/P2Q3R(MPLOP"A76O.31@+5&>^R
M@[9CI8VS"LF_I^9"VFTVI9D"K#ZJL/LR\C/ 57/Q-VRUA^]'P>A)% HE? J7
M+(R84!+B%>3_-C[(L_510XTUU.9'#?5+J!=%(C"=LHID=?=ERZ;+58RRNS>K
M8I2X4) V#O/4%H&X:\H0>QJ$2*C8#!%"X&YALU),=:@1FZ,Y)"09/IR$!BRJ
MJ"^W?O+(NO:I%D0.CN&A*'RUZIIBW>H!*\/&[M?;40"* _/!5 :W#]HN4M7D
M/?SL1?W[)Z$""3((E.)_N(H*)M-9PMIWJ"Z%7H4J*WT(2QS*)]$\$?;E>^ 6
M+%?A#Z5^M]G$XS,T<3H*RU0&LG.(6@G95EGJG$$V];&UKQ"68.^;_^"/0( K
M1(@_R0IM'-LSMX#P-O:C!XZU3]OC3[&S3Z&-89]DX$>B.1F36"O@.OIONS/O
M618SX+YQ8.4!EQ=*4S5?9B9K59K=:I2F DE>F'^BZU1SLW-1*/E-J^JKW5:[
M6QW!4O(=Q#:Z>HWG^8+*-. O64[=2WGX4XY)56-QCJ$S(:Z\F_3!46^"HZP,
M1W$V4J""ZF2>1$K@+: ,Z05T I^7)7Y*6;681X<*[F$E4^*#Y[^:<G3Y<^:6
MC)44[.&_H@#^X/8WS^UVAMN+-*O$UP-]G8RH"FT2"F,&C!6/-=ZPCF^:G".Z
MY3F\(@UJ8/"(^,IPRA"&'B=JHY@N;X$$S4(#+6+&%X,S$6!:B=^_GP3@Y"B+
M4[MMU,8D<7\SS3/<=!K@TR-6&:7NG(KB8BP6RG09Z7/F%+:_,7-#M<C&-%*%
MNA$2_PZLEO_P.3FPV+2C?H2TD "7108=+8/U]^"]5=:@ODRQ'+$@2WDE!RE!
M\D=^\B1+>@I>I=U2$P4O&.(F%ZV0[9>7+L<9(G( JN+%'*Q3=FR53X$F)I:,
M^B0_U:X6O<3B36]'R4&6U6B!0^Q/$W[WF.I(J_KOBZKZ&P R]VB-2O?#,2L!
M+/)F[8YIM>SV^A(]CED=^=93B 6E*I(U_WA:@2=1/&)EN\)HI9&'KSZA7* W
MMI)0@[O)4$.Z&06.\+W$M270)M-BJ+E0-%,6:G\43/[*8."H9AJI3<[I6/+*
M,6G3#Z#V&J2,PB<&4VT[+V?G!IX2&T>Y,L :6O6+);7%#&"R@T6Y8F:D\B5T
MTW_W!XA@(H9$ONT3Y-@H"DAHOKR(0^J45.?7@;M7@+J73!*]PQX"5LPV82-J
M\9.4V3 1%?1 NT:>D1_+PB?A$Q[%&P9R2A65:4N?8 I."X9.N"G&2]9%17N?
MMQ*PI.J^4NA.]?E>GW,IKYD?/0D!3;W:B@[<0T@<6?].O_N$JY=UX*SE.F:S
M/^77Q"JQ?!G,D_\P6W84(E5%#"R]+Q)TE+>,IJM%##TV[I3B88BFO8_+887G
M(1_&1XB#<#*IVAE&OB^'^17=8O3[_)^I@966S=.<15ECSQLID!5D!#++;P24
M*FR)I\R $EY$7[=V"C_2(8A&?EK6/V;P&\L1/6^"&W//2=\L9^G>/LFK\4CC
M.M&D?F&DH":HH>*B46GE2K3I.HO9:[6IE!O'K(+U'>A.@F1#2[<8E(U[4G@-
M;"?3UW)]<HSPF\.A.CKY:#9"D/ET6/)U+QVQS'2>V]/X1"VA^<2,4GR9'( H
MDL-???@%"K4P[3&+F<#!%B0QF8CN'ALS,?1I+A"&QME,H12I;^BKH)N1/Q*8
M^A4ZY. Y0Z5E%Y&BYF\Y&OQQ.,%;+5 F+RBN=<$==YD;'PPB&I&AMC'Q9KGY
M&2>R IO!NE#@!$4@A^)'(')I(#$D&/P#LD XF>_L)W@Z>C,X!E+1X=@$KDU*
MU>[\RECWH$C:E'93H8SF:I/@\R-"!A';YK QM6\5HX%C=*R%SA.L+-4R26,^
M8[5X/0=J8R,R7:I&J[_(_%;0J]$=_VR^,8U:XVH>SO>''ZVP7_*OB@NFUO+&
M0%1TC1ZJ\[FAE?#K.L.YS6A25@C"]XCMUPD/6VR7VD+C!TPRNFM7E(Q$2V$E
M^JMM;E!_J?O2THV]"T7&;*<87@YG)R6A3 :GB*PL%<R'Y,0JQ7C7(^(*(!+K
M-)S(YV3[=<6[O.SW(TEQ#LW)$]K8#YVK5^)!)\);*7L&7X[,ELNQ-7E17PS&
ME5 7MD#8(N F4,P,CY['K+A(S&A\=H51<[F&BPK?<?>MW$ 8O9!VZ,ZHW;@>
M]U2$C"#IA*=3(IV*.BNW272( -+9!'M>;[R?JQ$8FPP?L:UHL)<WCMN7"S3P
M;![;?8*[5_B>[%2VU+8R_D.EE;3/Q%AY#NHF[[Q:2<G!O[%[7HXPRH$R,TM5
MW-7\V@Y2*SC]=2E87\1 >&=")ZLPM,( JX;P@X??BFFJ)6]A!3W8 <XPU2AX
MP/#8X.LDOO#5B C/3%!>RJFG21%_XE%#-;YNY#WR$: ,[S #GD]E1 00J*2F
M"(Q.V1GEAFG@#C.#!#HB7PRCVP%593$#FG HO/2[LBIHH#.Q+&>0Z;Q[9=9'
M2YH?A'("PMQDH\O415"M$[#H?]:*^UX[@WP;BDK;'T6E6%1JO;VBTO7KBO67
MK98-;)W3!AC9C!A2"\.5E"*<N3]\; A+#&?TBQ)'956-+(-?#8O.1E_P^'%,
M!AT]A67L[^$O]P35@S@CV60G;[OQ94"]\/GJXVAX9[:;#X7<-&0PZ#$-22&T
MT)R(8[\GU!_\0N2#&IC@\->()]IO_0F8>$Q2LO)/3@F=?T6\0QMCEO769Q4'
MH^ O1*:A^B".TW^+5F?,X_%DH/L_O;$828:S8KR?I$]G\&:.^$6GB$?GC>(P
MC=/+@ :"[_L*(?1<"%ZG*581)N_I.$!OC5AWA'+Z=-HX^'0L5)6NPNR26I6(
M\@?:D5H9,#>H4W&Q^<P &E"%,"(L7R!R#!$+T]>A%]JNW>TZMM52T0O5H@/)
MM[D33W/J*J,$Q<LN8K"W/N)/LG*,S!"Q#%41LZC!QME$D05D;(G[0:5QTL#C
MD,D'E7.CE2*)BN?B>-90MM.(I3([LVBYN2EN<0[!R'OT(E^,P*',G+"?V7Q@
MQJ ,93>U#U6.$V-R=+88;T0I5CD[> "/X2%;C"#26"#.E6\0)#I/ZQ0PF2?#
MQ!@J'^%NG^#-VED,3O(@3@=;T#B<4$V.TGS;)U%DR>W@?\VB(!X$?2GQ@UCC
MO57\;)5FV(S^RO@D<-E'<[.OA%S(KI"K'\0-\P>,OC0N,<YA?^7%"4DB 5=&
M6;#_^%&8#I'D#H%L#-O&2,&)%TV 3/&E'U%@>"4!@^XF P;GX-MR1_@2TQ69
MN/>;C2#DH)?5C%G.B5=T?CZ/AF:(U4KC"8(YB)!$/YGT0BKSRS9%8,(,)B 3
M$=S!!Y,'+/-@(.;>\V_QJ7GL\# :]^!':*^G8Z+S.(.(*"BR[0I$/P?FY\:<
M^)E)Y>_>DR:*Z/;@Q3Y% C]I8IIG">JKH.,@8..7A+C+@=5G<C4$2%F#/5F<
MTL">?HYGG1N++= .O5&? .E9/'00C&9)&FB9)S\BYU,>C!I,J?LEG@?NHY@O
M#X@06E\U+MYU_]X?S$8X+B0G,L!2#/J]R> K6]=J$/,LH^5V+-MPC'+$/,="
M!TBBUP6>&C&>U#$HF8!8:C$*'P^*\>VVJEJP&FE/H=?KP<%;&.!G 2R+>6P6
M>A=L#JGZW[O6;L7#BN(1]=$=E$ @AO]^&WT^1)$)8HB]'K'NV&]!(/'9@[K&
M?D-0'?2OO3,IH-@O;KB48C]E9)7RW688*'.;7 :\9QFHD]U#D@_:O"XIQ2\J
M.*,%P9_6NI^KM'"K)+F^E3NC?W_1<&(UQOT*WTOB#Q&[OZ@*GJ7]>:C[->Q^
M#?B:SR='[E7;@,4)FV*6\K<PCGMB6/I-J*!Q\D0HW>%"4)RN:70<Q[;6UQI@
M[QZ:>K=MZFW3>57(G&\,G*[Z!C66,5_]24CQ4"*E,/][W/QGL-P7J:FO/T?B
MO#82+PI]F3-VF*:=<ZGF_:=%B%II6+Q*\#O!=)SGSLGCO!BR;2NLM[C0:[>[
M;L=U<5[0,X6> T+/UMUN1W?:]7C$+PU\UT 4+(&!YZ0\G//>N%N['#I>';&<
M9V#>K0+@;F'^+73 %U/.3JMMF$X9GUK-^=3=/30.&NCE J)_:.@-:.@&_LUY
M.-F?4P]'^7#<FR%:&8CGBOPEG!(?S5/SK5HP2V X+TBY!GQ8N<\Y ;T)M\EL
M=6VWZZQOKB".GS-UP[!TT^DN@>;](8@W[BJ5FOG5'M1BXOO#NF]\-U=GW+=W
M#UMZ%V>-=%M;9]NO$-2ZH4%_E!?U"_+JVS7@2]7$RNSWSMKM]Y<'@7F=Z:^F
MYCE/LWXD5#:]LX^$RD="96G/@-_B#:54NI12:=FZTWE=P\X^_(2/E,H&4BJL
M;H[IW8_TRG(.&)=X<W[89A(L($3?=8)%Y>B/9,L"OMI2BGM5[IIK?J1;MD>U
M?*1;/M(M6\V"[RW=4B&;UYYP<2U*N)B&;G?LCX3+5MV#%3E2RTOJU9!T[6;W
MVC,?KDV9CVY;;QGUXPU?38KC:P-#^MTG.981SBNSFYT73W-LR?#,C:.J=#Y0
M51!5Q7Y[J"I;-*KO.)S@!AF&ZE40_W4,@A8D"?QKF0[F%I@2&^Q@SNR&1I;3
M;C3<SMMM8$XQ;#,P^ C3, T3A*(A!%T9?E+Z=!-"%<C2K,]H%@'-)!(OPD$@
M.J#LB6:0,%GH[B"9,=!L O%"%!/:\-A[(DA$GP%DGX(BC^ ;7WU"?<"!!K.(
MP%J.PPB!5.D9_9";CO7C.(YA6:=?SX[I06#%$1!& ?/:\!_#Z';6Z,FXNX>6
M:^B&,1\7/=!Z0.\1.&)HZ,P8['&$V.0HE9&^?80D(QQ%!)]'H,J8PVS<>X@L
MG\'8\ :$&JX%<([]I QM)CT?H,: (^ PT YJ6P^G/J-WS #,Z82'H_ Q?I53
M0 C_5>#<K@"/H669FT1\%3MYLY*K%+PQQ7&.Q5 X?VY4@C(C*/-[50A*0$(.
MWAC'$OXJA2"0UR6>PIV&"Z;A]!"&K*.@%0K<*3:114),\<D13L>@+_ I$@QD
M1WFE0$*($8"0S\93 :MQ(E;=5(2X:'R!KHU]GTEUFDL6"#E>,_: W?C"Q= #
M06<48LCB^12.LU!0-FGV"1L>BGLIW;&8\B 0MW/B"R>>Y9P]'8&.X)$,^49*
MM8IEX4D$L7(4>A[8DS#,8W\.8OY?L\$=^P+#?T"\2S:! [_Q_[?W;4V-(]N:
M[_,K'#6S)R#"L"U9OJA[!Q$4!=V<Z2IJ@.J.\W1"V#)HRI;8D@W%^?6S+GF3
ME+H8;*!H7KH+D*W,E2O7?7T+E1M^1&Q(@_82VY!X#1$6--/#. 3 1H@9)$2R
M@'7,PS)5C'SH&P1$PEY_,?"%QL]-^=8J"I#=4N3 "=P[1(^J/N9NF8[B@*<&
M-!T-X!#PQ0(8GZ[*E-D(#AW'$^_A))K@%@->Q=.6I\RH*8W[F"8$@Z*VLXV]
MY !BEPJ[A(%4C*$OPD8@SC-VPG* 6#6'SLP/$@H9 <;O=X[T+!F"<X%#7A 2
MB/F2(A!_:F(",NDQG$.6QC6BTJ$89ZN(@:<EOES>/GF#%^&R2*>V<X.$Y$:
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M>G$Z^.T1-YH(Z?@$HXC=B1TX'DE$FW!=LS$%0W*&AU+E4-ED,4DAD>0 1D^
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MK<1:P?UVI? IWK\IUQGSL/,P5W$[2;)E=<7YDGM/FTO7:HOQ=1&^K,HW_FS
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M_?Q+N;>W82)W/4:@6:OYW/(_F;UW<"&,&N<IW (8_W*F0R66<2YDJH2.X-K
ME33FFOLH#=RTB8Y4($8JC"]W-UO'#E\Q>]\TLP6W.GO3W,7;%7(4YQG=9WLG
M19P*^@-^2\68?]Q';E+9]JVSWO^H>_K[X&CX[N_/2&[>BVA^A/?T8:\?D=]F
MA#_7)C<*;Q7<)!A%AL XHKTD'X&@@JOG7;'*%5F_@ZNW9+-UP )NND_=^[U+
M&R@36[X^#[CR3W&>BAC.=DIG9DCA2>(,GH&C;[="+4<ZU-E2Y!%R0(\IA_(2
M>2S, OSZ4F<SL<(F@2T"*1GBV3(TL0 F&98<N?LMOO=Q*)Q)&B]@IW"W10R,
M::'59;ME27X>FTP8&%!/@%]%F9 F ;O*P/8NXG !VP<"<&6KNZ(/PRQ%H%-X
M-$X[<'_@;972>:IY$L9+I58OU1S6"]JB#.BI5&52@\:9E0O=WA$U=AO9;1L;
M;A?#WK#_O@_<Y?2M&+[K"_9!W+L-9Q6)^[@S_M G\3K)=CQZ32W'MW:9K]:U
M6ZS7"3.38?A$39U&A;IW"P88[(8V#+!G3TS>0I&Q]LTM[)K-%C*.([A/$8KB
ME268?#Q;,4X:PZ2Y50]VJX+"I;;AW:HQ]6]SP;*8?S!B1WT9*SA$>!_D\A3N
M*-HY[NW-%I/D*5Q8A9J9D.-QG 82+ASKPFXYL()Y'L'YLGI-_CY@"_L"A+M5
M P.4YO -DET(L#?C,#9P:S=<#7P>; ?H<_"''(6@#<:PMBC.A/J"&B2-#L)6
M)QHN&>X),;<JO^K@!GK'(S9VX?@V8KGOE[,8+L*R?LHK^!]QJ?43W]W?T)1,
M&][6\+8'XVTJFLKIYBI#R;3DF/D:LJ\HR,=\5>5GL**#!1B$,'J]=M X1+9A
MIBLTSRG&#:9VX,=^R$2OD4 Z&H=Y8",ZEGWG*;+.-,ZG,W$)?"Y3$;)6&>*Y
MJA#8<1J#6!!S)4$LP &#$6-9N*%'HLPR1QX=E;A)"HP[,)UVBW<37IZ/X)6.
M&.4@+X!Q(L5D$IT%SG0R3\S-TE^HB,Y!)HF2*0ED.#4]AT--T!GJ[A0Y/T;P
MW")&&8Q'D*3*J'2A?'WBN]2@%]. X$SRC,\;=0<9P.:29AV+F89#5MD,.9TP
MF8P"F0:D^=O)NJ)'Z@$\'RX[[M=V"^0>2+BY2A4<ILFG4V4R%Q<$*6@];[C\
M%<\:2E)8>Z#4'-UI2W_%'?(/P3@F#ID<4X7+[N!2\8/%0L>AISMITVY=Z>]9
MC_5O/9CV]<12M\C;B2HWZ7_M[8FW6H7!K^(,^.L^C/QGKH!X8 %B;\_B=UX?
M#3ZZU?GCO_R^9H*?\+<1G+I*B]\.0CG^+%YV7\$WP?'H ):P\KT<IKO_SW[]
M'#ZFYKM&H$!^WALI('+X^(0VPQ_TIYI!\?O]+_$NKW^\E2F]'7^.6\Z[_,#G
M7R4]_N^3\TEN[)1\VS_JG_>.Q7'O=W%V?OIN<# 8UL"A&J )SGR> Q=^^6*T
M]\J&4)!57Q3&3[O5_S*>R6B*N(\,&?++7W[XL2.D$7(.TA[8^SKRPW]E%?[1
M$3-X=Z1 # 8*;L*<(RXL(L9QGF:&91WK.$ZDM%OPB(SJ/*TV@(YK0R75\VWM
M!&J4D;;R9PZ2BA\IC.Z8!?%(&FVN"--SX)SL/!?4:[>.5V).W@Z.884@V,.E
MLUY1&.JH5F#[/CC>]:I7#@B9T#-@>U>=!7H"2P<%7IM;00W*X'_ISHM-93:,
M@)'A&W0%G*"O8]((4PD"/EN/G\&7$HG@Q]9\H768 XTZ)[HIG><<RJNXS^&G
MC/3,C$B=<4(AJHWP99<S1<_"7J'+P'>IX/&-4#,B.I'"C&<J@$,)R)68J#%&
MB2V!CE#"P898<D255L=!]QX1B(_TWE]-Q>T6JF\R T5]1GL=1TS0Q3&ALX0=
M);?V#*,-D%&8M6,G!,K @)X8ZW2<SU$M'>-GP3P[>K>8"Y70V!DM%'')=%*/
M<-,)VB>[=/5F.@U .4@9GJ.S&=T!2[= .W.CP@5.AT2XHV'"ZBL[=.<E$B&J
MHO@H<"!GQ4AC8B"JC*^N-7MV:5MF<D%.+*4Q$EJSSDD:S\N=Y%4K>!D7<NV>
MD@..7VRWJE9U$P3=IL+Q<5-] ^.>AZ<G%_U_?>B?'/8O2D!UHVM49AY$@5[H
M( <VX/$0(&^'Y6FWK@+SV(M?Z[S=);D+IJ/)1W\H]D>A($Y32=;I&"8-Z8*-
M4XW.$O1DP/_B3>^*C\[:M')0?E91NT5P!8/"(3? _:Q^\J%[T?64(QJS4'9
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M$Y"3I0@,2ZV*JI(XI3B6KM01\-1CX]M@M&Q4C@V8&F@ ,JS%*DGBY4^.T5<
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M;>_\_,KM=+H7'S]4:A7[?'WEMF?//XFDFJJQ13,OZ*LT5:.B;"+#=$CMU=Z
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MBX6,PZE7@F^AC%&1#'AB=]<W,I!<2]J"S!(,&SIBFBHU%/.M3QJ;(%A:549
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M#BN''^F@<F.M5J'V87&FSXG]^5#.6OY'=[]RH1<;?]]2JWQP]N+,^6776[;
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M"-@='0;]FA/H67-'CS[]BER\,^M7Z[\!4$L#!!0    ( .*,?EQ_9 0^X@,
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MW$A<+"*<!SV>,1+AO--Y1CFM"',)- +O3CL;=>P)M06EDD.K:F@#X,%3@Q:
M>V1%5<DA1D<*!E46A!--YQP,J+#\BFX8OH-H^6()6A)TR5O3@;)V1V$#,183
MX'P/&]X1E)"3([N+PP&PY;KSS,#H\EF DA@<81MCS5N<@VD4 A2!PE"^(7DZ
M?_PWG/C8@J'Q4G@C\BW<4RH1[%8^FZ8X$%6\C9O8*#1$E@4=_ )]0-V#J_C
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MU;:?K*"0]:J-UI2-7]N*VHG%IJ;[C 5ATU04QXP<ZOL''VL%YC$&(:C>'H=
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M_.W9[^18_^/U+S__\/\!4$L#!!0    ( .*,?ERG:/N@G!8   "+   5
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M3MO Z/N=WGFOTW\BM19/H&*N7R(V#%]Y$QU@"5R$GI'Y##FF4@JAN5Z*&(
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M$I/6O S61M8X!:[#$:6H@C><W<+PK8=,'[V[Y&<M3$$GCF(<#]D-%;LBQ20
MWZAMT]A&DEB_<88JV8)QI*GQB!:BS_9X*6LBMHEY/XXVC3E4,>B3(\SC"3O#
M>9ZC*G^\E)ARYZA[2L&I)0NZG\1%><24B*F)I:"-+=2R&7[EADQWMUIZA.9*
MCY_TNKDF8,9[P]E"/+VZ&GHNQ&X*^Z1IC&.>CYSJ:2_-F#<6H$9:8IPL<%PM
M<ZS7B,P9>9J#H69= <Z81\[R?S)9I!Q#HEYC2R+/T,:1,F7@!A@33"B-*&$0
M9"AV%Z/$6%!0P&PAP\=X8'*0LI?C+%27+0_M'2I97.S]56F;K!QHV&N[LPZ
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MR>2U*_MS:J.J4Z21W?&@ J/L E:4Z@<*YB:#4Y<RGU-KUKS,/BUYF;UYS6'
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M&_[5?X\+ 5+"]12'7M<-#H^4O[*<<N"2JL-A3H!S'K,-[S$9V1_].2M*@%Z
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M,"LACWVTC*P.%2Y8HV=1/OCLR&6F!:\-G"FNG\R<RZWA:ND3;[[N^:DC-ZX
MU.7AK4"LA[#H*?"%'07%; 8T/SERH6XT]NLH3RD]0;HR(K/S<S'?4LIX@0?C
MYP#.COB47B.W](J:$KA,^F_T[EBX#+94AU6JQ(+I!#AK/X>>S1-'P4P\K#+9
MJ_D4^,:.PAR[D'(\0\M/HI"^NH^!+^Q(&FW@!(7X,@.5:D8/XB;#B0>_ O]Z
M#P5-PY%<VY="N,^MV 5?UY$V(8!,#P_X'HYD+O=6^*)(J9!O NGB*+&""Y@F
M;^WIY.<GCB0E%RX='. [.+K5Z@5+/YE908)\#G!FDBF(09[ODYL@@-X'P)K%
MHV4Y,A??LC1?OQT++W(K@/PI3*ZH&4+WQZ6&$3E5SY$]IT)P!*N#>DU"<CT5
M. (>]SYY0T&<!F5.*ZF; TLN?Z(CAFBCZ:?E-4$>UY.6$CF4&3!U?0]Z>2]5
M#PTVC^#<[Q O2LOFT,J*QP=[9(^].;*&+H$J >VXCX)+OK+B4JA#3;%K*CA:
MFMZV5MQ:P5,+IPXWX +#"CU_4A@,[P@3?QJ6.&T%Z%M4XG3<=L'95I982.TV
M"RX_R*[5B??18?7]MGBH=FK=)WPF3-7WAZ6&/WPC1&Q#@WH>1BQ)_%'.L22I
MX\3T]]B89I!IG1NW&61:3=B:R@$3.=4WIL8C75B O4%A!-%]%<WY9:?R+4_=
MLXY96$@ XDTVHP3)53Y^SC( Q2R6*P#E=\A=I5\RCX=D=5?Q8.&M>^KV#"OA
M!< L6^.MFN'0S_),A0&PB)A(JCT4R*[5BF%N_SXN6_%74H#L5EIOLF[IUWFC
MY_(NB89,R*Q2D[_'Y63[R'*!U7X*Y<6NU7#8U^@]GLZF7S(J4*B%1_6P$NH3
M;M,R$Y3&8K<!J&;!40&H:\\N%0_]<4ER,1OR0-;8#B?>ZB';56R_9>6Z(.0F
MR\<D+F=\"8#91RV!XT;HO'CI8W9!EB\CH]OQ #3U),D6B?CLYKX%P*[?23Z,
MBTI>AH4GPM<PBZ<*$+RCZD%<%%D^IZ\A=]$<E*";69+,_RCC)/X/M4<8?]P-
M>,C@=\,),$LZ00&^+1?$LEJU!ZAKE7T$>LKU^RM5U@AS)6VK+_L2CEYT7[.T
MG/ 3!JP\&KZ+U>.M4,V$;2LP^YZZW7.KW/_P2M^0Y6*.V5D 5[E56GW/\K_H
ME7P9O<9EE, %(DZ,5F]XZIZXRNCOCZ94EP:71!F_D1M"BB4?"E(NA.NI;7'J
M*(NHG[#G+L.D%Q&5MO0:!*BBK8,E0@BU&1161]BM;O;^QKAB?\P)D2;'*/?!
MH7"4X</15AY*\KH%ZJ*(C&IBA-ZUY>T:]-MTF,S@S% =HB#_GH&K?K.+RL8A
M_9?H1?2UFW\Q*.DAMN'I==Q"O52X!_D].%,E51C"]7 A.LI6YL*$^02\'8"'
MJY9(/*A6*BRSX#=5J\M?BZX.AJIGP>EQFXNZ"^]:YX=^J:R?ZB75\LGH8GX=
M#2>[:W7HH/-<X ='>=*:L.]_3CL4V7\JT,-59FJ=EF'T:<ZAOL!"?;&!VI5,
MW;A667\35CZO+C]4;0,)XXA[KLB8Y/FN?MD'WGY9>,NHH7=+87R+1[,HN8R*
M2?]'E(^6_M-%CQP!TA:>#!JNJ]J8Z6N2S0EY(/E;#-,B>(KX-_#/%0 N@%X\
M9M2,VOX=.KE\R\I_D?*>#+.7%%P8 FHU]CXJF5S5!XJ,\(OY]B\2M0K_ + ;
M7+4@9CTWV.'^%DWI'[<@E:I;ZHW@H?  JQT?(WC6R>@VW0(6@9_J$7#2'>D3
M_*.V):DNYILE=]$<_HF=/WH:%T[5E7E6E/D,?BV60DQ$E\9>"%1TQ2];7U86
M?E.N!QP<W>X\[X18. E6@R2R&D?JO[SDY(5*NS_2 O10H-?*\<R]@)&[0.FP
M7_^UKT)?)-'PKVQ6+@/0]"O'V<*-#\R?L!:&@S$RT&3W#:"SVVT2O5'SV'\8
M7S_F\<N+H.I-LAZ"!U8#O;RL@,N,,0=X30UR"OB[ 7!7.ELQS+,?5^0U*V)A
MQ>SV&@JKJ[XFMW<#J=FS_AUT $?TW ^=2P'F+P;H'?4NV%81I7I8=2'(<$<T
M%ZB\^DKR,@WKW"_='_TA.+KPF2MOL "N+XI. ZIMP&6.OH[%+D-=5QS&8%@H
MD%>S?'WS+Q,ZR _VDQ@AS&;@.4<MVP4 ,L^1(7*[>P$W1[X_B%;%HQCR8C<F
MHHS[1.N!^QQ9C2L'<#\=+3S B"9DDBV@C'N(R2/)IP;8P#;0KAW9HLU&IT6=
M',*(IWH!O<68I%M\FO;]N<6NK@;M#_3V--!Z?5QZ'7\& "#5TR4JF<01H"HN
MP-+&GRHHC"6R1QAL>0.RTD?=W\%O/D%76 17\8W-8=LCB%%E!_+DG'E#'#-F
MT2@M05+$HQIE0Y+8*6#!DLN?PG<S<IE6S6"OIM#I4[=$!]E H1/ZL3,N"\(R
MDC]ES38(9*7@"$NZT%6BFN5-6#)YKPS(M&BCFBKL)>=/BSXS!FJR2,M:ZQ>G
M;>>LTE5=+!:<[2(,=>Y11%VHAE0(0C]R^B5R2,($[ =:;=0KN\->7P= %_/J
M/<\$"JIYDCP/KDH>LQI [!T?/OLX*@<,D?54:0E5XB*K#)'$:$G5QHWMUM!B
MA'1!%C!B#Z-7S*)"$4D423TDUDD2OHRR5T>)9:6 _292HM4NNL02T/O@FG4"
MHFHT@VMY*KS!./3"%7QZ=O,W10)9]2CR$!V T694BNJ7.M0D>9HJ6L4RV %(
MZ78K6;&-4P]&4Z]9$^N9L,>9>8K\WRJ1#$MK_6*F)@]I[=I<)*D"CINO2=5N
MN6YPG>;K$19= HP=C'0P@EZGOABI7O@STLTL&F-8U(PUD0-6[]LJC\9&<4+G
M-.W2;"QA M8=;!2"8^V@ W#WJ2O-/=/%U;1 J]55:LCKV8.CA#HT4"6!1H6\
M9_1 66G:AJG<MI54XOME>[BS^84E_MC+R*LA3&HDT821= SPR[QJ@7?T2O>1
M(<R 4W$M= ! $ND W.'FG03\BJNU<<ZTFA0@)73 UH)QUP.LM1ZPB5FKAX*W
MNJ%L4EPS28+UBK$](Y&U9+::)>J>D<5^VM9A<4U3L;&#HE)SMFG=?A!^#?1L
MQ@9S.]WS83:=TN.1C1_BES0>Q\,(TJ*'$"T A39+XF%,VIWU67^Z4%&0LO@'
M25BD=E:4E[,\)\)6[*+E].M\LMH!=4GK@9S6PJE=&ML!](:G9W$;H7*6P<!P
M5[,PHF)_G-OV3U20GSCJ7W<3Q8O<LHOY^H__B$E.!=)D_H6\D432\ VW&5C
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M.PHT;0.S=<D6,(QM\XOD=L,_ +!TUC//H'G->;6_NP>-A/BE ZAV9X:/A"O
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M!I$,6/X[_.>9WMG_]?\!4$L#!!0    ( .*,?ESJSP8 HVX  $P'!0 5
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M3*=,V2M"RW?SRE*N[30$+$_UD=!5I9W$9[:Q%8S!(C![F->^CVN_#S4^(1T
MA11EV:HPA2 >NI^2H+P/M*XU'/-LNGM\";_R4L]\>VXN/A2[8C^_B8A7S6.A
MS%",J9TA3N&65\E;N=A0[#VM<11)=-!*YHJ%!F-MXT695U@U;\520S&W\-YF
M 1OA/$:6QXSO#(M/B_)#,?PSB=@JXE&Q'U;K\Z#<4 S^PL;8WV+R&C]A+R$Q
M#OA%J%JCE>7M,SSSEW2R"T)&9Y*F.$EYC]Y$7MD-J*FP?59O&8WH8<WT4SE
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M_.K8K$/H%[@ZBGLB[-X57BO-I=T;V@IXK!!%6T)R+=C9J@J[%R/B$2+2!>@
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M55IS>R/N7$T5;F/5^VQMA?'%94CDVP5Y8%,>4GCD=KPCHC,:J8SW=)$-U4:
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M@\VK78;,)9T+4+FC&0LX9[?DBW2+7W#TH9KYFN+C$45S&DBR+W\*,67$UC5
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M%6SJ/SIE\Q$B8<M>?84?W+-GUJ'VD_.MP!@UUW#Y;*HS'LN.,IE=O[$OPT3
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M@9(/=I:EUGXULR5$CE0#24<AG"=,4OX8-X^QR(NG%,MY><_^]X'-:CZ5)W'
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M1@YY$"Q@^TU)#%9N'/NG((GJ,R4GR[W:"X31M_<DQ>B/-@^1/<H5.1:I+C4
M?^-N>!$YST>Z 056MOCJW! "9KGY^>LK4$;)HB^4(@/H9;H'&:LF_$F"QA%B
M[:'LAD?A "A0',P94QXT+2T+B;AS*4\DB/834%7"0>3$(9*U*'#,59N9*1I)
M&PW[0GI @2^% LEZL@62-;0V#/%6^5//\B0=+0M 8A:15W1S%FAEL:9DMUH_
M4 +ONH3N82'7\>PZA1:IP 6?)*F4/!4- H:$;!%R.X$]3^'=01(>&^Y^0VG
M;.L39@O9&,I;0WSG+& ;GK'L!Z@D!>C,HT: S6?1>YQ.O03D?@D#'%SN/R<
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M/^@UO>CWU,/]<\",P+U)T\JJ4/)9LRC7C1<*+#23U>1.W.Z#.4!S["CL;ZP
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M1V9^'6T*N;O+$U[!2O>(MX2*J,3,.G&YES_V,AOUB^03?L&4[8Y_PWMVTH$
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M:/D"73G11H^!&;5+[5!AI)]P#"Y.;.I/@DT8A^"B ["/,@]I)Q0309K/7Z]
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MZ%2#""=#/#0V=OR=&2AJP:F2YL&HT;^X99_8E^HK]I]G+\%__?\ 4$L#!!0
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MO4K_&!$BK-4FG0>7HMZ=-+:G@K3RDI#W JA9:R4JB1'ZUB:C+>BC8.JOX,Z
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M]"E3H]KA6FN#S+FP-R3G1QD^2)I+B]23:*FUL>I$H$ND8FL\X#:%/;3IDK\
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M9L6RFUD9-FPT'G\#UN^!EVA %8]BJ.Z>EK=6VK:)]6'S]91FSN9?H = *$A
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M-#4X+3$P:U]P>7)O<&AY=&4R+FAT;5!+ 0(4 Q0    ( .*,?EPY&RBH0R0
M -?S   5              "  4V& @!E83 R.#(T-3@P,65X,3DM,2YH=&U0
M2P$"% ,4    " #BC'Y<*LXQJ4<'   Z)@  %0              @ '#J@(
M96$P,C@R-#4X,#%E>#,Q+3$N:'1M4$L! A0#%     @ XHQ^7#C%R1! !P
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M,#(X,C0U.# Q97@T+34N:'1M4$L! A0#%     @ XHQ^7*=H^Z"<%@   (L
M !4              ( !2BL# &5A,#(X,C0U.# Q97@Y-RTQ+FAT;5!+ 0(4
M Q0    ( .*,?ESTI< -1A$  /6W   1              "  1E" P!P86EI
M+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( .*,?ESAI .V# 8  ,%%   5
M          "  8Y3 P!P86EI+3(P,C4Q,C,Q7V-A;"YX;6Q02P$"% ,4
M" #BC'Y<)&OX$VLW  #]F0, %0              @ '-60, <&%I:2TR,#(U
M,3(S,5]D968N>&UL4$L! A0#%     @ XHQ^7.K/!@"C;@  3 <% !4
M         ( !:Y$# '!A:6DM,C R-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M .*,?EP<S2$TE44  .&"!  5              "  4$ ! !P86EI+3(P,C4Q
A,C,Q7W!R92YX;6Q02P4&      T #0!I P  "48$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>ea0282458-10k_pyrophyte2_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:paii="http://pyrophyteacquisitioncorp2.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="paii-20251231.xsd" xlink:type="simple"/>
    <context id="cref_619992257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_193655120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">paii:ProbabilityOfMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1954112812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1680536946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1779705651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1075758566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1064750139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_246701486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_200602150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1093905091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1330416410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_333300986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_779585586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1486745643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1062301092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_73988315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1879775354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1292095244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_157283163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1284032524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1618928315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_668677484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_87236569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_22280331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1901841206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2120962183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_874887864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1104949232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-05</startDate>
            <endDate>2025-05-05</endDate>
        </period>
    </context>
    <context id="cref_1318038427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-05</instant>
        </period>
    </context>
    <context id="cref_770479516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:FounderShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-05</startDate>
            <endDate>2025-05-05</endDate>
        </period>
    </context>
    <context id="cref_1692716169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1491172312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="cref_2109124231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1950299307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1549419295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_1113090420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-19</instant>
        </period>
    </context>
    <context id="cref_525945823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1626106670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1462063775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="cref_1093598802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1940925763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_61013207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1272538016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">paii:InitialBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_329624284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">paii:InitialBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1595368894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1844658907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_606805414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1830146596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_820702892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="cref_1609389963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-05</startDate>
            <endDate>2025-05-05</endDate>
        </period>
    </context>
    <context id="cref_2136458884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">paii:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-05</instant>
        </period>
    </context>
    <context id="cref_259502220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_745494576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1273128513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_474135015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="cref_1057160995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="cref_726704442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-24</instant>
        </period>
    </context>
    <context id="cref_1673988012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="cref_116935946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:ClassBNonredeemableOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1891084432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:RedeemableClassAOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_638126375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_467896768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_891586060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">paii:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_454030801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="cref_1352642449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="cref_700951886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">paii:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="cref_967608479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="cref_947942404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="cref_1953308297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_923664865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="cref_477826121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_2146548669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1079647625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1759141991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_13105706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_55172024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_532706043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1270821457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1356153804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1257381007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_500152996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_92406311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">paii:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1220869833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-24</instant>
        </period>
    </context>
    <context id="cref_403242642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1607445284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-30</instant>
        </period>
    </context>
    <context id="cref_1134978814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-30</instant>
        </period>
    </context>
    <context id="cref_443960089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1069151183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:ClassAOrdinarySharesParValue00001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_536182311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">paii:UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_575041159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_1124168248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">paii:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_794524015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_50662810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_337383641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_226959058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1343794665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_326000575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_52832062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_1577949154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_1886441502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2088902046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002069238</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="uref_193655120">
        <measure>pure</measure>
    </unit>
    <unit id="uref_246701486">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_200602150">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_599377219">
        <measure>paii:segment</measure>
    </unit>
    <unit id="uref_779585586">
        <measure>shares</measure>
    </unit>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_1692716169"
      id="fc_174561091"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1330416410"
      id="fc_912153279"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:CommonStockOtherValueOutstanding
      contextRef="cref_333300986"
      id="fc_1028152249"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_575041159"
      id="fc_575041159"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:WorkingCapitalLoanOutstanding
      contextRef="cref_333300986"
      id="fc_936727067"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="cref_1879775354"
      id="fc_162488177"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="cref_333300986"
      id="fc_216117793"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_333300986"
      id="fc_1602604156"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1124168248"
      id="fc_1124168248"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_794524015"
      id="fc_794524015"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_50662810"
      id="fc_50662810"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_337383641"
      id="fc_337383641"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_575041159"
      id="fc_930201705"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_1124168248"
      id="fc_441132902"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_794524015"
      id="fc_2113113059"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1270821457"
      id="fc_1534900816"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_226959058"
      id="fc_226959058"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_55172024"
      id="fc_2071760065"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1270821457"
      id="fc_495288907"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_226959058"
      id="fc_592782723"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1343794665"
      id="fc_1343794665"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_326000575"
      id="fc_326000575"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_1343794665"
      id="fc_1488256648"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="cref_1270821457"
      id="fc_346808071"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="cref_226959058"
      id="fc_1769645716"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_1270821457"
      id="fc_661146650"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_226959058"
      id="fc_1020165411"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_55172024"
      id="fc_371079441"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_1330416410"
      id="fc_901471383"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_226959058"
      id="fc_264447317"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_1257381007"
      id="fc_128932335"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_532706043"
      id="fc_2077135401"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_55172024"
      id="fc_1617784863"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_1330416410"
      id="fc_2114542320"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_226959058"
      id="fc_1999784281"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_1257381007"
      id="fc_1161507624"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_532706043"
      id="fc_1015604165"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_55172024"
      id="fc_1858594186"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_1330416410"
      id="fc_172479364"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits
      contextRef="cref_226959058"
      id="fc_1742904851"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits
      contextRef="cref_1257381007"
      id="fc_585283673"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_226959058"
      id="fc_1630524161"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_1257381007"
      id="fc_145799748"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_532706043"
      id="fc_1687994771"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_55172024"
      id="fc_2115620742"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_1330416410"
      id="fc_1261419997"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_333300986"
      id="fc_1169747210"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_333300986"
      id="fc_601645145"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1879775354"
      id="fc_1175639479"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1879775354"
      id="fc_1867186661"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_52832062"
      id="fc_52832062"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_52832062"
      id="fc_996209133"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_1330416410" id="fc_832639951">http://fasb.org/srt/2025#ChiefFinancialOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:EntityTaxIdentificationNumber contextRef="cref_619992257" id="fc_560829149">00-0000000</dei:EntityTaxIdentificationNumber>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_226959058"
      id="fc_1934720917"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_1257381007"
      id="fc_2001304571"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_55172024"
      id="fc_1526338219"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_226959058"
      id="fc_1584484121"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1257381007"
      id="fc_1701195832"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_55172024"
      id="fc_821862778"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1270821457"
      id="fc_1645021734"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_226959058"
      id="fc_1210222640"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1257381007"
      id="fc_1836776887"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_55172024"
      id="fc_244269380"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="cref_1257381007"
      id="fc_915645759"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1270821457"
      id="fc_1539544538"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_226959058"
      id="fc_1861594894"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1257381007"
      id="fc_822270604"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_532706043"
      id="fc_1247507169"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <dei:EntityPublicFloat
      contextRef="cref_1844658907"
      decimals="0"
      id="fc_227438756"
      unitRef="uref_200602150">0</dei:EntityPublicFloat>
    <us-gaap:StockholdersEquity
      contextRef="cref_1577949154"
      id="fc_1577949154"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1356153804"
      id="fc_131930771"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_1356153804"
      id="fc_1789097633"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_1356153804"
      id="fc_444998111"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_1356153804"
      id="fc_1757372007"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_1356153804"
      id="fc_1046165585"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_1356153804"
      id="fc_878587040"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1356153804"
      id="fc_1702605431"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1356153804"
      id="fc_521991325"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="cref_1356153804"
      id="fc_346553776"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1356153804"
      id="fc_1924657242"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable
      contextRef="cref_1270821457"
      id="fc_35026678"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable
      contextRef="cref_226959058"
      id="fc_605456837"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable
      contextRef="cref_1257381007"
      id="fc_1906154546"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="cref_333300986"
      id="fc_1532244282"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="cref_333300986"
      id="fc_1353994326"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="cref_1886441502"
      id="fc_1886441502"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="cref_2088902046"
      id="fc_2088902046"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_1692716169"
      id="fc_899188066"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1879775354"
      id="fc_492491914"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1879775354"
      id="fc_459141205"
      unitRef="uref_779585586"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_333300986"
      id="fc_1781603387"
      unitRef="uref_200602150"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="cref_619992257" id="ixv-6739">0002069238</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="cref_619992257" id="ixv-6740">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_619992257" id="ixv-6741">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="cref_619992257" id="ixv-7547">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="cref_619992257" id="ixv-7548">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="cref_619992257" id="ixv-7549">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="cref_619992257" id="ixv-7550">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_619992257" id="ixv-7551">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_619992257" id="ixv-7552">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_619992257" id="ixv-7553">001-42752</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_619992257" id="ixv-7554">PYROPHYTE ACQUISITION CORP. II</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_619992257" id="ixv-7555">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="cref_619992257" id="ixv-7556">3262 Westheimer Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_619992257" id="ixv-7557">Suite 706</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_619992257" id="ixv-7558">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="cref_619992257" id="ixv-7559">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="cref_619992257" id="ixv-7560">77098</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="cref_619992257" id="ixv-7561">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_619992257" id="ixv-7562">701-4243</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="cref_536182311" id="ixv-7563">Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-half of one redeemable warrant</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_536182311" id="ixv-7564">PAII.U</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_536182311" id="ixv-7565">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="cref_1069151183" id="ixv-7566">Class A Ordinary Shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_1069151183" id="ixv-7567">PAII</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_1069151183" id="ixv-7568">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="cref_443960089" id="ixv-7569">Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_443960089" id="ixv-7570">PAII WS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_443960089" id="ixv-7571">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="cref_619992257" id="ixv-7572">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="cref_619992257" id="ixv-7573">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="cref_619992257" id="ixv-7574">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_619992257" id="ixv-7575">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_619992257" id="ixv-7576">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_619992257" id="ixv-7577">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_619992257" id="ixv-7578">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="cref_619992257" id="ixv-7579">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="cref_619992257" id="ixv-7580">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="cref_619992257" id="ixv-7581">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="cref_619992257" id="ixv-157">true</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1134978814"
      decimals="0"
      id="ixv-7582"
      unitRef="uref_779585586">20041150</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1607445284"
      decimals="0"
      id="ixv-7583"
      unitRef="uref_779585586">7225721</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="cref_619992257" id="ixv-7584">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="cref_619992257" id="ixv-2980">As a blank check company, we have no operations and therefore do not have any operations of our own that face cybersecurity threats. However, we do depend on the digital technologies of third parties, and as noted in &#x201c;&lt;i&gt;Item 1A. Risk Factors&lt;/i&gt;&#x201d; of this Form 10-K, any sophisticated and deliberate attacks on, or security breaches in, systems or infrastructure or the cloud that we utilize, including those of third parties, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. Because of our reliance on the technologies of third parties, we also depend upon the personnel and the processes of third parties to protect against cybersecurity threats, and we have no personnel or processes of our own for this purpose. Our board of directors oversees risk for our Company, and prior to filings with the SEC, our board of directors reviews our risk factors, including the descriptions of the risks we face from cybersecurity threats, as described in &#x201c;&lt;i&gt;Item 1A. Risk Factors&lt;/i&gt;&#x201d; of this Form 10-K.</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="cref_619992257" id="ixv-7585">we have no operations and therefore do not have any operations of our own that face cybersecurity threats.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="cref_619992257" id="ixv-7586">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="cref_619992257" id="ixv-7587">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="cref_619992257" id="ixv-2982">our board of directors reviews our risk factors, including the descriptions of the risks we face from cybersecurity threats, as described in &#x201c;&lt;i&gt;Item 1A. Risk Factors&lt;/i&gt;&#x201d; of this Form 10-K.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="cref_619992257" id="ixv-7588">board of directors</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_619992257" id="ixv-7589">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_619992257" id="ixv-7590">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_619992257" id="ixv-7591">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_619992257" id="ixv-7592">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="cref_619992257" id="ixv-7593">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorOpinionTextBlock contextRef="cref_619992257" id="ixv-4476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Opinion on the Financial Statements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have audited the accompanying balance sheet of Pyrophyte Acquisition Corp. II (the &#x201c;Company&#x201d;) as of December 31, 2025 and the related statements of operations, changes in shareholder&#x2019;s deficit and cash flows for the period from May 1, 2025 (Inception) through December 31, 2025, and the related notes to the financial statements (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of Pyrophyte Acquisition Corp. II as of December 31, 2025 and the results of its operations and its cash flows for the period from May 1, 2025 (Inception) through December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="cref_619992257" id="ixv-7594">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="cref_619992257" id="ixv-7595">New York, New York</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="cref_619992257" id="ixv-7596">100</dei:AuditorFirmId>
    <us-gaap:Cash
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7597"
      unitRef="uref_200602150">442500</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7598"
      unitRef="uref_200602150">301930</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7599"
      unitRef="uref_200602150">744430</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7600"
      unitRef="uref_200602150">204013247</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7601"
      unitRef="uref_200602150">45228</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:Assets
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7602"
      unitRef="uref_200602150">204802905</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7603"
      unitRef="uref_200602150">38948</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7604"
      unitRef="uref_200602150">25000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7605"
      unitRef="uref_200602150">63948</us-gaap:LiabilitiesCurrent>
    <paii:DeferredUnderwritingFeesPayableNoncurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7606"
      unitRef="uref_200602150">9399690</paii:DeferredUnderwritingFeesPayableNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7607"
      unitRef="uref_200602150">9463638</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="cref_1879775354"
      decimals="4"
      id="ixv-7608"
      unitRef="uref_246701486">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="cref_1879775354"
      decimals="0"
      id="ixv-7609"
      unitRef="uref_779585586">20041150</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="cref_1879775354"
      decimals="2"
      id="ixv-7610"
      unitRef="uref_246701486">10.08</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="cref_1879775354"
      decimals="0"
      id="ixv-7611"
      unitRef="uref_200602150">204013247</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_333300986"
      decimals="4"
      id="ixv-7612"
      unitRef="uref_246701486">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7613"
      unitRef="uref_779585586">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1879775354"
      decimals="4"
      id="ixv-7614"
      unitRef="uref_246701486">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1879775354"
      decimals="0"
      id="ixv-7615"
      unitRef="uref_779585586">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1901841206"
      decimals="4"
      id="fc_452725222"
      unitRef="uref_246701486">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1901841206"
      decimals="0"
      id="fc_1945644932"
      unitRef="uref_779585586">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1901841206"
      decimals="0"
      id="fc_193369983"
      unitRef="uref_779585586">7225721</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1901841206"
      decimals="0"
      id="fc_1801047499"
      unitRef="uref_779585586">7225721</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="cref_1901841206"
      decimals="0"
      id="fc_544349580"
      unitRef="uref_200602150">723</us-gaap:CommonStockValue>
    <paii:ShareSubscriptionReceivable
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7621"
      unitRef="uref_200602150">353445</paii:ShareSubscriptionReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7622"
      unitRef="uref_200602150">-8321258</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7623"
      unitRef="uref_200602150">-8673980</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7624"
      unitRef="uref_200602150">204802905</us-gaap:LiabilitiesAndStockholdersEquity>
    <paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised
      contextRef="cref_403242642"
      decimals="0"
      id="ixv-7626"
      unitRef="uref_779585586">946428</paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionsIsNotExercised>
    <paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised
      contextRef="cref_1220869833"
      decimals="0"
      id="ixv-7627"
      unitRef="uref_779585586">83850</paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionIsPartiallyExercised>
    <paii:StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited
      contextRef="cref_92406311"
      decimals="0"
      id="ixv-7628"
      unitRef="uref_779585586">30231</paii:StockIssuedDuringPeriodSharesShareBasedCompensationsForfeited>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7629"
      unitRef="uref_200602150">628213</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7630"
      unitRef="uref_200602150">-628213</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7631"
      unitRef="uref_200602150">3601747</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestIncomeOther
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7632"
      unitRef="uref_200602150">329</us-gaap:InterestIncomeOther>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7633"
      unitRef="uref_200602150">2973863</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_500152996"
      decimals="0"
      id="ixv-7634"
      unitRef="uref_779585586">13598470</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_500152996"
      decimals="0"
      id="ixv-7635"
      unitRef="uref_779585586">13598470</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_500152996"
      decimals="2"
      id="ixv-7636"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_500152996"
      decimals="2"
      id="ixv-7637"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_116935946"
      decimals="0"
      id="ixv-7638"
      unitRef="uref_779585586">6911596</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_116935946"
      decimals="2"
      id="fc_1256945023"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_116935946"
      decimals="0"
      id="ixv-7640"
      unitRef="uref_779585586">6997607</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_116935946"
      decimals="2"
      id="fc_888586232"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareDiluted>
    <paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised
      contextRef="cref_477826121"
      decimals="0"
      id="ixv-7643"
      unitRef="uref_779585586">946428</paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised>
    <paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised
      contextRef="cref_923664865"
      decimals="0"
      id="ixv-7644"
      unitRef="uref_779585586">83850</paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="cref_1953308297"
      decimals="0"
      id="ixv-7645"
      unitRef="uref_779585586">30231</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1257381007"
      decimals="0"
      id="fc_2072477435"
      unitRef="uref_779585586">7255952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1257381007"
      decimals="0"
      id="fc_1986056237"
      unitRef="uref_200602150">726</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_532706043"
      decimals="0"
      id="fc_205363762"
      unitRef="uref_200602150">24274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1330416410"
      decimals="0"
      id="fc_158012640"
      unitRef="uref_200602150">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="cref_1257381007"
      decimals="0"
      id="ixv-7650"
      unitRef="uref_779585586">-30231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_1257381007"
      decimals="0"
      id="ixv-7651"
      unitRef="uref_200602150">-3</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited
      contextRef="cref_532706043"
      decimals="0"
      id="ixv-7652"
      unitRef="uref_200602150">3</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7653"
      unitRef="uref_779585586">20041150</paii:StockIssuedDuringPeriodSharesProceedsFromTheSaleOfClassAUnits>
    <paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7654"
      unitRef="uref_200602150">200411500</paii:StockIssuedDuringPeriodValueProceedsFromTheSaleOfClassAUnits>
    <paii:StockIssuedDuringPeriodValuePaidUnderwritersFees
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7655"
      unitRef="uref_200602150">-2625000</paii:StockIssuedDuringPeriodValuePaidUnderwritersFees>
    <paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7656"
      unitRef="uref_200602150">-9399690</paii:StockIssuedDuringPeriodValueDeferredUnderwritingFeesPayable>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7657"
      unitRef="uref_200602150">-3724648</paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_532706043"
      decimals="0"
      id="ixv-7658"
      unitRef="uref_200602150">3724648</paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants>
    <paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7659"
      unitRef="uref_200602150">3724648</paii:StockIssuedDuringPeriodValueFairValueOfPublicWarrants>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7660"
      unitRef="uref_200602150">-487752</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_532706043"
      decimals="0"
      id="ixv-7661"
      unitRef="uref_200602150">-255209</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7662"
      unitRef="uref_200602150">-255209</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_532706043"
      decimals="0"
      id="ixv-7663"
      unitRef="uref_200602150">5050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7664"
      unitRef="uref_200602150">5050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable
      contextRef="cref_1356153804"
      decimals="0"
      id="ixv-7665"
      unitRef="uref_200602150">-353445</paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable>
    <paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7666"
      unitRef="uref_200602150">-353445</paii:StockIssuedDuringPeriodValueShareSubscriptionReceivable>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="cref_1270821457"
      decimals="0"
      id="ixv-7667"
      unitRef="uref_200602150">-19838837</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="cref_532706043"
      decimals="0"
      id="ixv-7668"
      unitRef="uref_200602150">8543716</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="cref_55172024"
      decimals="0"
      id="ixv-7669"
      unitRef="uref_200602150">11295121</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7670"
      unitRef="uref_200602150">19838837</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="cref_55172024"
      decimals="0"
      id="ixv-7671"
      unitRef="uref_200602150">2973863</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7672"
      unitRef="uref_200602150">2973863</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_13105706"
      decimals="0"
      id="ixv-7673"
      unitRef="uref_779585586">20041150</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_13105706"
      decimals="0"
      id="ixv-7674"
      unitRef="uref_200602150">204013247</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1759141991"
      decimals="0"
      id="ixv-7675"
      unitRef="uref_779585586">7225721</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1759141991"
      decimals="0"
      id="ixv-7676"
      unitRef="uref_200602150">723</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1079647625"
      decimals="0"
      id="ixv-7677"
      unitRef="uref_200602150">-353445</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_2146548669"
      decimals="0"
      id="ixv-7678"
      unitRef="uref_200602150">-8321258</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7679"
      unitRef="uref_200602150">-8673980</us-gaap:StockholdersEquity>
    <paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised
      contextRef="cref_477826121"
      decimals="0"
      id="ixv-7680"
      unitRef="uref_779585586">946428</paii:NumberOfSharesSubjectedToForfeitureIfOverAllotmentOptionIsNotExercised>
    <paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised
      contextRef="cref_923664865"
      decimals="0"
      id="ixv-7681"
      unitRef="uref_779585586">83850</paii:NumberOfUnitsSubjectedToForfeitureIfOverAllotmentOptionsIsPartiallyExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="cref_1953308297"
      decimals="0"
      id="ixv-7682"
      unitRef="uref_779585586">30231</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7683"
      unitRef="uref_200602150">2973863</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7684"
      unitRef="uref_200602150">3601747</us-gaap:InvestmentIncomeInterestAndDividend>
    <paii:FormationAndOperatingExpensesPaidInExchangeForFounderShares
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7685"
      unitRef="uref_200602150">5000</paii:FormationAndOperatingExpensesPaidInExchangeForFounderShares>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7686"
      unitRef="uref_200602150">347158</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7687"
      unitRef="uref_200602150">38948</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7688"
      unitRef="uref_200602150">25000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7689"
      unitRef="uref_200602150">-906094</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7690"
      unitRef="uref_200602150">200411500</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7691"
      unitRef="uref_200602150">-200411500</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7692"
      unitRef="uref_200602150">200411500</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7693"
      unitRef="uref_200602150">4396555</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7694"
      unitRef="uref_200602150">3047961</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7695"
      unitRef="uref_200602150">201760094</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7696"
      unitRef="uref_200602150">442500</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7697"
      unitRef="uref_200602150">442500</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <paii:PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7698"
      unitRef="uref_200602150">-300000</paii:PrivatePlacementWarrantsIssuedThroughForgivenessOfPromissoryNoteRelatedParty>
    <paii:OfferingCostsPaidThroughTheIssuanceOfFounderShares
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7699"
      unitRef="uref_200602150">20000</paii:OfferingCostsPaidThroughTheIssuanceOfFounderShares>
    <paii:PrepaidExpensePaidThroughPromissoryNoteRelatedParty
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7700"
      unitRef="uref_200602150">300000</paii:PrepaidExpensePaidThroughPromissoryNoteRelatedParty>
    <paii:DeferredUnderwritingFeesPayable
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7701"
      unitRef="uref_200602150">9399690</paii:DeferredUnderwritingFeesPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="cref_619992257" id="ixv-5738">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="fin_006" style="display: inline-block;"&gt;&lt;/span&gt;NOTE 1&#x2014; ORGANIZATION AND BUSINESS OPERATIONS&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pyrophyte Acquisition Corp.&#160;II (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on May&#160;1, 2025. The Company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#x201c;Business Combination&#x201d;). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any Business Combination target with respect to an initial Business Combination with the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; As of December 31, 2025, the Company had not yet commenced operations. All activity for the period from May&#160;1, 2025 (inception) through December 31, 2025 relates to the Company&#x2019;s formation and initial public offering (the &#x201c;Initial Public Offering&#x201d;). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering and sale of Private Placement Warrants (defined below). The Company has selected December&#160;31 as its fiscal year end. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, the Company consummated its Initial Public Offering of 17,500,000 units (the &#x201c;Units&#x201d;). The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $175,000,000, which is described in Note 3. Each Unit consists of one Class A ordinary share, par value $0.0001 per share (the &#x201c;Class A Ordinary Shares&#x201d;) and one-half of one redeemable warrant (each whole warrant, a &#x201c;Public Warrant&#x201d;) of the Company. Each Public Warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment. The Company granted UBS Securities LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the &#x201c;Underwriters&#x201d;) in the Initial Public Offering a 45-day option to purchase up to 2,625,000 additional Units to cover over-allotments, if any. On July 24, 2025, the Underwriters partially exercised their over-allotment option to purchase an additional 2,541,150 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $25,411,500. The Underwriters forfeited their option to purchase the remaining 83,850 Units under their over-allotment option. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of 5,050,000 warrants (the &#x201c;Private Placement Warrants&#x201d;) at a purchase price of $1.00 per Private Placement Warrant (the &#x201c;Private Placement&#x201d;) to Pyrophyte Acquisition II LLC (the &#x201c;Sponsor&#x201d;) and the Company&#x2019;s independent directors, generating gross proceeds to the Company of $5,050,000. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Transaction costs amounted to $12,767,651, including $9,399,690 in deferred underwriting fees, $2,625,000 in upfront underwriting fees, and $742,961 in other offering costs related to the Initial Public Offering. In addition, cash of $1,500,000 (including share subscription receivable of $353,445) was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; As a result of the Initial Public Offering and subsequent partial exercise of the over-allotment option, a total of $200,411,500 of the net proceeds from the Initial Public Offering and the sale of the over-allotment option units was deposited in a U.S.-based Trust Account maintained by Continental Stock Transfer &amp;amp; Trust Company, acting as trustee (the &#x201c;Trust Account&#x201d;). Except with respect to interest earned on the funds in the Trust Account that may be released to the Company to pay its taxes, the proceeds from the Initial Public Offering held in the Trust Account will not be released until the earlier of (i) the consummation of the initial Business Combination and (ii) the distribution of the Trust Account proceeds as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses. &lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The proceeds held in the Trust Account are invested only in U.S. government treasury bills with a maturity of one hundred eighty-five (185) days or less or in money market funds that meet certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;) and that invest only in direct U.S. government obligations or in an interest bearing demand deposit account. Funds will remain in the Trust Account until the earlier of (i) the consummation of the initial Business Combination or (ii) the distribution of the Trust Account proceeds as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete a Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held and taxes paid or payable on the income earned on the Trust Account) at the time of the signing of an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Upon the closing of the Initial Public Offering, an aggregate of $10.00 per Unit sold in the Initial Public Offering was held in a Trust Account as cash and will be invested only in U.S.&#160;government treasury obligations with a maturity of 185&#160;days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act, which invest only in direct U.S.&#160;government treasury obligations, or held as cash; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the initial Business Combination. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that it holds investments in the Trust Account, the Company may, at any time (based on the management team&#x2019;s ongoing assessment of all factors related to the potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in cash or in an interest or non-interest bearing demand deposit account at a U.S.&#160;chartered commercial bank with consolidated assets of $100&#160;billion or more selected by the trustee that is reasonably satisfactory to the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to pay the Company&#x2019;s taxes, the proceeds from the Initial Public Offering and the sale of the Private Placement Warrants will not be released from the Trust Account until the earliest to occur of (i)&#160;the completion of the Company&#x2019;s initial Business Combination (including the release of funds to pay any amounts due to any public shareholders who properly exercise their redemption rights in connection therewith), (ii)&#160;the redemption of any public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company&#x2019;s amended and restated memorandum and articles of association (A)&#160;in a manner that would affect the substance or timing of the Company&#x2019;s obligation to redeem 100% of its public shares if it does not complete an initial Business Combination within 24&#160;months from the closing of the Initial Public Offering or (B)&#160;with respect to any other material provision relating to the rights of holders of Class A Ordinary Shares (the &#x201c;Public Shareholders&#x201d;) or pre-initial Business Combination activity or (iii)&#160;the redemption of the Company&#x2019;s public shares if it is unable to complete a Business Combination within 24&#160;months from the closing of Initial Public Offering, subject to applicable law. If the Company does not complete an initial Business Combination within 24&#160;months from the closing of the Initial Public Offering, the Company and the Underwriters have agreed that (1)&#160;the Underwriters will forfeit any rights or claims to their deferred underwriting discounts and commissions, including any accrued interest thereon, then in the Trust Account; and (2)&#160;that the deferred Underwriters&#x2019; discounts and commissions will be distributed on a pro rata basis, together with any accrued interest thereon (which interest shall be net of taxes paid or payable) to the Public Shareholders. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company will provide its Public Shareholders with the opportunity to redeem, regardless of whether they abstain, vote for, or vote against the Company&#x2019;s initial Business Combination, all or a portion of their Public Shares in connection with the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two&#160;business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account (net of taxes paid or payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations and on the conditions described herein. The amount in the Trust Account is initially anticipated to be $10.00 per Public Share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the Underwriters. The Company&#x2019;s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their redemption rights with respect to their Founder Shares (as defined in Note 4) and Public Shares in connection with the completion of the Company&#x2019;s initial Business Combination. Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction with their initial Business Combinations and provide for related redemptions of Public Shares for cash upon completion of such initial Business Combinations even when a vote is not required by law, if a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, it will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the U.S.&#160;Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and file tender offer documents with the SEC prior to completing its initial Business Combination. The Company&#x2019;s amended and restated memorandum and articles of association require these tender offer documents to contain substantially the same financial and other information about the initial Business Combination and the redemption rights as is required under the SEC&#x2019;s proxy rules. If, however, a shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, it will, like many special purpose acquisition companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval, it will complete its initial Business Combination only if it obtains the approval of an ordinary resolution under Cayman Islands law and its amended and restated memorandum and articles of association, which requires the affirmative vote of at least a majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. However, if the Company&#x2019;s initial Business Combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of its initial Business Combination will require the approval of a special resolution, which requires the affirmative vote of at least two-thirds of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company. However, the participation of the Company&#x2019;s Sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions, if any, could result in the approval of an initial Business Combination even if a majority of the Public Shareholders vote, or indicate their intention to vote, against such initial Business Combination. For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of the initial Business Combination once a quorum is obtained. The Company&#x2019;s amended and restated memorandum and articles of association require that at least five clear&#160;days&#x2019; notice will be given of any general meeting. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Class A Ordinary Shares subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; If the Company seeks shareholder approval of the Business Combination, a majority of the issued and outstanding shares voted must be voted in favor of the Business Combination.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Pursuant to the Company&#x2019;s amended and restated memorandum and articles of association, if it has not completed its initial Business Combination within 24 months from the closing of the Initial Public Offering, it will as promptly as reasonably possible but not more than ten&#160;business days thereafter (and subject to lawfully available funds therefor), redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of amounts not previously released to the Company for permitted withdrawals and up to $100,000 of interest to pay liquidation expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders&#x2019; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete its initial Business Combination within 24 months from the closing of the Initial Public Offering. However, if the Sponsor or management team acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the prescribed time period. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <paii:YearOfInception contextRef="cref_1330416410" id="ixv-7702">May&#160;1, 2025 (inception) through December 31, 2025</paii:YearOfInception>
    <paii:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1673988012"
      decimals="0"
      id="ixv-7703"
      unitRef="uref_779585586">17500000</paii:UnitsIssuedDuringPeriodSharesNewIssues>
    <paii:PriceIssuedPerShare
      contextRef="cref_1673988012"
      decimals="2"
      id="ixv-7704"
      unitRef="uref_246701486">10</paii:PriceIssuedPerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_1673988012"
      decimals="0"
      id="ixv-7705"
      unitRef="uref_200602150">175000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <paii:NumberOfSharesInEachUnit
      contextRef="cref_947942404"
      decimals="0"
      id="ixv-7706"
      unitRef="uref_779585586">1</paii:NumberOfSharesInEachUnit>
    <paii:PriceIssuedPerShare
      contextRef="cref_967608479"
      decimals="4"
      id="ixv-7707"
      unitRef="uref_246701486">0.0001</paii:PriceIssuedPerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_700951886"
      decimals="2"
      id="ixv-7708"
      unitRef="uref_246701486">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1352642449"
      decimals="0"
      id="ixv-7709"
      unitRef="uref_779585586">2625000</paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues>
    <paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1057160995"
      decimals="0"
      id="ixv-7710"
      unitRef="uref_779585586">2541150</paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_726704442"
      decimals="2"
      id="ixv-7711"
      unitRef="uref_246701486">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_1057160995"
      decimals="0"
      id="ixv-7712"
      unitRef="uref_200602150">25411500</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <paii:SharesIssuedSharesShareBasedPaymentArrangementForfeited
      contextRef="cref_454030801"
      decimals="0"
      id="ixv-7713"
      unitRef="uref_779585586">83850</paii:SharesIssuedSharesShareBasedPaymentArrangementForfeited>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1273128513"
      decimals="0"
      id="ixv-7714"
      unitRef="uref_779585586">5050000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <paii:ClassOfWarrantsAndRightsIssuedPricePerWarrant
      contextRef="cref_891586060"
      decimals="2"
      id="ixv-7715"
      unitRef="uref_246701486">1</paii:ClassOfWarrantsAndRightsIssuedPricePerWarrant>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_891586060"
      decimals="0"
      id="ixv-7716"
      unitRef="uref_200602150">5050000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <paii:TransactionCosts
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7717"
      unitRef="uref_200602150">12767651</paii:TransactionCosts>
    <paii:DeferredUnderwritingFeesPayableNoncurrent
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7718"
      unitRef="uref_200602150">9399690</paii:DeferredUnderwritingFeesPayableNoncurrent>
    <paii:UpforntUnderwritingFees
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7719"
      unitRef="uref_200602150">2625000</paii:UpforntUnderwritingFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="cref_467896768"
      decimals="0"
      id="ixv-7720"
      unitRef="uref_200602150">742961</us-gaap:DeferredOfferingCosts>
    <us-gaap:Cash
      contextRef="cref_467896768"
      decimals="0"
      id="ixv-7721"
      unitRef="uref_200602150">1500000</us-gaap:Cash>
    <paii:ShareSubscriptionReceivable
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7722"
      unitRef="uref_200602150">353445</paii:ShareSubscriptionReceivable>
    <paii:NetProceedsAmount
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7723"
      unitRef="uref_200602150">200411500</paii:NetProceedsAmount>
    <paii:USTreasuryGovernmentBillsMaturityTerm contextRef="cref_1330416410" id="ixv-7724">P185D</paii:USTreasuryGovernmentBillsMaturityTerm>
    <paii:MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7725"
      unitRef="uref_193655120">0.80</paii:MinimumPercentageOfFairMarketValueOfBusinessAcquisitionToTrustAccountBalance>
    <paii:MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7726"
      unitRef="uref_193655120">0.50</paii:MinimumOwnershipPercentageToBeAcquiredForNotToBeRegisteredAsAnInvestmentCompany>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="cref_467896768"
      decimals="2"
      id="ixv-7727"
      unitRef="uref_246701486">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:OtherAssets
      contextRef="cref_333300986"
      decimals="-9"
      id="ixv-7728"
      unitRef="uref_200602150">100000000000</us-gaap:OtherAssets>
    <paii:SharesRedemptionObligationPercentage
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7729"
      unitRef="uref_193655120">1</paii:SharesRedemptionObligationPercentage>
    <paii:NewlyAdjustedIssueSharePrice
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7730"
      unitRef="uref_246701486">10</paii:NewlyAdjustedIssueSharePrice>
    <paii:InterestToPayDissolutionExpenses
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7731"
      unitRef="uref_200602150">100000</paii:InterestToPayDissolutionExpenses>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_619992257" id="ixv-5787">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 2&#x2014;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Going Concern, Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; As of December 31, 2025, the Company had a cash balance of $442,500. Following the closing of the Initial Public Offering, the Company&#x2019;s liquidity needs are satisfied through using net proceeds from the Initial Public Offering and the sale of Private Placement Warrants for existing accounts payable, identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the initial Business Combination. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; If the Company&#x2019;s estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination or because it becomes obligated to redeem a significant number of its Public Shares upon completion of an initial Business Combination, in which case the Company may issue additional securities or incur debt in connection with such initial Business Combination. In addition, in order to finance transaction costs in connection with an initial Business Combination, the Company&#x2019;s officers, directors and initial shareholders may, but are not obligated to, provide it with loans up to $1,500,000 as the Company may require (&#x201c;Working Capital Loans&#x201d;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company expects to incur additional significant costs in pursuit of its financing and acquisition plans, including the proposed business combination. The Company has until 24 months from the IPO to complete a Business Combination or cease all operations other than those required for the purpose of liquidation. In connection with management&#x2019;s evaluation of the Company&#x2019;s ability to continue as a going concern in accordance with FASB ASC Topic 205-40, &#x201c;Presentation of Financial Statements &#x2013; Going Concern,&#x201d; the Company&#x2019;s liquidity concerns raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the date the audited financial statements are available to be issued. The Company intends to satisfy its liquidity needs through the Working Capital Loans that may be provided by its officers, directors and initial shareholders. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to satisfy its obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or the &#x201c;Securities Act&#x201d;, as modified by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act&#160;of&#160;2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;span style="font-weight: bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $442,500 in cash and &lt;span style="-sec-ix-hidden:fc_1532244282"&gt;no&lt;/span&gt; cash equivalents as of December 31, 2025.&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Marketable Securities Held in Trust Account&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, the assets held in the Trust Account were invested in money market funds that invest solely in U.S. treasury securities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company&#x2019;s Class A Ordinary Shares that were sold as part of the units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Class A Ordinary Shares in connection with the Company&#x2019;s liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies ordinary shares subject to redemption outside of permanent (deficit) equity as the redemption provisions are not solely within the control of the Company. Each Unit consists of one Class A Ordinary Share and one-half of one Public Warrant. As such, the initial carrying value of Class A Ordinary Shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The Class A Ordinary Shares are subject to ASC 480-10-S99 and are currently not redeemable as the redemption is contingent upon the occurrence of events mentioned above. According to ASC 480-10-S99-15, no subsequent adjustment is needed if it is not probable that the instrument will become redeemable. The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Gross proceeds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200,411,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-left: 9pt"&gt;Class A Ordinary Shares issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,512,442&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9pt"&gt;Fair value of Public Warrants at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,724,648&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Remeasurement of Class A Ordinary Shares to redemption value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,838,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Class A Ordinary Shares subject to possible redemption at December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Fair Value Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; There were no investments, assets or liabilities requiring fair value measurement as of December 31, 2025 except marketable securities held in Trust Account of $204,013,247, which is determined to be a Level 1 measurement. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluates its equity-linked financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounted for the Public Warrants issued in connection with the Initial Public Offering and the Private Placement Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the instruments continue to be classified in equity. The over-allotment option was deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and would be accounted for as a liability pursuant to ASC 480. The over-allotment option was partially exercised on July 24, 2025, and the over-allotment liability recorded by Company was reversed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the units between Class A Ordinary Shares and warrants, prorate, allocating the Initial Public Offering proceeds to the assigned value of the warrants and to the Class A Ordinary Shares. Offering costs allocated to the Class A Ordinary Shares were charged to temporary equity and offering costs allocated to the Public and Private Placement Warrants were charged to shareholders&#x2019; deficit as Public and Private Placement Warrants, after management&#x2019;s evaluation, are accounted for under equity treatment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Subscription Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company records stock issuances at the effective date. If the subscription is not funded upon issuance, the Company records a subscription receivable as an asset on a balance sheet, except when subscription receivable is not received prior to the issuance of financial statements at a reporting date in satisfaction of the requirements under ASC 505-10-45-2, in which case, the subscription is reclassified as a contra account to stockholders&#x2019; deficit on the balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for income taxes under ASC Topic&#160;740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statements and tax basis of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; ASC Topic&#160;740 clarifies the accounting for uncertainty in income taxes recognized in an entity&#x2019;s financial statements and prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are &lt;span style="-sec-ix-hidden:fc_1353994326"&gt;no&lt;/span&gt; significant uncertain tax positions requiring recognition in the Company&#x2019;s financial statements. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#x2019;s tax provision was zero for the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Net Income Per Ordinary Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company complies with accounting and disclosure requirements of ASC 260, &#x201c;Earnings Per Share.&#x201d; Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary shares outstanding during the period. For the period from May 1, 2025 (inception) through December 31, 2025, the Company did not consider the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase Public Shares in the calculation of diluted income per ordinary share, since their inclusion is contingent on a future event. A reconciliation of the net income per ordinary share is stated below. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For The&lt;br/&gt; Period&#160;From&lt;br/&gt; May&#160;1, &lt;br/&gt; 2025&lt;br/&gt; (Inception)&lt;br/&gt; Through &lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Basic Earnings Per Share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,971,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,598,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic net income per share, Class A Ordinary Shares subject to possible redemption&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to non-redeemable Class B Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Net income allocable to non-redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,002,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt"&gt;Denominator: Weighted Average Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,911,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic net income per share, Class B non-redeemable ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Diluted Earnings Per Share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,963,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,598,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to non-redeemable Class B Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Net income allocable to non-redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,010,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,997,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Diluted net income per share, Class B non-redeemable ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in the statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The warrants are not precluded from equity classification, and will be accounted for as such on the date of issuance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for Founder Shares issued to its independent directors in accordance with SEC Staff Accounting Bulletin 5T and ASC 718, &#x201c;Compensation-Stock Compensation.&#x201d; The fair value of the Founder Shares issued in this arrangement was determined using the implied stock price as of the date of the Initial Public Offering of the Company&#x2019;s Class A Ordinary Shares and the probability of the success of the initial Business Combination.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting contextRef="cref_619992257" id="ixv-5792">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <paii:GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock contextRef="cref_619992257" id="ixv-5799">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Going Concern, Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; As of December 31, 2025, the Company had a cash balance of $442,500. Following the closing of the Initial Public Offering, the Company&#x2019;s liquidity needs are satisfied through using net proceeds from the Initial Public Offering and the sale of Private Placement Warrants for existing accounts payable, identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the initial Business Combination. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; If the Company&#x2019;s estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete an initial Business Combination or because it becomes obligated to redeem a significant number of its Public Shares upon completion of an initial Business Combination, in which case the Company may issue additional securities or incur debt in connection with such initial Business Combination. In addition, in order to finance transaction costs in connection with an initial Business Combination, the Company&#x2019;s officers, directors and initial shareholders may, but are not obligated to, provide it with loans up to $1,500,000 as the Company may require (&#x201c;Working Capital Loans&#x201d;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company expects to incur additional significant costs in pursuit of its financing and acquisition plans, including the proposed business combination. The Company has until 24 months from the IPO to complete a Business Combination or cease all operations other than those required for the purpose of liquidation. In connection with management&#x2019;s evaluation of the Company&#x2019;s ability to continue as a going concern in accordance with FASB ASC Topic 205-40, &#x201c;Presentation of Financial Statements &#x2013; Going Concern,&#x201d; the Company&#x2019;s liquidity concerns raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the date the audited financial statements are available to be issued. The Company intends to satisfy its liquidity needs through the Working Capital Loans that may be provided by its officers, directors and initial shareholders. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to satisfy its obligations.&lt;/p&gt;</paii:GoingConcernLiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:Cash
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7732"
      unitRef="uref_200602150">442500</us-gaap:Cash>
    <paii:WorkingCapitalLoans
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7733"
      unitRef="uref_200602150">1500000</paii:WorkingCapitalLoans>
    <paii:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="cref_619992257" id="ixv-5809">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or the &#x201c;Securities Act&#x201d;, as modified by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act&#160;of&#160;2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;</paii:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="cref_619992257" id="ixv-5827">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;span style="font-weight: bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="cref_619992257" id="ixv-5837">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $442,500 in cash and &lt;span style="-sec-ix-hidden:fc_1532244282"&gt;no&lt;/span&gt; cash equivalents as of December 31, 2025.&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7734"
      unitRef="uref_200602150">442500</us-gaap:Cash>
    <paii:MarketableSecuritiesHeldInTrustAccountPolicyTextBlock contextRef="cref_619992257" id="ixv-5846">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Marketable Securities Held in Trust Account&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, the assets held in the Trust Account were invested in money market funds that invest solely in U.S. treasury securities.&lt;/p&gt;</paii:MarketableSecuritiesHeldInTrustAccountPolicyTextBlock>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="cref_619992257" id="ixv-5854">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company&#x2019;s Class A Ordinary Shares that were sold as part of the units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Class A Ordinary Shares in connection with the Company&#x2019;s liquidation, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies ordinary shares subject to redemption outside of permanent (deficit) equity as the redemption provisions are not solely within the control of the Company. Each Unit consists of one Class A Ordinary Share and one-half of one Public Warrant. As such, the initial carrying value of Class A Ordinary Shares classified as temporary equity was the allocated proceeds determined in accordance with ASC 470-20. The Class A Ordinary Shares are subject to ASC 480-10-S99 and are currently not redeemable as the redemption is contingent upon the occurrence of events mentioned above. According to ASC 480-10-S99-15, no subsequent adjustment is needed if it is not probable that the instrument will become redeemable. The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Gross proceeds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200,411,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-left: 9pt"&gt;Class A Ordinary Shares issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,512,442&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9pt"&gt;Fair value of Public Warrants at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,724,648&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Remeasurement of Class A Ordinary Shares to redemption value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,838,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Class A Ordinary Shares subject to possible redemption at December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="cref_619992257" id="ixv-7735"> The Class A Ordinary Shares subject to possible redemption reflected on the balance sheet as of December 31, 2025 are reconciled in the following table:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Gross proceeds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200,411,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-left: 9pt"&gt;Class A Ordinary Shares issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,512,442&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9pt"&gt;Fair value of Public Warrants at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,724,648&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Plus:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Remeasurement of Class A Ordinary Shares to redemption value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,838,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Class A Ordinary Shares subject to possible redemption at December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_73988315"
      decimals="0"
      id="ixv-7736"
      unitRef="uref_200602150">200411500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <paii:ClassAOrdinarySharesIssuanceCosts
      contextRef="cref_73988315"
      decimals="0"
      id="ixv-7737"
      unitRef="uref_200602150">-12512442</paii:ClassAOrdinarySharesIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_73988315"
      decimals="0"
      id="ixv-7738"
      unitRef="uref_200602150">-3724648</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="cref_73988315"
      decimals="0"
      id="ixv-7739"
      unitRef="uref_200602150">19838837</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="cref_1879775354"
      decimals="0"
      id="ixv-7740"
      unitRef="uref_200602150">204013247</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="cref_619992257" id="ixv-5913">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Fair Value Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="cref_619992257" id="ixv-5927">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; There were no investments, assets or liabilities requiring fair value measurement as of December 31, 2025 except marketable securities held in Trust Account of $204,013,247, which is determined to be a Level 1 measurement. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="cref_638126375"
      decimals="0"
      id="ixv-7741"
      unitRef="uref_200602150">204013247</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:DerivativesPolicyTextBlock contextRef="cref_619992257" id="ixv-5957">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluates its equity-linked financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounted for the Public Warrants issued in connection with the Initial Public Offering and the Private Placement Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the instruments continue to be classified in equity. The over-allotment option was deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and would be accounted for as a liability pursuant to ASC 480. The over-allotment option was partially exercised on July 24, 2025, and the over-allotment liability recorded by Company was reversed.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <paii:OfferingCostsPolicyTextBlock contextRef="cref_619992257" id="ixv-5965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses of Offering.&#x201d; Deferred offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 470-20, &#x201c;Debt with Conversion and Other Options,&#x201d; addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the units between Class A Ordinary Shares and warrants, prorate, allocating the Initial Public Offering proceeds to the assigned value of the warrants and to the Class A Ordinary Shares. Offering costs allocated to the Class A Ordinary Shares were charged to temporary equity and offering costs allocated to the Public and Private Placement Warrants were charged to shareholders&#x2019; deficit as Public and Private Placement Warrants, after management&#x2019;s evaluation, are accounted for under equity treatment.&lt;/p&gt;</paii:OfferingCostsPolicyTextBlock>
    <paii:SubscriptionReceivablePolicyTextBlock contextRef="cref_619992257" id="ixv-5971">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Subscription Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company records stock issuances at the effective date. If the subscription is not funded upon issuance, the Company records a subscription receivable as an asset on a balance sheet, except when subscription receivable is not received prior to the issuance of financial statements at a reporting date in satisfaction of the requirements under ASC 505-10-45-2, in which case, the subscription is reclassified as a contra account to stockholders&#x2019; deficit on the balance sheet.&lt;/p&gt;</paii:SubscriptionReceivablePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="cref_619992257" id="ixv-5977">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for income taxes under ASC Topic&#160;740, &#x201c;Income Taxes,&#x201d; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statements and tax basis of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; ASC Topic&#160;740 clarifies the accounting for uncertainty in income taxes recognized in an entity&#x2019;s financial statements and prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are &lt;span style="-sec-ix-hidden:fc_1353994326"&gt;no&lt;/span&gt; significant uncertain tax positions requiring recognition in the Company&#x2019;s financial statements. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#x2019;s tax provision was zero for the periods presented.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="cref_619992257" id="ixv-5997">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Net Income Per Ordinary Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company complies with accounting and disclosure requirements of ASC 260, &#x201c;Earnings Per Share.&#x201d; Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary shares outstanding during the period. For the period from May 1, 2025 (inception) through December 31, 2025, the Company did not consider the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase Public Shares in the calculation of diluted income per ordinary share, since their inclusion is contingent on a future event. A reconciliation of the net income per ordinary share is stated below. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For The&lt;br/&gt; Period&#160;From&lt;br/&gt; May&#160;1, &lt;br/&gt; 2025&lt;br/&gt; (Inception)&lt;br/&gt; Through &lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Basic Earnings Per Share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,971,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,598,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic net income per share, Class A Ordinary Shares subject to possible redemption&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to non-redeemable Class B Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Net income allocable to non-redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,002,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt"&gt;Denominator: Weighted Average Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,911,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic net income per share, Class B non-redeemable ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Diluted Earnings Per Share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,963,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,598,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to non-redeemable Class B Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Net income allocable to non-redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,010,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,997,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Diluted net income per share, Class B non-redeemable ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="cref_619992257" id="ixv-7742"> A reconciliation of the net income per ordinary share is stated below.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For The&lt;br/&gt; Period&#160;From&lt;br/&gt; May&#160;1, &lt;br/&gt; 2025&lt;br/&gt; (Inception)&lt;br/&gt; Through &lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Basic Earnings Per Share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,971,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Basic weighted average shares outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,598,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic net income per share, Class A Ordinary Shares subject to possible redemption&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to non-redeemable Class B Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Net income allocable to non-redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,002,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify; padding-bottom: 1.5pt"&gt;Denominator: Weighted Average Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,911,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic net income per share, Class B non-redeemable ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Diluted Earnings Per Share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Net income allocable to Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,963,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Basic and diluted weighted average shares outstanding, Redeemable Class A Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,598,470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Basic and diluted net income per share, Class A Ordinary Shares subject to possible redemption&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: justify"&gt;Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Numerator: Net income allocable to non-redeemable Class B Ordinary Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Net income allocable to non-redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,010,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-style: italic; text-align: justify"&gt;Denominator: Weighted Average Non-Redeemable Class B ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,997,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Diluted net income per share, Class B non-redeemable ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="cref_1891084432"
      decimals="0"
      id="ixv-7743"
      unitRef="uref_200602150">1971714</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1891084432"
      decimals="0"
      id="ixv-7744"
      unitRef="uref_779585586">13598470</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1891084432"
      decimals="2"
      id="ixv-7745"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="cref_116935946"
      decimals="0"
      id="ixv-7746"
      unitRef="uref_200602150">1002149</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_116935946"
      decimals="0"
      id="ixv-7747"
      unitRef="uref_779585586">6911596</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_116935946"
      decimals="2"
      id="ixv-7748"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="cref_1891084432"
      decimals="0"
      id="ixv-7749"
      unitRef="uref_200602150">1963480</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1891084432"
      decimals="0"
      id="ixv-7750"
      unitRef="uref_779585586">13598470</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1891084432"
      decimals="2"
      id="ixv-7751"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="cref_116935946"
      decimals="0"
      id="ixv-7752"
      unitRef="uref_200602150">1010383</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_116935946"
      decimals="0"
      id="ixv-7753"
      unitRef="uref_779585586">6997607</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_116935946"
      decimals="2"
      id="ixv-7754"
      unitRef="uref_246701486">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="cref_619992257" id="ixv-6204">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7755"
      unitRef="uref_200602150">250000</us-gaap:CashFDICInsuredAmount>
    <paii:WarrantsPolicyTextBlock contextRef="cref_619992257" id="ixv-6211">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in the statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The warrants are not precluded from equity classification, and will be accounted for as such on the date of issuance.&lt;/p&gt;</paii:WarrantsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="cref_619992257" id="ixv-6221">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for Founder Shares issued to its independent directors in accordance with SEC Staff Accounting Bulletin 5T and ASC 718, &#x201c;Compensation-Stock Compensation.&#x201d; The fair value of the Founder Shares issued in this arrangement was determined using the implied stock price as of the date of the Initial Public Offering of the Company&#x2019;s Class A Ordinary Shares and the probability of the success of the initial Business Combination.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_619992257" id="ixv-6228">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <paii:InitialPublicOfferingTextBlock contextRef="cref_619992257" id="ixv-6234">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 3&#x2014;INITIAL PUBLIC OFFERING&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on July 16, 2025. On July 18, 2025, the Company consummated the Initial Public Offering of 17,500,000 Units, generating gross proceeds of $175,000,000. On July 24, 2025, the Underwriters partially exercised their over-allotment option to purchase an additional 2,541,150 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $25,411,500. The Underwriters forfeited their option to purchase an additional 83,850 Units. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Each Unit consists of one Class A Ordinary Share and one-half of one redeemable Public Warrant. Each whole warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment as described, and only whole warranty is exercisable. The warrants will become exercisable 30&#160;days after the completion of the Company&#x2019;s initial Business Combination and will expire five&#160;years after the completion of the Company&#x2019;s initial Business Combination, or earlier upon redemption or liquidation. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of an aggregate of 5,050,000 Private Placement Warrants to the Sponsor, at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $5,050,000. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Each Private Placement Warrant is exercisable for one Class A Ordinary Share at a price of $11.50 per share. If the initial Business Combination is not completed within 24 months from the closing of the Initial Public Offering, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis and will expire five years after the completion of the Company&#x2019;s initial Business Combination or earlier upon redemption or liquidation. As the Sponsor will agree, subject to limited exceptions, not to transfer, assign or sell any of the Private Placement Warrants (including their underlying securities) until 30 days after the completion of the initial Business Combination. &lt;/p&gt;</paii:InitialPublicOfferingTextBlock>
    <paii:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1673988012"
      decimals="0"
      id="ixv-7756"
      unitRef="uref_779585586">17500000</paii:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_1673988012"
      decimals="0"
      id="ixv-7757"
      unitRef="uref_200602150">175000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1057160995"
      decimals="0"
      id="ixv-7758"
      unitRef="uref_779585586">2541150</paii:AdditionalUnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_726704442"
      decimals="2"
      id="ixv-7759"
      unitRef="uref_246701486">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_1057160995"
      decimals="0"
      id="ixv-7760"
      unitRef="uref_200602150">25411500</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <paii:SharesIssuedSharesShareBasedPaymentArrangementForfeited
      contextRef="cref_474135015"
      decimals="0"
      id="ixv-7761"
      unitRef="uref_779585586">83850</paii:SharesIssuedSharesShareBasedPaymentArrangementForfeited>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1284032524"
      decimals="2"
      id="ixv-7762"
      unitRef="uref_246701486">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <paii:ExercisableWarrantsTerm contextRef="cref_1330416410" id="ixv-7763">P30D</paii:ExercisableWarrantsTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1273128513"
      decimals="0"
      id="ixv-7764"
      unitRef="uref_779585586">5050000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <paii:ClassOfWarrantsAndRightsIssuedPricePerWarrant
      contextRef="cref_745494576"
      decimals="2"
      id="ixv-7765"
      unitRef="uref_246701486">1</paii:ClassOfWarrantsAndRightsIssuedPricePerWarrant>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7766"
      unitRef="uref_200602150">5050000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_259502220"
      decimals="2"
      id="ixv-7767"
      unitRef="uref_246701486">11.5</us-gaap:SharesIssuedPricePerShare>
    <paii:ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination contextRef="cref_1330416410" id="ixv-7768">P30D</paii:ThresholdNumberOfTradingDaysForDeterminingSharePriceFromDateOfBusinessCombination>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="cref_619992257" id="ixv-6256">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 4&#x2014;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Founder Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; On May&#160;5, 2025, the Sponsor made a capital contribution of $25,000, or approximately $0.003 per share, to cover certain of the Company&#x2019;s expenses, for which the Company issued 7,255,952 Founder Shares to the Sponsor. The Founder Shares included up to 946,428 of the Founder Shares subject to forfeiture by the Sponsor for no consideration to the extent the Underwriters&#x2019; over-allotment was not fully exercised. The Underwriters had 45 days after the closing of the Initial Public Offering to exercise their over-allotment option. On July 24, 2025, the Underwriters partially exercised their over-allotment option as part of the Initial Public Offering. As such, 30,231 Founder Shares were forfeited by the Sponsor. All share and per share data has been retroactively restated. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; In June 2025, the Sponsor transferred&#160;30,000&#160;of the Company&#x2019;s Founder Shares to each of the Company&#x2019;s three independent directors. These&#160;90,000&#160;Founder Shares were not subject to forfeiture. The allocation of the Founder Shares to the directors is in the scope of ASC 718. Under ASC 718, share-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Company used the implied stock price as of the date of the Initial Public Offering of the Company&#x2019;s Class A Ordinary Shares and the probability of the success of the initial Business Combination. The fair value of the&#160;90,000&#160;Founder Shares granted to the Company&#x2019;s directors was $216,637&#160;or $2.41&#160;per share. The Founder Shares were granted subject to a performance condition, the performance of the duties of an independent director through and the occurrence of an initial Business Combination. Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under ASC 718. The Company determined the performance conditions are not considered probable, and, therefore,&#160;&lt;span style="-sec-ix-hidden:fc_912153279"&gt;no&lt;/span&gt;&#160;share-based compensation expense was recognized as of December 31, 2025. As of December 31, 2025, the unrecognized stock compensation expense was $216,637. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Founder Shares are designated as Class B ordinary shares and, except as described below, are identical to the Class A Ordinary Shares included in the Units sold in the Initial Public Offering, and holders of Founder Shares have the same shareholder rights as Public Shareholders, except that (i) the Founder Shares are subject to certain transfer restrictions, as described in more detail below, (ii) the Founder Shares are entitled to registration rights, (iii) the Company&#x2019;s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (A) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of the Company&#x2019;s initial Business Combination, (B) waive their redemption rights with respect to their Founder Shares and Public Shares in connection with a shareholder vote to approve an amendment to the Company&#x2019;s amended and restated memorandum and articles of association (1) to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Company&#x2019;s initial Business Combination or to redeem 100% of the Company&#x2019;s Public Shares if the Company has not consummated an initial Business Combination within 24 months from the closing of the Initial Public Offering, (2) with respect to any other material provisions relating to shareholders&#x2019; rights or pre-initial Business Combination activity, (3) waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete the Company&#x2019;s initial Business Combination within the 24 months from the closing of the Initial Public Offering, although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the initial Business Combination within such time period and to liquidating distributions from assets outside the Trust Account and (4) vote any Founder Shares held by them and any Public Shares purchased during or after the Initial Public Offering (including in open market and privately negotiated transactions) in favor of the initial Business Combination (including any proposals recommended by the Company&#x2019;s board of directors in connection with such Business Combination) (except with respect to any Public Shares which may not be voted in favor of approving the Business Combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations or guidance relating thereto), (iv) the Founder Shares are automatically convertible into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Company&#x2019;s initial Business Combination or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment as described herein and in the amended and restated memorandum and articles of association, and (v) prior to the closing of the Company&#x2019;s initial Business Combination, only holders of Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing in a jurisdiction outside the Cayman Islands (including any special resolution required to amend the constitutional documents or to adopt new constitutional documents, in each case, as a result of approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Founder Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the initial Business Combination or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares, or any other equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to or in connection with the closing of the initial Business Combination, the ratio at which Class B ordinary shares convert into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, 26.5% of the sum of (i) the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering (including any Class A Ordinary Shares issued pursuant to the Underwriters&#x2019; over-allotment option and excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor and the Underwriters), plus (ii) all Class A Ordinary Shares and equity-linked securities issued or deemed issued in connection with the Company&#x2019;s initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Company&#x2019;s Sponsor or any of its affiliates or to the Company&#x2019;s officers and directors upon conversion of Working Capital Loans) minus (iii) any redemptions of Class A Ordinary Shares by Public Shareholders in connection with an initial Business Combination; provided that such conversion of Founder Shares will never occur on a less than one-for-one basis. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company&#x2019;s initial shareholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (i)&#160;one year after the completion of the initial Business Combination and (ii)&#160;the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company&#x2019;s shareholders having the right to exchange their Class A Ordinary Shares for cash, securities or other property (except to certain permitted transferees and under certain circumstances). Notwithstanding the foregoing, if the last sale price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20&#160;trading days within any 30-trading&#160;day period commencing at least 150&#160;days after the completion of the Company&#x2019;s initial Business Combination, the Founder Shares will be released from this lock-up. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Promissory Note&#x2014;Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Sponsor has agreed to loan the Company an aggregate of up to $300,000 under an unsecured promissory to be used for a portion of the expenses in connection with the Initial Public Offering. The loan was non-interest bearing, unsecured and due at the earlier of December 31, 2025 or the closing of the Initial Public Offering. As of the Initial Public Offering date of July 18, 2025, the $300,000 note was fully utilized by the Company. In connection with the private sale of 5,050,000 warrants as described above in Note 4, the Company settled the outstanding note through the issuance of 300,000 Private Placement Warrants to the related party. The 300,000 Private Placement Warrants are included in the total of 5,050,000 in connection with the Initial Public Offering. The Company determined that the carrying value and fair value of the note are the same as the fair value of the Private Placement Warrants given in exchange for the note. As of December 31, 2025, there are &lt;span style="-sec-ix-hidden:fc_1028152249"&gt;no&lt;/span&gt; amounts outstanding under the note and the note is no longer available to be drawn.&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Share Subscription Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; On July 19, 2025, in connection with the sale of the Private Placement Warrants, the Sponsor should have deposited $353,445 of the net proceeds into the Company&#x2019;s bank account. This amount still has not been received as of December 31, 2025. The Company has accounted for the amount due as a share subscription receivable within shareholders&#x2019; deficit. The amount is non-interest bearing, due on demand and expected to be settled in the near term. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Private Placement Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; On July 18, 2025, the Sponsor purchased an aggregate 5,050,000 Private Placement Warrants at a price of $1.00 per whole Private Placement Warrant in a private placement that occurred simultaneously with the closing of the Initial Public Offering. Each whole Private Placement Warrant is exercisable for one whole Class A Ordinary Share at a price of $11.50 per share. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; If the initial Business Combination is not completed within 24&#160;months from the closing of the Initial Public Offering, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis and will expire five&#160;years after the completion of the Company&#x2019;s initial Business Combination or earlier upon redemption or liquidation. As the Sponsor will agree, subject to limited exceptions, not to transfer, assign or sell any of the Private Placement Warrants (including their underlying securities) until 30&#160;days after the completion of the initial Business Combination. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Administrative Support Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; Commencing on the effective date of the Initial Public Offering, the Company entered into an agreement with the Sponsor to pay an aggregate of $35,000 per month for office space, utilities and secretarial and administrative support. Upon completion of the initial Business Combination or its liquidation, the Company will cease paying these monthly fees. For the period from May 1, 2025 (inception) through December 31, 2025, the Company recognized $192,500 in administrative fees. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Working Capital Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#x2019;s Sponsor or an affiliate of its Sponsor or certain of its officers and directors may, but are not obligated to, loan the Company funds as may be required on a non-interest bearing basis. If the Company completes its initial Business Combination, the Company would repay such loaned amounts. In the event that the initial Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay such loaned amounts but no proceeds held in the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into Private Placement Warrants at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. The terms of such loans by the Company&#x2019;s Sponsor or its affiliates, or its officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; As of December 31, 2025, &lt;span style="-sec-ix-hidden:fc_936727067"&gt;no&lt;/span&gt; such Working Capital Loans were outstanding. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1609389963"
      decimals="0"
      id="ixv-7769"
      unitRef="uref_200602150">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_2136458884"
      decimals="3"
      id="ixv-7770"
      unitRef="uref_246701486">0.003</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1609389963"
      decimals="0"
      id="ixv-7771"
      unitRef="uref_779585586">7255952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <paii:NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised
      contextRef="cref_1609389963"
      decimals="0"
      id="ixv-7772"
      unitRef="uref_779585586">946428</paii:NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised>
    <paii:NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised
      contextRef="cref_820702892"
      decimals="0"
      id="ixv-7773"
      unitRef="uref_779585586">30231</paii:NumberOfSharesToBeForfeitedIfOverallotmentOptionIsNotExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1830146596"
      decimals="0"
      id="ixv-7774"
      unitRef="uref_779585586">30000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <paii:NumberOfSharesNotSubjectToForfeiture
      contextRef="cref_606805414"
      decimals="0"
      id="ixv-7775"
      unitRef="uref_779585586">90000</paii:NumberOfSharesNotSubjectToForfeiture>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="cref_1595368894"
      decimals="0"
      id="ixv-7776"
      unitRef="uref_779585586">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
      contextRef="cref_1844658907"
      decimals="0"
      id="ixv-7777"
      unitRef="uref_200602150">216637</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <paii:GrantedPricePerShare
      contextRef="cref_1595368894"
      decimals="2"
      id="ixv-7778"
      unitRef="uref_246701486">2.41</paii:GrantedPricePerShare>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="cref_333300986"
      decimals="0"
      id="fc_1026132719"
      unitRef="uref_200602150">216637</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage
      contextRef="cref_329624284"
      decimals="2"
      id="ixv-7780"
      unitRef="uref_193655120">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage
      contextRef="cref_1272538016"
      decimals="3"
      id="ixv-7781"
      unitRef="uref_193655120">0.265</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage>
    <paii:CommonStockStockPriceTrigger
      contextRef="cref_61013207"
      decimals="2"
      id="ixv-7782"
      unitRef="uref_246701486">12</paii:CommonStockStockPriceTrigger>
    <paii:CommonStockThresholdTradingDays contextRef="cref_1940925763" id="ixv-7783">P20D</paii:CommonStockThresholdTradingDays>
    <paii:CommonStockThresholdConsecutiveTradingDays contextRef="cref_1940925763" id="ixv-7784">P30D</paii:CommonStockThresholdConsecutiveTradingDays>
    <paii:NumberOfDaysAfterInitialBusinessCombination contextRef="cref_1940925763" id="ixv-7785">P150D</paii:NumberOfDaysAfterInitialBusinessCombination>
    <paii:AggregateUnsecuredPromissoryAmount
      contextRef="cref_1093598802"
      decimals="0"
      id="ixv-7786"
      unitRef="uref_200602150">300000</paii:AggregateUnsecuredPromissoryAmount>
    <paii:PromissoryNotePayableFullyUtilizedAfterIPO
      contextRef="cref_1462063775"
      decimals="0"
      id="ixv-7787"
      unitRef="uref_200602150">300000</paii:PromissoryNotePayableFullyUtilizedAfterIPO>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_1549419295"
      decimals="0"
      id="ixv-7788"
      unitRef="uref_200602150">5050000</us-gaap:WarrantsAndRightsOutstanding>
    <paii:IssuanceOfPrivatePlacementWarrantsWithRelatedParty
      contextRef="cref_1626106670"
      decimals="0"
      id="ixv-7789"
      unitRef="uref_779585586">300000</paii:IssuanceOfPrivatePlacementWarrantsWithRelatedParty>
    <paii:IssuanceOfPrivatePlacementWarrantsWithRelatedParty
      contextRef="cref_525945823"
      decimals="0"
      id="ixv-7790"
      unitRef="uref_779585586">300000</paii:IssuanceOfPrivatePlacementWarrantsWithRelatedParty>
    <paii:InitialPublicOfferings
      contextRef="cref_525945823"
      decimals="0"
      id="ixv-7791"
      unitRef="uref_779585586">5050000</paii:InitialPublicOfferings>
    <us-gaap:EscrowDeposit
      contextRef="cref_1113090420"
      decimals="0"
      id="ixv-7792"
      unitRef="uref_200602150">353445</us-gaap:EscrowDeposit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1549419295"
      decimals="0"
      id="ixv-7793"
      unitRef="uref_779585586">5050000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1549419295"
      decimals="2"
      id="ixv-7794"
      unitRef="uref_246701486">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="cref_1549419295"
      decimals="0"
      id="ixv-7795"
      unitRef="uref_779585586">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_1950299307"
      decimals="2"
      id="ixv-7796"
      unitRef="uref_246701486">11.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="cref_2109124231" id="ixv-7797">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <paii:ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination contextRef="cref_333300986" id="ixv-7798">P30D</paii:ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination>
    <paii:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7799"
      unitRef="uref_200602150">35000</paii:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
    <us-gaap:AdministrativeFeesExpense
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7800"
      unitRef="uref_200602150">192500</us-gaap:AdministrativeFeesExpense>
    <paii:MaximumLoansConvertibleIntoWarrants
      contextRef="cref_2109124231"
      decimals="0"
      id="ixv-7801"
      unitRef="uref_200602150">1500000</paii:MaximumLoansConvertibleIntoWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_2109124231"
      decimals="2"
      id="ixv-7802"
      unitRef="uref_246701486">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_619992257" id="ixv-6330">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 5&#x2014;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict, the Israel-Hamas war and the conflict between the United States and Israel and Iran, as well as recent developments to U.S. tariff policies. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the U.S., the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. &#x2000;The invasion of Ukraine by Russia, the Israel-Hamas war, the conflict between the United States and Israel and Iran and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the Israel-Hamas war, and the conflict between the United States and Israel and Iran and subsequent sanctions or related actions or the ongoing trade and tariff policy changes by the U.S. or other countries could adversely affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Registration Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The holders of the (i) Founder Shares, which were issued in the Private Placement prior to the closing of the Initial Public Offering, (ii) Private Placement Warrants and the Class A Ordinary Shares underlying such Private Placement Warrants and (iii) Private Placement Warrants that may be issued upon conversion of Working Capital Loans will have registration rights to require the Company to register a sale of any of the Company&#x2019;s securities held by them and any other securities of the Company acquired by them prior to the consummation of the Company&#x2019;s initial Business Combination pursuant to a registration rights agreement signed on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain &#x201c;piggyback&#x201d; registration rights with respect to registration statements filed subsequent to the Company&#x2019;s completion of the Company&#x2019;s initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Underwriting Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; On July 18, 2025, the Company paid a cash discount of 1.5% of the per Unit Initial Public Offering price on the base Units sold in the Offering (or $2,625,000 in aggregate) to the Underwriters at the closing of the Initial Public Offering, with an additional fee of 4.5% of the gross Initial Public Offering proceeds with respect to the base Units sold in the Offering (and 6.0% of the per Unit Initial Public Offering price on the Units sold pursuant to the Underwriters&#x2019; over-allotment option) payable only upon the Company&#x2019;s completion of its initial Business Combination (the &#x201c;Deferred Discount&#x201d;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; A Deferred Discount of $9,399,690, including the partial exercise of the over-allotment option, will become payable to the Underwriters from the amounts held in the Trust Account solely in the event the Company completes its initial Business Combination. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <paii:PercentageOfCashDiscountOnInitialPublicOffering
      contextRef="cref_1491172312"
      decimals="3"
      id="ixv-7803"
      unitRef="uref_193655120">0.015</paii:PercentageOfCashDiscountOnInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_1491172312"
      decimals="0"
      id="ixv-7804"
      unitRef="uref_200602150">2625000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <paii:PercentageOfAdditionalFeeOnInitialPublicOffering
      contextRef="cref_1491172312"
      decimals="3"
      id="ixv-7805"
      unitRef="uref_193655120">0.045</paii:PercentageOfAdditionalFeeOnInitialPublicOffering>
    <paii:PercentageOfInitialPublicOfferingSoldToUnderwriters
      contextRef="cref_1491172312"
      decimals="3"
      id="ixv-7806"
      unitRef="uref_193655120">0.06</paii:PercentageOfInitialPublicOfferingSoldToUnderwriters>
    <paii:DeferredDiscount
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7807"
      unitRef="uref_200602150">9399690</paii:DeferredDiscount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_619992257" id="ixv-6366">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 6&#x2014;SHAREHOLDERS&#x2019; DEFICIT&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; &lt;span style="font-weight: bold;"&gt;Preference Shares&#x2014;&lt;/span&gt;The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. As of December 31, 2025, there were &lt;span style="-sec-ix-hidden:fc_899188066"&gt;&lt;span style="-sec-ix-hidden:fc_174561091"&gt;no&lt;/span&gt;&lt;/span&gt; preference shares issued or outstanding. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt; &lt;span style="font-weight: bold;"&gt;Class A Ordinary Shares&#x2014;&lt;/span&gt;The Company is authorized to issue 200,000,000 Class A Ordinary Shares at par value of $0.0001 each. Holders of the Company&#x2019;s Class A Ordinary Shares are entitled to one vote for each share. As of December 31, 2025, there were &lt;span style="-sec-ix-hidden:fc_492491914"&gt;&lt;span style="-sec-ix-hidden:fc_459141205"&gt;no&lt;/span&gt;&lt;/span&gt; Class A Ordinary Shares issued or outstanding (excluding 20,041,150 shares subject to possible redemption). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt; &lt;span style="font-weight: bold;"&gt;Class&#160;B Ordinary Shares&#x2014;&lt;/span&gt;The Company is authorized to issue a total of 20,000,000 Class&#160;B ordinary shares at par value of $0.0001 each. On May&#160;5, 2025, the Company issued 7,255,952 Class&#160;B ordinary shares to the Sponsor (the &#x201c;Founder Shares&#x201d;) for $25,000, or approximately $0.003 per share, which included an aggregate of up to 946,428 shares that were subject to forfeiture to the extent that the Underwriters&#x2019; over-allotment option was not exercised in full or in part. In June 2025, the Sponsor transferred&#160;30,000&#160;of the Company&#x2019;s Founder Shares to each of the Company&#x2019;s three independent directors. On July 24, 2025, the Underwriters partially exercised their over-allotment option and forfeited their right remaining Units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. As of December 31, 2025, there were 7,225,721 Class&#160;B ordinary shares issued and outstanding. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Class&#160;B ordinary shares will automatically convert into Class A Ordinary Shares at the time of the Company&#x2019;s initial Business Combination (with such conversion taking place immediately prior to, simultaneously with, or immediately following the time of the initial Business Combination, as may be determined by the Company&#x2019;s directors) or earlier at the option of the holder on a one-for-one basis (subject to adjustment for share subdivisions, share dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional Class A Ordinary Shares, or equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which Class&#160;B ordinary shares convert into Class A Ordinary Shares will be adjusted (unless the holders of a majority of the outstanding Class&#160;B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Ordinary Shares issued and issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 26.5% of the sum of (i)&#160;the total number of all ordinary shares outstanding upon the completion of the Initial Public Offering (including any Class A Ordinary Shares issued pursuant to the Underwriters&#x2019; over-allotment option but excluding the Class A Ordinary Shares underlying the Private Placement Warrants issued to the Sponsor), plus (ii)&#160;all Class A Ordinary Shares and equity-linked securities issued or deemed issued in connection with the Company&#x2019;s initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Company&#x2019;s Sponsor or any of its affiliates or to the Company&#x2019;s officers and directors upon conversion of working capital loans) minus (iii)&#160;any redemptions of Class A Ordinary Shares by Public Shareholders prior to or in connection with an initial Business Combination. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; If the Company enters into an initial Business Combination, it may (depending on the terms of such an initial Business Combination) be required to increase the number of Class A Ordinary Shares which the Company is authorized to issue at the same time as the Company&#x2019;s shareholder votes on the initial Business Combination to the extent the Company seeks shareholder approval in connection with the initial Business Combination. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each ordinary share (except as otherwise expressed in the Company&#x2019;s amended and restated memorandum and articles of association). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt; &lt;span style="font-weight: bold;"&gt;Warrants&#x2014;&lt;/span&gt;As of December 31, 2025, there were 15,070,575 warrants outstanding (10,020,575 Public Warrants and 5,050,000 Private Placement Warrants). Each whole warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, subject to adjustment as described herein. Only whole warrants are exercisable. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company will not be obligated to issue any Class A Ordinary Shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A Ordinary Shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue a Class A Ordinary Share upon exercise of a warrant unless the Class A Ordinary Share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a Unit containing such warrant will have paid the full purchase price for the Unit solely for the Class A Ordinary Share underlying such unit.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The warrants will become exercisable 30 days after the completion of the Company&#x2019;s initial Business Combination, which may be within one year of the Initial Public Offering. However, because the warrants will be exercisable until their expiration date of up to five years after the completion of the initial Business Combination, in order to comply with the requirements of Section 10(a)(3) of the Securities Act following the consummation of the initial Business Combination, under the terms of the warrant agreement, the Company has agreed that, as soon as practicable, but in no event later than 20 business days, after the closing of its initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement or a new registration statement covering the registration under the Securities Act of the Class A Ordinary Shares issuable upon exercise of the warrants and thereafter will use its commercially reasonable efforts to cause the same to become effective within 60 business days following its initial Business Combination and to maintain a current prospectus relating to the Class A Ordinary Shares issuable upon exercise of the warrants until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A Ordinary Shares issuable upon exercise of the warrants is not effective by the sixtieth (60) business day after the closing of the Company&#x2019;s initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Company&#x2019;s Class A Ordinary Shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; &lt;span style="font-weight: bold;"&gt;&lt;i&gt;Redemption of warrants for cash when the price per Class A Ordinary Share equals or exceeds $18.00&lt;/i&gt;&lt;/span&gt; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company may redeem the outstanding Public Warrants for cash:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol"&gt;&lt;/span&gt;in whole and not in part;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol"&gt;&lt;/span&gt;at a price of $0.01 per warrant; upon not less than 30&#160;days&#x2019; prior written notice of redemption (the &#x201c;30-day redemption period&#x201d;); and &#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol"&gt;&lt;/span&gt;if, and only if, the last reported sale price of the Class A Ordinary Shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) for any 20&#160;trading days within a 30&#160;trading day period ending on the third&#160;trading day prior to the date on which the Company send the notice of redemption to the warrant holders&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the Class A Ordinary Shares issuable upon exercise of the warrants is effective and a current prospectus relating to those Class A Ordinary Shares is available throughout such 30&#160;trading day period and the 30&#160;day redemption period. If and when the Public Warrants become redeemable by the Company, it may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. The Company has established the last of the redemption criterion discussed above to prevent a&#160;redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of the Class A Ordinary Shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Anti-dilution adjustments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; If (x) the Company issues additional Class A Ordinary Shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A Ordinary Shares (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and the volume weighted average trading price of the Class A Ordinary Shares during the 20 trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Private Placement Warrants (including the Class A Ordinary Shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants sold as part of the units in the Initial Public Offering.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company accounts for the 15,070,575 warrants issued in connection with the Initial Public Offering (including 10,020,575 Public Warrants and 5,050,000 Private Placement Warrants) in accordance with the guidance contained in ASC 815-40. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_1692716169"
      decimals="0"
      id="ixv-7808"
      unitRef="uref_779585586">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_1692716169"
      decimals="4"
      id="ixv-7809"
      unitRef="uref_246701486">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1879775354"
      decimals="0"
      id="ixv-7810"
      unitRef="uref_779585586">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1879775354"
      decimals="4"
      id="ixv-7811"
      unitRef="uref_246701486">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="cref_73988315" id="ixv-7812">one</us-gaap:CommonStockVotingRights>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="cref_1879775354"
      decimals="0"
      id="ixv-7813"
      unitRef="uref_779585586">20041150</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1901841206"
      decimals="0"
      id="ixv-7814"
      unitRef="uref_779585586">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1901841206"
      decimals="4"
      id="ixv-7815"
      unitRef="uref_246701486">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_770479516"
      decimals="0"
      id="ixv-7816"
      unitRef="uref_779585586">7255952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_770479516"
      decimals="0"
      id="ixv-7817"
      unitRef="uref_200602150">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_1318038427"
      decimals="3"
      id="ixv-7818"
      unitRef="uref_246701486">0.003</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="cref_1104949232"
      decimals="0"
      id="ixv-7819"
      unitRef="uref_779585586">946428</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_874887864"
      decimals="0"
      id="ixv-7820"
      unitRef="uref_779585586">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="cref_2120962183"
      decimals="0"
      id="ixv-7821"
      unitRef="uref_779585586">30231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1901841206"
      decimals="0"
      id="ixv-7822"
      unitRef="uref_779585586">7225721</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1901841206"
      decimals="0"
      id="ixv-7823"
      unitRef="uref_779585586">7225721</us-gaap:CommonStockSharesOutstanding>
    <paii:ConvertibleStockConversionRatio1
      contextRef="cref_1330416410"
      decimals="3"
      id="ixv-7824"
      unitRef="uref_193655120">0.265</paii:ConvertibleStockConversionRatio1>
    <us-gaap:CommonStockVotingRights contextRef="cref_1330416410" id="ixv-7825">one</us-gaap:CommonStockVotingRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1062301092"
      decimals="0"
      id="ixv-7826"
      unitRef="uref_779585586">15070575</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1486745643"
      decimals="0"
      id="ixv-7827"
      unitRef="uref_779585586">10020575</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_779585586"
      decimals="0"
      id="ixv-7828"
      unitRef="uref_779585586">5050000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1284032524"
      decimals="2"
      id="ixv-7829"
      unitRef="uref_246701486">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <paii:WarrantsExercisableTermAfterTheCompletionOfABusinessCombination contextRef="cref_73988315" id="ixv-7830">P30D</paii:WarrantsExercisableTermAfterTheCompletionOfABusinessCombination>
    <paii:InitialBusinessCombinationTerm contextRef="cref_22280331" id="ixv-7831">P1Y</paii:InitialBusinessCombinationTerm>
    <paii:WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering contextRef="cref_87236569" id="ixv-7832">P5Y</paii:WarrantsExercisableTermFromTheClosingOfTheInitialPublicOffering>
    <paii:ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination contextRef="cref_668677484" id="ixv-7833">P20D</paii:ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination>
    <paii:ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination contextRef="cref_1618928315" id="ixv-7834">P60D</paii:ThresholdPeriodForEffectiveWithinStatementAfterBusinessCombination>
    <paii:RedemptionOfPublicWarrants
      contextRef="cref_1284032524"
      decimals="2"
      id="ixv-7835"
      unitRef="uref_246701486">18</paii:RedemptionOfPublicWarrants>
    <paii:ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant
      contextRef="cref_157283163"
      decimals="2"
      id="ixv-7836"
      unitRef="uref_246701486">0.01</paii:ClassOfWarrantOrRightExercisableEntityMayRedeemRedemptionPricePerWarrant>
    <paii:ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant contextRef="cref_1330416410" id="ixv-7837">P30D</paii:ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrant>
    <paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays contextRef="cref_1330416410" id="ixv-7838">P30D</paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger
      contextRef="cref_1292095244"
      decimals="2"
      id="ixv-7839"
      unitRef="uref_246701486">18</paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger>
    <paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="cref_157283163" id="ixv-7840">P20D</paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays contextRef="cref_157283163" id="ixv-7841">P30D</paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice
      contextRef="cref_1292095244"
      decimals="2"
      id="ixv-7842"
      unitRef="uref_246701486">18</paii:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1062301092"
      decimals="2"
      id="ixv-7843"
      unitRef="uref_246701486">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice
      contextRef="cref_1879775354"
      decimals="2"
      id="ixv-7844"
      unitRef="uref_246701486">9.2</paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice>
    <paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7845"
      unitRef="uref_193655120">0.60</paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPricePercentageOfEquityProceedsFromIssuance>
    <paii:CommonStockThresholdTradingDay contextRef="cref_73988315" id="ixv-7846">P20D</paii:CommonStockThresholdTradingDay>
    <paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice
      contextRef="cref_333300986"
      decimals="2"
      id="ixv-7847"
      unitRef="uref_246701486">9.2</paii:PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice>
    <paii:PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7848"
      unitRef="uref_193655120">1.15</paii:PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuances>
    <paii:ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7849"
      unitRef="uref_246701486">18</paii:ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption>
    <paii:PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance
      contextRef="cref_1330416410"
      decimals="2"
      id="ixv-7850"
      unitRef="uref_193655120">1.80</paii:PercentageOfWarrantsExercisePriceAdjustedToPriceReceivedInNewIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1062301092"
      decimals="0"
      id="ixv-7851"
      unitRef="uref_779585586">15070575</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1486745643"
      decimals="0"
      id="ixv-7852"
      unitRef="uref_779585586">10020575</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_779585586"
      decimals="0"
      id="ixv-7853"
      unitRef="uref_779585586">5050000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_619992257" id="ixv-6460">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 7&#x2014;SEGMENT INFORMATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC Topic&#160;280, &#x201c;Segment Reporting,&#x201d; establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company&#x2019;s chief operating officer decision maker (&#x201c;CODM&#x201d;), or group, in deciding how to allocate resources and assess performance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Company&#x2019;s CODM has been identified as the &lt;span style="-sec-ix-hidden:fc_832639951"&gt;Chief Financial Officer&lt;/span&gt;, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reportable segment. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the statements of operations as net income or loss. The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income or loss and total assets, which include the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Marketable securities held in Trust Account&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For The &lt;br/&gt; Period&#160;From&lt;br/&gt; May&#160;1,&lt;br/&gt; 2025 &lt;br/&gt; (Inception) &lt;br/&gt; Through &lt;br/&gt; December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;628,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Dividends and interest earned on marketable securities held in the Trust Account&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,601,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;General and administrative costs are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete an offering and eventually a Business Combination within the Business Combination period. The CODM also reviews general and administrative expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. General and administrative expenses, as reported on the statement of operations, are the significant segment expenses provided to the CODM on a regular basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All other segment items included in net income or loss are reported on the statement of operations and described within their respective disclosures.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_1330416410" id="ixv-6467">The Company&#x2019;s CODM has been identified as the Chief Financial Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reportable segment.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:NumberOfReportableSegments
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7854"
      unitRef="uref_599377219">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="cref_619992257" id="ixv-6479">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income or loss and total assets, which include the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Marketable securities held in Trust Account&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For The &lt;br/&gt; Period&#160;From&lt;br/&gt; May&#160;1,&lt;br/&gt; 2025 &lt;br/&gt; (Inception) &lt;br/&gt; Through &lt;br/&gt; December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;628,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Dividends and interest earned on marketable securities held in the Trust Account&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,601,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:MarketableSecurities
      contextRef="cref_333300986"
      decimals="0"
      id="ixv-7855"
      unitRef="uref_200602150">204013247</us-gaap:MarketableSecurities>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7856"
      unitRef="uref_200602150">628213</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="cref_1330416410"
      decimals="0"
      id="ixv-7857"
      unitRef="uref_200602150">3601747</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="cref_619992257" id="ixv-6530">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 8&#x2014;FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 by level within the fair value hierarchy:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify; padding-bottom: 1.5pt"&gt;Marketable securities held in Trust Account&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1886441502"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2088902046"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The Public Warrants were valued using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The value of the Public Warrants as of the IPO date was $3,724,648 or $0.37 per warrant. The Public Warrants have been classified within shareholders&#x2019; deficit and will not require remeasurement after issuance. The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Warrants as of the Initial Public Offering date using level 3 inputs: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;July 18,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Market price of public stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.77&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Probability of merger&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="cref_619992257" id="ixv-6534">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2025 by level within the fair value hierarchy:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify; padding-bottom: 1.5pt"&gt;Marketable securities held in Trust Account&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;204,013,247&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1886441502"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2088902046"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="cref_1093905091"
      decimals="0"
      id="ixv-7858"
      unitRef="uref_200602150">204013247</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_200602150"
      decimals="0"
      id="ixv-7859"
      unitRef="uref_200602150">3724648</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_246701486"
      decimals="2"
      id="ixv-7860"
      unitRef="uref_246701486">0.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="cref_619992257" id="ixv-7861">The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Warrants as of the Initial Public Offering date using level 3 inputs:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;July 18,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;Market price of public stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.77&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Probability of merger&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1064750139"
      decimals="2"
      id="ixv-7862"
      unitRef="uref_193655120">9.81</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1075758566"
      decimals="2"
      id="ixv-7863"
      unitRef="uref_193655120">6.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1779705651"
      decimals="4"
      id="ixv-7864"
      unitRef="uref_193655120">0.0377</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1680536946"
      decimals="4"
      id="ixv-7865"
      unitRef="uref_193655120">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1954112812"
      decimals="4"
      id="ixv-7866"
      unitRef="uref_193655120">0.0911</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_193655120"
      decimals="4"
      id="ixv-7867"
      unitRef="uref_193655120">0.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_619992257" id="ixv-6628">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 9&#x2014;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date through March 30, 2026, the date that the financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_1986056237"
          xlink:label="fc_1986056237"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_544349580"
          xlink:label="fc_544349580"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_205363762"
          xlink:label="fc_205363762"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1945644932"
          xlink:label="fc_1945644932"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_193369983"
          xlink:label="fc_193369983"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_226959058"
          xlink:label="fc_226959058"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_592782723"
          xlink:label="fc_592782723"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_452725222"
          xlink:label="fc_452725222"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1801047499"
          xlink:label="fc_1801047499"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_158012640"
          xlink:label="fc_158012640"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1534900816"
          xlink:label="fc_1534900816"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2071760065"
          xlink:label="fc_2071760065"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_495288907"
          xlink:label="fc_495288907"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2072477435"
          xlink:label="fc_2072477435"
          xlink:type="locator"/>
        <link:footnote id="fref_1001053603" xlink:label="fref_1001053603" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This number includes an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters partially exercised their over-allotment option and forfeited their right to purchase the remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited 30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1986056237"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_544349580"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_205363762"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1945644932"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_193369983"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_226959058"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_592782723"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_452725222"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1801047499"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_158012640"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1534900816"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2071760065"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_495288907"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2072477435"
          xlink:to="fref_1001053603"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_888586232"
          xlink:label="fc_888586232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1256945023"
          xlink:label="fc_1256945023"
          xlink:type="locator"/>
        <link:footnote id="fref_1453435609" xlink:label="fref_1453435609" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This number excludes                                             an aggregate of up to 946,428 Class B ordinary shares subject to forfeiture if the over-allotment                                             option is not exercised in full or in part by the underwriters. On July 24, 2025, the underwriters                                             partially exercised their over-allotment option and forfeited their right to purchase the                                             remaining 83,850 units under the over-allotment option. As a result, the Sponsor forfeited                                             30,231 Class B ordinary shares. All share and per share data have been retroactively applied.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_888586232"
          xlink:to="fref_1453435609"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1256945023"
          xlink:to="fref_1453435609"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
